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Thesis!summary!
This! thesis! explores! the!use!of! large! integrated!health!administrative!datasets!and!other!epidemiologic!methods! to!evaluate!blindness!and!the!safety,!quality!and! outcomes! of! eye! care! provided! for! three! major! blinding! eye! diseases!(cataract,!diabetic!retinopathy!and!ageHrelated!macular!degeneration!(ARMD))!in!Western! Australia! (WA).! The!WA! population! is! ideal! for! populationHbased!research! that! is! representative! of! the! wider! Australian! context.! Trends! and!outcomes! of! cataract! surgery! in! WA! were! explored! using! large! integrated!hospital! administrative! datasets.!Major! changes! in! cataract! surgery! technique!have!occurred!over!a!21Hyear!period!in!WA,!culminating!in!the!introduction!of!sameHday! phacoemulsification! surgery! and! an! exponential! rise! in! surgical!volume.! The! impact! of! serious! complications! of! cataract! surgery! on! patient!quality! of! life! is! significant.! Fortunately! despite! increased! cataract! surgery!volume! surgical! safety! has! improved! and! the! trend! in! major! serious! sightHthreatening!complications!(i.e.!retinal!detachment,!intraHocular!lens!dislocation,!endophthalmitis,! wound! dehiscence! and! dropped! nucleus)! has! declined! by!nearly!50%!during!each!5Hyear!period!since!1980.!Retinal!detachments!are!the!most! common! sightHthreatening! complication! where! males,! younger! patients!and! those! having! complicated! cataract! surgery! requiring! anterior! vitrectomy!were! at! higher! risk.! Cataract! surgery! requiring! anterior! vitrectomy! is! a!major!risk! factor! for! all! serious! sightHthreatening! complications.! The! number! of!surgeries! requiring! anterior! vitrectomy! increased! when! phacoemulsification!was!first!introduced!in!WA!but!thereafter!declined.!Major!risk!factors!were!male!gender,!age!<50!years!or!>80!years,!and!surgery!in!public!hospitals.!!Limitations! in! administrative! databases! lead! to! the! exploration! of! how!alternative!epidemiological!methods!and!data!sources!may!be!brought!together!to! provide! an! alternative! view! on! outcomes.! A! postHmarketing! surveillance!study!combined!integrated!hospital!administrative!data!with!surgeon!logbooks!and!databases!to!examine!the!safety!of!antiHvascular!endothelial!growth!factor!inhibitors! for! the! treatment! of! ARMD.! It! found! the! risk! of! stroke! and!gastrointestinal!bleeding!events! is! low!while!myocardial! infarctions!were!over!twice!the!community!rate.!This!increased!rate!equates!to!a!marginal!increase!in!
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the! absolute! risk! for! myocardial! infarct.! This! marginal! increase! must! be!weighed! against! the! significant! potential! to! avoid! blindness! with! treatment,!which!on!an!individual!at!least,!may!be!acceptable.!Blindness!is!poorly!coded!in!hospital!administrative!datasets.!The!epidemiology!of!blinding!eye!disease!study!(EBEDS)!demonstrated!that!the!WA!blind!register!is!relatively!precise! in! its!diagnostic!accuracy! for! the!major!cause!of!blindness!and! moderately! good! in! accurately! ascribing! blindness.! However,! a! unique!captureHrecapture! technique! used! to! calculate! the! prevalence! of! blindness! in!WA!demonstrated!over!half!the!blind!population!is!unknown!to!government!and!blind! service! providers.! This! population! represents! an! important! group! of!vulnerable! people! who! have! increased! mortality,! poorer! quality! of! life! and!greater!use!of!health!services!than!those!who!are!not!blind.!!The!remote!Aboriginal!Australian!population!are!vulnerable!with!poor!access!to!health! care! and! also! poorly! represented! in! hospital! administrative! data.! A!unique!Goldfields! eye! health! survey! allowed! the! study! of! the!major! causes! of!vision! loss! in! remote! eastern! Goldfields! communities! in! WA! over! a! 12Hyear!period.! The! major! causes! of! vision! loss! are! preventable! or! treatable,! and!diabetes!has!a!major!association.!Despite!this,!screening!for!diabetic!retinopathy!is! very! poor! and! highlights! deficiencies! in! community! screening! in! these!vulnerable!remote!populations.!A! national! Australian! survey! of! general! practitioners! (GPs),! optometrists! and!ophthalmologists! was! conducted! to! ascertain! current! diabetic! retinopathy!screening!and!management!practices.!This!showed!an!improvement!in!diabetic!retinopathy!screening!and!management!since!the!publication!of!National!Health!and!Medical!Research!Council!guidelines.!Optometrists!are!the!most!motivated!to! participate! in! community! screening! for! diabetic! retinopathy! yet! have! the!least! knowledge! compared! to! ophthalmologists! and! GPs.! GPs! report! major!barriers!to!performing!dilated!retinal!examinations!including!lack!of!confidence!in! detecting! signs;! while! optometrists! are! the! better! equipped,! further!education!is!recommended!if!they!are!to!take!on!community!screening.!  
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Exegesis!
1.Explanatory!overview! !
5!
Vision! loss!and!blindness!presents!a!significant!health!concern.! It!ranks!as! the!seventh!leading!cause!of!loss!of!wellbeing,1!and!is!associated!with!greater!social!dependence,! increased! morbidity! (including! increased! risk! of! falls)2,3! and!poorer! quality! of! life.4H7! It! is! also! costly,! costing! Australia! AU$9.85! billion! in!2004.8!Vision!problems!affect!over!half!of!the!Australian!population!and!vision!impairment!or!blindness!affects!approximately!half!a!million!Australians.9,10!Age!is!the!single!most!important!risk!factor!for!vision!impairment!and!blindness:!the!risk!increases!threefold!for!each!decade!over!the!age!of!40.!In!Australia!39%!of!people!over!90yrs!of!age!are!vision!impaired.10!Future!projections!for!an!ageing!and! growing! population! predict! the! number! of! people! with! vision! loss! in!Australia!will!double!by!2020.10,11!!Blinding!eye!disease!is!a!Australian!national!health!priority.12!Over!75%!of!cases!of!blindness!and!vision!loss!in!Australia!are!avoidable!!H!the!major!causes!being!(after!refractive!error)!ARMD,!cataract,!glaucoma!and!diabetic!retinopathy.13H15!Addressing!these!problems!requires!an!understanding!of!who!are!affected!and!ophthalmic! care! they! are!provided.! In!particular,!we!need! to!understand!how!this! care! is! being! delivered! and! utilised,! who! are! the! vulnerable! or! at! risk!populations,! and!what! are! the! outcomes! of! those! services!we!provide.! Armed!with! this! knowledge! we! can! then! devise! and! implement! strategies! for!improvement.!!Health! services! research! examines! the! relationship! between! the! provision,!effectiveness! and! efficient! use! of! health! services! and! the! health! needs! of! the!population.! It!has! a!broad! scope! that! covers!multiple!disciplines!and! research!methodologies.16!The!Institute!of!Medicine!Committee!on!Quality!Health!Care!in!America!state!health!systems!should!be!able!to!deliver!health!services!that!are!safe,! effective,!patientHcentred,! timely,! efficient!and!equitable.17!Measuring! the!ability! of! a! health! system! to! deliver! on! these! goals! is! a! key! part! of! health!services! research!and! forms! the!basis!of! this! thesis!as! it!pertains! to!blindness!and!blinding! eye!disease! in!WA.! In! addition! to! the! epidemiology!of! blindness,!three!of!the!blinding!eye!diseases!are!a!particular!focus!for!this!thesis.!i. Cataract!–!Is!a!major!focus.!Ready!and!timely!access!to!modern!cataract!surgery! facilities! in!WA!means!cataracts!are! rarely!blinding! though! the!
6!
complications!of!surgery!can!be.!While!cataract!surgery!is!very!safe,!over!13,000!cataract!operations!are!performed!each!year!in!WA!so!even!rare!complications!have!the!potential!to!produce!significant!morbidity!in!the!community.!!ii. Diabetic! retinopathy! H! Diabetes! prevalence! continues! to! grow! across!most! developed! countries! and! the! burden! of! diabetic! retinopathy!expected!to!follow.!Diabetic!retinopathy,!if!not!treated,!causes!permanent!loss! of! vision! and! eventually! blindness! due! to!macular! oedema,! retinal!neovascularization,! retinal! ischemia! or! tractional! retinal! detachment.!Prevention! of! vision! loss! from! diabetic! retinopathy! relies! on! early!detection! and! early! treatment! that! is! supported! by! comprehensive!community! screening.! This! is! particularly! so! in! remote! and! Aboriginal!communities!where!rates!of!diabetes!are!high!and!access!to!health!care!is!poor.!iii. AgeKrelated!macular!degeneration!(ARMD)!H!ARMD!is!the!leading!cause!of!irreversible! blindness! in! elderly! population.! There! are! two! forms!characterised! by! predominantly! photoreceptor! atrophy! (‘dry’)! and!gradual!vision! loss,!or! the!development!of!choroidal!neovascularisation!(CNV)!(‘wet’)!and!sudden!profound!vision!loss.!Prior!to!2005!an!effective!treatment! for! wet! ARMD! was! not! available! and! patients! simply! went!blind! and! little! could! be! done! to! alter! the! progression! of! disease.! The!widespread! introduction! of! the! vascular! endothelial! growth! factor!inhibitors! (antiHVEGF)! in! 2005! revolutionized! the! treatment! and!prognosis! for! this! disease.18,19! The! treatment! has! been! taken! up! with!great!zeal! in!WA,!although!concerns!still!persist!regarding! the!systemic!safety! of! antiHVEGF! agents.! There! is! a! distinct! need! for! postHmarketing!surveillance!for!assessing!its!safety.!!! !
7!
2.Aims!and!objectives!The! primary! goal! was! to! evaluate! the! epidemiology! of! blindness! and!particularly!the!state!of!ophthalmic!care!in!WA!pertaining!to!important!aspects!of!important!potentially!blinding!eye!diseases!i.e.!cataract,!diabetic!retinopathy,!and!ARMD.!An! overHarching! theme!was! to! also! explore! how! this! goal!may! be!achieved! utilising! existing! data! sources! available! for! health! services! research.!While!hospital!administrative!databases!offer!the!power!of!large!numbers!that!are! truly! populationHbased! they! lack! clinical! detail! to! allow! inHdepth! study! of!ophthalmic!diseases!and!health!outcomes.!For!this,!alternative!data!sources!and!methodologies!such!as!clinical!surveys!and!registries!are!explored.!The!following!outlines!the!specific!aims!and!objectives!for!this!thesis.!
Aim!1.!Establish!how!representative!the!WA!population!is!of!the!
Australian!population!Objective!1. Compare! the!WA!population!key!socioHdemographic!and!health!economic! indicators! to! the! Australian! national! average! and!individual!state!and!territory!averages.!!
Aim! 2.! Use! linked! hospital! administrative! data! to! evaluate!
cataract!surgery!complications!and!outcomes!in!WA!!Objective!2. Measure! the! rates! and! trends! of! major! sightHthreatening!complications!of!cataract!surgery!in!Western!Australia.!Objective!3. Evaluate! the! major! risk! factors! for! pseudophakic! retinal!detachment!after!phacoemusification!Objective!4. Describe! the! trends! in! complicated! cataract! surgery! and!calculate! the! increased! risk! of! adverse! outcomes! following!complicated!cataract!surgery.!Objective!5. Measure!the!impact!of!a!major!blinding!complication!of!cataract!surgery!(e.g.!postoperative!endophthalmitis)!on!patient!reported!quality!of!life.!! !
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Aim! 3.! Use! clinical! registers! to! supplement! hospital!
administrative! data! in! assessing! the! safety! of! vascular!
endothelial!growth!factor!inhibitors!(antiNVEGF)!for!ARMD.!Objective!6. Determine!whether!treatment!with!antiHVEGF!for!wet!ARMD!increases!the!risk!of!hospitalisation!or!death!for!cerebrovascular!or!cardiovascular!events.!!Objective!7. Evaluate!whether!an!association!exists!between!the!cumulative!dose!of!intravitreal!ranibizumab!or!bevacizumab!and!risk!of!cerebrovascular!or!cardiovascular!events!for!patients!with!wet!AMD.!
Aim!4.!Use!a!blind!registry!and!captureNrecapture!techniques!to!
describe!the!epidemiology!of!blindness!in!WA.!!Objective!8. Validate! the! clinical! diagnosis! and! cause! of! blindness! in! the!existing!WA!blind!registry.!!Objective!9. Use!captureHrecapture!techniques!to!validate!existing!population!estimates!of!blindness!in!WA.!Objective!10. Integrate! the! blind! registry! with! the! WADLS! to! determine!associations! between! blindness! and! cause! of! death,! coHmorbidities!and!health!services!utilization.!
Aim!5.!Use!an!electronic!clinical!register!to!evaluate!the!causes!
of! blindness! and! the! impact! of! diabetes! on! remote! Aboriginal!
communities!in!WA.!Objective!11. Determine!the!major!causes!of!vision!loss!in!remote!Aboriginal!communities.!!Objective!12. Determine!the!prevalence!of!diabetic!retinopathy!among!diabetic!Aboriginal!patients!in!remote!Aboriginal!WA!communities.!Objective!13. Evaluate!the!adequacy!of!eye!screening!for!Aboriginals!with!diabetes.!
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Aim! 6.! Use! clinical! survey! methods! to! evaluate! diabetic!
retinopathy!screening!and!management!practices.!Objective!14. Describe!diabetic!retinopathy!screening!and!management!practices!of!Australian!GPs,!Ophthalmologists!and!Optometrists.!Objective!15. Identify!barriers!in!adhering!to!recommended!diabetic!retinopathy!screening!and!management!practices!experienced!by!eye!care!providers!and!factors!associated!with!these.!Objective!16. Evaluate! the! longHterm! impact! of! the! 1997! NHMRC! Diabetic!Retinopathy! Management! Guidelines! on! improving! diabetic!retinopathy! screening! and!management! practices! amongst! eye!care!providers.!! !
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3.Thesis!overview!This!thesis!comprises!the!summation!of!a!large!body!of!work,!undertaken!over!the! course! of! several! projects,! to! address! the! thesis! aims! and! objectives.! It! is!divided! into! 4!major! chapters! supported! by! 15!papers! published! in! the! peerHreviewed!literature!(including!6!where!the!candidate!was!first!author).!Chapter!1!begins!with!a!literature!review.!A!description!of!the!WADLS!and!how!administrative! data! are! used! for! health! services! and! ophthalmic! research! is!explored.! This! chapter! forms! the! basis! of! a! review! paper! currently! under!consideration!for!publication!in!Survey!of!Ophthalmology!(Appendix!5).!Chapter!2!addresses!the!first!aim!to!evaluate!the!representativeness!of!the!WA!population! of! the! widerHAustralian! context,! therein! supporting! the! external!validity!of!findings!presented!in!subsequent!chapters!of!this!thesis.!(1!paper)!Chapter!3!addresses!the!second!aim!to!describe!sightHthreatening!complications!of! cataract! surgery! using! administrative! databases! In! doing! so,! this! chapter!demonstrates! how! these! datasets! support! research! in! ophthalmic! trends! and!outcomes.!(3!papers)!Chapter! 4! addresses! the! final! aims! and! explores! how!other! data! sources!may!valueHadd! to! research! arising! from! administrative! databases.! This! is! achieved!across! five! themes! –! the! epidemiology! of! blindness,! postHmarketing!surveillance,! vulnerable! and! isolated! populations,! quality! of! life! and! clinician!knowledge! and! practices.! The! risk! of! cardiovascular! events! after! antiHVEGF!treatment!for!ARMD!is!estimated!in!one!paper.!The!epidemiology!of!blindness!in!WA,! including! quality! of! life! for! blind! people,! is! described! across! five! papers.!Trends!in!diabetic!retinopathy!and!the!causes!of!vision!loss!in!Aboriginals!from!the!remote!Eastern!Goldfields!region!of!WA!are!described!in!another!paper.!The!impact!of!postoperative!endophthalmitis!after!cataract!surgery!on!quality!of!life!is! described! in! one! paper.! Knowledge! surrounding! diabetic! retinopathy!screening!guidelines!and!current!management!practices!of!health!professionals!involved! in!eye!care! (ophthalmologists,!optometrist!and!GPs)!are!described! in!three!papers.!(10!papers)!! !
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Chapter!1!
1.The!‘big!data’!revolution:!!a!review!of!
large!administrative!databases,!data!
integration!and!ophthalmic!research!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !
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1.1. Introduction!
[This!Chapter!forms!the!basis! for!a!review!paper!under!review!for!publication!in!
Survey!of!Ophthalmology!(Appendix!5)]!!!“Big!data”!is!a!relatively!new!concept!that!describes!data!so!large!and!complex!that! it! exceeds! the! storage!or! computing! capacity!of!most! systems! to!perform!timely!and!accurate!analyses.20,21!Health!generates!huge!amounts!of!data!from!a!wide!array!of!sources!such!as!electronic!health!records!(EHR),!health!insurance!claims,!and!even!smart!phone!applications!that!monitor!patient!health.!It!is!the!subject! of! intense! interest! as! industry! and! researchers! alike! realize! the! huge!potential! in! extracting! value! from! existing! data! systems.! The! ‘big! data!revolution’! is! being! increasingly! supported!by!national! governments,!who! are!funding!initiatives!designed!to!develop!and!capitalize!on!big!data.21,22!Even! before! the! big! data! revolution,! health! researchers! have! long! recognized!the! value! in! large! administrative! databases.23! The! last! decade! has! seen! a!dramatic!increase!in!the!their!use!for!ophthalmic!research.24,25!These!databases!contain!a!wealth!of!information!that!can!now!be!accessed!in!a!timely!and!costHefficient!manner!due!to!advances!in!computing!power!and!the!development!of!new! analytical! methodologies.26! These! advances! have! also! facilitated! data!linkage!or! integration!processes!that!offer!greater!utility!over!using! individual!databases!for!health!research!e.g.!linking!pharmaceutical!claims!data!to!hospital!discharge!data!allows!study!of!health!outcomes!associated!with!medication!use.!It!promises! the!potential! for!more,! almost! limitless,! amounts!of!data!available!for!research.!!The!health! research! landscape! in!Australia!has! recognised! this! revolution!and!there! is! now! an! imperative! to! develop! and! capitalise! on! our! available! health!administrative!data!through!data!integration!processes.!!In!this!chapter,!large!administrative!databases!and!data!linkage!systems!in!place!today! will! be! reviewed! including! their! benefits! and! limitations! for! health!research,!and!how!they!have!been!used!for!research!in!ophthalmology.!! !
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1.2. Administrative!data!and!data!integration!
1.2.1. Administrative!data!characteristics!Administrative! databases! used! in! health! research! are! preHexisting! datasets!whose!primary!purpose! is! the! storage!of! information! routinely! collected! from!the!point!of! service,!usually! for!billing!purposes!e.g.!hospital! insurance! claims!information! and! pharmaceutical! billing! data.! The! variables! typically! recorded!range! widely! but! generally! include:! a! patient! specific! identification! number,!demographic! details! (e.g.! name,! sex,! date! of! birth,! and! address)! and! limited!clinical!data!(e.g.!diagnostic/procedural!codes!in!health!insurance!claims!data!or!drug! codes! in! pharmaceutical! claims!data).! These! database! are! normally! very!large,! cover! large! defined! populations! within! a! given! health! jurisdiction,! and!span!years!if!not!decades!of!service.!Clinical!registries!are!different!to!administrative!databases;!they!are!designed!to!collate! detailed! clinical! information,! usually! for! quality! assurance! and! clinical!audit.!Only! a! few! truly!populationHbased!ophthalmic! registries! currently! exist,!though! this! number! is! increasing.! Those! most! notable! are! the! cataract!surgery,27,28!and!corneal!transplant!registries.29H31!These!registers!are!powerful!tools! for! health! research! due! to! the! level! of! detailed! clinical! information! they!contain!that!current!administrative!databases!simply!cannot!match.!
1.2.2. Data!integration!Data!integration,!or!data!linkage,!is!defined!as!the!"bringing!together!from!two!or!more!different!sources,!data!that!relate!to!the!same!individual,!family,!place!or!event".32!The!concept!was!most!eloquently!described!by!Dr!Halbert!L!Dunn!in!1946! when! he! proposed! the! concept! of! a! "Book! of! life".33! Such! a! book! is!comprised! of! records! from! significant! events! in! a! person’s! life! H! their! birth,!education,! marriage,! divorce,! illness! and! finally! their! death.! He! suggested!records! relating! to! these!events! could!be! collated! to! form!a!person's!personal!file!and!that!collating!these!files!on!a!populationHwide!basis!would!be!useful!in!generating! knowledge! in! a! wide! range! of! areas,! particularly! for! health! and!welfare!organisations.!He!defined!this!process!as!'record!linkage'!!H!a!term!that!has! evolved! into! the!more!broadly! encompassing! term!of! 'data! integration’! to!
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recognise! that! information! can! come! from!sources!beyond!our!old!fashioned!concepts!of! 'records'! e.g.! geospatial! information!systems.!
Data!linkage!techniques!The! linkage! of! two! or! more! datasets!requires! identifiers! that! are! common! to!all!datasets.34,35!Such!identifiers!may!be!unique!(e.g.! a! patients! insurance! number),! or!partial! (e.g! names,! date! of! birth,! gender,!place! of! birth,! postcode! etc)! and! are!matched! using! any! of! three! general!techniques:!i. Unique! matching! (deterministic! matching)! H! data! are! linked!according!to!unique!identifiers!e.g.,!health!insurance!number.!This!would!be!the!most!expeditious!way!to! link!data!yet! few!datasets!share!a!common!identifier!limiting!the!potential!data!that!can!be!linked.! In!addition,!due! to! the!potential! for!recording!errors! this!method!may!only!identify!80H85%!of!true!matches.35!ii. Fuzzy!matching! H! data! are! linked! according! to!partial! identifiers!(usually!multiple).!This!technique!allows!for!a!margin!for!error!by!linking!records!that!are!almost!the!same.!The!computer!will!either!present!a!choice!of!matches! to! the!user!or!will! rely!on!a!scoring!system!to!confirm!a!match.!This!usually!identifies!85H90%!of!true!matches.35!iii. Probabilistic!matching! H! the!decision! regarding! a!match! is!made!using!decision!rules!that!are!built!into!a!software!package.!These!are!based!on! the!probability! that! two!records!are! from!different!people!given!they!have!the!same!identifiers.!The!probabilities!are!then! aggregated! to! form! a! score! and! a! link! is! confirmed! if! a!predefined!threshold!is!reached.!This!typically!identifies!95H99%!of!true!matches!with!a!1H2%!false!positive!rate.34H36!
Figure!1N1!Dr!Halbert!Dunn!(1896!H!1975)!!
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1.2.3. Benefits!and!limitations!for!health!research!Since!research!arising!from!administrative!data!is!observational!by!nature!there!has!been! some! skepticism! regarding! its! value.37,38! This! is! compounded!by! the!heavy!emphasis!on!randomized!controlled!trials!(RCT)!as!the!‘gold!standard’!for!evaluating! treatment,! which! ignores! the! limitations! inherent! in! RCT!methodology.! RCTs! do! not! reflect! realHlife! community! practice,! leaving!clinicians!to!use!their!judgment!in!extrapolating!findings!from!trials!that!relate!to! a!highly! selected!patient! that! is! seldom!encountered.!Observational! studies!using! large! databases! can! complement! RCTs! by! going! some! way! towards!addressing! their! limitations.38! Their! large! size! provides! wholeHpopulation!capture;!thereby!avoiding!nonHrepresentative!samples!and!selection!bias,!which!may! occur! in! randomized! trials.! They! measure! the! true! effectiveness! of! an!intervention! that! is! based! on! actual! ‘real! world’! practice! unlike! the! highly!controlled! environment! in! RCTs.! They! are! also! better! powered! to! study! rare!events! and! small! effect! sizes!due! to! very! large! sample! sizes,! and! the! typically!long! time! span! covered! by! many! databases! enables! longHterm! events! to! be!examined.!Recall!bias!and!bias!related!to!nonHparticipation!and!loss!to!followHup!is!minimized!since!all!eligible!people!are!included!and,!because!these!databases!are!primarily!created!for!administrative!purposes,!individual!patient!consent!is!usually!not!required!or!warranted.32,39!The!advantages!and!social!benefits!of!research!arising!from!large!administrative!data!and!data!linkage!systems!over!traditional!research!methods!are!significant!and!include:!i. decreased! cost! of! research:! using! existing!data! is! a! relatively! cheap!and!effective!alternative!to!primary!data!collection.34,39!!ii. increased! efficiency! of! research:! access! to! existing! clinical!information! vastly! reduces! time! compared! to! studies! requiring!primary! data! collection.! This! is! particularly! important! when!assessing! safety! of! new! treatments! such! as! postHmarketing!surveillance!of!new!drugs.40!iii. conservation!of!patient!privacy:! the!privacy!of! individual!patients! is!conserved!since!it!is!usually!not!necessary!for!personal!identifiers!to!
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be! provided! to! researchers.41! Using! deHidentified! administrative!databases! also! conserves! the! privacy! of! all! patients,! regardless! of!whether! they!would!have! given! consent.!A! consentHbased! approach!conserves!the!privacy!only!of!those!who!do!not!participate,!usually!at!a!cost!of!making!the!research!impractical.42!iv. adding! value! to! existing! information! assets:! integrating! datasets!generates! a! greater! return! on! investment! in! routine! administrative!data! sets! and! facilitates! quality! improvement! of! data! through! the!linkage!process.43!Limitations!of!studies!using!administrative!data!surround!the!use!of!data!whose!primary!purpose!is!not! for!research.24,25,44!The!researcher!should!be!cognisant!of!how!the!data!was!collected!and!coded.!The!first!hurdle!relies!on!the!patient!with!a!particular!condition!seeking!care!–!if!it!is!not!serious!enough!to!warrant!seeking! health! care! it!will! not! be! recorded! and! cannot! be! studied.! There! also!needs! to!be!a!code!attached! to! the!condition!or!procedure!of! interest! (usually!International! Classification! of! Diseases! codes! (ICD)! e.g.! ICDH10)! and! any!additional! uncoded! clinical! data! cannot! be! studied.! Codes!may!not! be! specific!enough! to! allow! more! detailed! study! e.g.! ‘glaucoma’! rather! than! ‘pigment!dispersion!glaucoma’;!and!may!not!necessarily!indicate!severity!of!a!condition.!Establishing! laterality! to! a! particular! eye! is! a! major! problem! since! many!datasets!historically!did!not!record!this!information!and!may!limit!investigation!of!adverse!events.!Data!quality!and!completeness!will!tend!to!vary!across!databases!and!variables!being! studied.! Some! errors! are! less! likely! to! occur! e.g.! coding! for! primary!surgical!procedures;!while!others!have!been!shown!to!be!prevalent!e.g.!omitted!coding! for! secondary! diagnoses.25,44,45! Databases! may! also! change! over! time!with!changes!in!codes!and!the!addition!or!deletion!of!variables.!The!way!data!is!generated!or!collated!may!also!vary!between!datasets!and!with!time.44!It! is! essential! that! the! researcher! intimately! understand! how! their! data! was!generated!and!how!it!may!have!evolved!over!time.!A!close!working!relationship!between! researcher! and! data! custodian! is! essential! if! errors! in! analysis! and!interpretation!are!to!be!avoided.!Validation!studies!with!chart!review!can!help!
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quantify! the! size! of! these! issues!within! any! given! data! collection! e.g.! diabetic!macular!edema,46!acute!glaucoma,47!eye!drop!therapy!in!glaucoma!patients,48,49!and!endopthalmitis.50!Care!must!also!be!taken!when!calculating!incidence/prevalence!or!generalizing!results!to!the!wider!population!since!many!databases!contain!a!limited!subset!of!the!population!that! is!unlikely!to!be!representative!of! the!whole.!For!example,!the!US!Medicare!database!only!includes!those!older!than!65!years!or!disabled!or!poor;!while!health! insurance!company!claims!data! is! limited!to! those!who!can!afford!health!insurance!and!omits!vulnerable!lower!socioeconomic!groups!and!racial! minorities! without! insurance! who! are! more! likely! to! need! care.! The!limited!coverage!of!insurance!databases!also!means!loss!to!followHup!can!be!an!issue!when!patients!move!in!and!out!of!the!insurance!organization.!Conversely!databases! in! jurisdictions! with! universal! health! care,! and! particularly! data!linkage!systems,!are!truly!populationHbased!and!so!are!readily!generalized!with!very! little! loss! to! followHup! and! can! offer! true! measures! of! incidence! and!prevalence.!Finally,! analysis! of! these! databases! should! take! into! account! the! risk! of!confounding! due! to! comorbidity,! socioHdemographic! factors! and! effect!modification.24,25! Multivariate! modeling! and! other! techniques! can! be! used! to!adjust!for!these!effects!so!long!as!they!are!present!in!the!data.!!If! these! limitations! are! addressed! in! the! study! design,! data! analysis! and!interpretation;! then! any! study! findings! using! administrative! data! can! still!provide!valuable!additional!information!to!the!available!evidence.!! !
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1.3. International!data!linkage!systems!Prior! to! the! turn! of! the! century! there! were! only! a! handful! of! data! linkage!systems!worldwide.!However,!data!linkage!involving!medical!records!has!been!available! for! decades.! These! well! established! systems! that! were! key! to! the!development!of!data!linkage!will!now!be!discussed.!!
1.3.1. The!Oxford!record!linkage!study!(ORLS)!The!ORLS!was!established!by!Acheson!in!1962!as!the!worlds!first!data!linkage!system.51!He!had!alluded!to!the!benefits!of!developing!such!a!system!in!the!BMJ!in!1961!when!he! stated! that! the! analysis! of!medical! records! linked!nationally!would!
‘…!provide!excellent!morbidity!statistics!and!create!a!science!of!prognosis...These!
would!be!a!base!from!which!field!studies!of!the!epidemiology!of!the!important!
diseases!of!the!day!would!spring…‘!52!The! ORLS! was! initially! a! jointly! funded! project! between! the! NHS’s! Oxford!Regional! Health! Authority! and! the! Oxford! University! Unit! of! Clinical!Epidemiology! and! produced! ad! hoc! analyses! for! health! care! providers! and!specific! multiHcentre! audit! reports! annually.53! It! comprises! over! 10! million!records! from! a! historical! population! of! over! five!million! people! in! the!Oxford!region;! consisting! of! computerised,! irreversibly! anonymised! abstracts! of!records! of! morbidity,! births! and! deaths! since! 1963! linked! using! nationally!approved!identifiers!of!subject!and!institution.54!In!1999,!responsibility!for!the!ORLS! was! transitioned! to! The! Oxford! University! Unit! of! HealthHCare!Epidemiology.! At! the! same! time! a! directive! was! delivered! from! The! English!national! Department! of! Health! to! cease! collecting! data! pertaining! to! patients’!names!and!addresses.!With! the!mainstay!of! it’s! linkage!methodology!removed!(patients’!names!and!addresses)!the!collection!of!data!for!the!ORLS!ceased!and!subsequently! all! patient! identifiers! were! stripped! from! the! data! sets.53! The!ORLS!remained!at!a!standstill!until!the!UK!regulatory!framework!caught!up!and!the!unit!was!commissioned!to!link!hospital!and!mortality!data!across!the!whole!of! England! in! 2003.53! This! provided! the! data! that! allowed! the! ORLS! to! be!maintained!to!the!present!date.!
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The!ORLS!has! been!used! to! study! longHterm! trends! in! hospital! admissions! by!individual! specialty! and! clinical! condition,! studies! of! postoperative! mortality!and!other!adverse!outcomes!of!care,!studies!of!suicide!risk!after!discharge!form!psychiatric!care,!studies!of!associations!between!clinical!conditions!and!studies!of! the! use! of! hospital! care! by! the! elderly! and! the! ‘compression! of!morbidity’!hypothesis.53!
1.3.2. Information!and!statistics!division!Scotland!(ISD!
Scotland)!Scotland!was!the!first!country!internationally!to!be!able!to!perform!a!wide!range!of!population!health! studies!using! linked!data!at!a!national! level.! ! In!1974,!an!Information!and!Statistics!Division!was!created!to!collect,!store!and!disseminate!statistical! information! about! all! patients! treated! within! the! National! Health!Service! in! Scotland.! The! linked! data! sets! included! morbidity,! maternity,!neonatal! and! mental! health! records,! cancer! notifications! and! records! of!ambulance! and! emergency! centre! attendances.! ! In! 1992,! a! Scottish! Central!Population! Index! issued! a! single,! unique! NHS! identification! number! to! each!individual!in!the!entire!population!of!Scotland!and!this!has!been!also!available!for!matching.!At! present,! data! linkage! in! Scotland! uses! routine! automated! probabilistic!matching! of! personal! identifiers,! with! minimal! clerical! review.! ! Research!supported!by!the!system!has!studied!patient!stays!and!episodes,!incidence!and!prevalence!of!diseases,!multiple!admissions,!pathways!of!care,!caseHcontrol!and!cohort! studies;! the! system! has! also! been! used! for! national! audits! and! to!generate!outcome!indicators.55!
1.3.3. The!Manitoba!Population!Health!Information!System!The! Canadian! University! of! Manitoba! Centre! for! Health! Policy! houses! the!Manitoba!Population!Health! Information!System!and! is! jointly! funded! through!government! and! competitive! research! grants.56! The! provincial! health!department! of! Manitoba! has! supplied! anonymised! electronic! health! care!utilisation! files! to! a! repository! at! the! Centre! since! the! 1970s.! These! files! are!linkable! using! a! scrambled! identifier! called! the! Manitoba! Health! Services!Commission! number,! which! is! unique! to! a! family! rather! than! an! individual!
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(creating!issues!when!children!leave!home).56!Manitoba!Health!does!not!have!a!data!linkage!unit,!but!employs!consultants!on!an!ad!hoc!basis!for!this!purpose.!!The! repository! contains! over! one! billion! records! from! the! Manitoba! Health!Services! Insurance! Plan! Registry,! as! well! as! health! insurance! claims! from!physicians!and!health!care!facilities,!hospital!files,!medical!claims!from!patients!and! longHterm! care! data.56! The! Manitoba! Office! of! Vital! Statistics! and! Cancer!Care!also!provide!data!to!the!repository.56!Whilst!not!a!government!agency,! the!centre!has!a!contract!with! the!provincial!health!authority!to!complete!five!major!studies!of!health!care!annually.56!Project!topics! are! selected! from! a! larger! list! and! jointly! negotiated! by! the! Deputy!Minister! for! Health! and! the! Director! of! Centre.56! Studies! in! Manitoba! have!focused!on!the!quality!of!care,!service!provision!by!regional!health!authorities,!physician!workforce,!financial!and!cost!issues.57!
1.3.4. Population!Data!British!Columbia!The!British!Columbia!Linked!Health!Database!(BCLHD)!was!established!by!the!Centre! for! Health! Services! and! Policy! Research! at! the! University! of! British!Columbia! in!1996.! ! It! oversaw!over!120!projects!using! the!Database.! In!2009,!the!BCLHD!and!its!data!holdings!transitioned!to!Population!Data!BC.!Population!Data!BC!was!established!as!an!interHjurisdictional!system!to!aid!in!research!on!the! ‘determinants! of! human! health,! wellHbeing! and! development’.! Linkage! of!data! across! sectors,! such! as! health,! education,! early! childhood! development,!workplace!and!the!environment!are!possible!through!the!service.58!!!The!system!covers! the! data! sets! of! the! medical! services! plan,! PharmaCare,! hospital!separations,! continuing! care,! birth! registrations,! death! registrations,! mental!health! episode! care! records,! early! childhood! data,! Worker’s! Compensation!Board!and!the!British!Columbia!Cancer!Agency!cancer!incidence!file,!and!spatial!data.58!
1.4. Data!linkage!in!Australia!The!Population!Health!Research!Network!(PHRN)!was!established!as!a!national!network!in!2009!to!provide!data!linkage!infrastructure!across!Australia!as!part!of! the! National! Collaborative! Research! Infrastructure! Strategy.! It! is! funded!
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jointly! by! the! Australian! Commonwealth! Government,! State! and! Territory!governments,!universities,!and!research!institutes.!The!PHRN!is!project!lead!by!The!University! of!Western!Australia! and! comprises! a! network!of! data! linkage!units! that!services!each!State!and!Territory! in!Australia!and!two!national!data!linkage!units!for!crossHjurisdictional!linkages!(Figure!1H2).!59!A!unique!feature!of!the!PHRN!is!the!development!of!the!Secure!Unified!Research!Exchange! (SURE)! by! the! Sax! Institute.! This! purpose! built! remoteHaccess! data!research! laboratory! allows! researchers! to! work! on! approved! data! extracts!through!a!virtual! computer!while! the!data! remains! stored! in!a!highly! secured!environment.! The! benefits! are! that! it! minimizes! the! risk! of! privacy! and!confidentiality!breaches!since!data!are!not!stored!on!local!computers/networks,!improves! the! accessibility! of! data! to! researchers,! and! facilitates! collaboration!between!researchers!across!institutes.60!!The! facilities! and! infrastructure! developed! by! the! PHRN! make! it! unique!worldwide! since! very! few! countries! (notably! the! UK,! Canada! and! some!Scandinavian! countries! such! as! Sweden! and! Demark)! have! the! capability! to!perform!populationHbased!data!linkage.!!
PHRN!
Data!linkage!units!
National!The!Data!Integration!Services!Centre!(Australian!Institute!of!Health!and!Welfare)!Centre!for!Data!Linkage!(Curtin!University)!
State/Territory!Centre!for!Health!Record!Linkage!(NSW!Ministry!of!Health)!Data!Linkage!Branch,!Department!of!Health,!Western!Australia!Queensland!Research!Linkage!Group!(Queensland!Health)!SAHNT!DataLink!(University!of!South!Australia)!Tasmanian!Data!Linkages!Unit!(University!of!Tasmania)!Victorian!Data!Linkages!(Department!of!Health,!Victoria)!
Project!partners!
Australian!Institute!of!Health!and!Welfare!Curtin!University!NSW!Ministry!of!Health!The!Department!of!Health,!Victoria!The!Department!of!Health,!Western!Australia!The!Sax!Institute!The!Tasmanian!Department!of!Health!and!Human!Services!Telethon!Kids!Institute!The!University!of!Queensland!The!University!of!South!Australia ! ! !!
Figure!1N2!N!Overview!of!the!Population!Health!Research!Network!(PHRN)!
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1.5. The!WA!Data!Linkage!System!(WADLS)!
1.5.1. Western!Australian!population!Western! Australia! covers! a! land! area! of! 2.5!million! square! kilometres!with! a!population! of! 2.4! million! people.61! Its! capital! city,! Perth,! is! one! of! the! most!isolated!in!the!world.!The!vast!majority!of!the!population!(>70%)!is! located!in!the! state's! southwestern! corner! and! the! remainder! scattered! sparsely! across!the!state.!The!population!is!bordered!by!the!Indian!Ocean!to!the!west!and!a!vast!expanse! of! desert! to! the! east.62! This! relative! geographical! isolation!minimises!the!degree!to!which!patients!travel!outHofHstate!to!use!health!care!services!and!creates!a!'captive'!population!that!is!ideal!for!populationHbased!research.!
1.5.2. The!WADLS!technology!The! WADLS! is! administered! by! the! Data! Linkage! Branch! within! the! WA!Department! of! Health.63! It! uses! best! practice! computerised! probabilistic!matching! to! create! a! dynamic! master! linkage! key! between! more! than! 40!populationHbased! administrative! and! research! health! data! collections! in!WA).!The! linkages!mean! that! the! total! historical! population! (3.7!million! over!more!than!30!years)!can!be!researched!for!all!major!diseases,!disease!risk!factors!and!health!service!utilisation!and!outcomes.!!The!system!is!built!on!a!foundation!of!nine! core! elements:! ! birth,! death! and! marriage! registrations,! hospital!separations,! midwives'! and! cancer! notifications,! mental! health! service!encounters,! emergency! presentations! and! electoral! roll! registrations.! ! A! key!aspect!of!the!systems!design!is!the!separation!of!linkageHrelated!processes!from!those!operating!on!sensitive!clinical!and!service!data.!!Thus,!the!WADLS!is!not!a!database! repository! but! instead! consists! of! pointers! or! indices! to! source! data!elements!known!as!the!Master!Linkage!Key.64!The!data!to!which!it!points!is!still!maintained!under!the!jurisdiction!of!individual!data!custodians!and!only!upon!a!formal!data!request!is!the!data!retrieved!from!the!relevant!custodian.!The!WADLS!is!both!retrospective!and!prospective,!being!updated!routinely!with!the!additional!capability!for!creating!links!within!and!between!new!external!and!internal! data! resources.! Linkages! are! identified! using! probabilistic! matching!techniques,65! based! on! unit! medical! record! number! (unique! only! to! public!hospitals),! full! name! and! address,! phonetic! compression! algorithms! and!
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demographic!information!such!as!date!of!birth,!gender!and!postcode.!Linkage!to!health!related!events!for!individual!subjects!are!ordered!chronologically!to!form!a! 'chain! of! links'.! These! links! are! readily! broken! and! reHjoined! to! insert! new!links!or!to!delete!incorrect!ones!allowing!huge!flexibility!for!expansion.!Clerical!checking! is!undertaken! for!possible!matches! in!a! 'grey!zone'!between!definite!matches!and!nonHmatches.!The!accuracy!of!linkages!has!been!well!validated!with!the!average!proportion!of!invalid! links! (false! positives)! and!missed! links! (false! negatives)! estimated! as!0.11%.66! An! audit! in! 2001! and! 2002,! involving! sampling! and! detailed! clerical!scrutiny! of! linked! chains! that! may! contain! up! to! 2000! links,! resulted! in! an!estimate!of!<!0.3%!of!chains!containing!one!or!more!incorrect!links.67!
Geocoding!A!unique! feature! of! the!WADLS! is! the! ability! to! assign! latitude,! longitude! and!census! areas! to! data! using! locally! developed! address! parsing! software! and!spatially!referenced!data!sets!provided!from!the!WA!Land!Information!System.!These! geocoded! references! can! be! used! to! associate! health! events! with!environmental! attributes! and! to! provide! unprecedented! accuracy! in! the!assignment! of! social! disadvantage! and! remoteness! indices.68! This! enables! the!geographic!distribution!of!patients! to!be!defined!at! a! given!point! in! time!and,!combined!with! linked!health!data,! it! supports! a! crossHsectional! view!of! socioHdemographic! determinants! of! health! service! utilisation! and! outcomes,! and! a!longitudinal!view!of!residential!history!in!patients!with!chronic!conditions.!
Genealogical!linkage!(Family!Connections)!!The!Family!Connections!Register!aims!to!contain!family!links!between!children!and!legally!registered!parents.69!The!aim!is!to!identify!family!links!of!all!nuclear!families! (mothers,! fathers!and!children)! that! include!at! least!one!child!who!a)!was!born! in!WA! from!1950!onwards! and!b)! is! or!was! registered!on! the!State!Electoral! Roll! and! resident! in! WA! for! at! least! one! year! from! 1980! onwards.!Family!links,!used!in!combination!with!linked!health!records,!allows!populationHbased!genetic!and!human!genome!research!with!emphasis!on!characterisation!of!geneHgene!and!geneHenvironment!interactions.!
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1.5.3. Data!access!and!privacy!In!response!to!rising!concerns!for!patient!privacy!there!has!been!an!increase!in!the!legislative!and!regulatory!requirements!for!access!to!linked!health!data!for!medical!and!health!research.!This!has!resulted!in!a!broader!system!of!protocols!being! developed! progressively! within! the!WADLS! to! address! the! concerns! of!consumers!and!data!custodians!with!respect!to!privacy!and!data!release.64!Access!to!the!WADLS!is!granted!only!to!researchers!who!have!the!appropriate!Human! Research! Ethics! Committee! approvals! to! conduct! their! research! and!who!have!been!given!permission!by!the!relevant!data!custodians.!This!ensures!the! data! requested! is! appropriate! for! the! proposed! research.! Strict! protocols!
Core!data!system!Birth!registrations!Death!registrations!Marriage!registrations!!Hospital!serparations!Mental!health!clients!Cancer!notitications!Midwives'!notitications!Emergency!presentations!!Electoral!roll!
WA!government!Road!safety!Child!pretection!Education!Corrective!services!Disability!services!
WA!health!Pathology!Notitiable!diseases!Pharmacy!Drugs!&!alcohol!Trauma!
Geocoding! Diseases!Registers!Surveys!Tissue!banks!
Children!Birth!defects!Cerebral!palsy!Child!surveillance!Birth!cohorts!Twins!registry!
Families!Births!Deaths!Marriages!
Figure!1N3!The!Western!Australian!data!linkage!system!
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designed! to! protect! confidentiality! and! security! of! the! data! must! then! be!followed,!and!researchers!are!strongly!encouraged!to!use!unidentifiable!data.63!Rather!than!increasing!the!risk!to!privacy!in!the!community!it!has!been!shown!that! the! WADLS! has! significantly! reduced! the! exposure! of! private! and!confidential!person!health!information!in!WA.!This!is!because!access!to!personal!details! in! linked! data! is! confined! to! a! small! linkage! group! that! adhere! to!rigorous,!strict!privacy!and!confidentiality!requirements.!As!linked!data!sources!have! come! online! the! requirement! for! named! data! in! studies! has! declined!dramatically!from!90%!in!1990!to!36%!in!2003.41!Information!systems!have!been!developed!using!data!linkage!methodologies!in!numerous! sites! across! the! globe! to! provide! infrastructure! that! supports!research.57,70!Systems!that!are!historically!well!known!internationally! for!their!record! linkage! research! include! but! are! not! limited! to:! the! Oxford! Record!Linkage! Study,! the! Scottish! Record! Linkage! System,! Rochester! Epidemiology!Project,!Manitoba!Population!Health! Information!System,! the!British!Columbia!Linked!Health!Database,!and!the!WADLS.57,66!! !
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1.6. Use!of!large!administrative!databases!in!
ophthalmic!research!Large!administrative!databases!and!their!linkage!have!been!used!in!ophthalmic!research!for!decades!across!a!broad!range!of!studies!including!studies!of!disease!surveillance,! disease! aetiology,! health! service! utilisation! and! health! outcomes!(including!postHmarketing!surveillance):!
1.6.1. Disease!surveillance!Data! on! prevalent! or! incident! events! is! required! to! understand! patterns! of!disease!in!the!community!and!may!be!readily!available!in!health!administrative!databases! (with! the! caveats! already! outlined).! Large! datasets! are! particularly!useful!in!the!study!of!rare!diseases!due!to!the!sheer!size!of!the!population!they!cover;! and! since! many! span! decades,! they! are! also! ideal! for! studying! the!longitudinal! patterns! of! disease.! For! example,! the! incidence! of! primary! angle!closure!glaucoma!(PACG)!was!first!described!by!Erie!et!al!in!1997!using!hospital!administrative! data! from! the! Rochester! Epidemiology! Project! (REP);! they!reported!an!annual!incidence!of!8.3!per!100,000!(95%!CI,!5.6H11.0)!in!the!over!40! year! olds! in!Olmstead!County,!Minnesota! for! 1980H1992.71!A! similar! study!using! hospital! admission! data! in! Singapore! by!Wong! et! al! in! 2000! found! the!annual!incidence!of!PACG!in!an!Asian!population!was!higher!at!11.1!per!100,000!(95%!CI,!10.4H11.8).72!Hu!et!al!used!wholeHpopulation!health! insurance!claims!data! from! 503,687! people! in! Taiwan! to! describe! the! relationship! between!cataract! surgery! and! admission! for! acute! angle! closure! over! the! eightHyear!period!1997H2004.!They!found!a!significant!correlation!between!the!decline! in!acute!angle!closure!and!the!rise!in!cataract!surgery!(Spearman!rank!r!=!H0.407,!P!<! 0.001).73! Numerous! other! studies! have! examined! the! incidence! and/or!prevalence! of! a! range! of! eye! conditions! including! glaucoma,74H78! diabetic!retinopathy,78,79! ageHrelated! macular! degeneration! (ARMD),79,80! coHmorbidity!with!ARMD,81,82! retinal!detachment,83H85! sixth!nerve!palsy,86! strabismus,87!dryHeye! disease,88! retinopathy! of! prematurity,89! ocular! trauma,90H92! retinal! vein!occlusion,93! endophthalmitis,92,94H98! and! spinal! surgery! related! posterior!ischemic!optic!neuropathy.99!
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It!should!be!noted!that!most!standHalone!datasets!capture!only!a!subset!of! the!population!and!are! limited! in! their! ability! to!derive! true!population! incidence!and!prevalence!measures.!Data!linkage!can!improve!this!by!facilitating!analysis!across!multiple!data!sources!in!a!single!population!to!allow!greater!accuracy!in!the! identification!of! incident! events.! For! example,! linking! cancer! registry!data!with!data!from!a!local!cancer!referral!centre!in!Germany!increased!the!incidence!of!uveal!melanoma!by!nearly!four!times!compared!to!using!cancer!registry!data!alone!(from!2.3!to!8.6!cases!per!million!PY).100!
1.6.2. Disease!aetiology!Although!it! is!not!possible!to!establish!causality! in!retrospective!observational!studies,! administrative! database! studies! can! assist! in! identifying! potential!factors! in! the!aetiology!of!ocular!disease! to!direct! further! study! in!a! time!and!cost! efficient!manner.! This! is! particularly! useful! in! the! study! of! rare! diseases!when! large! numbers! are! required! in! order! to! establish! any! meaningful!associations.! Vajdic! et! al! used! data! from! the! Australian! nationwide! kidney!dialysis! and! transplant! registry,! linked!with! the! cancer! registry,! to! generate! a!cohort!large!enough!to!study!the!association!between!immunosuppression!and!the! rare! disease! ocular! squamous! cell! carcinoma! (SCC).! The! study! included!10,180!renal!transplant!patients!over!86,898!personHyears!followHup!and!found!a! 20Hfold! increase! in! the! incidence! rate! of! ocular! SCC! in! immunosuppressed!patients! (IRR! 19.5,! 95%! CI! 6.3H45.5).101! They! were! the! first! to! report! on! the!association!outside!of!the!known!link!with!human!immunodeficiency!virus!and!added! further! weight! to! the! hypothesis! that! immunodeficiency! has! a! role! in!ocular!SCC.!In!another!more!recent!study,!Bonamy!et!al!reported!findings!from!their!populationHbased! study!using! linked!population! registries! examining! the!risk!of!late!retinal!detachment!in!preterm!infants!born!in!Sweden.102!This!large!study! of! over! 3! million! births! spanned! 35! years! since! 1973! with! a! median!followHup!of!17.4!years.!Retinal!detachments!after!preterm!birth!are!rare!with!just! 0.029! cases! per! 1000! personHyears.! Significant! risk! factors! were! birth!before! 32! weeks! and! male! gender.! The! risk! (HR)! of! retinal! detachment! for!extremely!preterm!infants!(<28!weeks)!and!preterm!infants!(28H31!weeks)!was!19.2! (95%!CI! 10.3H35.8)! and! 4.32! (95%!CI! 2.70H6.90)! respectively! for! infants!
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born!1973H1986;!which!decreased!to!8.95!(95%!CI!3.98H20.1)!and!2.80!(95%!CI!1.38H5.69)! respectively! for! infants! born! 1987H2008! after! the! introduction! of!routine!retinopathy!of!prematurity!screening.!Males!were!over!twice!as!likely!to!have!a!late!retinal!detachment!(HR!2.56,!95%!CI!2.08H2.78).!Other! examples! include!a! study!on! the! association!between! reduced! sunshine!exposure! and! increased! angle! closure! glaucoma;103! genetics! and! open! angle!glaucoma;104! diabetes! and! an! increased! risk! of! glaucoma,105! sixth! nerve!palsy86,106! and! acute! conjunctivitis;107! risk! factors! for! central! retinal! vein!occlusion;108! and! the! lack! of! association! between! vitamin! D! deficiency! and!macular!degeneration.109!
1.6.3. Health!service!utilisation!Understanding!patterns!and! trends! in!eye! service!use! is! essential! to! adequate!planning! by! governments! and! agencies! to! anticipate! service! needs! and! costs.!This! is! particularly! important! in! understanding! variations! in! the! patterns! of!care! between! clinical! subHpopulations! (e.g.! sociodemographic! and! geographic!groups)!to!identify!areas!of!service!deficiency!or!inefficiency.!!Large! health! administrative! databases! are! ideal! for! studies! of! health! service!utilisation!since!they!are!derived!from!the!delivery!of!these!services.!This!means!every! clinical! service! encounter! is! ‘captured’! to! provide! an! entireHpopulation!cohort!on!which!to!conduct!research!without!the!need!to!extrapolate! findings.!The!richness!of!information!on!service!provision!contained!in!these!databases!is!reflected! in! the! volume! of! ophthalmic! research! published! in! this! area.! The!majority!of! studies!have!examined! trends!and!patterns!of!ophthalmic!services!use!over!time,!and!across!socioHdemographic!and!geographic!groups.!Particular!attention! was! paid! to! trends! in! eye! surgery! and! use! of! ophthalmic! drugs!(particularly!for!glaucoma).!
Patterns!of!care!Establishing!trends!in!ophthalmic!service!use!over!time!is!easily!achieved!using!administrative!databases!since!most!span!decades.!The!first!data!linkage!study!to!examine!trends!in!ophthalmic!services!was!by!the!ORLS,!in!the!Oxford!region!of!the!UK!in!1991.110!The!study!found!the!use!of!ophthalmic!services!increased!16.3%! over! an! 11Hyear! period! (1975H1985),! while! the! length! of! stay! per!
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admission!to!hospital!decreased.!Subsequently!Ellwein!et!al!analyzed!data!from!the! US!Medicare! database! of! over! 65! year! olds! to! look! at! trends! in! eye! care!utilisation!and!the!type!of!providers!providing!this!service.111,112!They! found!a!6.7%!rise!(41.4%!to!48.1%)!in!the!proportion!of!people!accessing!eye!services!between! 1991! and! 1998;! and! that! ophthalmologists! provided! the!majority! of!eye!care!billed!under!Medicare!(71%).!Identifying! areas! of! service! deficiency! or! overHservicing! is! important! in! the!equitable! distribution! of! limited! health! resources! particularly! to! vulnerable!populations.!Such!patterns!of!service!delivery!are!readily!identified!using!health!administrative!databases!that!cover!large!population!cohorts!across!geographic!and! demographic! boundaries.! This! allows! patterns! of! service! delivery! across!socioeconomic,!race,!gender,!and!geographic!groups!to!be!examined.!In!WA!we!used! linked! wholeHpopulation! hospital! administrative! data! to! describe! the!growing! inequity! in! the! cataract! surgery! rate! for! rural/remote! (metropolitan!patients! had! 24%! more! surgery)! and! lower! socioeconomic! groups! (the!disadvantaged!had!9%!less!surgery),!despite!an!overall!improvement!in!access!to! cataract! surgery.113H115! Other! studies! have! examined! similar! socioeconomic!and! geographic! variations! in! cataract! surgery! utilisation! in! the! UK! using! the!ORLS116!and!the!US!using!Medicare!data.117H119!!Racial!variation!in!the!treatment!of!glaucoma!was!reported!in!several!US!studies!using!Medicare/Medicaid!data.!Most!found!the!rates!of!eye!service!use!in!blacks!were! as! much! as! 50%! lower! than! whites! despite! an! increased! prevalence! of!glaucoma!in!the!black!population.120H124!!Other! examples! of! studies! of! patterns! of! eye! service! utilisation! in! specific!populations!include!those!in!women!,125!children,126!and!diabetics.127,128!!
Trends!in!surgery!Surgical! trends! are! particularly! suited! to! study! using! large! administrative!databases! since! such! encounters! are! almost! universally! recorded.! Cataract!surgery! rates! have! increased! dramatically! in! studies! from! most! Western!countries! since! the! adoption! of! phacoemulsification,! with! most! reporting! a!doubling! in! rates! every! 10! years119,129H134! that! are! projected! to! increase!further.135! Conversely! the! introduction! of! prostaglandin! analogues! and!
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increased! uptake! of! laser! trabeculoplasty136! has! seen! the! rate! of! glaucoma!filtering! surgery! decline! significantly! by! between! 29! and! 75%!over! a! 10Hyear!period! since! the! midH1990s.137H141! Retinal! procedures! have! also! changed!significantly! in! the! US! medicare! population! between! 1997! and! 2007,!particularly!an!explosion!in!intravitreal!injections!(<5000!procedures!in!1997!to!812,413!procedures!in!2007);!72%!increase!in!vitrectomy!and!69%!decrease!in!scleral! buckle! only! surgery;! and! an! 86%! increase! in! pan! retinal!photocoagulation!procedures.142!
Pharmacoepidemiology!Patient! compliance! with! prescribed! treatment! in! chronic! diseases! such! as!glaucoma! is! notoriously! poor.143! Pharmaceutical! claims! and! health! insurance!databases! have! been! used! extensively! in! the! US! to! study! general! trends! and!patterns!in!eye!drop!utilisation!and!the!factors!affecting!their!use.144H148!Claims!data!has!the!advantage!over!other!research!methods!since!they!avoid!recall!bias,!which!can!be!problematic!in!studies!that!rely!on!selfHreporting.!Patient!adherence!and!persistence!with!their!glaucoma!medication!provides!an!insight! into! compliance! and! also! the! effectiveness! and! tolerability! associated!with! a! particular! drug! or! class! of! drug.! Reardon! et! al! used! health! and!pharmaceutical!claims!data!from!the!Protocare!Sciences!managed!care!database!to!study!over!28,000!patients!aged!over!20!years!who!were!dispensed! topical!ocular! hypotensives.149H152! They! found! that! discontinuation! rates! were! high;!only!33%!of!those!prescribed!latanoprost!were!still!using!it!after!12!months!and!continued! use! in! other! drug! classes!were! even! lower! (19%).! They! also! found!latanoprost! had! less! rates! of! discontinuation! compared! to! all! other! glaucoma!medications,!including!the!other!prostaglandin!analogues.!Similar!findings!were!reported!in!later!studies.!Nordstom!et!al!found!half!of!patients!had!discontinued!treatment! by! 6! months! and! that! those! taking! prostaglandins! were! 60%! less!likely! to! discontinue! compared! to! betaHblockers! and! carbonic! anhydrase!inhibitors.153!Other!studies!using!claims!data!further!support!the!findings!from!these! studies,154H161! including! one! from! Australia! using! national! populationHbased! pharmaceutical! claims! for! 357,099! patients! that! confirmed! superior!persistency!for!prostaglandins.162!!
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Pharmacoepidemiology! studies! using! administrative! data! have! their! own!unique!limitations.25!Caveats!that!should!be!considered!when!estimating!patient!compliance!include:!inaccuracies!when!a!patient!is!given!sample!medications!or!their!medication!is!obtained!from!outside!their!insurance!plan;!being!unable!to!ascertain!whether!cessation!of!a!prescription!is!due!to!a!management!decision!by! the! patient’s! physician! or! a! nonHcompliant! patient;! and! that! simply!dispensing! a! prescription! does! not! mean! the! patient! is! actually! using! the!medication! as! prescribed.! We! also! know! from! validation! studies! using! chart!review! that! for! glaucoma,! claims! data! alone! tends! to! overestimate! disease!severity! and! is! not! able! to! correctly! identify! which! patients! are! truly! new! to!treatment.25,48,49!The!Glaucoma!Adherence!and!Persistency!Study!attempted!to!address! some!of! these! limitations!by!using! a! combination!of! health! insurance!claims! data! and! pharmacy! claims! data,! validated! with! chart! review! and!structured!interview!of!patients!and!physicians.49!Even!taking!these!factors!into!account,!adherence!and!persistency!rates!were!still!poor.!They!found!that!only!10%!of!patients!were!continuously!persistent!with!prescribed!treatment!over!a!1!year!period!and!at!1!year!only!59%!were!adherent!to!any!ocular!hypotensive!treatment.!
1.6.4. Health!outcomes!In! contrast! to! traditional! clinical! trials,! health! outcomes! research! examines!clinical! practice! as! it! is! actually! performed! in! the! community! to! answer!questions! about! ‘real! world’! effectiveness.! Health! administration! databases,!being! born! out! of! actual! practice,! are! therefore! particularly! well! placed! for!outcomes! research.! They! also! do! not! suffer! from! some! of! the! limitations!inherent! in! other! traditional! cohort,! caseHcontrol! and! randomized! controlled!trials.!Studies!of!health!outcomes!in!ophthalmic!research!have!generally!focused!on! surgical! safety,!monitoring! adherence! to! best! practice,! and!postHmarketing!surveillance.!
Surgical!safety!!Outside! of! the! clinical! trials,! monitoring! surgical! safety! typically! relies! on!reporting!adverse!events!through!case!series!from!single!or!multiple!centers!or!clinics.!Events!identified!in!this!way!may!be!selective!or!incomplete.!They!do!not!
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necessarily!reflect!the!practice!occurring!in!the!wider!community!where!there!is!likely! significant! variation! in! surgical! case! mix! and! complexity,! surgeon!experience! and! quality! of! available! equipment.! While! clinical! registries! may!address! most! of! these! issues,! administrative! datasets! are! more! likely! to! be!complete!and!less!easily!‘gamed’.!!The!excellent!safety!profile!of!cataract!surgery!requires!very!large!sample!sizes!over! prolonged! periods! of! time! to! identify! and! adequately! study! trends! and!risks! of! adverse! events.! Using! Medicare! data,! Stein! et! al! found! just! 0.5%! of!220,000! cataract! surgeries! resulted! in! a! serious! adverse! event!over! a!13Hyear!period! (1994H2006);! and! because! of! the! large! sample! size! they! were! able! to!report! on! a! significant! declining! trend.163! Bell! et! al! found! surgeon! operative!volume!was! important! in! the! risk! of! adverse! outcomes! by! pooling! data! from!provincial! health! insurance! claims! data! for! over! 230! surgeons! and! 284,797!cataract! surgeries! in! Ontario;! surgeons! performing! over! 1000! cataract!procedures! per! year! had! 0.1%! adverse! events! compared! to! 0.8%! in! those!performing!50H250!procedures!(OR!0.14,!95%CI!0.09H0.23).164!!A! large! sample! size! is! particularly! relevant! to! the! study! of! rarer! events! e.g.!endophthalmitis.! Studies! using! health! insurance! claims! and! hospital!administrative!data!showed!the!incidence!of!endophthalmitis!ranged!between!1!and!2!per!1,000!surgeries.96,98,165H170!Sample!sizes!in!excess!of!100,000!in!these!studies!allowed! identification!of!potential! risk! factors! including! increased!risk!in!males,!the!elderly,!complicated!surgery,! lower!surgeon!volume, and!surgery!in!private!facilities.96,98,165H170!Javitt! et! al! used! US! medicare! claims! data! to! be! the! first! to! demonstrate! a!statistically!significant!increased!risk!of!retinal!detachment!after!intracapsular,!extracapsular! and! phacoemulsification! cataract! surgery.167,171! They! found!greatest! risk! of! retinal! detachment! with! intracapsular! surgery! (1.55%)! and!were!the!first!to!describe!an!increased!risk!with!phacoemulsification!compared!to! extracapsular! surgery! (1.17%! vs! 0.9%).! They! also! found! statistically!significant! increased!risk! in!males!(RR!1.66),!younger!patients!(RR!3.70!65H69!vs! 80H89! yrs),! whites! (RR! 3.85)! and! surgery! where! anterior! vitrectomy! was!performed!(RR!4.5).!It!was!only!through!a!large!sample!size!that!they!were!able!
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to! confirm! these! findings! (which! had! previously! been! suspected! but! not!confirmed!due!to!limited!sample!sizes!of!previous!studies).!Other!large!database!studies!have!since!confirmed!these!findings.84,172H176!!The! combination! of! relatively! uncommon! procedures! and! rare! complications!further!highlights!the!need!for!wholeHpopulation!methodology!and!large!sample!sizes.!Haargaard!et!al!demonstrated!this!in!their!report!of!the!longHterm!risk!of!retinal! detachment! after! paediatric! cataract! surgery! in! Denmark! 1977! –!2005.177! Despite! 28! years! of! data! and! 1043! eyes! (656! children)! having!paediatric! cataract! surgery,! only! 25! eyes! (23! children)! developed! a! retinal!detachment.! They! demonstrated! that! 3%! of! children! with! isolated! paediatric!cataract!will!develop!a! retinal!detachment!within!20yrs!of! surgery.!Significant!risk! factors!were!mental! retardation! (23%)! and! cataract! plus! other! ocular! or!systemic! pathology! (16%).! Importantly! primary! posterior! capsulotomy! and!anterior!vitrectomy!did!not!increase!the!risk!of!retinal!detachment.!One! caveat!of!purely!database! studies! is! their! limited!ability! to! study!a!broad!range!of!risk!factors!as!they!may!not!be!coded,!or!the!accuracy!of!coding!for!that!risk!is!inconsistent!e.g.!smoking.!CaseHcontrol!methodologies!using!chart!review!for!the!cases!and!a!random!sample!of!the!unHaffected!population!may!overcome!this! problem.! For! example! the! Endophthalmitis! Population! Study! of!Western!Australia! used! populationHwide! hospital! administrative! data! for! an! entire!cataract! surgery! cohort! of! 117,083! over! a! 20Hyear! period! and! 205! cases! of!endophthalmitis.!Every!case!of!endophthalmitis!was!validated!with!chart!review!and! a! nested! caseHcontrol! study! was! used! to! identify! important! surgical! and!nonHsurgical! risk! factors,! including! previously! unreported! associations! with!winter!procedures!(OR!1. 48!95%!CI!1.00–2.18)!and!concurrent!eyelid!surgery!(OR!23.50,!95%!CI!8.50–64.98).169,170!!A! similar! nested! caseHcontrol! study! examined! risk! factors! for! retinal!detachment!after!cataract!surgery!in!the!Medicare!population!was!conducted!by!Tielsch! et! al178! after! their! previous! claims! data! study! suggested! a! fourHfold!increased!risk!after!Nd:YAG!capsulotomy.179!They!confirmed! this! risk! (OR!3.8,!95%! CI! 2.4H5.9)! along! with! other! risk! factors! for! retinal! detachment! that!
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included:!axial!length,!a!history!of!lattice!degeneration!or!retinal!detachment!or!ocular!trauma,!and!refractive!error.178!The! other! cataract! surgery! outcomes! studied! using! linked! data! include! the!impact!of!cataract!surgery!on!the!increased!risk!of!corneal!oedema;180!reduced!vehicle! crash! risk! through! linkage! with! road! accident! databases;181,182!surprisingly! increased! risk! of! falls,! through! linkage! with! emergency! room!databases;183,184! reduced! admission! for! depression,! through! linkage! to!mental!health!services;185!and!reduced!risk!of!death,!by!linking!to!death!registers.186,187!Studies!reporting!outcomes!for!other!surgical!procedures!are!fewer!in!number!and!include!adverse!events!after!glaucomaHrelated!procedures188H190,!pars!plana!vitrectomy,191!and!penetrating!keratoplasty.192!
Monitoring!adherence!to!best!practice!Administrative! datasets! are! being! increasingly! used! to! audit! adherence! by!patients! and! their! physicians! to! ‘best! practice’.! They! are! felt! to! offer! a! more!accurate!picture!of!real!world!practice!since!they!are!not!affected!by!recall!bias!present! in! traditional! surveys! or! clinical! registries.! Screening! for! diabetic!retinopathy! is!particularly! suited! to! such!an!approach!due! to!wellHestablished!clinical!guidelines!and! the!ability! to! readily! identify! service!encounters!within!most!administrative!datasets.!Reports!from!health!claims!databases!suggest!eye!examination!rates!for!diabetics!are!universally!poor.!Wang!et!al!found!only!53%!of! 175,015!diabetic!Medicare! beneficiaries! had! at! least! 1! eye! care! visit! in! a! 1!year!period,!and!only!67%!within!2!years.193!Similar!proportions!were!reported!using!claims!data!elsewhere!in!the!US.74,127,194H197!While!in!Nova!Scotia,!Canada!longitudinal! claims!data!over!10!years! showed!only!14.4%!of!diabetics!had!at!least! one! eye! examination! consistently! each! year.198! Factors! consistently!associated! with! less! attendance! were! younger! age,! male! gender,! ethnic!minorities,! lower! education! level,! and! lower! socioeconomic! status.193,197,199!Direct!mail! reminders! to! improve! low! attendance!was! studied! but! they!were!found!to!have!only!a!short!lived,!modest!effect!at!best..200,201!!The! practice! patterns! of! physicians! treating! glaucoma! has! received! some!attention.! Friedman! et! al! found! using! health! insurance! data! that! 17%! of!glaucoma! suspects! and! 16%! diagnosed! with! glaucoma! did! not! have! a!
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documented!followHup.!They!also!found!only!half!of!these!patients!had!at! least!one! VF! test!within! the! followHup! period! and! just! 13%!had! optic! disc! imaging!(median! followHup! 440! days).202 Coleman! et! al! found! less! than! half! of! US!medicare!patients!undergoing!glaucoma!surgery!had!gonioscopy!performed! in!the! preceding! 4H5! years,203 and just! 70%! had! a! field! test! in! the! preceding! 1!year.204!More recently Stein et al demonstrated a change in practice for glaucoma 
monitoring with use of visual field testing falling by 44% while the use of other 
ocular imaging modalities increased by 147% from 2001 to 2009.205!!
PostCmarketing!surveillance!Monitoring! the! safety! of! new! drugs! or! medical! devices! following! their!widespread!release!into!the!community!is!an!important!part!of!health!outcomes!research.!Approvals!for!their!use!are!based!on!stringent!testing!in!the!setting!of!highly! controlled! clinical! trials;! but! these! trials! are! generally! limited! by! small!samples!sizes!of!select!populations!that!perhaps!bear! little!resemblance!to!the!wider! clinical! setting! where! the! products! are! used.! So! postHmarketing!surveillance! becomes! essential! to! assess! the! safety! of! new! medical! products!once!released.!Information!regarding!medication!safety!is!typically!managed!through!national!drug! surveillance! bodies! e.g.! the! US! Food! and! Drug! Administration! (FDA)!agency.!Reporting!adverse!events!to!these!bodies!commonly!relies!on!voluntary!submission,! which! may! be! from! multiple! sources! i.e.! directly! from! the!manufacturing!company,!the!public,!or!independent!organizations.!The!problem!with!this!approach!is! it!cannot!provide!useful!population!incidence!rates!since!the!population!at!risk!is!not!quantified.!There!is!also!significant!underHreporting!and!variability!in!the!quality!of!reporting.206!Administrative!databases!are!ideal!to!assist!in!postHmarketing!surveillance!due!to! their! large! population! cohorts! allowing! rare! adverse! events! to! be! studied,!ready! access! to! current! data,! and! relative! cost! effectiveness! compared! to!traditional!trials.!The!US!FDA!has!recognized!their!value!in!several!reports,!and!they!recommended!a!greater!use!of!populationHbased!datasets!to!enhance!postHmarketing!surveillance!systems.207!!
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There!are!a!limited!number!of!studies!making!use!of!administrative!and!linked!datasets!in!postHmarketing!surveillance!of!ophthalmic!drugs!and!devices!despite!them! being! ideal! for! this.! French! et! al! have! published! several! studies! using!clinical! and! pharmacy! data! from! the! US! Veterans! Health! Administration!database! that! explored! the! association! between! drugs! and! eye! disease.! They!found!a!temporal!relationship!between!commencement!of!amantadine!and!the!onset! of! corneal! edema! in! a! small! proportion! of! patients! (0.12%),! which!supported!earlier!case!reports!of!the!association.208!They!reported!that!479,489!men! using! phosphodiesterase! inhibitors! had! a! small,! but! not! significant,!increased! risk!of! anterior! ischemic!optic!neuropathy;209,210! and!no! association!with!central!serous!retinopathy.211!They!also!found!no!association!between!the!bisphosphonates!and!uveitis/scleritis!(OR!1.23,!95%!CI!0.85H1.79).212!In!another!study! they! demonstrated! an! interesting! reduced! risk! of! death! with! any!glaucoma!medication!(OR!0.93;!95%!CI!0.90H0.95),213!which!confirmed!findings!from!earlier!large!database!studies.214,215!The! safety! of! the! antiHVEGF! treatments! for! neovascular! ARMD! was! recently!studied.! French! et! al! found! no! difference! in! the! risk! of! mortality! for!bevacizumab!or! ranibizumab! (OR!0.89,!95%CI!0.74H1.06)! in! a! cohort!of!3,210!patients!given!intravitreal!antiHVEGF!and!117,364!unexposed!ARMD!patients.216!This!was! supported! by! a! Canadian! study! that! used! insurance! claims! data! for!91,378!patients!in!Ontario.217!!Other!examples! include! finding!no!risk!of!congestive!heart! failure!with!topical!glaucoma! medications;218! inconsistent! results! about! the! reduction! in! Nd:YAG!laser! capsulotomy! rates! with! the! introduction! of! square! edge! intraHocular!lenses,219!an! increased!risk!of!retinal!detachment!with!oral! fluoroquinolnes,220!and!the!apparent!protective!effect!of!statins!in!open!angle!glaucoma.221!!
1.6.5. Health!economics!Determining! the! cost! and! demand! for! ophthalmic! services! is! important! for!health!care!planning,!particularly!in!the!climate!of!dwindling!health!budgets!and!rapidly!increasing!health!care!costs.!Administrative!data!are!particularly!useful!for! estimating! these! costs! since! they! are! recorded! at! the! point! of! service! and!usually!contain!billing!information!to!calculate!actual!costs.!!
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Examples! are! numerous,! particularly! studies! using! Medicare! claims! data.!Findings!have!included:!cataract!surgery!cost!USD$2500!in!1991;222!there!was!a!10H25%!decrease!in!the!cost!of!eye!care!to!Medicare!during!the!1990s!despite!an! increase! in! the! proportion! of! beneficiaries! receiving! eye! care! (due! to! a!reduction!of!cataract!surgery!payments);111,223!physician!reimbursement!as!fee!for!service!is!associated!with!approximately!twice!the!rate!and!cost!of!cataract!surgery!compared!to!a!cost!capitation!model;224!fee!cuts!for!ophthalmic!surgery!increased!volume!but!had!no!effect!on!overall!cost;225!increasing!surgeon!supply!increased!access! to! surgeons!but!did!not! increase! the!demand! for! services!by!individual! patients;! 226! vision! loss! is! associated! with! and! extra! USD$2,193! to!$4,443! in! health! care! costs! or! USD$2.14! billion! for! the! entire! Medicare!population! in! 2003;227! introducing! prostaglandins! for! glaucoma! increased!adherence!without! significantly! increasing! costs;155! and! there! is! an! increased!cost! associated! with! postHoperative! complications! like! endophthalmitis!(US$16,142! higher! claims! per! case)228! and! cystoid! macular! edema! (40H50%!higher! claims! and! payments).229! Studies! have! also! examined! the! cost! of!providing! specific! ophthalmic!medications! (e.g.! eye! drops),230,231!while! others!have! quantified! the! health! expenditure! associated! with! diabetic!retinopathy232,233! and! diabetic! macular! oedema;234! ARMD;235,236! and! primary!open!angle!glaucoma!(USD!$242!to!$1,570).137,237,238!
1.7. Conclusion!Large!administrative!and!linked!databases!are!readily!available!and!rich!sources!of! information! for! ophthalmic! research.! Much! use! has! already! been! made! of!them!with!a!trend!towards!increasing!output!as!researchers!realise!their!value!in! addressing! a! wide! range! of! research! questions,! particularly! relating! to!ophthalmic!service!utilisation!and!outcomes.!The!WALDS!is!a!well!established,!validated!and!internationally!regarded!rich!resource!that!is!ideal!for!populationHbased!research!in!ophthalmology.!While!administrative!datasets!are!not!without!their! limitations,! many! of! these! can! be! overcome!with! the! appropriate! study!design,! analysis! and! careful! interpretation.! Their! benefits! in! providing! a! ‘real!world’! view! of! ophthalmic! disease,! services! and! outcomes! in! a! timely! fashion!that!conserves!the!health!dollar!should!not!underHestimated.! !
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2.1. Background!The! WA! population! is! isolated! and! vast! H! only! 10%! of! the! total! Australian!population!reside!in!the!state!and!most!(>70%)!are!concentrated!in!its’!capital!city,!Perth.!The!rest!of!the!population!are!scattered!over!an!area!over!ten!times!the!size!of!the!United!Kingdom.!This!population!is!separated!from!the!rest!of!the!Australian!population!by!an!expanse!of!desert! to!east!and! the! Indian!ocean! to!the! west! (Figure! 2H1).61! While! one! may! surmise! this! could! create! a! ‘captive’!population!ideal!for!longitudinal,!wholeHpopulation!research;!anecdotally!there!is! concern! that! this! isolation! may! lead! to! systematic! socioHdemographic! and!socioeconomic! differences.! Thus! limiting! the! generalizability! of! any! research!findings!produced!from!populationHbased!research!in!WA.!With! this! in! mind,! the! following! paper! explores! how! the! WA! population!compares! to! other! Australian! states! and! territories! in! key! socioHdemographic!and! economic! indicators.! Demonstrating! that! the!WA! population! is! similar! to!other!Australian!jurisdictions!adds!weight!to!the!argument!that!findings!arising!from! populationHbased! research! in! WA! are! externally! valid! to! the! rest! of!Australia.!! !
Figure!2N1!!N!Western!Australia.!(Google!Earth)!
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Abstract
Objective. To evaluate the extent to which Western Australian (WA) represents the broader Australian population in
terms of key socio-demographic and health economic indicators.
Methods. We compared key demographic, social and health economic indicators across all Australian States and
Territories from Australian government publications in the census years 1991–2006. Jurisdictional averages (JAs) were
calculated as the mean (!s.d.) or median (!range). Observed jurisdiction indicators were compared with the JA and
ranked according its representativeness of the JA.
Results. WA was among the three closest jurisdictions to the national JA for all socio-demographic and health
economic indicators examined, with the exception of uptake of private health insurance (ranked 6th) and per-capita
health expenditure (ranked 5th). The Northern Territory and Australian Capital Territory were least representative for the
majority of indicators. Excluding the proportions of people living in rural or remote areas (0–100%) and of indigenous
origin (0.4–28.8%), variations in the indicators across the jurisdictions were relatively small.
Conclusions. Population differences between Australia’s States were small, whereas Australia’s Territories were
least representative of the JA. WA was the most representative population of Australia’s eight jurisdictions and continues
to be in a strong position to contribute to knowledge of the Australian health system that is applicable Australia-wide.
What is known about the topic? The Western Australian Data Linkage system (WADLS) is a highly successful and
productive research tool that facilitates population-based health research. A potential criticism and concern of this
research surrounds the representativeness of the WA population to other Australian States and Territories. Anecdotally,
there is a perception that WA’s isolation from other Australian populations may lead to systematic socio-demographic and
socioeconomic differences; thus limiting the generalisability of research findings.
What does this paper add? This paper compares Australia’s State and Territory population profiles and allows
researchers to determine the extent to which contextual issues concerning key socio-demographic and health economic
indicators may affect the external validity of population-based research arising from any one jurisdiction.
What are the implications to practitioners? In the absence of previous evaluations in this area and with the continued
emergence of new data linkage systems around the country, this information is important for health researchers and
policy makers who may wish to draw conclusions and make policy decisions that rely upon extrapolating findings from
population-based studies.
Additional keywords: data linkage, demography, population-based research, socioeconomics.
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Introduction
Western Australia’s (WA) population is one of the most
geographically isolated in the world1 The majority (>70%) of
the States 2.1million residents are concentrated in it’s south-
western corner and the remainder are scattered widely over an
area occupying one-third of the Australian continent.1 This
population has been the subject of over 700 population-based
health research projects over the last 10–15 years facilitated by
the existence of longitudinal, whole-population, routinely-
collected administrative health and medical data collections
linked through WA Data Linkage System (WADLS).2
Research using data provided through the WADLS has varied
widely in focus and comprised aetiological, utilisation and
outcomes research on whole-population samples.3–8 Although
the general relevance of findings from these studies to the WA
population is seldom challenged, the validity of extrapolating
the findings to other Australian jurisdictions has anecdotally
been questioned. It is argued that the isolation of WA from
other Australian States and Territories could lead to systematic
socio-demographic and socioeconomic differences from the
remainder of the nation, thereby possibly reducing the external
validity of research based on the WADLS for the rest of
Australia.
Despite such claims, no evaluation has hitherto been reported
to support or dispel the suggestion that the geographical
isolation of WA leads to non-representativeness of the rest of
the country. Consequently, the degree to which research findings
on the WA population can be readily applied to the wider
Australian context has remained an open question. External
validity and the generalisability of research findings to other
populations plays a crucial role in their translation into health
policy and practice.9 Our aim was to evaluate the extent to which
WA is, or is not, representative of other Australian jurisdictions
in terms of key population socio-demographic and health
economic indicators.
Methods
We examined key demographic, social and health economic
indicators on the Australian States and Territories in the
census years 1991, 1996, 2001 and 2006. Demographic and
social indicators examined included median age, sex ratio,
percent indigenous population, rural or remote population
ratio, out-of-State migration, and proportion of low-income
families. Health economic indicators examined included the
number of available hospital beds, the proportion of the
population disabled, overall health expenditure, Medicare
Benefits Schedule (MBS) claims, Pharmaceutical Benefits
Scheme (PBS) and Repatriation Pharmaceutical Benefits
Scheme (RPBS) payments and the proportion of the
population privately ensured. These indicators were selected
because we felt they are important in health research due to
their common use as covariates (e.g. age and sex) or due to
their association with health outcomes (e.g. family income).
Out-of-State migration was chosen due to its importance in
loss-to-follow-up.
Values for each indicator were sourced from publications
of the Australian Bureau of Statistics (ABS),10–22 the
Australian Institute of Health and Welfare,23–26 the Public
Health Information Development Unit,27 Medicare
Australia28,29 and the Private Health Insurance Administrative
Council.30 Where data were not recorded for a particular
census year, data for the year closest to the census year were
substituted. Data on low-income families and the prevalence of
disability were obtained from special surveys conducted
outside of census years.20–22,27 The definitions for each
indicator were those used in their source publications and are
shown in Table 1.
An eight State and Territory jurisdiction average of each
indicator was calculated as the mean! s.d. or median and
range across all Australian States and Territories in each
observation year. The jurisdictional average is distinct from
the Australian average (calculated by dividing the national
total of the indicator by the total Australian population) and
recognises that a great deal of administration and decision-
making concerning delivery of health services occurs at the
State and Territory level. Research findings arising from any
one jurisdiction or the nation as a whole should be interpreted
in the knowledge of that diversity.
State and Territories were ranked according to their
percentage difference from the eight-jurisdiction average for
each indicator and closest three identified. An exception to this
general method was that for out-of-State migration where we
identified the three jurisdictions with the lowest absolute level of
outward migration. This was because we took the view that the
lowest possible outward migration was far more valuable to
improving the internal validity of epidemiological and health
services research results than the external validity of proximity
to the jurisdictional average.
Results
Socio-demographic profile
Comparison of socio-demographic indicators is shown in
Table 2. Sex ratios were approximately equal across the States
and Territories since 1991, except in the Northern Territory
(NT) where men outnumbered women by 8–11%. All
jurisdictions except the NT were approximately representative
of the eight-jurisdictional average with WA among the three
most representative States for sex ratio in 1991, 1996 and 2001.
The WA population was the most representative for median
age in all census years. The youngest population was in the NT
(median age 4.5–5.3 years younger than the jurisdictional
average), whereas South Australia (SA) had the oldest
population (median age 2.2–2.7 years older than the
jurisdictional average).
The proportion of the population who self-identified as
indigenous varied considerably across the jurisdictions. In the
NT 25–29% of its population were indigenous, whereas WA,
Queensland (QLD) and Tasmania had the next highest
proportions of indigenous people (range 3.0–3.7%). The
Australian Capital Territory (ACT), Victoria (VIC) and New
South Wales (NSW) had the lowest (0.4–2.1%).
The NT also had the highest proportion of its population
living in rural or remote areas where, based on ARIA criteria
(a commonmethod of classifying remoteness in epidemiological
research),31 100% of the population live in outer regional,
remote or very remote areas. Conversely, the ACT had no
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rural or remote residents (0%). The percentage of the WA and
SA populations living in rural or remote areas were the most
consistently representative of the jurisdictional average across
all census years.
Out-of-State migration averaged 2.7–3.2% in most
Australian States and Territories. VIC had the lowest out-of-
State migration, estimated at!2.4% since 1991. SA andWA had
the second and third lowest levels respectively in most years,
with levels consistently below 3.0%. WA was among the three
jurisdictions with the lowest percent out-of-State migration in
1996, 2001 and 2006.
The proportion of households classed as having low-income
was 19.1 and 20.4% for the eight-jurisdictional average in
1996 and 2006 respectively. The NT and ACT had the lowest
proportion of low-income families recorded, although it
should be noted that the NT data mainly pertained to its urban
population. NSW andWAwere most consistently representative
of the jurisdictional average, being within 0.5% of the average
in 1996 and 2001.
Health economic profile
Comparison of health economic indicators is shown in
Table 3. The number of available public acute and psychiatric
hospital beds per 1000 people averaged 2.7–3.0. All
jurisdictions except SA and the ACT were among the closest
three jurisdictions to the average at least once from 1996–2006.
WA was never more than 0.2 beds per 1000 people from the
jurisdiction average.
Total health expenditure has averaged $2191–$4017 per
person across the jurisdictions since 1996–97. Spending was
comparable for all except the NT, where spending was
$252–$937 more per person. NSW and VIC were consistently
among the three most representative, whereas the total health
expenditure of WA ranked the fourth most representative of the
average ($112–$184 less per person than the jurisdiction
average).
Medicare payments in the NT were $180–$308 less per
person, and PBS and RPBS payments $68–$230 less per
person than the jurisdiction with the highest expenditure. The
most representative jurisdictions in terms of per capita
Medicare payments were WA ($292.60–$462.40) and TAS
($288.50–$479.40), whereas for PBS and RPBS payments
they were WA ($61–$252) and QLD ($75–$285).
The proportion of the population privately insured was
highest in WA (47.4–48%) and lowest in the NT (30.6–
34.2%). TAS, QLD and VIC were the most representative of
the eight-jurisdiction average (41.5–43.6%).
Table 1. Definitions used by data sources for socio-demographic and health economic indicators
ARIA, Accessibility and Remoteness Index of Australia
Indicator Definition
Socio-demographic
Median age Age in years.10
Sex ratio Men per 100 women.10
Indigenous population Percentage of State and Territory population who identify themselves as being of Aboriginal or Torres Strait
Islander origin.11–14
Rural or remote population
1991 Population clusters of <1000 people or holiday villages of <250 dwellings (i.e. not urban).15
1996 Population clusters <200 dwellings (i.e. not an urban centre or locality).16
2001 onwards ARIA score >2.4 (i.e. outer regional, remote and very remote populations).17,18
Out-of-state migration The number of long-term residentsA who left the State and Territory to go overseas or to another Australian State
and TerritoryB with an intended absence of 12 months or more expressed as a percentage of the State and
Territory population in that year.19
Low income households
1996 Families with an income <$21 000 per annum.27
2006 Households in the second and third equivalised disposable incomeC deciles.20
Health economic
Available beds The total number of public acute and psychiatric hospital beds available per 1000 population.23–25
Health expenditure The total recurrent health expenditure from all sources including; State and Territory governments, Australian
Government, private health insurance funds, individuals (through out-of-pocket payments) and providers
of injury compensation cover. All totals are expressed as per person, based on the mean resident population
in each year.26
Medicare benefits paid The total expenditure on Medicare items in each State and Territory per person enrolled with Medicare Australia.28
Pharmaceutical benefits paid The total expenditure on Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme items
in each State and Territory per person enrolled with Medicare Australia.29
Private health insurance The number of persons with private health insurance as a percentage of the State and Territory population.30
Disabled population Disability was defined as persons with any limitation, restriction or impairment, which has lasted, or is likely to last,
for at least six months and which restricts everyday activities. The number of disabled persons was expressed
as a proportion of the State and Territory population at the time.21,22
ALong-term residents refers to those people who have resided in the State and Territory for 12 months or more.
BInterstate migration was identified through a change in address registered with Medicare.
CEquivalised household income is the household income that is adjusted for the number of adults living in a household, allowing comparison across
households of different sizes.
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Table 2. Comparison of selected socio-demographic indicators for each Australian State and Territory with the eight-jurisdictional average (JA)
Values in bold are the three Australian States and Territories closest to the jurisdictional average (except for out-of-State migration where the three lowest
values are in bold)
Year NSW VIC QLD SA WA TAS NT ACT JA (s.d.)A
Sex ratio (males per 2006 98.2 98.0 99.7 97.5 102.0 97.3 108.0 98.3 99.9 (3.6)
100 females) 2001 98.6 97.0 99.1 97.7 100.2 97.1 109.7 97.4 99.6 (4.2)
1996 98.6 97.6 100.4 97.9 101.1 97.6 111.0 98.5 100.3 (4.5)
1991 99.1 98.4 100.4 98.5 101.2 98.4 109.8 100.0 100.7 (3.8)
Median age (years) 2006 36.8 36.7 36.0 38.7 36.2 38.8 30.9 34.8 36.1 (2.5)
2001 35.9 35.8 35.0 37.6 34.9 37.2 29.6 33.3 34.9 (2.5)
1996 34.4 34.3 33.3 35.6 33.1 34.6 27.8 31.3 33.1 (2.5)
1991 32.9 32.5 31.8 33.6 31.5 32.4 26.9 29.5 31.4 (2.2)
Indigenous 2006 2.1 0.6 3.3 1.7 3.0 3.5 27.8 1.2 2.6
population (%) 2001 2.0 0.6 3.5 1.7 3.5 3.7 28.8 1.2 2.8
1996 1.7 0.5 3.0 1.4 3.1 3.1 27.3 1.0 2.4
1991 1.2 0.4 2.4 1.2 2.7 2.0 25.0 0.6 1.6
Rural or remote 2006 7.1 5.0 18.1 15.2 15.8 35.2 100.0 0 15.5
population (%)B 2001 8.0 5.4 21.8 15.8 17.2 36.5 100.0 0 11.9
1996 9.4 10.6 16.2 11.0 10.7 21.3 18.1 0.6 10.8
1991 12.3 13.0 20.0 14.8 14.2 27.6 31.6 1.4 14.5
Out-of-state 2006 3.1 2.4 2.9 2.4 2.6 3.0 8.6 7.7 2.9
migration (%) 2001 3.2 2.4 3.2 2.6 2.8 3.5 9.8 7.7 3.2
1996 2.5 2.3 3.0 2.7 2.6 3.1 9.9 8.0 2.8
1991 2.6 2.3 3.0 2.3 2.7 2.7 10.9 7.6 2.7
Low income 2006 20.4 21.5 19.7 21.0 20.1 25.9 13.9 8.5 20.4
households (%) 1996 20.0 19.1 20.8 22.9 18.5 23.5 16.6 11.2 19.5
AMedian values are given instead of means for the percentage of indigenous, rural or remote, and low income households due to the significant range
in values.
BThe definition of rural or remote populations published by the ABS changed in each year. Prior to 2001 this was based on number of dwellings. From 2001
onwards the ARIA index was used.
Table 3. Comparison of selected Australian health economic indicators for each Australian State and Territory with the eight-jurisdictional
average (JA)
Values in bold are the three Australian States and Territories closest to the jurisdictional average
Year NSW VIC QLD SA WA TAS NT ACT JA (s.d.)
Available bedsA 2005–06 2.9 2.4 2.5 3.2 2.5 2.7 2.8 2.2 2.7 (0.3)
(per 1000 population) 2000–01 2.7 2.6 2.8 3.4 2.9 2.3 2.9 2.2 2.7 (0.3)
1996–97 3.3 2.7 3.3 3.6 2.9 2.8 3.2 2.5 3.0 (0.4)
Health expenditure 2005–06 3970 3927 3660 4070 3905 3633 4954 – 4017 (443.2)
($ per capita) 2001–02 2993 3144 2830 2995 2908 3338 3439 – 3092 (225.6)
1996–97 2161 2176 2104 2037 2008 2410 2442 – 2191 (171.7)
Medicare benefits paid 2006 592.8 542.1 528.3 541.0 462.4 479.4 284.8 427.0 488.9 (95.5)
($ per capita) 2001 406.5 385.6 366.9 394.5 336.2 348.8 185.7 313.9 346.6 (70.4)
1996 357.2 337.2 319.1 324.2 292.6 288.5 177.3 269.7 299.7 (55.6)
PBS and RPBS benefits 2006 306 299 285 320 252 329 99 224 264 (75.4)
paid ($ per capita) 2001 236 227 221 252 197 260 78 176 206 (58.5)
1996 149 133 128 139 111 147 43 93 118 (35.6)
1992 90 73 75 77 61 80 22 48 66 (21.7)
Private health 2006 44.7 42 40.3 43.6 47.4 41.8 30.6 – 41.5 (5.3)
insuranceB (%) 2001 45.5 44.7 42.4 45.8 48 44.6 34.2 – 43.6 (4.5)
1996 44.7 42 40.3 43.6 47.4 41.8 30.6 – 41.5 (5.3)
Disabled 2003 17.7 19.9 22.5 22.6 21.4 22.6 – 15.8 20.4 (2.7)
populationC (%) 1998 19.3 18.0 19.9 22.4 19.5 22.3 – 17.2 19.8 (2.0)
AAvailable public acute and psychiatric hospital beds.
BThe percentage of the population who are privately ensured in the ACT is included in the NSW figure.
CThe data from the NT regarding disabled persons are considered unreliable for reporting.
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The proportions of disabled people across the jurisdictions
averaged 20%. WA (19.5–21.4%) and QLD (19.9–22.5%)
were closest to the eight-jurisdiction average in all years,
whereas the ACT had the lowest proportion of disabled
persons (15.8–17.2%).
Discussion
Large-scale health research involving whole populations has
become a practical reality since the introduction of data
linkage systems and the techniques needed to analyse their
complex linked datasets.32 Although only a handful exist
worldwide,32–36 their number is growing as evidence of their
value in population-based health research has mounted.2 In
Australia, data linkage forms part of the National
Collaborative Research Infrastructure Strategy, whereby new
data linkage systems in other Australian States and Territories
will join those in WA and NSW as part of a national future
roadmap for population health research.37 Consequently, the use
of data linkage research infrastructure is only likely to continue
to grow within Australia and questions about their external
validity will continue to arise.
Our study facilitates comparison of Australia’s State and
Territory population profiles and helps researchers to
determine the extent to which key socio-demographic and
health economic indicators may affect the external validity of
research arising from any one jurisdiction. We found that
despite its isolation and comprising only one-tenth of the
Australian population,1 WA was highly representative of other
Australian State and Territory populations, being among the
three jurisdictions closest to the eight-jurisdictional average in
all but two of the indicators examined (proportion privately
insured and per capita health expenditure). In reality,
differences in indicators between Australian States other than
the proportions of rural and remote residents and people of
indigenous origin are relatively minor and the generalisability
of research results arising from any Australian State is probably
a reasonable presumption.
We found the ACT and NT were the least representative
jurisdictions in Australia for most of the socio-demographic
and health indicators compared. The NT had the youngest
population; the highest proportion of men, indigenous people,
low-income families, proportion living in rural or remote areas
and rate of out-of-State migration. In terms of its health
economic indicators, the NT had the highest per capita health
expenditure, lowest uptake of private health insurance and
lowest MBS and PBS and RPBS benefits paid. The ACT had
the second youngest population and the lowest proportion of
indigenous people, rural or remote population, low-income
families, and disabled people.
Rural or remote and indigenous populations of Australia
are important in health research since they often have poorer
access to health services and other resources due to factors
such as distance and cultural barriers, which ultimately leads
to inequalities in health outcomes.5,38–40 It could be argued that
the NT, TAS and QLD with their larger rural or remote
populations are better suited for population-based research
involving the health issues that affect them. Similarly, the NT
had by far the highest proportion of its population who were
indigenous (1 in 4) making it also better suited to indigenous
research.
Out-of-state migration may cause systematic error in
population-based studies due to loss-to-follow-up. We found
that outward migration was relatively low for most of the
Australian States. This was particularly for VIC, SA and WA
where levels were less than 2.8% per annum and are low by
international standards.41 Outward migration levels for
Australia’s Territories were high (10.9 and 8.0% for the NT
and ACT respectively), which could lead to erroneous research
findings due to loss-to-follow-up.
It should be noted that data presented here are aggregate
data sourced from routine publically available documents
produced by Australian Government departments, particularly
ABS Australian Census data.10–22 Australian Census data are
subject to several known sources of error, including respondent
error, processing error, partial responses and under-
ascertainment.42 As such, the accuracy of the information
presented is subject to the quality of data reported in these
publications. However, with the possible exception of the
ascertainment of indigenous status, levels of such error are
unlikely to vary much across the Australian jurisdictions.
Conclusion
We found WA was the most representative of the Australian
States and Territories although realistically there is little
variation between Australia’s jurisdictions for most of the
socio-demographic and health economic indicators that we
examined. The exceptions to this were for the ACT and NT,
which were markedly different to the State jurisdictions,
particularly for their rural or remote and indigenous population
profiles. In the absence of previous evaluations in this area
and with the continued emergence of new data linkage
systems around the country, this information is important for
health researchers and policy makers who may draw conclusions
and make policy decisions that rely upon extrapolating findings
from population-based studies.
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3.1. Background!Modern! cataract! surgery!has!undergone! several! transformations! over! the! last!three! decades! from! intracapsular! (ICCE)! to! extracapsular! extraction! (ECCE)!with! IOL! in! the! late!1970s,! to!small! incision!phaocemulsification!with! foldable!IOL! during! the! late! 1980s,! and! then! to! sutureless! phacoemulsification! in! the!1990s.130,131!The!transition!away!from!ICCE!has!been!associated!with!improved!outcomes,239,240! although! it! is! unclear! whether! the! same! can! be! said! for! the!transition!to!phacoemulsification.!The!introduction!of!phacoemulsification!has,!however,! contributed! to!reduced!operating!and!patient! recovery! time,!making!modern!sameHday!outpatient!cataract!surgery!a!reality.241!The!result!has!been!an!exponential! increase! in! cataract! surgery! rates! in!most!developed!countries!such!that!it!has!become!one!of!the!most!common!surgical!procedures!performed!today.130,131!!While!major!complications!of!cataract!surgery!remain!uncommon,28!even!rare!complications! have! the! potential! to! cause! considerable! visual! burden! in! the!community! where! large! volumes! of! surgery! are! performed.242! Retinal!detachment,! dropped! nucleus! (retained! lens! fragments),! corneal!decompensation,! IOL! dislocation,! wound! dehiscence,! and! postoperative!endophthalmitis!are!serious!complications!of!cataract!surgery!that!cause!severe,!potentially!permanent,!visual!morbidity!that!often!requires!costly!intervention.!The! serious! complications! examined! in! this! thesis! were! retinal! detachment,!pseudophakic!corneal!oedema,!IOL!dislocation,!dropped!nucleus!(retained!lens!fragments),! and!wound! dehiscence.! This! list! is! by! no!means! exhaustive! since!other! sightHthreatening! complications!may!occur! e.g.! cystoid!macular!oedema,!suprachoroidal! haemorrhage,! and! posterior! capsule! opacification.! However,!they!were!chosen!specifically!since!a)!they!encompass!the!most!common!of!the!sightHthreatening! cataract! surgery! complications;! and! b)! they! all! require! a!hospital! admission! and! surgery! in! order! to! treat! them! (and! thus! a! HMDC!record).! Other! complications! such! as! cystoid! macular! oedema! and! posterior!capsule!opacification,!whilst! important,! are!generally! treated!on!an!outpatient!basis!and!not!identifiable!within!the!HMDC.!! !
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Table!1!N!Previously!published!rates!of!retinal!detachment!after!cataract!surgery.!
Author(s) Location Time period Number of procedures 
Incidence 
(%) 
Follow-up 
time 
 
Population-based studies 
Sheu et al (2007)243 Taiwan 1999 – 2001 9,388 1.16 6 yrs 
Erie et al (2006)84 USA 1980 – 2004 10,256 0.71 5 yrs 
Norregaard et al (1996)244 Denmark 1985 – 1987 10,493 0.93 4 yrs 
Ninn-Pedersen and Bauer (1996)245 Sweden 1986-1990 5,878 0.18 2 yrs 
Javitt et al (1994)167 USA 1986 - 1988 57,103 0.81 3 yrs 
Javitt et al (1991)171 USA 1984 338,141 0.9 – 1.55 4 yrs 
Stark (1983)246 USA 1978 – 1982 11,428 0.6 12-14 mths 
 
Multi-centre studies 
     
Norregaard (1999)242  USA 
Denmark 
Manitoba 
Barcelona 
1991 - 1993 1,349 0.1 48hrs 
Desai et al (1999)247 UK 1997 15,787 0.165 3 mths 
Desai (1993)248 UK 1990 998 0.1 3 mths 
Khatibi et al (2008)249 USA 1996 – 2005 4,501 0.76 Up to 10yrs 
 
Single-centre studies 
     
Nielsen & Naeser (1993)250 Denmark  1,726 0.41 ~39 mths 
Naeser et al (1998)251 Denmark 1984 – 1986 1,041 2.8 10 yrs 
Russell et al (2006)252 New Zealand 1992 – 1993 1,793 1.17 10 yrs 
Boberg-Ans et al (2006)172 Denmark 1996 – 1998 6,352 0.93 8 yrs 
Tuft et al (2006)253 UK 1994 - 2003 63,298 0.41 Up to 10 yrs 
Coonan et al (1985)254 USA 1973 - 1983 842 1.4 Up to 10 yrs 
Chitkara & Smerdon (1997)255 UK 1987 - 1991 1,552 0.3 Up to 4 yrs 
Percival et al (1983)256 UK 1972 – 1981 1,324 0.8 - 3.6 Up to 10yrs 
Ripandelli et al (2007)257 Italy 1997 - 1999 453 3.1 5 yrs 
Alio et al (2007)258 Spain 1996 – 2000 439 3.3 5 yrs 
Alldredge et al (1998)259 USA  80 0 Up to 6 yrs 
Olsen & Olson (2000)260 USA 1976 – 1997 2,739 0.4 – 5.4 Up to 22 yrs 
Szijártó et al (2007)261 Hungary 1994 - 2004 11,098 0.36 Up to 10 yrs 
Bhagat et al (2007)262 USA 2000 – 2005 755 0.1 Intra-operative 
Haargaard et al (2008)263 Denmark 1977 – 2001 1,138 2.3  
Stark et al (1983)246 USA 1975 - 1983 1,344 0.8 – 3.5 3 – 76 mths 
Smith et al (1987) 264 USA 1978 – 1986  2,330 1.7 12 mths 
Zaidi et al (2006)265 UK 2002 – 2004 1,000 0.2 2 weeks 
Monica (2005)266 USA 1994 – 2003 3,500 0.17 5 yrs 
Holland et al (1992)267 USA 1983 - 1986 600 1.7 > 6 mths 
Riley et al (2002)268 New Zealand 2000 476 0 1 mth 
Ozbek  et al (2007)269 Turkey 1999 – 2006 414 1.9 4 – 92 mths ! !
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The!reported!incidence!of!these!complications!varies!considerably:!
• Retinal! detachment! can! occur! either! as! a! primary! complication! of!cataract!surgery!or!as!a!result!of!other!adverse!events!such!as!dropped!nucleus.!It!may!affect!up!to!5.4%!of!cataract!surgery!patients!depending!on! the! year! of! surgery! and! procedure! type! (Table! 1).! Risk! factors! that!have! been! identified! include! a! younger! age! at! the! time! of! operation,!surgery! complicated! by! posterior! capsule! rupture,! axial! myopia! and!subsequent!Nd:YAG!laser!capsulotomy.84,167,172,243,244,246,251,252,255,261,264!!
• Pseudophakic! corneal! oedema! typically! requires! expensive! corneal!transplantation! to!achieve!optimal!visual!outcomes.! It!may!occur!many!years! following!surgery!and!so!many!of! the!studies!of! its! incidence!are!limited! by! short! followHup! time! (Table! 2).! The! reported! incidence! also!varies!widely!in!studies!(0H5.3%),!reflecting!the!varying!followHup!times!and!surgical!procedure!types.!
• IOL! dislocations! may! occur! anytime! postoperatively! and! typically!requires! surgery! i.e.! IOL! repositioning! or! exchange.!Most! reports! of! its!incidence!are! from!case! reports!with! relatively! little!known!of! the! true!incidence.! The! handful! of! studies! are! limited! by! short! followHup! with!most!reporting!only!early!postHoperative!events!(Table!3).  
• Wound! dehiscence! incidence! varies! widely! in! reports,! largely! due! to!differences!in!procedure!type!(Table!4).!!
• Dropped! nucleus! is! more! common! in! many! countries! since!phacoemulsification! was! introduced! (Table! 5).! Up! to! 37%! of! patients!with!a!dropped!nucleus!may!be!left!with!poor!residual!vision.270,271!There!are! currently! no! reports! of! sufficient! duration! to! examine! how! its!incidence!has!changed!over!time.!!
• Postoperative! endophthalmitis! following! cataract! surgery! accounts! for!around! 60H70%! of! all! cases! of! endophthalmitis.! This! complication!was!the!focus!of!the!Endophthalmitis!Population!Study!of!WA!(EPSWA)!that!preceded! this! thesis.! ! EPSWA! found! that! endophthalmitis! causes!blindness! or! severe! visual! impairment! in! 70%! of! affected! patients,272!
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occurs! in!as!many!as!one! in! five!hundred!cataract!cases! (25H30!cases!a!year!in!WA)!(Table!6),!and!has!increased!in!parallel!with!the!6%!annual!increase!in!cataract!surgery!over!the!last!20!years.95!Most!previous!studies!of!cataract!surgery!complications!involved!a!single!center!or!small!groups!of!surgeons!and!were!adversely!affected!by!small!sample!sizes!or!short!followHup.!Low!case!numbers!complicate!statistical!comparisons,!while!short!followHup!makes!it!difficult!to!examine!trends!over!time,!particularly!the!impact! of! changing! surgical! technique.! The! low! incidence! of! complications!makes!populationHbased!longitudinal!studies!using!hospital!administrative!data!the! best! model! to! evaluate! surgical! outcomes! and! complications! of! cataract!surgery.!
3.2. General!methods!The!methods!used!to!identify!and!validate!the!cataract!surgery!cohort!and!those!who!had!a!subsequent!major!sightHthreatening!complication!for!this!thesis!are!herein! described.! Specific! methods! relating! to! data! analysis! and! subgroup!analysis! pertinent! to! individual! papers! are! outlined! in! detail! in! the! relevant!papers.!
3.2.1. Data!source!In!WA! all! cataract! surgery! can! only! be! performed! in! health! facilities! licensed!with! the! WA! Department! of! Health.! It! is! incumbent! upon! these! facilities! to!provide!the!WA!Department!of!Health!with!data!from!all!admissions,!including!sameHday! admissions.! Data! provided! includes! patient! demographics,! coHmorbidities,!primary!and!secondary!diagnoses,!and!any!procedures!undertaken!or!complications!arising!during!the!admission!recorded!at!discharge.!This!data!encompassing!all!admissions! from!all!WA!hospitals!(public!and!private)! forms!the!Hospital!Morbidity!Data!Collection!(HMDC);!one!of!the!core!data!sets!of!the!WADLS.!
3.2.2. Linked!data!extraction!The!WADLS!was!used!to!extract!hospital!discharge!data!from!the!HMDC!for!all!patients! who! underwent! surgery! for! cataract! extraction! or! a! lensHrelated!procedure!during!1980!to!2001.!! !
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Table!2!–!Previously!published!rates!of!pseudophakic!corneal!oedema.!
Author(s) Location Time period Number of procedures 
Incidence 
(%) 
Follow-up 
time 
 
Population-based studies 
     
Canner et al (1992)180 USA 1984 338,141 0.52 – 1.02 4 yrs 
Stark et al (1983)246 USA 1978 – 1982 11,428 0.1 12 - 14 mths 
 
Multi-centre studies 
     
Jaycock et al (2009)28 UK 2001 – 2006 16,731 5.18 31 days 
Desai (1993)248 UK 1990 998 0.4 3 mths 
 
Single-centre studies 
     
Zaidi et al (2006)265 UK 2002 – 2004 1,000 0.7 2 weeks 
Monica (2005)266 USA 1994 – 2003 3,500 0 5 yrs 
Chitkara & Smerdon (1997)255 UK 1987 - 1991 1,552 0.06 Up to 4 yrs 
Holland et al (1992)267 USA 1983 - 1986 600 0.33 > 6 mths 
Stark et al (1983)246 USA 1975 – 1983 1,344 0.1 76 mths 
Riley et al (2002)268 New Zealand 2000 476 0.4 1 mth 
Wegener et al (1998)273 Denmark 1994 - 1995 951 0.1 - 
Baggensen & Ehlers (1997)274 Denmark 1986 – 1988 2455 5.3 5 – 7 yrs 
Naeser et al (1998)251 Denmark 1984 – 1986 1,041 2.3 10 yrs !!
Table!3!–!Previously!published!rates!of!IOL!dislocation!after!cataract!surgery.!
Author(s) Location Time period Number of procedures 
Incidence 
(%) Follow-up time 
 
Multi-centre studies 
     
Norregaard (1999)242  USA 
Denmark 
Manitoba 
Barcelona 
1991 - 1993 1,349 0.2 48hrs 
Desai (1993)248 UK 1990 998 0.3 3 mths 
Stark et al (1983)246 USA 1978 – 1982 11,428 0.5 12-14 mths 
Jaycock et al (2009)28 UK 2001 – 2006 16,731 0.22 31 days 
Desai et al (1999)247 UK 1997 17,257 0.1 48hrs post op 
 
Single-centre studies 
     
Jin et al (2005)275 USA 1998 – 2004 6,630 0.29 > 3 mths 
Stark et al (1983)246 USA 1975 - 1983 1,344 0.3 -6.0 3 – 76 mths 
Riley et al (2002)268 New 
Zealand 
2000 483 0.41 Day 1 
Ozbek et al (2007)269 Turkey 1999 – 2006 414 0 4 – 92 mths 
Wegener et al (1998)273 Denmark 1994 - 1995 951 0.4 - 
Rutar et al (2009)276 USA 2006 - 2007 320 0.62 90 days 
Chitkara & Smerdon (1997)255 UK 1987 - 1991 1,552 0 Up to 4 yrs !! !
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Table!4!–!Previously!published!rates!of!wound!dehiscence!after!cataract!surgery.!
Author(s) Location Time period Number of procedures 
Incidence 
(%) Follow-up time 
 
Multi-centre studies 
     
Jaycock et al  (2009)28 UK 2001 – 2006 16,731 0.14 31 days 
Norregaard (1999)242  USA 
Denmark 
Manitoba 
Barcelona 
1991 - 1993 1,349 0.4 48hrs 
Desai (1993)248 UK 1990 998 0.4 3 mths 
Desai et al (1999)247 UK 1997 17,257 1.2 48hrs post op 
 
Single-centre studies 
     
Zaidi (2006)265 UK 2002 – 2004 1,000 1.1 2 weeks 
Monica (2005)266 USA 1994 – 2003 3,500 0 5 yrs 
Ball & McCleod (2001)277 UK 1986 – 1993, 
1996 -1998 
9,800 0.22  
Quraishy & Casswell 
(1996)278 
UK 1986 – 1993 ~5,600 ~0.37  
Holland et al (1992)267 USA 1983 – 1986 600 0.33 > 6 mths 
Riley et al (2002)268 New 
Zealand 
2000 483 1.9 Day 1 
Rutar et al (2009)276 USA 2006 - 2007 320 0.3 90 days 
Arango & Margo (1998)279 USA 1988 – 1996 2,041 1.5 3 mths 
Naeser et al (1998)251 Denmark 1984 – 1986 1,041 2.1 10 yrs 
Chitkara & Smerdon 
(1997)255 
UK 1987 - 1991 1,552 1.3 4mths - 4 yrs !
Table!5!–!Previously!published!rates!of!dropped!nucleus!during!cataract!surgery.!
Author(s) Location Time period Number of procedures Incidence (%) 
 
Multi-centre studies 
    
Norregaard (1999)242  USA 
Denmark 
Manitoba 
Barcelona 
1991 - 1993 1,349 0.3 
Jaycock et al (2009)28 UK 2001 – 2006 55,567 0.18 
Misra & Burton (2005)280 UK 2002 – 2003 1,883 0.11 
Stilma et al (1997)270 Netherlands 1992 – 1994 41,460 – 52,788 0.09 – 0.9 
Desai et al (1999)247 UK 1997 17,257 0.3 
 
Single-centre studies 
    
Zaidi (2006)265 UK 2002 – 2004 1,000 0.1 
Riley et al (2002)268 New Zealand 2000 488 0.8 
Rutar et al (2009)276 USA 2006 - 2007 320 0.93 
Bhagat et al (2007)262 USA 2000 – 2005 755 0.97 
Seward et al (1993) UK 1990 400 0.25 !! !
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Table!6!–!Previously!published!rates!of!endophthalmitis!after!cataract!surgery.!
Author(s) Location Time period Number of procedures 
Incidence 
(per 1,000) 
 
Population-based studies 
Montan et al (2002)281 Sweden 1998 54,666 1.06 
Versteegh et al (2000)282 Netherlands 1996-1997 71,028 1.52 
Wegener et al (1998)273 Denmark 1994-1995 951 0.00 
Norregaard et al (1997)283 Denmark 1985-1987 19,426 3.14 
Javitt et al (1994)167 USA 1986-1987 57,103 0.77 
Javitt et al (1991)166 USA 1984 324,032 1.36 
 
Multi-centre studies 
Norregaard (1999)242  USA 
Denmark 
Manitoba 
Barcelona 
1991 - 1993 1,349 0 
Versteegh et al (2000)282 Netherlands 1996-1997 33,750 1.16 
Schmitz et al (1999)284 Germany 1996 340,633 0.78 
Desai et al (1999)247 United Kingdom 1997 15,787 1.65 
Desai 38 (1993)248 United Kingdom 1990 (1 week) 98 3.00 
Fisch et al (1991)285 France 1988-1989 26,731 3.23 
 
Single-centre studies 
Monica (2005)266 USA 1994 – 2003 3,500 0 
Mayer et al (2003)286 United Kingdom 1991-2001 18,191 1.65 
Riley et al (2002)268 New Zealand 2000 488 2.05 
Eifrig et al (2002)287 USA 1995-2001 21,972 0.36 
Yorston et al (2002)288 Africa 1999 1,800 0.00 
Ernest et al (2000)289 Czechoslovakia 1990-1999 13,247 2.57 
Colleaux et al (2000)290 Canada 1994-1998 13,886 0.72 
Bohigian (1999)291 USA 1985-1996 19,269 0.62 
Aaberg et al (1998)292 USA 1990-1994 18,530 0.92 
Somani et al (1997)293 Canada 1989-1996 13,285 2.41 
Chitkara et al (1997)255 United Kingdom 1987-1991 1,552 1.93 
Stanila (1996)294 Romania 1990-1995 759 3.95 
De Gottrau et al (1994)295 Switzerland 1983-1992 6,954 1.15 
Kattan et al (1991)296 USA 1984-1989 23,625 0.72 
Kattan et al (1991)296 USA 1976-1982 7,552 0.93 
Fahmy (1975)297 Denmark 1964-1974 4,498 5.33 
Allen et al  (1974)298 USA Not stated 36,000 0.86 
Christy et al (1973)299 Pakistan 1957-1972 77,093 4.96 
Bhagat et al (2007)262 USA 2000 – 2005 755 0 !! !
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Data!was!selected!using!the!time!period!relevant!International!Classification!of!Diseases!(ICD)!codes!for!diagnoses!and!procedures!i.e.!ICDH9!for!1980H87,!ICDH9CM! for! 1988H98,! and! ICDH10HAM! for! 1999! onwards.300,301! The! specific!procedures! extracted! were! intracapsular! extraction! of! lens! (ICCE),!extracapsular! extraction! of! lens! (ECCE),! phacoemulsification! (Phaco),! other!cataract!extraction,!and!lensHrelated!operations.!The!specific!ICD!codes!used!to!identify!these!procedures!are!detailed!in!Table!7.!Each!complication!was!also!identified!using!specific!ICD!procedure!codes!(Table!7).!Diagnosis! codes!were!not!used!since!preliminary!analysis! found!a! reduced!number!of!potential!complications!were!flagged!using!diagnosis!codes!only,!and!no!additional!benefit!was!conferred!when!used!in!combination!with!procedure!codes! (presumably! since! all! admission! for! the! complications! examined! will!involve!a!surgical!procedure).!Only! those!cases! that!occurred!during! the!same!admission! as! the! cataract! procedure! or! after! the! cataract! procedure! were!considered.!
3.2.3. Database!validation!Validation!of!coded!sightHthreatening!complications!identified!in!the!HMDC!was!undertaken!using!medical!record!review!(Figure!3H1).!Validation!was!essential!since! the! HMDC! does! not! code! for! laterality! of! procedures! and! without!validation! it! is! impossible! to! determine! accurately! whether! a! complication!identified!occurred!in!the!same!eye!as!the!associated!cataract!surgery.!
!
!
Figure!3N1!Results!of!chart!validation!of!potential!cataract!surgery!complications!in!WA.!
! !
Potential!cases!(n=5,595)!
Contirmed!case!(n=2,087)! Not!a!complication!(n=3,221)! Chart!not!available!(n=323)!
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Table!7!–!International!classification!of!diseases!procedural!codes!used!to!identify!potential!postHoperative!complication!after!cataract!surgery!in!WA!1980!to!2001.!
Item 
Procedure codes 
ICD 9 
1980 – 1987 
ICD 9 CM 
1988 – June 1999 
ICD 10AM 
June 1999 onwards 
 
Procedure Type    
Intracapsular 5-144 13.11, 13.19 42698-00, 42702-00, 42702-01 
Extracapsular 5-142, 5-145 13.2, 13.3, 13.51, 13.59 42698-01, 42698-04, 42702-02, 42702-03, 42702-08, 42702-09 
Phacoemulsification - 13.41 - 13.43 42698-02, 42698-03, 42702-04, 42702-05, 42702-06, 42702-07 
Lens procedure 5-147, 5-149 13.70, 13.71, 13.72, 13.9 
42701-00, 42701-01, 42703, 
90077-00 
Other cataract 
extraction 5-146 
13.64, 13.65, 13.66, 
13.69 
42734-00, 42719-00, 42719-02, 
42698-05, 42788-00, 42722-00, 
42731-00, 42702-10, 42702-11, 
42731-01, 42716-00 
    
Complication Type    
Retinal detachment 5-152, 5-153, 5-156 14.3 – 14.59, 14.9 42773-00, 42773-01, 42776-00, 42809-01, 90079-00 
Intraocular lens 
dislocation 5-147, 5-149 13.70, 13.72, 13.8 
42701-00, 42701-01, 42703-00, 
42704-00, 42704-01, 42710-00, 
42713-00 
Dropped nucleus 5-149, 5-157 13.9, 14.70 – 14.79 
42702-10, 42702-11, 42719-01, 
42722-01, 42725-00, 42731-01, 
42740-05, 9007-00 
Pseudophakic corneal 
edema 
5-113, 5-119, 5-125 
5-129 
10.44, 10.49, 11.53, 
11.6, 11.60, 11.61, 
11.62, 11.63, 11.64, 
11.69 
42659-00, 42653-00 
42671-00, 90064-00, 
42632-00, 42638-00, 
42653-01, 42656-00, 90067-00 
Wound dehiscence 5-124, 5-126 11.5, 11.51, 11.52, 11.59, 12.83, 12.66 
42551-00, 42551-01, 42551-02, 
42554-00, 
42635-00, 42667-00, 
42857-00, 42857-01, 
90060-00, 90066-00 !There!were! 5,595! patients! identified! in! the!HMDC!who! had! a! potential! sightHthreatening! complication! of! their! cataract! surgery! between! January! 1980! and!December! 2001.! Chart! review!was! an! extensive! and! timeHconsuming! process!that!took!over!2!years!to!complete.!Each!hospital!in!WA!where!cataract!surgery!was!performed! since!1980!was! contacted! and! approval! for! review!of!medical!records!maintained!at! their! site!was!obtained.!Many!records!were!held! in!offHsite! storage! due! to! the! long! time! since! surgery!was! performed!which! further!complicated!access! to!previous!surgical!notes.!Despite! these!difficulties!a!high!proportion!of! the!potential!complications! identified!were!validated!(>94%)!by!chart!review!(Figure!3H1).!
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3.2.4. !Ethics!approval!All!work!for!the!complications!of!cataract!surgery!project!undertaken!as!part!of!this!thesis!was!carefully!reviewed!and!approved!by!the!Human!Research!Ethics!Committees! at! Curtin! University! of! Technology,! The! Western! Australian!Department! of! Health,! and! each! of! the! hospitals! involved! in! the! study.!(Appendix!1).!!
3.3. Research!output!
Published!manuscripts!!This!chapter!resulted!in!the!publication!of!three!substantial!papers!in!the!peerHreviewed! ophthalmic! literature.! The! first! paper! begins! with! an! inHdepth!overview! of! the! trends! in! complications! over! the! study! period.! The! second!paper! explores! retinal! detachment! following! modern! phacoemulsification!cataract! extraction! and! the! major! associated! risk! factors.! The! final! paper!explores!trends!in!complicated!cataract!surgery!over!the!study!period!and!how!complicated!surgery!affects!the!risk!of!subsequent!serious!complications.!!
Conference!and!media!presentations!Research! findings! arising! from! this! chapter! were! presented! at! local,! national!and!international!conferences!as!free!paper!talks!and!poster!presentations.!The!paper!describing!risk!factors!for!retinal!detachment!was!the!subject!of!a!media!release! in! the! American! Academy! of! Ophthalmology! EyeNet! magazine! and!formed! the! basis! for! a! continuing! medical! education! article! on! the!internationally!regarded!MedScape!website.!
Translational!projects!The!data!validation!process!identified!a!significant!shortcoming!in!our!ability!to!monitor! cataract!outcomes! in!WA,!and! that!was! the! inability! to!access! clinical!information!in!a!timely!and!efficient!manner.!The!lack!of!coding!for!laterality!in!the!HMDC! is!a!major!barrier!as! is! the! lack!of!operative!detail! in! the!database.!This!severely!limits!our!ability!to!identify!a!changing!trend!for!specific!adverse!events! and! important! operative! risk! factors! important! in! cataract! surgery!outcomes! without! having! to! perform! extensive! chart! validation! that! is! time!consuming!and!costly.!By!the!time!any!research!findings!are!available!it!is!likely!
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to! be! years! after! the! event.! With! this! in! mind! we! developed! a! webHbased!electronic! cataract! auditing! and! reporting! system! –! eCAT! (Appendix! 3).! The!vision! is! for! this! to! be! used! across! all! public! and! private! facilities! in!WA! and!available! for! data! linkage! with! the! HMDC! to! allow! rapid! analysis! of! adverse!outcomes,!without!the!need!for!chart!review.!I!wrote!the!grant!application!for!the!Australian!Government!National!Eye!Health!Initiative!Demonstration!Grants! (Round!2)! to! fund! the! implementation!of! this!system!as!a!pilot!project!across!the!public!teaching!hospitals!in!WA!(Appendix!4).! This! was! successful! in! securing! AUD$163,883! inc! GST! in! funding.! This!project!is!ongoing!(Appendix!3).!! !
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3.4. Published.manuscripts. .
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Whole Population Trends in Complications
of Cataract Surgery over 22 Years in
Western Australia
Antony Clark, MBBS(Hons),1,2 Nigel Morlet, FRACS, FRANZCO,1,2,3 Jonathon Q. Ng, MBBS, PhD,1,2,3
David B. Preen, BSc(Hons), PhD,1,3 James B. Semmens, MSc, PhD1,2
Objective: To examine the trends in major complications of cataract surgery in the Western Australian
population over 22 years.
Design: Population-based study.
Participants: We included 129 982 cataract/lens surgery patients across 46 health facilities.
Methods: Using the Western Australian Data Linkage System, we identified all patients who underwent
cataract/lens surgery in Western Australia between 1980 and 2001. Complications of interest were identified from
those patients admitted to hospital or who underwent unplanned surgery after cataract surgery and were
validated by medical record review.
Main Outcome Measures: Admission for retinal detachment, dropped nucleus, wound dehiscence, pseu-
dophakic corneal edema, intraocular lens (IOL) dislocation, and postoperative endophthalmitis requiring surgery.
Results: There were 129 982 cataract/lens procedures and 2087 (1.6%) complications. Complications fell
almost 70% over the study period. Retinal detachment (n ! 905; 0.70%) was most common, followed by IOL
dislocation (n ! 361; 0.28%), endophthalmitis (n ! 228; 0.18%), wound dehiscence (n ! 227; 0.17%),
pseudophakic corneal edema (n ! 207; 0.16%), and dropped nucleus (n ! 159; 0.12%). The incidence of
complications lessened over time, except for IOL dislocations, which has increased since 1995. Overall, the risk
of complications after phacoemulsification halved since it was introduced in the late 1990s (incidence rate ratio,
0.52; 95% confidence interval, 0.37–0.74), whereas complications after extracapsular extraction (ECCE) have
increased over recent years.
Conclusions: Cataract surgery remains an extremely safe procedure with comparatively few major
complications. Changes in operative techniques have been accompanied by a significant decrease in
complication rates over time, although the increase in IOL dislocations and complications after ECCE
warrants further study.
Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials
discussed in this article. Ophthalmology 2011;118:1055–1061 © 2011 by the American Academy of Ophthalmology.
Modern cataract surgery technique has changed significantly
over the last 30 years from intracapsular (ICCE) to extracap-
sular extraction (ECCE) with intraocular lens (IOL) in the late
1970s, to small incision phacoemulsification during the late
1980s, followed by the adoption of sutureless phacoemulsifi-
cation with foldable IOL in the 1990s.1,2 The transition to
phacoemulsification is credited with reducing operating and
patient recovery times and paving the way for same-day,
outpatient cataract surgery.3 Although the transition away from
ICCE was associated with fewer complications, it remains
unclear whether phacoemulsification is safer than ECCE.
Cataract surgery is the most commonly performed opera-
tive procedure today,1,2 with few complications.4 However,
when large volumes are involved, even rare complications of
cataract surgery have the potential to cause considerable visual
burden in the community. Major complications include retinal
detachment, postoperative endophthalmitis, IOL dislocation,
pseudophakic corneal edema, dropped nucleus (retained lens
fragments), and wound dehiscence. The reported incidence of
these complications varies considerably.1,4–27 Both retinal
detachment and postoperative endophthalmitis are well
characterized in population-based studies. The incidence of
retinal detachment from these studies ranged between 0.6%
and 1.5%, depending on year and procedure type,5–15
whereas postoperative endophthalmitis ranged between
0.1% and 0.3%.1,16,17 The incidence of IOL dislocation is
reported as 0.2% to 6.0%, although most studies are case
reports or have follow-up limited only to early postoperative
events.4,9,18–21,28 Similarly, the reported incidence of pseu-
dophakic corneal edema (0%–5.2%)4,9,12,19,22,23 is limited
in many studies by short follow-up time. Dropped nucleus is
more common in many countries since the introduction of
phacoemulsification, with studies reporting an incidence of
0.1 to 0.3%.4,18,22,24,25 Wound dehiscence rates also vary
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widely (0%–2.1%), largely owing to differences in proce-
dure type and classification.4,15,18,19,22,23,26,27
Most previous studies of cataract surgery complications
involved a single center or small groups of surgeons and
were adversely affected by small sample sizes or short
follow-up. Low case numbers complicate statistical com-
parisons, and short follow-up makes it difficult to examine
trends over time, particularly the impact of changing oper-
ative techniques. The low incidence of complications makes
population-based longitudinal studies the best model to
evaluate surgical outcomes and complications of cataract
surgery. Our aim was to examine the trends of some im-
portant complications of cataract surgery in the entire West-
ern Australian population over 22 years. This is the first
report in a series to examine the trends and characteristics of
the major complications of cataract surgery in Western
Australia.
Methods
We conducted a whole-population, retrospective, longitudinal
study of clinically important complications of cataract and lens
surgery from 1980 to 2001 using linked administrative data from
the Western Australian Data Linkage System. Specifically, we
examined retinal detachment, IOL dislocation, pseudophakic cor-
neal edema, dropped nucleus, endophthalmitis, and wound dehis-
cence. We previously reported the trends in the incidence of
endophthalmitis after cataract surgery in Western Australian from
1980 to 2000, and present the additional cases from 2001.
Data Source
Cataract surgery in Western Australia may only be performed in
health facilities licensed by the Western Australian Department of
Health. These facilities must provide the Western Australian
Department of Health with data from all admissions, including
same-day admissions. The data routinely recorded at discharge
include patient demographics, comorbidities, primary and sec-
ondary diagnoses, and any procedures undertaken or complica-
tions arising during the admission. These data, encompassing
all admissions from all Western Australian hospitals (public and
private), form the Hospital Morbidity Data Collection (HMDC),
which is one of the core data sets of the Western Australian
Data Linkage System.29
We used the Western Australian Data Linkage System to
extract hospital discharge data from the HMDC for all patients
who underwent cataract extraction or a lens procedure from 1980
to 2001. These data were linked to the State Mortality Register and
allowed us to account for loss to follow-up because of death. Data
were coded using the relevant International Classification of Dis-
eases (ICD) codes for diagnoses and procedures (ICD-9 for 1980–
87, ICD-9CM for 1988–98, and ICD-10-AM for 1999 on-
wards).30,31 The procedures extracted included ICCE, ECCE,
phacoemulsification, “other” cataract extraction, and lens opera-
tions (Table 1; available online at http://aaojournal.org).
Identification of Complications
Only complications that required hospital admission or surgical
treatment (necessitating hospital admission) were considered cases
because they were more likely to be reliably identified in the
HMDC. Additionally, these cases were more likely to be vision
threatening or clinically important. Complications (except endo-
phthalmitis) were identified using ICD procedure codes detailed in
Table 1 (available online at http://aaojournal.org). Except for en-
dophthalmitis, diagnosis codes were not used because preliminary
analysis found a reduced number of potential complications were
identified using diagnosis codes only. No additional benefit was
conferred by diagnosis codes used in combination with procedure
codes because all admissions for the complications examined
involve an operative procedure. Only those complications that
occurred during or after the same admission as the cataract pro-
cedure were considered cases. The method of selecting and vali-
dating the endophthalmitis cohort was different to that of the other
complications and has been described elsewhere.1,32,33
Data Validation
There were 6286 potential cases identified within the HMDC
dataset. Each case was validated by hospital record review to
confirm the type of complication and that the complication oc-
curred in the same eye as the associated cataract/lens procedure
(laterality is not recorded in the HMDC). For all confirmed cases,
we also recorded important operative information about the cata-
ract operation such as procedure type, IOL insertion, IOL type, and
other concurrent procedures. We were unable to validate 363
(5.8%) potential cases because the required hospital record was
unavailable or it was not possible to accurately confirm whether a
true complication occurred. These were excluded from analysis.
Although desirable, it was not logistically possible to obtain
information regarding patient’s preoperative ocular status, such as
cataract type, that would allow patient stratification into low- and
high-risk groups for further analysis. This is because such vari-
ables are not routinely collected within the HMDC dataset.
Statistical Analysis
Descriptive analysis was performed to characterize the cataract
surgery patient cohort and those who had a complication of inter-
est. Using univariate analyses, the annual incidence rate of each
complication was calculated as the crude incidence per 1000
procedures. Because of the impact of differing follow-up times for
late complications, trends in the incidence of each complication
were analyzed differently depending on whether they tended to
occur intraoperatively, in the early postoperative period (within the
first 3 months after surgery), or later in the postoperative period.
For intraoperative and early postoperative complications (dropped
nucleus, wound dehiscence, and endophthalmitis) the incidence
rate per 1000 procedures was calculated for each 5-year period and
the incidence rate ratio comparing each subsequent time period
was calculated using Poisson regression adjusting for age and
gender.
We used survival analysis to compare the time to event as the
cumulative incidence for each late complication (retinal detach-
ment, IOL dislocation, and pseudophakic corneal edema) in each
5-year period. Using Cox proportional hazards regression adjusted
for age and gender, we calculated the hazard ratio and 95%
confidence intervals (CI), comparing the hazard rate for each
complication in each subsequent time period. This allowed us to
take into account the differences in follow-up time and censoring
of patients. All statistical analysis was performed using STATA
10.0 (StataCorp, College Station, TX); all standard errors were
adjusted for clustering of procedures around individuals using
generalized estimating equations.
Ethical Considerations
This study was approved by the Human Research Ethics Commit-
tees at Curtin University of Technology, The Western Australian
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Department of Health, and each of the hospitals involved in the
study. All data analysis was carried out on deidentified data.
Identifying patient information was provided only for potential
cases for the purposes of data validation and subsequently de-
stroyed upon completion of data validation.
Results
There were 129 082 cataract/lens procedures performed across 46
health care facilities in Western Australia between 1980 and 2001
(Table 2; available online at http://aaojournal.org). The majority
(n ! 69 575; 53.9%) were performed from 1995 to 2001, with
phacoemulsification the most commonly performed operation (n!
65 061; 50.1%) followed by ECCE (n ! 47 868; 36.8%), “other”/
lens procedures (n ! 11 899; 9.2%) and ICCE (n ! 5153; 4.0%).
Females accounted for 58% of the cohort and most patients (n !
90 744; 70.3%) were aged !70 years. Just over half (n ! 69 317;
53.7%) of the procedures were performed in the private sector and
the majority (n ! 117 077; 90.7%) in metropolitan areas. Average
length of follow-up was 6.6 years (SD, 5.0; range, 0–22.4).
There were 2087 (1.6%) confirmed complications. The most
frequent complication was retinal detachment (n ! 905; 0.7%),
followed by IOL dislocation (n ! 361; 0.28%), endophthalmitis
(n ! 228; 0.18%), wound dehiscence (n ! 227; 0.17%), pseudo-
phakic corneal edema (n ! 207; 0.16%), and dropped nucleus
(n ! 159; 0.12%). Complications were almost twice as common
for men than women (2.06% vs 1.28%; P"0.001). This trend was
seen with retinal detachment (1.02% vs 0.46%; P"0.001), IOL
dislocation (0.37% vs 0.21%; P"0.001), wound dehiscence
(0.21% vs 0.15%; P!0.003), and dropped nucleus (0.15% vs
0.10%; P ! 0.014).
Complications also varied across 10-year age groups. Retinal
detachments were more common with decreasing age, whereas
cases of IOL dislocation, corneal edema, and dropped nucleus
were more common with increasing age. There was no difference
in the incidence of wound dehiscence or endophthalmitis over the
10-year age groups. Complications were most common for ICCE
and ECCE procedure types (approximately 2%), whereas compli-
cations were half as common after phacoemulsification (2% vs
0.98%; P"0.001).
Trends over Time
The overall incidence of major cataract surgery complications
steadily declined over the study period (Fig 1). This was most
evident for corneal transplant for pseudophakic corneal edema,
which fell by 48% for every 5 years since 1980 (5-year RR, 0.52;
95% CI, 0.44–0.61; P"0.001); retinal detachment, which has
fallen by 20% every 5 years since 1980 (5-year RR, 0.80; 95% CI,
0.75–0.85; P"0.001), and wound dehiscence (5-year RR, 0.76;
95% CI, 0.68–0.85; P"0.001; Table 3). There was no significant
change in the incidence of endophthalmitis over the study period.
The incidence of dropped nucleus increased from a negligible rate
pre-1990 to 1.87 per 1000 procedures during 1995 to 2001 (5-year
RR, 1.74; 95% CI, 1.16–2.63; P ! 0.008). The 5-year cumulative
incidence of IOL dislocations improved initially (declining from a
peak of 0.55% in 1980–1984 to 0.17%–0.18% in 1985–1994), but
increased to 0.30% in 1995 to 2001.
Extracapsular Extraction versus
Phacoemulsification
The incidence of all complications except dropped nucleus was
generally lower for phacoemulsification compared with ECCE
(Fig 2). However, after adjusting for age, sex gender, and year of
surgery, only IOL dislocations (RR, 0.47; 95% CI, 0.35–0.63) and
wound dehiscence (RR, 0.12; 95% CI, 0.08–0.18) were signifi-
cantly different (Table 2; available online at http://aaojournal.org).
Compared with ECCE, the rate of complications after phaco-
emulsification consistently improved over the study period (Table
4). Over a similar transition period, complications for ECCE
initially fell to a low during the midtransition period, but then
increased slightly. This trend was particularly evident for retinal
detachment, IOL dislocation, wound dehiscence, and dropped nu-
cleus (Fig 2).
Discussion
The rate of complications after cataract surgery in Western
Australia fell by almost 70% from a peak of 3% in the early
1980s to 1% per annum by 2001. A direct comparison of our
results with other published studies is difficult because of a
lack of consistency in categorizing complications and be-
cause most previous investigations reported only intraoper-
ative and early postoperative events without considering
long-term complications.
The greatest decrease over the study period was seen for
retinal detachment and pseudophakic corneal edema. Reti-
nal detachment was the most common complication and had
a 5-year cumulative incidence of 0.63%. This was similar to
a previous study from Olmstead County that also used
population-based record linkage methodology. The re-
searchers reported the 5-year cumulative incidence of reti-
nal detachment after cataract surgery between 1980 and
2004 was 0.71%, increasing to 1.79% after 20 years.6 How-
ever, there are no studies that have reported the change in
incidence over an extended time. Our findings support the
findings of previous studies5,6,34 that the risk of retinal
detachment after phacoemulsification was no greater than
for ECCE.
We observed a substantial decline in the rate of pseudopha-
kic corneal edema requiring corneal transplant over the study
period. The crude rate after phacoemulsification was 85% less
Figure 1. Trend in cataract/lens surgery (---) and the incidence of major
complications (dropped nucleus, wound dehiscence, retinal detachment,
intraocular lens dislocation, endophthalmitis and pseudophakic corneal
edema) per 1000 procedures (—) in Western Australia (1980–2001).
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than after ECCE although, with only 20 cases after phacoemul-
sification, we were not able to confirm a significant difference.
To our knowledge, there are no studies that have reported on
the change in the incidence of pseudophakic corneal edema
with which we can compare our results. Canner et al35 reported
the rate of re-hospitalization for corneal edema or transplant in
a single cohort of 325 348 cataract procedures performed in
1984 was 1.06%, 0.52% and, 0.55% for ICCE, ECCE, and
phacoemulsification procedures, respectively, and 0.68%
overall. Although we found similar results during the same
period (early 1980s), the rate of corneal transplantation for
pseudophakic corneal edema has dramatically declined
since that time. Studies reporting on the trend in the crude
number of corneal transplants performed for pseudophakic
corneal edema are conflicting with reports of increasing and
decreasing trends.36,37 It is not possible to ascertain whether
these numbers relate to an increase or decrease in the actual
incidence per cataract procedure. The decline in cases of
pseudophakic corneal edema undergoing corneal transplanta-
tion in Western Australia is likely multifactorial. Significant
improvements in operative techniques, instrumentation, IOL
design, and viscoelastics used in cataract surgery have oc-
curred over the study period, all of which act to reduce corneal
endothelial damage.38 Additionally, follow-up time after
phacoemulsification was shorter than for ECCE and ICCE,
leading to fewer cases being counted and to an underestimation
of the true incidence.
The transition to phacoemulsification had a significant
impact on the rate of wound dehiscence, which halved over
the study period in line with the introduction of small
incision surgery. Our procedure-specific rate of wound de-
hiscence is similar to previous reports,4,18,19,22,23,26 demon-
strating the safety of small incision cataract surgery over
ICCE and ECCE at approximately one tenth the rate of
wound dehiscence.
Phacoemulsification was also associated with a dramatic
increase in the incidence of dropped nucleus from negligible
rates before 1990. The number in our study (0.12%) was
low compared with most previous studies, which have re-
ported rates between 0.09% and 0.97%.4,18,22,24,25 The sub-
sequent decline in the incidence of dropped nucleus found
in our study has not been described previously and may be
due to a combination of surgeon learning curve and im-
provements in phacoemulsification operating technique and
equipment.
In this study, IOL dislocations have almost doubled
since 1985 to a 5-year cumulative incidence of 0.30% in
1995 to 2001. Early reports elsewhere are similar.39,40 A
Swedish study of cataract surgeries in a single center
between 2000 and 2005 found that the number of sec-
ondary IOL operations had tripled, whereas the number
of cataract surgeries had only doubled.39 Most eyes with
IOL dislocation had features that would categorize them as
challenging cases. Davis et al40 studied 86 spontaneous late
(!3 months) in-the-bag IOL dislocations during 2000 to
2008, reporting a significant increase after 2006. They
found that patients with pseudoexfoliation or a history of
previous vitreoretinal surgery were important predictors for
late IOL dislocation.
Since 1995, ECCE was associated with an increased rate
of IOL dislocations, dropped nucleus, and wound dehis-
cence. This is the first report that complications associated
with ECCE have increased and the reasons are unclear. It
may be due to surgeon classification bias because ECCE is
now mainly used for more complex cataracts or after failed
phacoemulsification. Other possible explanations include
the smaller number of ECCE procedures during the period
(resulting in a large increase in incidence with only small
changes in the number of complications); and increasing
inexperience with ECCE, as phacoemulsification has be-
come the predominant technique.
Major strengths of our study are its whole-population
design spanning 22 years and the large number of cases
allowing for increased precision. We used routinely col-
lected administrative data whose main purpose is not for
clinical research. Although this may be criticized owing to
concerns regarding data accuracy,41 our careful chart review
ensured validation of those complications found. Prior val-
Table 3. Trend in Overall Incidence of the Major Complications of Cataract/lens Surgery in Western Australia 1980 to 2001
(A) Intraoperative and early post-operative complications (per 1,000 cataract/lens procedures)
1980–1984 1985–1989 1990–1994 1995–2001 All years IRR! 95% CI P-value
Endophthalmitis 2.17 (1.36–3.29) 1.61 (1.11–2.26) 1.91 (1.44–2.48) 1.66 (1.37–1.99) 1.75 (1.53–1.99) 0.94 (0.82–1.07) 0.33
Wound dehiscence 2.57 (1.68–3.76) 2.63 (1.98–3.44) 2.01 (1.53–2.60) 1.26 (1.00–1.55) 1.75 (1.53–1.99) 0.76 (0.68–0.85) "0.001
Dropped nucleus N/A N/A 1.06 (0.71–1.54) 1.87 (1.56–2.22) 1.31 (1.11–1.53) 1.74 (1.16–2.63) 0.008
(B) Late post-operative complications (5-year cumulative incidence (%))
1980–1984 1985–1989 1990–1994 1995–2001 All years HR† (95% CI) P-value
Retinal detachment 1.05 (0.87–1.28) 0.85 (0.72–0.98) 0.60 (0.52–0.69) 0.45 (0.39–0.52) 0.63 (0.58–0.68) 0.80 (0.75–0.85) "0.001
IOL dislocation 0.55 (0.37–0.80) 0.17 (0.12–0.24) 0.18 (0.14–0.24) 0.30 (0.26–0.34) 0.26 (0.23–0.29) 1.07 (0.92–1.23) 0.39
Pseudophakic corneal
edema
0.28 (0.19–0.41) 0.12 (0.08–0.18) 0.09 (0.06–0.13) 0.05 (0.03–0.08) 0.10 (0.08–0.12) 0.52 (0.44–0.61) "0.001
N/A # not applicable; IOL # intraocular lens.
Numbers in brackets are 95% confidence intervals (CI).
*Age and sex adjusted incidence rate ratio (IRR) and 95% CI of a complication in each 5-year group after 1980.
†Age and sex adjusted hazard ratio (HR) and 95% CI of a complication in each 5-year group after 1980.
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idation of cataract procedure coding errors also enabled us
to correct for any miscoding in the denominator cohort.33
Because all complications identified in this study were
based on either readmission to hospital for surgery or ad-
ditional surgery being performed during the same admission
as the cataract surgery, it is likely we have underestimated
the true number of cases. Not all complications require
surgery (e.g., the treating surgeon may decide not to operate
or the patient may refuse further surgery). Some complica-
tions can also be treated as a minor procedure in the out-
patient setting and may be missed (e.g., placing a corneal
suture for wound dehiscence or performing laser therapy for
retinal tears and small retinal detachments). However, we
estimate the number of cases missed owing to such outpa-
Figure 2. Comparison of trends in the incidence of major complications of cataract/lens surgery (per 1000) between 1980 and 2001 for extracapsular
cataract extraction (ECCE) technique and phacoemulsification (a-h). The volume of each type of surgery in each year is shown in graphs (g) and (h).
Rate ratios (RR) and their 95% confidence intervals (CI) compare the complication rate of phacoemulsification with ECCE adjusted for age, gender, and
year of surgery (hazard ratios for retinal detachment, intraocular lens dislocation and pseudophakic corneal edema; incidence rate ratios for wound
dehiscence, endophthalmitis and dropped nucleus).
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tient treatment is likely to be negligible because the standard
practice in Western Australia over the study period was to
admit patients with these complications for operative man-
agement. Furthermore, because we identified those cases
serious enough to require further surgery, they are therefore
most likely to be clinically significant in terms of their
impact on vision and health resources.
The complication profile of cataract surgery in Western
Australia improved significantly between 1980 and 2001.
Although there was considerable change in operative tech-
nique, this alone may not be the sole reason for the reduc-
tion in complications; other factors not measured in this
study are likely involved. The increase in complications
after ECCE, and the increasing trend in IOL dislocation, is
concerning and warrants scrutiny.
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Table 1: International Classification of Disease codes used to identify cataract procedures and postoperative 
complications. 
 
Item 
Procedure codes 
ICD 9 
1980 – 1987 
ICD 9 CM 
1988 – June 1999 
ICD 10AM 
June 1999 onwards 
 
Procedure Type    
Intracapsular 5-144 13.11, 13.19 42698-00, 42702-00, 42702-01 
Extracapsular 5-142, 5-145 13.2, 13.3, 13.51, 13.59 42698-01, 42698-04, 42702-02, 42702-03, 42702-08, 42702-09 
Phacoemulsification - 13.41 - 13.43 42698-02, 42698-03, 42702-04, 42702-05, 42702-06, 42702-07 
Lens procedure 5-147, 5-149 13.70, 13.71, 13.72, 13.9 42701-00, 42701-01, 42703, 90077-00 
Other cataract extraction 5-146 13.64, 13.65, 13.66, 13.69 
42734-00, 42719-00, 42719-02, 42698-05, 
42788-00, 42722-00, 42731-00, 42702-10, 
42702-11, 42731-01, 42716-00 
    
Complication Type    
Retinal detachment 5-152, 5-153, 5-156 14.3 – 14.59, 14.9 42773-00, 42773-01, 42776-00, 42809-01, 90079-00 
Intraocular lens 
dislocation 5-147, 5-149 13.70, 13.72, 13.8 
42701-00, 42701-01, 42703-00, 42704-00, 
42704-01, 42710-00, 42713-00 
Dropped nucleus 5-149, 5-157 13.9, 14.70 – 14.79 42702-10, 42702-11, 42719-01, 42722-01, 42725-00, 42731-01, 42740-05, 9007-00 
Pseudophakic corneal 
edema 
5-113, 5-119, 5-125 
5-129 
10.44, 10.49, 11.53, 11.6, 
11.60, 11.61, 
11.62, 11.63, 11.64, 11.69 
42659-00, 42653-00 
42671-00, 90064-00, 
42632-00, 42638-00, 
42653-01, 42656-00, 90067-00 
Wound dehiscence 5-124, 5-126 11.5, 11.51, 11.52, 11.59, 12.83, 12.66 
42551-00, 42551-01, 42551-02, 42554-00, 
42635-00, 42667-00, 
42857-00, 42857-01, 
90060-00, 90066-00 
ICD = international classification of disease  
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Risk for Retinal Detachment After
Phacoemulsification
A Whole-Population Study of Cataract Surgery Outcomes
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Objectives: To estimate the long-term cumulative in-
cidence of and risk factors for retinal detachment (RD)
after phacoemulsification using linked administrative
medical data.
Methods: We used the Western Australian Data Link-
age System to identify patients who underwent phaco-
emulsification inWesternAustralia between January 1989
andDecember 2001. Retinal detachment caseswere those
patients requiring admission for RD surgery after phaco-
emulsification that were validated by medical record re-
view. Kaplan-Meier analysis was used to calculate a cu-
mulative incidence. Cox proportional hazards regression
modeling was used to determine the association be-
tween RD and risk factors, including patient demograph-
ics and operative and hospital factors. Some important
risk factors, including axial length andNd:YAG laser cap-
sulotomy, were not examined.
Results: We identified 237 RD cases following 65 055
phacoemulsification procedures, with a 10-year cumu-
lative incidence of 0.68% (95% CI, 0.56%-0.83%). Sig-
nificant risk factors were year of surgery (hazard ratio
[HR], 0.43; 95%CI, 0.28-0.66 [1999-2001 comparedwith
1989-1993] for each 5-year period after 1985), age
younger than 60 years (3.76; 2.83-5.00), male sex (1.91;
1.45-2.51), and anterior vitrectomy (27.60; 19.27-
39.52). Hospital location, patient rural or remote local-
ity, hospital cataract surgery volume, failed intraocular
lens insertion, length of stay, and patient insurance sta-
tus were not significantly associated with RD.
Conclusions: Risk for RD after phacoemulsification has
almost halved for each 5-year period since its adoption in
themid1980s.Youngerpatient ageandmale sexat surgery
significantly increasedrisk forRD.Phacoemulsificationre-
quiring anterior vitrectomy vastly increased risk for RD.
Arch Ophthalmol. 2012;130(7):882-888
R ETINALDETACHMENT(RD) ISone of the most frequentsight-threatening complica-tionsofmoderncataract sur-gery and complicates ap-
proximately 1% of all cataract operations
performed in Western countries.1-13 Mul-
tiple risk factors are implicated, including
patient factors (younger age,male sex, and
long axial length),1-4,8,11,14-16 operative fac-
tors (surgical technique, vitreous loss, and
posterior capsule rupture),2,6,11,13,17-20 and
postoperative factors (Nd:YAG laser pos-
terior capsulotomy).4,7 Operative tech-
nique has been implicated as a significant
risk factor for subsequent RD, particularly
because the abandonment of intracapsu-
lar cataract extraction in favor of extracap-
sular cataract extraction during the late
1970s resulted ina significantdecline in the
incidenceofpseudophakicRD.6,7,12,21,22 The
subsequent adoption of phacoemul-
sification cataract surgery as the current
procedure of choice has maintained this
reducedrisk forRD,1,2,7,12 despite initial con-
cerns associatedwith the surgeon learning
curve surrounding its adoption.6
Results of population-based investiga-
tions suggest that risk for RD after phaco-
emulsification may remain increased for
10 years after cataract surgery, yet few
studies1,2 followed up patients longer than
approximately 5 years. The objectives of
our study were to explore changes in the
long-term risk for RD after cataract sur-
gery over time since phacoemulsification
was first introduced and to identify im-
portant population-based risk factors for
RD after phacoemulsification in the en-
tire Western Australia (WA) population
using validated linked health administra-
tive data. Phacoemulsification was widely
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adopted inWAduring the late 1980s andby themid 1990s
had become the procedure of choice inmost cataract sur-
gical procedures.23 The Western Australian Data Link-
age System links routinely collected health administra-
tive data sets across the entireWA population, with data
sets dating from 1966 onward,24 and provides the unique
ability to study long-term postoperative complications
of phacoemulsification on a whole-population level.
METHODS
Weconductedawhole-population retrospective longitudinal study
of RD after phacoemulsification. Linked administrative medical
data in WA from January 1989 to December 2001 were used.
STUDY POPULATION
In WA, all cataract and lens-related surgical procedures may
only be performed in health facilities licensed with theWADe-
partment of Health. All facilities are required to provide data
from all admissions, including patient demographics, comor-
bidities, primary and secondary diagnoses, and any proce-
dures undertaken or complications arising during the admis-
sion. These data, including all admissions from allWAhospitals
(public and private), were obtained from the Hospital Morbid-
ity Data Collection, one of the core data sets of the Western
Australian Data Linkage System.24
We extracted hospital discharge data from theHospitalMor-
bidity Data Collection for all patients who underwent phaco-
emulsification cataract surgery between January 1989 toDecem-
ber 2001. Linkage with the State Mortality Register allowed us
to account for follow-up loss caused by patient deaths. Phaco-
emulsification procedures were identified using the Interna-
tional Classification of Diseases, 9th Revision, Australian Clinical
Modification (ICD-9-CM)25 codes for procedures 13.41 through
13.43 and the International Classification of Diseases, 10th Revi-
sion, Australian Modification (ICD-10-AM)26 codes 42698-02,
42698-03, 42702-04, 42702-05, 42702-06, and 42702-07.
CASE VALIDATION
All surgically treated RD cases were identified using specific
ICDprocedure codes associatedwithRD repair (ICD-9-CM codes
14.3 through 14.59 and 14.9 and ICD-10-AM codes 42773-00,
42773-01, 42776-00, 42809-01, and 90079-00). Only RD-
associated procedures that occurred after the associated phaco-
emulsification procedurewere considered. Potential caseswhere
an RD occurred before the first-ever cataract extraction opera-
tion, where eye traumawas involved or where vitreoretinal sur-
gery was performed concurrently were excluded.
As detailed elsewhere,12 all potential cases were validated
by reviewing the patient medical record to confirm that the
phacoemulsification procedure and RD occurred in the same
eye. Other important operative information, such as proce-
dure type, intraocular lens (IOL) insertion, IOL type, and any
other concurrent procedures, were recorded.
STATISTICAL ANALYSIS
Age was stratified into 10-year age groups (!50, 50-59, 60-
69, 70-79, and"80 years). Patient locality was defined as met-
ropolitan, rural, or remote on the basis of residential postcode
at the time of surgery. Patient insurance status (public or pri-
vate) was also recorded. The hospital typewas classified as pub-
lic or private, and the hospital location was classified as met-
ropolitan, rural, or remote. We also considered the cataract
surgery volume performed at each hospital during the study
period, where in the largest hospitals more than 5000 proce-
dures were performed, in the large hospitals 2000 to 5000 pro-
cedures were performed, in the medium hospitals 500 to 1999
procedures were performed, and in the small hospitals fewer
than 500 procedures were performed. Length of stay was cat-
egorized as follows: day case, overnight, or longer than 1 day.
Year of surgery was grouped as follows: 1989 to 1993, 1994 to
1998, or 1999 to 2001.
Kaplan-Meier analysis was used to calculate a cumulative
incidence of RD (as a percentage of cataract procedures),
whereby patients were censored at the time of death or at the
end of the follow-up period. Cox proportional hazards regres-
sion modeling was used to calculate hazard ratios (HRs) (95%
CIs) for each risk factor examined. Using generalized estimat-
ing equations, SEs were adjusted for clustering of procedures
around individuals. Important risk factors in Cox propor-
tional hazards regressionmodeling were selected using a back-
ward stepwise variable selection; all covariates were included
in an initial model, and the variable with the highest P value
was sequentially removed until the most parsimonious model
remained in which the P value for all variables was less than
.05. All the statistical analyses were performed using commer-
cially available software (STATA, version 10.0; StataCorp LP).
ETHICAL CONSIDERATIONS
This studywas approved by the human research ethics commit-
tees atCurtinUniversity (Perth, Australia), theWADepartment
of Health, and each of the hospitals involved in the study. Data
analysis was performed on deidentified data. Patient informa-
tion for potential cases was provided only for data validation.
RESULTS
In total, 65 055phacoemulsificationprocedureswere per-
formed on 46 258 patients in WA between January 1989
to December 2001, of which 237 (0.4%) were associated
with a subsequent admission forRDsurgery (Table). The
crude incidence of RD after phacoemulsification declined
by amean of 19% for each year after 1989 (incidence rate
ratio, 0.81; 95%CI, 0.77-0.84) (Figure1A). Themedian
timetoRDafterphacoemulsificationwas11months(range,
0-8.4 years), with the cumulative incidence increasing al-
most linearly from0.47%(95%CI,0.41%-0.54%)by5years
after surgery to0.68%(0.56%-0.83%)by10years after sur-
gery (Figure 1B). Characteristics of the patients undergo-
ing phacoemulsification procedures and those of the RD
cases are summarized in the Table.
The mean (SD) age of patients undergoing phaco-
emulsification procedures was 73.7 (10.3) years (age
range, 4-104.4 years). Men were slightly younger than
women at the time of surgery (mean difference, 2.4; 95%
CI, 2.2-2.6 years; P! .001). Most patients were female
(58.4%), lived in ametropolitan locality (83.9%), and had
private insurance (63.9%).
The mean (SD) age of RD cases was 64.4 (12.9) years
(age range, 24-93 years), and 62.4%were male. Younger
patient age andmale sexwere significantly associatedwith
an increased risk for RD identified in the univariate and
multivariate Cox proportional hazards regression mod-
els (Figure 2A and B). Compared with those 60 years
or older, patients younger than 60 years had almost a
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4-fold increased risk for RD (HR, 3.76; 95% CI, 2.83-
5.00; P! .001). Compared with women, men were ap-
proximately twice as likely to have an RD following their
cataract surgery (HR, 1.91; 95%CI, 1.45-2.51; P! .001).
Among RD cases, age was not significantly different be-
tween the sexes (P=.21). No other patient factors, in-
cluding locality and insurance status, were indepen-
dently associated with risk for RD.
An IOL was not inserted in 432 phacoemulsification
procedures (0.7%). In the univariate model, failed IOL
insertion was associated with an almost 5-fold in-
creased risk for subsequently having an RD (HR, 4.86;
95% CI, 2.57-9.20; P! .001) and with more than twice
the risk after adjustment for all other risk factors in the
multivariate model (2.28; 1.06-4.93; P=.04). However,
failed IOL insertion was not significant in the backward
stepwise method (excluded at P=.06).
Anterior vitrectomywas performed in 643 phacoemul-
sification procedures (1.0%) and in 48 RD cases (20.3%).
The 5-year cumulative incidence of RD after phacoemul-
sification inwhich anterior vitrectomywas performedwas
8.31% (95%CI, 6.14%-11.20%) and increased to approxi-
mately 15%by the endof the follow-upperiod (Figure 2D).
In the backward stepwise variable selection, anterior vi-
Table. Characteristics of Patients Undergoing Phacoemulsification Procedures in Western Australia Between January 1989
and December 2001 and Cox Proportional Hazards Regression Analysis of Risk Factors for Retinal Detachment
Variable
Phacoemulsification
Procedure,
No. (%)
(n=65 055)
Retinal
Detachment,
No. (%)
(n=237)
5-Year
Cumulative
Incidence, %
(95% CI)
Univariate Model
Multivariate Model
All Variables
Backward Stepwise
Variable Selection
HR (95% CI)
P
Value HR (95% CI)
P
Value HR (95% CI)
P
Value
Year of surgery
1989-1993 3974 (6.1) 49 (20.7) 0.96 (0.70-1.32) 1 [Reference] . . . 1 [Reference] . . . 1 [Reference] . . .
1994-1998 28 345 (43.6) 123 (51.9) 0.43 (0.36-0.51) 0.45 (0.31-0.63) !.001 0.48 (0.32-0.71) !.001 0.46 (0.32-0.66) !.001
1999-2001 32 736 (50.3) 65 (27.4) 0.25 (0.19-0.33)a 0.41 (0.27-0.62) !.001 0.45 (0.28-0.73) .001 0.43 (0.28-0.66) !.001
Age, y
"80 19 112 (29.4) 22 (9.3) 0.11 (0.07-0.18) 1 [Reference] . . . 1 [Reference] . . . 1 [Reference] . . .
70-79 28 800 (44.3) 75 (31.6) 0.33 (0.26-0.42) 2.42 (1.49-3.92) !.001 2.36 (1.45-3.85) .59 2.35 (1.45-3.83) .001
60-69 11 233 (17.3) 64 (27.0) 0.75 (0.57-0.98) 5.06 (3.09-8.28) !.001 4.28 (2.58-7.10) .001 4.38 (2.67-7.19) !.001
50-59 4052 (6.2) 43 (18.1) 1.51 (1.09-2.09) 9.59 (5.69-16.16) !.001 8.25 (4.79-14.23) !.001 8.65
(5.10-14.68)
!.001
!50 1858 (2.9) 33 (13.9) 1.99 (1.32-2.99) 13.08
(7.43-23.04)
!.001 9.46 (5.13-17.41) !.001 10.21
(5.71-18.25)
!.001
Sex
Female 37 991 (58.4) 89 (37.6) 0.30 (0.24-0.38) 1 [Reference] . . . 1 [Reference] . . . 1 [Reference] . . .
Male 27 064 (41.6) 148 (62.4) 0.70 (0.58-0.83) 2.37 (1.81-3.10) !.001 1.91 (1.45-2.51) !.001 1.91 (1.46-2.51) !.001
Failed intraocular
lens insertion
No 64 623 (99.3) 226 (95.4) 1.70 (0.81-3.54) 1 [Reference] . . . 1 [Reference] . . . . . . . . .
Yes 432 (0.7) 11 (4.6) 0.46 (0.40-0.53) 4.86 (2.57-9.20) !.001 2.28 (1.06-4.93) .04 . . . . . .
Anterior vitrectomy
No 64 412 (99.0) 189 (79.7) 0.39 (0.33-0.46) 1 [Reference] . . . 1 [Reference] . . . 1 [Reference] . . .
Yes 643 (1.0) 48 (20.3) 8.31 (6.14-11.20) 26.90
(19.40-37.24)
!.001 27.60
(19.27-39.52)
!.001 28.96
(20.43-41.05)
!.001
Patient locality
Metropolitan 54 565 (83.9) 183 (77.2) 0.44 (0.37-0.52) 1 [Reference] . . . 1 [Reference] . . . . . . . . .
Rural or remote 10 254 (15.8) 52 (21.9) 0.61 (0.45-0.84) 1.52 (1.12-2.08) .008 1.33 (0.89-1.96) .16 . . . . . .
Not classified 236 (0.4) 2 (0.8)
Patient insurance
Public 23 499 (36.1) 73 (30.8) 0.41 (0.32-0.52) 1 [Reference] . . . 1 [Reference] . . . . . . . . .
Private 41 548 (63.9) 163 (68.8) 0.49 (0.40-0.58) 1.14 (0.86-1.51) .37 0.80 (0.42-1.54) .51 . . . . . .
Other 8 (0.01) 1 (0.4)
Hospital type
Public 23 415 (36.0) 77 (32.5) 0.42 (0.33-0.54) 1 [Reference] . . . 1 [Reference] . . . . . . . . .
Private 41 640 (64.0) 160 (67.5) 0.49 (0.41-0.58) 1.13 (0.86-1.48) .40 1.57 (0.79-3.10) .20 . . . . . .
Hospital location
Metropolitan 58 614 (90.1) 214 (90.3) 0.47 (0.40-0.54) 1 [Reference] . . . 1 [Reference] . . . . . . . . .
Rural or remote 6419 (9.9) 23 (9.7) 0.46 (0.30-0.71) 1.08 (0.70-1.66) .73 0.77 (0.40-1.46) .42 . . . . . .
Not classified 22
Hospital cataract
surgery volume
#10 000 (n=2) 24 655 (37.9) 114 (48.1) 0.55 (0.45-0.67) 1 [Reference] . . . 1 [Reference] . . . . . . . . .
2000-5000 (n=9) 24 739 (38.0) 71 (30.0) 0.37 (0.28-0.47) 0.72 (0.53-0.97) .03 0.75 (0.49-1.14) .18 . . . . . .
500-1999 (n=12) 12 513 (19.2) 34 (14.3) 0.37 (0.26-0.54) 0.77 (0.52-1.13) .19 0.93 (0.60-1.45) .76 . . . . . .
!500 (n=23) 3148 (4.8) 18 (7.6) 0.72 (0.43-1.21) 1.51 (0.92-2.49) .11 1.66 (0.88-3.12) .12 . . . . . .
Length of stay
Day case 42 690 (65.6) 130 (54.9) 0.44 (0.36-0.54) 1 [Reference] . . . 1 [Reference] . . . . . . . . .
Overnight 11 311 (17.4) 46 (19.4) 0.47 (0.34-0.65) 1.13 (0.80-1.59) .50 0.97 (0.67-1.39) .86 . . . . . .
#1 d 11 054 (17.0) 61 (25.7) 0.53 (0.41-0.70) 1.18 (0.86-1.62) .30 0.95 (0.67-1.37) .80 . . . . . .
Abbreviations: Elipsis, not applicable; HR, hazard ratio.
aThree-year cumulative incidence.
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trectomy was associated with significantly increased risk
forRD,whichwas almost 30 times greater (HR, 28.96; 95%
CI, 20.43-41.05;P! .001) than operations inwhichno an-
terior vitrectomy was performed.
The crude incidence of anterior vitrectomyduring cata-
ract surgery declined in the first few years of phacoemul-
sification adoption in WA and leveled off thereafter at a
rate of 10 per 1000 phacoemulsification procedures per-
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Figure 1. Cohort of 65 055 phacoemulsification procedures in Western Australia between January 1989 and December 2001. A, Trends in the crude incidence of
retinal detachment. B, Twelve-year cumulative incidence of retinal detachment.
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Figure 2. Cohort of 65 055 phacoemulsification procedures in Western Australia between January 1989 and December 2001. Comparison of the cumulative incidence of
retinal detachment by patient age (A), sex (B), year of surgery (C), and whether anterior vitrectomy was performed during surgery (D) (P! .001 for all by log-rank test).
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formed (Figure3). The crude incidence of RD after cata-
ract surgery showed a similar decline early in the study
period and has continued to decline, despite the rate of
anterior vitrectomy remaineding constant.
Most phacoemulsification procedures (90.1%) were
performed inmetropolitan hospitals, and 64.0%were in
private hospitals. Two hospitals in WA performed more
than 10 000 phacoemulsification procedures, account-
ing for 37.9% of all phacoemulsification procedures per-
formed in the state. Twenty-three hospitals performed
fewer than 500 phacoemulsification procedures, which
accounted for less than 5% of the total cohort; 14 of these
hospitals were in rural or remote areas. A significant pro-
portion (83.0%) of phacoemulsification procedures in-
volved day case or overnight admissions.Nohospital vari-
able (location, cataract surgery volume, or public vs private
status) was significantly associated with risk for RD in
the univariatemodel or in themultivariatemodel (Table).
Most phacoemulsificationprocedures (50.3%)wereper-
formed between 1999 and 2001. Approximately a 50% re-
duction in the incidence of RDwas observed for each sub-
sequent year group, from a high of 0.96% from 1989 to
1993 to a low of 0.25% from 1999 to 2001 (Figure 2C).
After adjustment for all significant variables in the mul-
tivariatemodel, year of surgery remained significantly as-
sociatedwith risk for RD, such that theHRwas 0.43 (95%
CI, 0.28-0.66; P! .001) by 1999 to 2001 compared with
1989 to 1994.
COMMENT
Wefound that the cumulative incidenceofRDafter phaco-
emulsification was almost 0.2% at 1 year (Figure 1B). By
comparison, the annual incidence of rhegmatogenous RD
in the general population of similar age is reported to be
between 22 and 49 cases per 100 000 population.27-29 Al-
though thesemeasures are not directly comparable, it sug-
gests a substantially increased risk forRDafter phacoemul-
sificationabove thebaseline risk in thegeneral community.
Our findings are comparable with the incidence of RD
after phacoemulsification reported elsewhere.1-11,14,16,19,20
Manyof these studieswere limitedby their smaller sample
sizes,4,7-11,16,19,20 involved single clinical centers,4,7-11,16,19,20
or had short follow-up periods (!5 years).5,10,16,19,20 Our
whole-population study captured the entire cohort of pa-
tients undergoing phacoemulsification in a well-defined
population of 2.2 million people that is representative of
the Australian context.30,31 The WA population has com-
paratively low out-of-state emigration rates, representing
a stable population for longitudinal observation.31 In ad-
dition, a major limitation of previous research using ad-
ministrative medical data is the inability to confirm that
the eye that had the RDwas the same eye that underwent
cataract surgery.1,3,5,6 We manually validated all potential
RD cases using medical record review and are confident
in the details of not only the complication but also the as-
sociated surgical procedure.
We found that the cumulative incidence of RD after
phacoemulsification continued to increase up to 10 years
after surgery. Long-term follow-up data for cataract sur-
gery outcomes on a population-based level are lacking. A
population-based studywith a long follow-upperiod ("20
years) byErie et al2 reported that the cumulative incidence
of RD after extracapsular cataract extraction (including
phacoemulsification) was 0.71% at 5 years and 1.23% at
10 years for all the surgical procedures performed be-
tween1980 and2004 inOlmsteadCounty,Minnesota.Al-
though their cohort also included patients undergoing ex-
tracapsular cataract extraction, the authors reported no
significantdifference intheprobabilityofRDcomparedwith
that associatedwith phacoemulsification. In contrast, risk
forRDinourstudy(cumulative incidence,0.47%and0.68%
at5and10years, respectively)was substantially lower than
that reported by these authors and may be because of the
later time frame of our study.
The incidence of RD after phacoemulsification inWA
decreased significantly over time, with a steady decline
in the 5-year cumulative incidence from0.96% from1989
to 1993, to 0.43% from1994 to 1998, to 0.25% from1999
to 2001. This reduction remained significant after ad-
justment for patient sociodemographic, surgical, and hos-
pital factors. The large fall in incidence from the period
representing the adoptionof phacoemulsification into rou-
tine clinical practice inWA (1989-1993) to plateau there-
after is likely due to surgeon learning curve, althoughother
unmeasured factors, such as improvement in surgical tech-
nique and advances in equipment technology, may have
contributed to this result.
Less than 1%of phacoemulsification procedures in our
cohort involved an anterior vitrectomy, and failed IOL
insertion occurred in 0.7%. Although we were unable to
confirm every case of posterior capsule rupture that oc-
curred, the data provided for this study allowedus to iden-
tify every case of anterior vitrectomy. Our rate of ante-
rior vitrectomy during cataract surgery herein is within
the range of other contemporary studies.32,33 The 5-year
cumulative incidence of RD after phacoemulsification in
which anterior vitrectomy was performed was 8.31% in
our study,with a relative risk approaching 30 times higher
than that in surgical procedures in which no anterior vi-
trectomy was performed.
Many studies2,6,11,13,17,18,34 demonstrated an increased
risk for RD (range, 4.5-19.9 times higher) after surgical
procedures documenting posterior capsule rupture with
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Figure 3. Comparison of the crude incidence of anterior vitrectomy and
retinal detachment in a cohort of 65 055 phacoemulsification procedures in
Western Australia between January 1989 and December 2001.
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orwithout vitreous loss, although a few studies1,4,35 found
no change in risk. Anterior vitrectomy is generally per-
formed only in cataract surgery in which a posterior cap-
sule rupture has occurred with vitreous loss. Similarly,
failed IOL insertion would occur in situations of com-
plicated surgery in which capsule support is compro-
mised. Both events could be regarded as a surrogate
marker for complicated surgery involving posterior cap-
sule rupture and vitreous loss. These findings highlight
the importance of close follow-up monitoring in pa-
tients whose cataract surgery has been complicated by
posterior capsule rupture because of significant risk for
RD that may extend many years after surgery.
We confirm findings in previous large studies1-3,8,11 of
RD after cataract surgery that younger patient age and
male sex are significant risk factors for RD. Decreased
risk for RDwith age is contrary to that in the general com-
munity, where risk increases significantly with age.27-29
In our study, patients younger than 60 years undergo-
ing phacoemulsification were almost 4 timesmore likely
to have an RD compared with those who were 60 years
or older. Several theories have been postulated for why
younger patients are more likely to experience RD fol-
lowing phacoemulsification. One relates to vitreous
changes after cataract surgery. Ripandelli et al16 found
that posterior vitreous detachment occurred following
cataract surgery in 75.8% of patients without a history
of posterior vitreous detachment or lattice degenera-
tion. Given that 10% to 15% of posterior vitreous de-
tachment occurrences are associated with a retinal tear,
older patients may be protected from posterior vitreous
detachment because they are more likely to have al-
ready had phakic posterior vitreous detachment, which
tends to occur in individuals 60 years or older.15,36 Younger
eyes are also more likely to be abnormal in their devel-
opment of cataract (eg, traumatic cataract), and this may
predispose these eyes to pseudophakic RD.
Comparedwithwomen,men undergoing phacoemul-
sification were almost twice as likely to have an RD. The
increased risk for RD in men has been reported else-
where. In a population-based cohort similar to ours, Sheu
et al1 found that men had a 2.43 times higher risk for RD
after phacoemulsification than women. Althoughmen in
our study were younger on average than women, the ob-
served sex difference remained after adjusting for age. Sex
differences in the anatomy of the eye and vitreous have
beenpostulated as potential contributing factors.Men tend
to have longer axial length,37 while women tend toward
earlier posterior vitreous detachment.38 This may confer
a protective effect onwomen for subsequent RD after cata-
ract surgery. Men may also be more likely to experience
traumatic injury or to engage in activitieswhere eye trauma
is more likely owing to their occupation or lifestyle, plac-
ing them at higher risk for pseudophakic RD.
Our study has some limitations. Because all RD cases
in the study were identified based on readmission to the
hospital for surgery, we likely underestimated the true
number of cases in the population. In WA, the standard
practice for RD cases during the study period was repair
as an inpatient procedure. Procedures that may be per-
formed in an outpatient setting (eg, pneumatic retino-
pexy) andwere not capturedwere nonstandard and rarely
practiced. Even so, not all patients with RD will un-
dergo surgery (eg, the patient may refuse further sur-
gery), or theymay have an RD treated outside ofWA and
as such would not be captured in the data set. We be-
lieve that this number is likely small and that any resul-
tant bias is minimal.
Additional important risk factors for RD after cata-
ract surgery identified in other studies include axial length
and the use of Nd:YAG posterior capsulotomy. Axial
length of at least 25 mm has been significantly associ-
ated with increased relative risk for RD after cataract sur-
gery, approaching 6 times that of eyes with shorter axial
length.14,15 In their population-based study, Ninn-
Pedersen and Bauer4 found that for every 1-mm increase
in axialmyopia, the associated relative risk for RDwas 1.3.
Similarly, Nd:YAG laser posterior capsulotomy was asso-
ciated with increased risk for RD, with a relative risk of
4.9 documented in their study.4 Unfortunately, it was not
possible to analyze these factors in our study because nei-
ther characteristic is recorded in the Hospital Morbidity
Data Collection.
A strength of our study is its population-based de-
sign that includes awidely representative population, iden-
tifiesmost complications, and covers 12 years. Some limi-
tations exist surrounding the use of routinely collected
administrative medical data whose main purpose is not
for clinical research.39 The accuracy of such administra-
tive data is dependent on the quality of data processes
and systems that create these databases. However, the
Western Australian Data Linkage System is a well-
established and validated resource that has been used ex-
tensively in population-based health research.30,40We fur-
ther added to the quality of data in our study by careful
validation of RD via medical record review.
In conclusion, the incidence of pseudophakic RD has
declined markedly since the adoption of phacoemulsi-
fication cataract surgery in WA. As identified in previ-
ous studies, we confirm that younger patient age andmale
sex are important risk factors for subsequent RD. Com-
plicated operations necessitating anterior vitrectomy carry
significantly increased risk for RD. Knowledge about the
importance of such risk factors is important for physi-
cians to guide preoperative counseling and postopera-
tive review with patients.
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ABSTRACT.
Purpose: To describe trends, risk factors and outcomes of anterior vitrectomy
during cataract and intraocular lens (IOL) surgery.
Methods: All patients 16 years and older undergoing cataract and IOL surgery
in Western Australia (WA) from January 1980 to December 2001 (n = 115 815)
were included. Hospital administrative data were used to identify all cataract and
IOL procedures and subsequent admissions for retinal detachment, IOL
dislocation, endophthalmitis and pseudophakic corneal oedema. Data were
validated with chart review and analysed to identify trends and risk factors for
anterior vitrectomy and the risk of subsequent complications.
Results: In total, 1390 (1.2%) anterior vitrectomies were performed. The rate
increased with change in surgical technique. Significant risk factors for anterior
vitrectomy were age <50 years (OR 1.31), male sex (OR 1.23), IOL procedure
(OR 11.45) and operations in public hospitals (OR 1.99) or rural/remote (OR
1.40) areas. Anterior vitrectomy was strongly associated with increased risk of
retinal detachment (RD) (RR 18.5), endophthalmitis (RR 3.6), IOL dislocation
(RR 21.1) and pseudophakic corneal oedema (RR 17.3). Retinal detachments
and IOL dislocations occur earlier after anterior vitrectomy.
Conclusion: Anterior vitrectomy rates have remained stable since the introduc-
tion of phacoemulsification. Anterior vitrectomy is a major risk factor for serious
complications compared with uncomplicated surgery, particularly RD and IOL
dislocation. We identified an increasing trend in anterior vitrectomy being
performed during extracapsular and IOL surgery.
Key words: administrative data – anterior vitrectomy – cataract surgery – complication – data
linkage
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Introduction
Vitreous loss during cataract surgery
remains an inescapable reality of mod-
ern cataract surgery, even in the most
experienced surgeon’s hands. It typi-
cally occurs when the integrity of the
posterior capsule or lens zonules is
compromised allowing vitreous to pro-
lapse into the anterior chamber, requir-
ing anterior vitrectomy in most cases.
Beyond the immediate increase in
operation complexity and time, we
know that visual outcomes tend to be
poorer in the short and long term
(Frost et al. 1995; Ionides et al. 2001;
Tan & Karwatowski 2002; Johansson
et al. 2009). Post-operative complica-
tions such as high intraocular pressure,
prolonged inflammation, corneal
oedema and cystoid macular oedema
are commonly reported (Ionides et al.
2001; Tan & Karwatowski 2002; Jo-
hansson et al. 2009), while rare but
sight-threatening complications such as
retinal detachment and post-operative
endophthalmitis are also greatly
increased following vitreous loss (Bo-
berg-Ans et al. 2006; Ng et al. 2007;
Jakobsson et al. 2009; Clark et al.
2012; Solborg Bjerrum et al. 2013).
Single surgeons or surgical units are
limited in their ability to properly study
trends, risk factors and outcomes of
vitreous loss because it is uncommon.
Few studies have reported the rate of
significant post-operative complica-
tions associated with vitreous loss over
the long term (Boberg-Ans et al. 2006;
Ng et al. 2007; Jakobsson et al. 2009;
Johansson et al. 2009). Even fewer
have reported the change in rates of
vitreous loss over time (Lundstrom
et al. 2011).
We used whole population hospital
administrative data to examine the
trend in vitreous loss during 115 815
cataract and intraocular lens (IOL)
surgery between January 1980 and
December 2001 in Western Australia
(WA) using anterior vitrectomy as a
marker. The study period encompassed
two major changes in cataract surgery
technique, to extracapsular surgery
(ECCE) in the early 1980s and subse-
27
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quently phacoemulsification in the late
1980s/early 1990s. This gave us a
unique opportunity to examine the
effect of various factors, including sur-
gical technique and surgeon learning
curve, on the long-term incidence of
anterior vitrectomy and its risk of
serious sight-threatening complications
including retinal detachment, post-
operative endophthalmitis, pseudo-
phakic corneal oedema and IOL
dislocation (Clark et al. 2011, 2012).
Our previous work examined trends
in the incidence of major sight-threat-
ening complications of cataract surgery
(Clark et al. 2011) and identified ante-
rior vitrectomy as one of the major risk
factors for retinal detachment after
phacoemulsification (Clark et al.
2012). This study extends this work to
examine changes in the rates of ante-
rior vitrectomy across all cataract and
IOL procedures, the factors associated
with necessity for anterior vitrectomy
and the subsequent risk of major
complications in the longer term.
Methods
Study population
This retrospective whole population
cohort study used linked administrative
data from all public and private hospi-
tals in WA. The state of WA comprises
over 2 million people. Although it
covers an area larger than Western
Europe, the vast majority of people
and health services are concentrated in
the capital city of Perth. Intraocular
surgery in WA can only be performed
in health facilities licensed with the WA
Department of Health. It is a require-
ment that these facilities provide data
from all admissions, including same-
day admissions (public and private) to
the WA Department of Health. This
data includes patient demographics,
co-morbidities, primary and secondary
admission diagnoses, and any proce-
dures undertaken or complications
arising during the admission. It forms
the Hospital Morbidity Data Collec-
tion (HMDC), one of the core data sets
of the WA Data Linkage System
(WADLS; Holman et al. 1999).
We used the WADLS to extract
hospital admission data for all patients
aged 16 years and over who underwent
an ECCE, phacoemulsification cataract
extraction or IOL procedure (including
secondary IOL insertion and IOL
exchange) from 1980 to 2001. Patients
under 16 years were excluded as limited
anterior vitrectomy is a routine part of
paediatric cataract surgery in WA and
would not necessarily indicate a com-
plicated operation. A potential compli-
cation was identified by any subsequent
admission to hospital for a procedure to
treat retinal detachment, IOL disloca-
tion, pseudophakic corneal oedema or
endophthalmitis. Procedure data were
identified using the time period relevant
International Classification of Diseases
(ICD) procedure codes. There were
6287 potential complication cases man-
ually validated by reviewing the opera-
tive record. All data were linked to the
state death register and allowed us to
account for loss to follow-up due to
death. Further details on this method-
ology is outlined elsewhere (Clark et al.
2011).
Complications not requiring a pro-
cedure (e.g. cystoid macular oedema)
or where the procedure does not
require hospital admission (e.g. laser
posterior capsulotomy for posterior
capsule opacification) were not able to
be identified in the HMDC and could
not be included in the study and
adjusted for in the analysis. Similarly,
as visual acuity is not recorded in
HMDC, nor is it provided in the
operative record, visual outcomes were
not included.
Statistical analysis
The age- and sex-standardized rate of
anterior vitrectomy was calculated per
100 cataract and IOL procedures. Mul-
tivariate logistic regression modelling
was used to determine adjusted odds
ratio (OR) of risk factors for anterior
vitrectomy during cataract and IOL
surgery. These included patient age,
sex, private insurance status, hospital
type (public versus private), hospital
cataract and IOL surgery volume, and
year of surgery. The risk of a compli-
cation following anterior vitrectomy
was calculated using logistic regression
models for endophthalmitis and IOL
dislocation, and Cox-proportional haz-
ards regression models for retinal
detachment and pseudophakic bullous
keratopathy (to account for their
longer lead time and differing follow-
up periods; Clark et al. 2011). Both
models were adjusted for age, sex, year
of surgery and procedure type. Stan-
dard errors were adjusted for clustering
of procedures on individuals using
generalized estimating equations.
Multivariate linear regression mod-
els adjusting for age and sex were used
to compare the time to complication
for retinal detachment and IOL dislo-
cation for the anterior vitrectomy and
non-anterior vitrectomy cohorts. Kap-
lan–Meier failure curves were produced
comparing survival time between
groups.
An attributable risk associated with
anterior vitrectomy for each complica-
tion was calculated as the difference in
complication incidence in the anterior
vitrectomy cohort (Iexp) compared with
the uncomplicated cataract surgery
cohort (Iunexp), that is, AR =
Iexp!Iunexp. Number needed to harm
was calculated as 1/AR and represents
the number of anterior vitrectomies
required to result in an additional
complication. All analysis was per-
formed using STATA 11.0 (StataCorp,
College Station, TX, USA).
Ethics
This study was approved by the human
research ethics committees at Curtin
University, The University of Western
Australia, The WA Department of
Health, and each of the hospitals
involved in the study. All data analysis
was carried out on de-identified data.
Patient information was provided only
for potential cases for the purposes of
data validation.
Results
There were 115 815 patients aged
16 years and over who underwent cat-
aract or IOL surgery in WA between
January 1980 and December 2001
(Table 1). The majority were women
(58.1%) and older than 70 years
(71.3%). Most procedures were phaco-
emulsification (56.1%) in private
facilities (55.2%) between 1995 and
2001 (58.6%). IOL procedures con-
sisted of secondary IOL insertion
(n = 1755; 63.2%), IOL exchange
(n = 283; 9.2%), IOL repositioning
(n = 29; 1%) and unspecified IOL pro-
cedures (n = 817; 26.6%).
A total of 1390 anterior vitrectomies
were performed during cataract and
IOL surgery, accounting for 1.2% of
all procedures. The age- and sex-stan-
dardized rate of anterior vitrectomy
peaked at 4.8% [95% confidence inter-
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val (CI) 1.18–8.41] early in the study
period before declining to a steady rate
of approximately 1% by 1985. This
increased slightly towards 1.5% fol-
lowing the introduction of phacoemul-
sification in the early 1990s before
plateauing again at 1% by 1994. For
ECCE procedures, there was a ‘U’-
shaped curve with a steady increase in
the rate of anterior vitrectomy after a
low of 0.4% (95% CI 0.18–0.58) in
1990 to a high of 4.3% (95% CI 2.2–
6.5%) by 2001 (Fig. 1). Similarly, the
rate of anterior vitrectomy for IOL
procedures increased 5% per year over
the study period (IRR 1.05, 95% CI
1.03–1.07; Fig. 2).
Risk factors for anterior vitrectomy
are shown in Table 1. Greater risk of
vitreous loss and anterior vitrectomy
was seen in those younger than
50 years (OR 1.33, 95% CI 1.03–1.7);
men (OR 1.23, 95% CI 1.1–1.4); IOL
surgery (OR 11.45, 95% CI 9.7–13.6);
and surgery in public (OR 1.99, 95%
CI 1.7–2.3) or rural/remote (OR 1.40,
95% CI 1.2–1.7) hospitals. Phacoemul-
sification had 15% less risk of requiring
anterior vitrectomy than ECCE (OR
0.85, 95% CI 0.73–0.99). Hospital sur-
gical volume was not significantly asso-
ciated with rate of anterior vitrectomy.
There was no significant difference in
the risk of anterior vitrectomy between
the different types of IOL procedures
(Pearson chi squared 11.46, p = 0.09).
There were 236 complications of
interest following 212 cataract opera-
tions requiring anterior vitrectomy.
This accounted for 15% of the anterior
vitrectomy cohort compared with 1.1%
of the uncomplicated cataract surgery
cohort (Table 2). Retinal detachment
(8.7%) and IOL dislocation (4.5%)
were the most common complications
after anterior vitrectomy, while post-
operative endophthalmitis was the least
common (0.6%). In the multivariate
model controlling for age, sex, surgery
type and year of surgery, all complica-
tions were significantly increased after
anterior vitrectomy (Table 2). The
number needed to harm for anterior
vitrectomy was particularly low for
retinal detachment (12) and IOL dislo-
cation (21).
There was a significant difference in
the time to complication between the
anterior vitrectomy cohort and the
uncomplicated surgery cohort for reti-
nal detachments and IOL dislocations.
Retinal detachments occurred 1.6 years
earlier (95% CI 1.01–2.18, p < 0.001)
while IOL dislocations occurred
11 months earlier (95% CI 0.07–1.75,
p = 0.034) after controlling for age and
sex. Nearly half the number of retinal
detachments occurred within the first
year after complicated surgery, while it
took over 2 years before a similar
proportion occurred after uncompli-
cated surgery (Fig. 3A). Most IOL
dislocations occurred within the first
few months after surgery for both
complicated and uncomplicated opera-
tions. Where anterior vitrectomy was
performed, 75% of IOL dislocations
occurred within 6 months, compared
with <50% within 6 months for proce-
dures where anterior vitrectomy was
not performed (Fig. 3B).
Discussion
The overall incidence of anterior vit-
rectomy in our study was 1.2%, which
compares favourably to other studies
where the incidence ranged from 1.1%
to 5.4% (Ionides et al. 2001; Chan
et al. 2003; Nagashima 2004; Bhagat
et al. 2007; Narendran et al. 2009;
Lundstrom et al. 2011). We found
two main peaks in the rate of anterior
vitrectomy that coincided with signifi-
cant changes in surgical technique,
illustrating the impact of surgeon
learning curve on intraoperative com-
plications. The first was during the
transition from intracapsular to ECCE
in the 1980s and a second broader peak
occurred in the first half of the 1990s as
phacoemulsification was introduced.
The incidence has since stabilized at
around 1% as phacoemulsification
took over as the predominant
procedure (Fig. 1).
The reason for the increasing trend in
vitreous loss during ECCE in the latter
part of the study period is likely multi-
factorial. As phacoemulsification was
adopted, the complexity of patients
undergoing ECCE would have
increased as the technique would only
be used where phacoemulsification was
not felt possible (e.g. extremely dense
nucleus or significant zonular instabil-
ity). As surgeons becamemore comfort-
able with phacoemulsification, the
Table 1. Logistic regression model of risk factors for anterior vitrectomy during cataract and
intraocular lens (IOL) surgery in Western Australia (1980–2001).
Variable
Surgery
cohort
(n = 115 815)
Anterior
vitrectomy
(n = 1390)
Odds
ratio (95% CI) p-value*
Age, n (%)
80+ 33 248 (28.7) 386 (1.2) 1.00
70–79 49 332 (42.6) 500 (1.0) 0.87 (0.76–0.99) 0.039
60–69 21 635 (18.7) 291 (1.3) 1.11 (0.95–1.3) 0.206
50–59 7596 (6.6) 102 (1.3) 1.04 (0.83–1.3) 0.726
< 50 4004 (3.5) 111 (2.8) 1.31 (1.03–1.7) 0.029
Sex, n (%)
Female 67 300 (58.1) 710 (1.0) 1.00
Male 48 515 (41.9) 680 (1.4) 1.23 (1.11–1.4) <0.001
Operation type, n (%)
ECCE 47 718 (41.2) 449 (0.9) 1.00
Phacoemulsification 65 025 (56.1) 641 (1.0) 0.85 (0.73–0.99) 0.042
IOL 3072 (2.7) 300 (9.8) 11.45 (9.7–13.6) <0.001
Hospital volume, n (%)
>10 000 36 353 (31.4) 285 (0.8) 1.00
2000–10 000 62 911 (54.3) 922 (1.5) 1.14 (0.96–1.4) 0.144
<2000 16 551 (14.3) 183 (1.1) 0.80 (0.63–1.0) 0.06
Hospital type, n (%)
Private 63 921 (55.2) 514 (0.8) 1.00
Public 51 894 (44.8) 876 (1.7) 1.99 (1.7–2.3) <0.001
Metro 103 836 (89.7) 1183 (1.1) 1.00
Rural/remote 11 979 (10.3) 207 (1.7) 1.40 (1.2–1.7) <0.001
Year, n (%)
1980–1984 5226 (4.5) 93 (1.8) 1.00
1985–1989 17 947 (15.5) 162 (0.9) 0.72 (0.55–0.94) 0.017
1990–1994 24 783 (21.4) 270 (1.1) 1.09 (0.85–1.4) 0.496
1995–2001 67 859 (58.6) 865 (1.3) 1.62 (1.3–2.1) <0.001
* From a logistic regression model adjusting for all other variables in Table 1.
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complexity of cases reserved for ECCE
would likely further increase over the
course of the study period. Increased
complexity of cases is well reported to be
associated with higher risk of capsule
complications and subsequent vitreous
loss (Narendran et al. 2009). There are
also likely to be instances where ECCE
was performed only after attempted
phacoemulsification resulted in vitreous
loss requiring conversion to ECCE and
anterior vitrectomy. Finally, as sur-
geons are doing less ECCE, they are
likely to have become less skilled at
performing the procedure.
The rate of anterior vitrectomy dur-
ing IOL surgeries increased linearly
and doubled over the 21 years of the
study (Fig. 2). To our knowledge, no
other studies have reported the trend in
anterior vitrectomy during IOL surgery
with which to compare these findings.
The reason for this increase is not
immediately apparent. It is well
reported that IOL exchange procedures
have high rates of anterior vitrectomy
between 21% and 72% (Marques et al.
2007; Leysen et al. 2009), which is
potentially doubled if Nd/YAG laser
capsulotomy for posterior capsule
opacification was performed prior to
surgery (Leysen et al. 2009). The evo-
lution in IOL design over the study
period to allow in the bag placement
would conceivably increase the risk of
capsule complications during IOL
removal. Additionally, the widespread
adoption of acrylic lenses designed to
increase adherence to the capsule and
reduce posterior capsule opacification
would increase the risk of capsule
rupture during attempted removal over
less adherent PMMA and silicone
lenses used earlier in the study period
(Cooke et al. 2006).
The significance of age as a risk
factor for anterior vitrectomy is incon-
sistent across other studies. Narendran
et al. (2009) in their electronic cataract
data set study of 55 567 cataract oper-
ations in the UK found those older
than 80 years had an OR of 1.58 (95%
CI 1.20–2.08) compared with those
<60 years old. Others have found
either no significant difference or only
a small trend with increased age (Art-
Fig. 1. Age- and sex-standardized rate of anterior vitrectomy during extracapsular (ECCE) and
phacoemulsification (phaco) cataract surgery in Western Australia (1980–2001).
Fig. 2. Age- and sex-standardized rate of anterior vitrectomy during intraocular lens (IOL)
surgery in Western Australia (1980–2001).
Table 2. Risk of serious complication following cataract and IOL-related surgery where anterior vitrectomy was performed.
Complication n Anterior vitrectomies (%) RR (95% CI)* p-value AR (%) NNH
IOL dislocation 290 62 (4.5) 21.1 (15.1–29.5) <0.001 4.26 23
Post-operative endophthalmitis 187 8 (0.58) 3.6 (1.7–7.6) 0.001 0.42 239
Retinal detachment 688 121 (8.7) 18.5 (15.0–22.8) <0.001 8.21 12
Pseudophakic corneal oedema 140 26 (1.9) 17.3 (10.8–27.9) <0.001 1.77 56
* Relative risk – hazard ratio for retinal detachment and pseudophakic corneal oedema and odds ratios for IOL dislocation and post-operative
endophthalmitis. Controlled for patient age and sex, year, type of cataract surgery and location of surgery.
AR = attributable risk, NNH = number needed to harm, IOL = intraocular lens.
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zen et al. 2009; Lundstrom et al. 2011).
We found a bimodal risk where those
aged <50 years and 80+ years had
higher rates compared with the 60–
79 year group. This was significant in
the <50 year group and may be due
younger eyes being more likely to be
abnormal (e.g. traumatic cataract and
uveitic cataracts), which have an
increased risk of vitreous loss. The
older group possibly have denser cata-
racts and potentially weaker zonules,
whilst the 60–79 year group were the
ones most likely to have straightfor-
ward cataracts.
The effect of gender on risk for
anterior vitrectomy is similarly incon-
sistent across studies. We found similar
results to Narendran et al. (2009)
where men had 23% greater odds of
anterior vitrectomy. The Swedish Cap-
sule Rupture study group reported a
higher but not statistically significant
increase in posterior capsule rupture
rates for men. This greater risk may be
because men are more likely to suffer
ocular trauma and present later for
cataract surgery than women.
Patients operated in public hospitals
had nearly twice the risk of needing an
anterior vitrectomy compared with
those having surgery in private facili-
ties. There are socioeconomic and
health differences between patients
who attend public versus private insti-
tutions. Public patients in WA have
greater comorbidity and reduced access
to healthcare services (Semmens et al.
2003; Ng et al. 2005, 2006). They tend
to present late with more severe cata-
ract, contributing to a different surgical
case mix in the public setting with
inherently greater risk of complica-
tions. Additionally, trainee surgeons
operate exclusively in the public hospi-
tal setting and are known to have
increased rates of vitreous loss during
the surgical learning curve (Tan &
Karwatowski 2002; Bhagat et al.
2007; Johnston et al. 2010; Fong et al.
2012) with a reported odds ratio com-
pared with consultant surgeons of 3–4
times (Artzen et al. 2009; Narendran
et al. 2009).
Those having cataract and IOL sur-
gery in rural/remote hospitals were
more likely to undergo anterior vitrec-
tomy than their metropolitan counter-
parts. WA covers 2.5 million km2 with
a rural/remote population spread
across the vast state contributing to
reduced access and later presentations
for surgery leading to increased com-
plexity (Ng et al. 2006). Smaller rural
community hospitals also tend to be
equipped with older surgical equipment
that further increases the difficulty of
already challenging surgery.
All of the major sight-threatening
complications we examined were more
likely after surgery where anterior vit-
rectomy was required. This reinforces
the importance of appropriate patient
counselling following complicated sur-
gery regarding the potential for long-
term complications, particularly retinal
detachment.
Our study has several strengths. The
whole population design captured the
entire WA cataract surgery population
over a 20-year period providing excel-
lent opportunity to study complica-
tions such as retinal detachment, IOL
dislocations and pseudophakic corneal
oedema, which may occur many years
after surgery (Boberg-Ans et al. 2006;
Clark et al. 2011). The WA population
is ideal for population-based research
as its isolation with little outward
migration creates a stable, captured
cohort with little loss to follow-up.
Despite its isolation, WA remains
highly representative of the wider Aus-
tralian population in key demographic
indices, increasing external validity to
the wider Australian population (Clark
et al. 2010).
Limitations of our study relate to the
use of routinely collected hospital
administrative data that are not pri-
marily used for clinical research. The
accuracy of the data is dependent on
the surgeon accurately recording infor-
mation in the operation report and
clinical coders accurately coding this
information into the administrative
database. We are confident in the
quality of data in the WADLS, which
has been thoroughly validated over two
decades of population-based health
research in WA (Holman et al. 2008).
However, the true rate of vitreous loss
may be under-reported due to omis-
sions from the operating report. Vitre-
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Fig. 3. A comparison of the time to retinal detachment (A) and intraocular lens (IOL) dislocation
(B) for cataract surgery where anterior vitrectomy was and was not performed in Western
Australia (1980–2001; logrank p < 0.05 for both).
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ous complications are often stigmatized
among surgeons, and self-reported
rates may be lower than reality. Addi-
tionally, cases of vitreous loss where
anterior vitrectomy was not performed
for whatever reason will also not be
identified. Important sight-threatening
complications associated with vitreous
loss and managed on an outpatient
basis such as cystoid macular oedema
and ocular hypertension were not
recorded in the hospital administrative
data and so could not be included.
Similarly, outpatient procedures such
as Nd/YAG capsulotomy were not
recorded and thus could not be
adjusted for in the analysis.
In conclusion, we found the trend
for anterior vitrectomy during phaco-
emulsification was a decreasing one,
while ECCE and IOL surgeries have
shown an increasing trend likely due to
changes in surgical complexity and
surgeon experience. While overall rates
of anterior vitrectomy during cataract
surgery remain low, it is strongly asso-
ciated with serious post-operative com-
plications. Particular attention should
be paid to risk of retinal detachment
and IOL dislocation in the long term.
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. .
Trends and outcomes of anterior vitrectomy 
during cataract surgery 
A whole-population study of cataract surgery outcomes in Western Australia over 22 years. 
Introduction 
We examined the change in incidence of anterior vitrectomy 
in cataract surgery over time for all cataract operations 
performed in Western AustraIia (WA) between 1980 and 
2001. We also examined the association of anterior 
vitrectomy with the risk of a major sight-threatening 
complication of cataract surgery.  
 
Methods 
We used the WA Data Linkage System, which includes all 
State hospital and death records, to identify patients who 
underwent cataract surgery in all public and private hospitals 
in WA for 1980-2001.  All procedures where an anterior 
vitrectomy was performed during cataract surgery were 
identified using clinical procedure codes (ICD9, ICD9CM and 
ICD10). Potential sight-threatening complications were 
identified from those patients who underwent eye surgery 
following their cataract surgery.  All cases were validated by 
cross-referencing with the hospital medical record. 
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Table 1: Patient and surgical characteristics of cataract surgery 
where anterior vitrectomy was performed. 
Characteristic  N (%)  OR (95% CI)* 
Age (years)    
80 + 417 (1.1)  1.0 
70 - 79 545 (1.0)   0.87 (0.77-0.99) 
60 - 69  325 (1.3)   1.10 (0.95-1.3) 
50 - 59 121 (1.4)  1.05 (0.85-1.3) 
< 50 285 (5.4)   3.03 (2.57-3.57) 
Gender    
Female  843 (1.1) 1.0 
Male 861 (1.6) 1.25 (1.13-1.38) 
Cataract surgery type    
Phacoemulsification  643 (0.99)  1.0 
Extracapsular  479 (1.0)  1.41 (1.22-1.62) 
Intracapsular  127 (2.5)  3.31 (2.69-4.08) 
Lens procedure  310 (9.9)  10.9 (9.28-12.81) 
‘other’ cataract 145 (1.7) 2.44 (1.98-3.00) 
*odds ratio from a logistic regression model adjusted for all other variables in the table and 
year of surgery.   
Conclusion & Discussion!
The peaks in anterior vitrectomy coincide with major changes in surgical technique and 
may reflect a surgeon’s learning curve during the transition from intracapsular to 
extracapsular extraction and then to phacoemulsification. As expected, patients with 
anterior vitrectomy had a significantly higher higher risk of complication. 
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Figure 2: Risk of sight-threatening complications after cataract 
surgery where anterior vitrectomy is performed. Results 
1,704(1.3%) anterior vitrectomies were performed during 
129,982 cataract surgeries in WA 1980-2001 (Table 1). The 
incidence of anterior vitrectomy demonstrated two clear 
peaks in the early-1980s and early-1990s coinciding with 
the transition in surgical technique (Figure 1). 360 (21%) 
cataract surgeries involving anterior vitrectomy resulted in a 
sight-threatening complication. This included 50 (3.7%) 
retinal detachments, 9 (0.7%) pseudophakic bullous 
keratopathies, 35 (2.6%) IOL dislocations, 5 (0.4%) wound 
dehiscences, 55 (4.1%) dropped nuclei and 6 (0.4%) 
endophthalmitis cases (Figure 2). 
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Title!
Author Names!
Sight-threatening  
Complications of Cataract Surgery 
Antony Clark 
Study Aim 
•  To develop a validated dataset of the major sight-
threatening complications after cataract surgery 
1980-2001 
!  Retinal detachment 
!  Pseudophakic bullous keratopathy 
!  Dropped nucleus 
!  Wound dehiscence 
!  IOL dislocation 
!  To describe their trends in incidence over time 
Western 
Australia 
•  Combines ~8 million linked 
records from hospitals and other 
registries from 1980 
•  Encompasses the 
geographically isolated and 
stable WA population 
•  Provides the opportunity for 
large scale population- based 
studies 
. Perth 
The Western Australian Data 
Linkage System Study Method 
WA Data Linkage System 
•  Hospital admissions 1980–2001 
•  Episodes of cataract surgery (n=130,008) 
•  Episodes of ocular surgery for: 
"   Retinal detachment "   Pseudophakic bullous keratopathy  "   Wound dehiscence "   IOL Malposition "   Dropped nucleus  
Validation of potential complications (n=~5,600) 
•  Extensive chart review (n=~9,000) 
•  Confirm complication 
•  Obtain cataract operation details 
Retinal detachment surgery 
Introduction of ECCE!
Introduction of Phaco!
Year of cataract procedure
1980 1985 1990 1995 2000
5yr Incidence per 1, 000 cataract procedures
0
2
4
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N
um
ber of cataract procedures
0
2000
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8000
10000
12000
14000Retinal detachment surgery
Cataract procedures
Year of cataract procedure
1980 1985 1990 1995 2000
5yr C
um
ulative Incidence per 1,000 procedures
0
10
20
30
40
Extracapsular
Intracapsular
Phacoemulsification
Overall 5yr Cumulative Incidence = 0.62% (ECCE) 0.30% (Phaco)!
Previous studies: 5yr Cumulative Incidence = 0.6% - 1%1,2!
1.  Erie, JC et al. Risk of Retinal Detachment After Cataract Extraction, 1980-2004: A population-based study. Trans Am Ophthalmol Soc 2006; 104:167-175!
2.  Boberg-Ans, G et al . Longterm Incidence of Rhegmatogenous Retinal Detachment and survival in a deined population undergoing standardized phacoemulsification surgery.  Acta Ophthalmol Scand. 
2006; 84:613-618!
PK for pseudophakic bullous 
keratopathy after cataract surgery 
Year of cataract procedure
1980 1985 1990 1995 2000
5yr C
um
ulative Incidence per 1, 000 cataract procedures
0
1
2
3
4
5
N
um
ber of cataract procedures
0
2000
4000
6000
8000
10000
12000
14000
Penetrating keratoplasty for 
bullous keratopathy
Cataract procedures
Year of cataract procedure
1980 1985 1990 1995 2000
5yr C
um
ulative  Incidence per 1,000 cataract procedures
0
2
4
6
8
10
12
14
16
Extracapsular
Intracapsular
Phacoemulsification
Overall 5yr Incidence = 0.12% (ECCE) 0.02% (Phaco)!
Previous studies: 5yr incidence = 0.1%-0.5%1!
65#
# #
Surgery for wound dehiscence 
Year of cataract procedure
1980 1985 1990 1995 2000
Incidence per 1, 000 cataract procedures
0
1
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N
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ber of cataract procedures
0
2000
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10000
12000
14000
wound dehiscence
Cataract procedures
Year of cataract procedure
1980 1985 1990 1995 2000
Incidence per 1,000 procedures
0
5
10
15
20
25
Extracapsular
Intracapsular
Phacoemulsification
Overall Incidence = 0.31% (ECCE) 0.06% (Phaco)!
Previous studies: Incidence = 0.02%-0.8%1!
1. Ball JL, McLeod BK. Traumatic wound dehiscence following cataract surgery: a thing of the past? Eye 2001;15(Pt 1):42-4.!
IOL malposition requiring surgery 
Year of cataract procedure
1980 1985 1990 1995 2000
Incidence per 1, 000 cataract procedures
0
1
2
3
4
5
6
N
um
ber of cataract procedures
0
2000
4000
6000
8000
10000
12000
14000
Surgery for IOL malposition
Cataract procedures
Overall Incidence = 0.30% (ECCE) 0.19% (Phaco)!
Previous studies incidence = 0.2%-2%1,2!
1.  George JC, Crandall AS, Jones JJ. Changing Indications for and Improving Outcomes of IOL Exchange. Am J. Ophthalmol. 2005; 140:688!
2.  Hayashi K, Hirata, A and Hayashi, H. Possible Predisposing Factors for In-the-Bag and Out-of-the-Bag Intraocular Lens Dislocation and Outcomes of Intraocular Lens Exchange 
Surgery. Ophthalmology 2007; 114:967!
Year of cataract procedure
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In
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pe
r 1
,0
00
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at
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ac
t p
ro
ce
du
re
s
0
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16
18
Extracapsular
Intracapsular
Phacoemulsification
Surgery for dropped nucleus 
Year of cataract procedure
1980 1985 1990 1995 2000
Incidence per 1, 000 cataract procedures
0.0
0.5
1.0
1.5
2.0
2.5
3.0
N
um
ber of cataract procedures
0
2000
4000
6000
8000
10000
12000
14000
Surgery for dropped nucleus
Cataract procedures
Year of cataract procedure
1980 1985 1990 1995 2000
Incidence per 1,000 procedures
0
2
4
6
8
10
Extracapsular
Phacoemulsification
Overall Incidence = 0.11% (ECCE) 0.16% (Phaco)!
Previous studies incidence = 0.18% -1.0%1,2!
1.  Kim, JE et al. Retained lens fragments after phacoemulsification. Ophthalmology. 1994; 101:1827-1832!
2.  Jaycock P et al. The Cataract National Dataset electronic multi-centre audit of 55 567 operations: updating benchmark standards of care in the United Kingdom and 
internationally. Eye 2007!
Summary 
•  The incidence of surgery for retinal detachment and pseudophakic 
bullous keratopathy after cataract extraction has decreased 
dramatically since 1980 
•  The introduction of phacoemulsification has resulted in a decline in 
the rate of wound dehiscence since 1990 
•  There has been a rise in the incidence of surgery for dropped 
nucleus since phacoemulsfication was introduced - for both 
phacoemulsification and ECCE procedures  
•  IOL dislocation requiring surgery after ECCE has been gradually 
increasing over the last decade. 
•  The learning curve associated with the transition from ECCE to 
phaco does not appear to have resulted in an overall increase in 
major complications 
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s o
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 p
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t d
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s c
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t d
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 d
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e f
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f m
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m
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at
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t m
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e l
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s f
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 d
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at
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e d
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r c
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 d
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 d
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e r
isk
, a
nd
 
m
en
 h
ad
 n
ea
rly
 d
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 d
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 p
er
ce
nt
.  
Th
e a
ut
ho
rs
 co
nc
lu
de
d 
th
at
 th
es
e 
fin
di
ng
s h
av
e i
m
po
rt
an
t i
m
pl
ica
tio
ns
 
fo
r p
re
op
er
at
iv
e c
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f c
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e c
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s o
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ra
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l f
in
di
ng
s 
68#
Barclay.L..Retinal.detachment.decreases.after.
phacoemulsification..Medscape.Education.Clinical.Debriefs...
July.2012..[online:.
http://www.medscape.org.viewarticle/76831].
# .
30
/0
1/
13
 7:
27
 PM
Re
tin
al 
De
tac
hm
en
t R
isk
 D
ec
re
as
es
 A
fte
r P
ha
co
em
uls
ific
ati
on
 (p
rin
ter
-fr
ien
dly
)
Pa
ge
 1
 of
 6
ht
tp
://
ww
w.
me
ds
ca
pe
.or
g/
vie
wa
rti
cle
/7
68
31
1_
pr
int
w
w
w
.m
ed
sc
ap
e.
or
g
  
Th
is
 a
rt
ic
le
 is
 a
 C
M
E 
ce
rt
ifi
ed
 a
ct
iv
ity
. T
o 
ea
rn
 c
re
di
t f
or
 th
is
 a
ct
iv
ity
 v
is
it:
ht
tp
://
w
w
w
.m
ed
sc
ap
e.
or
g/
vi
ew
ar
tic
le
/7
68
31
1
C
M
E
 In
fo
rm
at
io
n
C
M
E 
R
el
ea
se
d:
 0
7/
30
/2
01
2;
 V
al
id
 fo
r c
re
di
t t
hr
ou
gh
 0
7/
30
/2
01
3
Ta
rg
et
 A
ud
ie
nc
e
Th
is
 a
rti
cl
e 
is
 in
te
nd
ed
 fo
r p
rim
ar
y 
ca
re
 c
lin
ic
ia
ns
, o
ph
th
al
m
ol
og
is
ts
, a
nd
 o
th
er
 s
pe
ci
al
is
ts
 c
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 b
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 d
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 m
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 c
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 b
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 d
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 d
at
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 d
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 b
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 b
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 c
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tio
n 
S
ta
te
m
en
ts
Fo
r P
hy
si
ci
an
s
M
ed
sc
ap
e,
 L
LC
 is
 a
cc
re
di
te
d 
by
 th
e 
A
cc
re
di
ta
tio
n 
C
ou
nc
il 
fo
r C
on
tin
ui
ng
 M
ed
ic
al
 E
du
ca
tio
n 
(A
C
C
M
E
) t
o 
pr
ov
id
e
co
nt
in
ui
ng
 m
ed
ic
al
 e
du
ca
tio
n 
fo
r p
hy
si
ci
an
s.
M
ed
sc
ap
e,
 L
LC
 d
es
ig
na
te
s 
th
is
 e
nd
ur
in
g 
m
at
er
ia
l f
or
 a
 m
ax
im
um
 o
f 0
.2
5 
A
M
A
 P
R
A
 C
at
eg
or
y 
1 
C
re
di
t(s
)™
 .
P
hy
si
ci
an
s 
sh
ou
ld
 c
la
im
 o
nl
y 
th
e 
cr
ed
it 
co
m
m
en
su
ra
te
 w
ith
 th
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at
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 d
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 c
re
di
t f
or
 th
is
 o
nl
in
e 
ed
uc
at
io
na
l a
ct
iv
ity
. F
or
 in
fo
rm
at
io
n 
on
ap
pl
ic
ab
ili
ty
 a
nd
 a
cc
ep
ta
nc
e 
of
 c
on
tin
ui
ng
 e
du
ca
tio
n 
cr
ed
it 
fo
r t
hi
s 
ac
tiv
ity
, p
le
as
e 
co
ns
ul
t y
ou
r p
ro
fe
ss
io
na
l l
ic
en
si
ng
bo
ar
d.
Th
is
 a
ct
iv
ity
 is
 d
es
ig
ne
d 
to
 b
e 
co
m
pl
et
ed
 w
ith
in
 th
e 
tim
e 
de
si
gn
at
ed
 o
n 
th
e 
tit
le
 p
ag
e;
 p
hy
si
ci
an
s 
sh
ou
ld
 c
la
im
 o
nl
y
th
os
e 
cr
ed
its
 th
at
 re
fle
ct
 th
e 
tim
e 
ac
tu
al
ly
 s
pe
nt
 in
 th
e 
ac
tiv
ity
. T
o 
su
cc
es
sf
ul
ly
 e
ar
n 
cr
ed
it,
 p
ar
tic
ip
an
ts
 m
us
t c
om
pl
et
e
th
e 
ac
tiv
ity
 o
nl
in
e 
du
rin
g 
th
e 
va
lid
 c
re
di
t p
er
io
d 
th
at
 is
 n
ot
ed
 o
n 
th
e 
tit
le
 p
ag
e.
 T
o 
re
ce
iv
e 
A
M
A
 P
R
A
 C
at
eg
or
y 
1
C
re
di
t™
, y
ou
 m
us
t r
ec
ei
ve
 a
 m
in
im
um
 s
co
re
 o
f 7
0%
 o
n 
th
e 
po
st
-te
st
.
Fo
llo
w
 th
es
e 
st
ep
s 
to
 e
ar
n 
C
M
E
/C
E
 c
re
di
t*
:
1.
 R
ea
d 
th
e 
ta
rg
et
 a
ud
ie
nc
e,
 le
ar
ni
ng
 o
bj
ec
tiv
es
, a
nd
 a
ut
ho
r d
is
cl
os
ur
es
.
2.
 S
tu
dy
 th
e 
ed
uc
at
io
na
l c
on
te
nt
 o
nl
in
e 
or
 p
rin
te
d 
ou
t.
3.
 O
nl
in
e,
 c
ho
os
e 
th
e 
be
st
 a
ns
w
er
 to
 e
ac
h 
te
st
 q
ue
st
io
n.
 T
o 
re
ce
iv
e 
a 
ce
rti
fic
at
e,
 y
ou
 m
us
t r
ec
ei
ve
 a
 p
as
si
ng
sc
or
e 
as
 d
es
ig
na
te
d 
at
 th
e 
to
p 
of
 th
e 
te
st
. W
e 
en
co
ur
ag
e 
yo
u 
to
 c
om
pl
et
e 
th
e 
A
ct
iv
ity
 E
va
lu
at
io
n 
to
 p
ro
vi
de
fe
ed
ba
ck
 fo
r f
ut
ur
e 
pr
og
ra
m
m
in
g.
Y
ou
 m
ay
 n
ow
 v
ie
w
 o
r p
rin
t t
he
 c
er
tif
ic
at
e 
fro
m
 y
ou
r C
M
E
/C
E
 T
ra
ck
er
. Y
ou
 m
ay
 p
rin
t t
he
 c
er
tif
ic
at
e 
bu
t y
ou
 c
an
no
t a
lte
r
it.
 C
re
di
ts
 w
ill
 b
e 
ta
lli
ed
 in
 y
ou
r C
M
E
/C
E
 T
ra
ck
er
 a
nd
 a
rc
hi
ve
d 
fo
r 6
 y
ea
rs
; a
t a
ny
 p
oi
nt
 w
ith
in
 th
is
 ti
m
e 
pe
rio
d 
yo
u 
ca
n
pr
in
t o
ut
 th
e 
ta
lly
 a
s 
w
el
l a
s 
th
e 
ce
rti
fic
at
es
 fr
om
 th
e 
C
M
E
/C
E
 T
ra
ck
er
.
*T
he
 c
re
di
t t
ha
t y
ou
 re
ce
iv
e 
is
 b
as
ed
 o
n 
yo
ur
 u
se
r p
ro
fil
e.
H
ar
dw
ar
e/
S
of
tw
ar
e 
R
eq
ui
re
m
en
ts
To
 a
cc
es
s 
ac
tiv
iti
es
, u
se
rs
 w
ill
 n
ee
d:
A
 c
om
pu
te
r w
ith
 a
n 
In
te
rn
et
 c
on
ne
ct
io
n.
In
te
rn
et
 E
xp
lo
re
r 7
.x
 o
r h
ig
he
r, 
Fi
re
fo
x 
4.
x 
or
 h
ig
he
r, 
S
af
ar
i 2
.x
 o
r h
ig
he
r, 
or
 a
ny
 o
th
er
 W
3C
 s
ta
nd
ar
ds
 c
om
pl
ia
nt
br
ow
se
r.
A
do
be
 F
la
sh
 P
la
ye
r a
nd
/o
r a
n 
H
TM
L5
 c
ap
ab
le
 b
ro
w
se
r m
ay
 b
e 
re
qu
ire
d 
fo
r v
id
eo
 o
r a
ud
io
 p
la
yb
ac
k.
O
cc
as
io
na
lly
 o
th
er
 a
dd
iti
on
al
 s
of
tw
ar
e 
m
ay
 b
e 
re
qu
ire
d 
su
ch
 a
s 
P
ow
er
P
oi
nt
 o
r A
do
be
 A
cr
ob
at
 R
ea
de
r.
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 D
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pr
int
m
on
th
s,
 in
cl
ud
in
g 
fin
an
ci
al
 re
la
tio
ns
hi
ps
 o
f a
 s
po
us
e 
or
 li
fe
 p
ar
tn
er
, t
ha
t c
ou
ld
 c
re
at
e 
a 
co
nf
lic
t o
f i
nt
er
es
t.
M
ed
sc
ap
e,
 L
LC
, e
nc
ou
ra
ge
s 
A
ut
ho
rs
 to
 id
en
tif
y 
in
ve
st
ig
at
io
na
l p
ro
du
ct
s 
or
 o
ff-
la
be
l u
se
s 
of
 p
ro
du
ct
s 
re
gu
la
te
d 
by
 th
e
U
S
 F
oo
d 
an
d 
D
ru
g 
A
dm
in
is
tra
tio
n,
 a
t f
irs
t m
en
tio
n 
an
d 
w
he
re
 a
pp
ro
pr
ia
te
 in
 th
e 
co
nt
en
t.
A
ut
ho
r(
s)
Ji
m
 K
lin
g
Fr
ee
la
nc
e 
w
rit
er
 fo
r M
ed
sc
ap
e,
 L
LC
.
D
is
cl
os
ur
e:
 J
im
 K
lin
g 
ha
s 
di
sc
lo
se
d 
no
 re
le
va
nt
 fi
na
nc
ia
l r
el
at
io
ns
hi
ps
.
E
di
to
r(
s)
La
ur
ie
 E
. S
cu
dd
er
, D
N
P,
 N
P
N
ur
se
 P
la
nn
er
, C
on
tin
ui
ng
 P
ro
fe
ss
io
na
l E
du
ca
tio
n 
D
ep
ar
tm
en
t, 
M
ed
sc
ap
e,
 L
LC
; C
lin
ic
al
 A
ss
is
ta
nt
 P
ro
fe
ss
or
, S
ch
oo
l
of
 N
ur
si
ng
 a
nd
 A
lli
ed
 H
ea
lth
, G
eo
rg
e 
W
as
hi
ng
to
n 
U
ni
ve
rs
ity
, W
as
hi
ng
to
n,
 D
C
D
is
cl
os
ur
e:
 L
au
rie
 E
. S
cu
dd
er
, D
N
P
, N
P
, h
as
 d
is
cl
os
ed
 n
o 
re
le
va
nt
 fi
na
nc
ia
l r
el
at
io
ns
hi
ps
.
C
M
E
 A
ut
ho
r(
s)
La
ur
ie
 B
ar
cl
ay
, M
D
Fr
ee
la
nc
e 
w
rit
er
 a
nd
 re
vi
ew
er
, M
ed
sc
ap
e,
 L
LC
D
is
cl
os
ur
e:
 L
au
rie
 B
ar
cl
ay
, M
D
, h
as
 d
is
cl
os
ed
 n
o 
re
le
va
nt
 fi
na
nc
ia
l r
el
at
io
ns
hi
ps
.
C
M
E
 R
ev
ie
w
er
(s
)
Sa
ra
h 
Fl
ei
sc
hm
an
C
M
E
 P
ro
gr
am
 M
an
ag
er
, M
ed
sc
ap
e,
 L
LC
D
is
cl
os
ur
e:
 S
ar
ah
 F
le
is
ch
m
an
 h
as
 d
is
cl
os
ed
 n
o 
re
le
va
nt
 fi
na
nc
ia
l r
el
at
io
ns
hi
ps
.
N
ew
s 
A
ut
ho
r: 
Ji
m
 K
lin
g
C
M
E
 A
ut
ho
r: 
La
ur
ie
 B
ar
cl
ay
, M
D
B
y 
th
e 
m
id
-1
99
0s
, p
ha
co
em
ul
si
fic
at
io
n 
ha
d 
be
co
m
e 
th
e 
pr
oc
ed
ur
e 
of
 c
ho
ic
e 
in
 m
os
t c
at
ar
ac
t s
ur
ge
rie
s 
in
 W
es
te
rn
A
us
tra
lia
. A
lth
ou
gh
 th
e 
ris
k 
fo
r r
et
in
al
 d
et
ac
hm
en
t (
R
D
) a
fte
r p
ha
co
em
ul
si
fic
at
io
n 
m
ay
 re
m
ai
n 
el
ev
at
ed
 fo
r a
 d
ec
ad
e
af
te
r c
at
ar
ac
t s
ur
ge
ry
, f
ol
lo
w
-u
p 
in
 m
os
t s
tu
di
es
 h
as
 n
ot
 e
xc
ee
de
d 
5 
ye
ar
s.
Th
is
 s
tu
dy
 b
y 
C
la
rk
 a
nd
 c
ol
le
ag
ue
s 
ai
m
ed
 to
 d
et
er
m
in
e 
ch
an
ge
s 
in
 th
e 
lo
ng
-te
rm
 ri
sk
 fo
r R
D
 a
fte
r c
at
ar
ac
t s
ur
ge
ry
 w
ith
tim
e 
si
nc
e 
ph
ac
oe
m
ul
si
fic
at
io
n 
w
as
 fi
rs
t i
nt
ro
du
ce
d.
 A
no
th
er
 o
bj
ec
tiv
e 
of
 th
is
 s
tu
dy
 w
as
 to
 id
en
tif
y 
po
pu
la
tio
n-
ba
se
d
ris
k 
fa
ct
or
s 
fo
r R
D
 in
 W
es
te
rn
 A
us
tra
lia
, u
si
ng
 v
al
id
at
ed
 li
nk
ed
 h
ea
lth
 a
dm
in
is
tra
tiv
e 
da
ta
.
A
fte
r a
do
pt
io
n 
of
 p
ha
co
em
ul
si
fic
at
io
n 
as
 th
e 
pr
oc
ed
ur
e 
of
 c
ho
ic
e 
to
 re
pa
ir 
ca
ta
ra
ct
s,
 th
e 
ris
k 
fo
r R
D
 d
ro
pp
ed
R
et
in
al
 D
et
ac
hm
en
t R
is
k 
D
ec
re
as
es
 A
fte
r
Ph
ac
oe
m
ul
si
fic
at
io
n 
CM
E
C
M
E
 R
el
ea
se
d:
 0
7/
30
/2
01
2;
 V
al
id
 fo
r c
re
di
t t
hr
ou
gh
 0
7/
30
/2
01
3
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pr
int
si
gn
ifi
ca
nt
ly
 b
et
w
ee
n 
19
89
 a
nd
 2
00
1,
 a
cc
or
di
ng
 to
 a
 s
tu
dy
 p
ub
lis
he
d 
in
 th
e 
Ju
ly
 is
su
e 
of
 th
e 
A
rc
hi
ve
s 
of
O
ph
th
al
m
ol
og
y.
 T
he
 s
tu
dy
 fu
rth
er
 e
va
lu
at
ed
 a
dd
iti
on
al
 ri
sk
 fa
ct
or
s 
fo
r R
D
 p
os
t–
ca
ta
ra
ct
 s
ur
ge
ry
 u
si
ng
ph
ac
oe
m
ul
si
fic
at
io
n.
R
D
 is
 th
e 
m
os
t c
om
m
on
 s
ig
ht
-th
re
at
en
in
g 
co
m
pl
ic
at
io
n 
af
te
r c
at
ar
ac
t s
ur
ge
ry
, a
ffe
ct
in
g 
1%
 o
f p
eo
pl
e 
un
de
rg
oi
ng
 th
e
pr
oc
ed
ur
e.
 P
re
vi
ou
s 
st
ud
ie
s 
ha
ve
 s
ug
ge
st
ed
 th
at
 ri
sk
 fo
r R
D
 m
ay
 re
m
ai
n 
he
ig
ht
en
ed
 u
p 
to
 1
0 
ye
ar
s 
af
te
r
ph
ac
oe
m
ul
si
fic
at
io
n,
 b
ut
 fe
w
 s
tu
di
es
 fo
llo
w
ed
 u
p 
pa
tie
nt
s 
fo
r l
on
ge
r t
ha
n 
5 
ye
ar
s.
To
 e
xa
m
in
e 
th
e 
lo
ng
-te
rm
 in
ci
de
nc
e 
an
d 
ris
k 
fa
ct
or
s 
fo
r R
D
 a
fte
r p
ha
co
em
ul
si
fic
at
io
n,
 A
nt
on
y 
C
la
rk
, M
B
B
S
, f
ro
m
 th
e
E
ye
 a
nd
 V
is
io
n 
E
pi
de
m
io
lo
gy
 R
es
ea
rc
h 
G
ro
up
 a
nd
 th
e 
C
en
tre
 fo
r P
op
ul
at
io
n 
H
ea
lth
 R
es
ea
rc
h,
 C
ur
tin
 H
ea
lth
In
no
va
tio
n 
R
es
ea
rc
h 
In
st
itu
te
, C
ur
tin
 U
ni
ve
rs
ity
, P
er
th
, A
us
tra
lia
, c
on
du
ct
ed
 a
 re
tro
sp
ec
tiv
e 
an
al
ys
is
 o
f 6
5,
05
5 
pa
tie
nt
s
w
ho
 u
nd
er
w
en
t t
he
 p
ro
ce
du
re
 in
 W
es
te
rn
 A
us
tra
lia
 b
et
w
ee
n 
Ja
nu
ar
y 
19
89
 a
nd
 D
ec
em
be
r 2
00
1.
 T
he
y 
us
ed
 th
e
W
es
te
rn
 A
us
tra
lia
n 
D
at
a 
Li
nk
ag
e 
S
ys
te
m
 to
 id
en
tif
y 
ca
se
s,
 fo
cu
si
ng
 o
n 
th
os
e 
w
ho
 re
qu
ire
d 
ad
m
is
si
on
 fo
r R
D
 s
ur
ge
ry
af
te
r p
ha
co
em
ul
si
fic
at
io
n.
 T
he
y 
al
so
 li
m
ite
d 
th
e 
ca
se
s 
to
 th
os
e 
th
at
 w
er
e 
va
lid
at
ed
 b
y 
m
ed
ic
al
 re
co
rd
 re
vi
ew
.
O
ve
r t
he
 c
ou
rs
e 
of
 1
0 
ye
ar
s,
 th
e 
re
se
ar
ch
er
s 
id
en
tif
ie
d 
23
7 
R
D
 c
as
es
, f
or
 a
 1
0-
ye
ar
 c
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 0
.6
8%
(9
5%
 c
on
fid
en
ce
 in
te
rv
al
 [C
I],
 0
.5
6%
 - 
0.
83
%
). 
Th
e 
cr
ud
e 
in
ci
de
nc
e 
of
 R
D
 a
fte
r p
ha
co
em
ul
si
fic
at
io
n 
de
cl
in
ed
 b
y 
a
m
ea
n 
of
 1
9%
 fo
r e
ac
h 
ye
ar
 a
fte
r 1
98
9 
(in
ci
de
nc
e 
ra
te
 ra
tio
, 0
.8
1;
 9
5%
 C
I, 
0.
77
 - 
0.
84
).
U
si
ng
 C
ox
 p
ro
po
rti
on
al
 h
az
ar
ds
 re
gr
es
si
on
 m
od
el
in
g,
 th
e 
re
se
ar
ch
er
s 
id
en
tif
ie
d 
si
gn
ifi
ca
nt
 ri
sk
 fa
ct
or
s 
th
at
 in
cl
ud
ed
ye
ar
 o
f s
ur
ge
ry
 (h
az
ar
d 
ra
tio
 [H
R
], 
0.
43
; 9
5%
 C
I, 
0.
28
 - 
0.
66
 [1
99
9 
- 2
00
1 
co
m
pa
re
d 
w
ith
 1
98
9 
- 1
99
3]
), 
ag
e 
yo
un
ge
r
th
an
 6
0 
ye
ar
s 
at
 ti
m
e 
of
 p
ha
co
em
ul
si
fic
at
io
n 
(H
R
, 3
.7
6;
 9
5%
 C
I, 
2.
83
 - 
5.
00
), 
m
al
e 
se
x 
(H
R
, 1
.9
1;
 9
5%
 C
I, 
1.
45
 -
2.
51
), 
an
d 
an
te
rio
r v
itr
ec
to
m
y 
(H
R
, 2
7.
60
; 9
5%
 C
I, 
19
.2
7 
- 3
9.
52
).
Th
e 
re
se
ar
ch
er
s 
fo
un
d 
no
 a
ss
oc
ia
tio
ns
 b
et
w
ee
n 
R
D
 ri
sk
 a
nd
 h
os
pi
ta
l l
oc
at
io
n,
 p
at
ie
nt
 ru
ra
l o
r r
em
ot
e 
lo
ca
lit
y,
 h
os
pi
ta
l
ca
ta
ra
ct
 s
ur
ge
ry
 v
ol
um
e,
 fa
ile
d 
in
tra
oc
ul
ar
 le
ns
 in
se
rti
on
, l
en
gt
h 
of
 s
ta
y,
 o
r p
at
ie
nt
 in
su
ra
nc
e 
st
at
us
.
M
uc
h 
Lo
w
er
 C
om
pl
ic
at
io
n 
R
at
es
 W
ith
 C
ur
re
nt
 T
ec
hn
iq
ue
s
"It
's
 a
no
th
er
 in
di
ca
to
r o
f h
ow
 m
uc
h 
be
tte
r t
he
 c
ur
re
nt
 s
ur
ge
ry
 is
 th
an
 th
e 
su
rg
er
y 
w
e 
w
er
e 
do
in
g 
20
 y
ea
rs
 a
go
. W
ith
ei
th
er
 p
ro
ce
du
re
, v
is
io
n 
w
as
 2
0/
20
 6
 w
ee
ks
 o
ut
, b
ut
 th
e 
co
m
pl
ic
at
io
n 
ra
te
s 
ar
e 
m
uc
h 
lo
w
er
 n
ow
," 
R
ob
er
t F
el
dm
an
,
M
D
, p
ro
fe
ss
or
 o
f o
ph
th
al
m
ol
og
y 
an
d 
vi
su
al
 s
ci
en
ce
 a
t t
he
 U
ni
ve
rs
ity
 o
f T
ex
as
 H
ea
lth
 S
ci
en
ce
 C
en
te
r a
nd
 p
re
si
de
nt
 o
f
th
e 
R
ob
er
t C
iz
ik
 E
ye
 C
lin
ic
 in
 H
ou
st
on
, t
ol
d 
M
ed
sc
ap
e 
M
ed
ic
al
 N
ew
s.
S
til
l, 
R
D
 is
 a
 c
om
pl
ic
at
io
n 
th
at
 s
ho
ul
d 
be
 n
ot
ed
. "
It 
is
 a
 ri
sk
 th
at
 is
 p
re
se
nt
 e
ve
n 
de
ca
de
s 
af
te
r s
ur
ge
ry
, e
ve
n 
th
ou
gh
 it
is
 a
 re
la
tiv
el
y 
lo
w
 ri
sk
, a
nd
 it
 a
ct
ua
lly
 in
cr
ea
se
s 
ov
er
 ti
m
e.
 P
at
ie
nt
s 
an
d 
cl
in
ic
ia
ns
 n
ee
d 
to
 d
is
cu
ss
 th
es
e 
ris
ks
 s
o 
th
at
th
ey
're
 a
w
ar
e 
of
 th
e 
sy
m
pt
om
s,
" A
bd
hi
sh
 R
. B
ha
vs
ar
, M
D
, d
ire
ct
or
 o
f r
es
ea
rc
h 
at
 th
e 
R
et
in
a 
C
en
te
r o
f M
in
ne
so
ta
 in
M
in
ne
ap
ol
is
 a
nd
 c
lin
ic
al
 c
or
re
sp
on
de
nt
 a
t t
he
 A
m
er
ic
an
 A
ca
de
m
y 
of
 O
ph
th
al
m
ol
og
y,
 to
ld
 M
ed
sc
ap
e 
M
ed
ic
al
 N
ew
s.
D
r. 
B
ha
vs
ar
 p
oi
nt
ed
 to
 th
e 
hi
gh
er
 ri
sk
 fo
r p
at
ie
nt
s 
w
ho
 w
er
e 
yo
un
ge
r t
ha
n 
60
 y
ea
rs
 a
t t
he
 ti
m
e 
of
 s
ur
ge
ry
. "
I t
hi
nk
 th
at
's
of
 c
rit
ic
al
 im
po
rta
nc
e,
" h
e 
st
at
ed
.
N
ei
th
er
 D
r. 
Fe
ld
m
an
 n
or
 D
r. 
B
ha
vs
ar
 w
as
 in
vo
lv
ed
 in
 th
e 
re
se
ar
ch
.
Th
e 
st
ud
y 
ha
d 
so
m
e 
lim
ita
tio
ns
. F
irs
t, 
th
e 
au
th
or
s 
w
er
e 
un
ab
le
 to
 a
sc
er
ta
in
 a
nd
 c
on
tro
l f
or
 c
er
ta
in
 im
po
rta
nt
 ri
sk
fa
ct
or
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4.1. Background!While! the! utility! of! hospital! administrative! data! in! supporting! longitudinal!observational!studies!of!cataract!surgery!outcomes!in!WA!was!demonstrated!in!Chapter! 3,! there! are! certain! areas! of! health! research! where! administrative!databases!alone!are!insufficient.!These!areas!include,!but!are!not!limited!to:!1) interventions!or!treatments!that!are!not!coded!in!administrative!datasets!or!simply!not!recorded!e.g.!medications!used!‘offHlabel’!or!treatments!outside!of!the!health!system;!2) populations!underHrepresented!or!not!represented!in!administrative!datasets!e.g.!isolated,!itinerate!and!minority!populations;!3) studies!where!attitudes!and!knowledge!are!of!interest!e.g.!physicians!attitudes!and!knowledge!regarding!diabetic!retinopathy!screening!and!management;!4) studies!of!qualitative!outcomes!e.g.!quality!of!life!in!valueHbased!studies.!Other!observational!epidemiological!methodologies!may!be!used!to!augment!or!supplement! the! data! found!within! health! and! other! administrative! databases.!Together!they!may!provide!useful!insights!into!the!subjective!impact!of!disease!or!adverse!events,!our!gaps!in!knowledge!about!the!services!required,!and!the!outcomes! from! treatments! initiated! or! performed! outside! of! the! hospital!system.!
4.1.1. Clinical!surveys!Clinical! survey’s! employ! a! range! of! nonHexperimental! observational! or!descriptive!methods!to!characterise!the!presence!or!absence!of!a!characteristic!of!interest!in!a!defined!group!of!people.302!The!researcher!has!full!control!over!the!data!collected!in!a!clinical!survey,!unlike!research!using!administrative!data!where! the! researcher! is! beholden! to! the! data! custodians! in! terms! of! what!variables!are!recorded.!Clinical!surveys!therefore!overcome!many!limitations!of!administrative! datasets! since! they! involve! the! direct! collection! of! detailed!clinical! information! on! defined! populations.! The! largest! crossHsectional! eye!health! surveys! in!Australia,! the!Melbourne!Visual! Impairment!project! and! the!Blue!Mountains!Eye!study!enrolled!over!3,000!participants!49!years!of!age!or!older.14,15! Similar! large! eye! health! surveys! elsewhere! included! the! Beaver!
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Dam303! and! Rotterdam304! health! studies.! The! sheer! breadth! of! data! collected!regarding! ocular! health! range! from! ocular! history! and! examination! to! ocular!biometry,! allowing! insight! into!disease!prevalence,! associations! and!outcomes!of! important! blinding! ophthalmic! disease! such! as! glaucoma,! macular!degeneration!and! cataract.!However!useful,! large! crossHsectional! surveys! such!as!these!are!generally!limited!by!their!expense.!Making!use!of! survey!questionnaires!may!also!help! to!explain! the!reason!why!certain! patterns! are! seen! in! linked! health! administrative! data! and! therefore!assist! in! formulating! clinical! practice! policies! that! allow! better! care! to! be!provided.! Additionally,! linkage! to! outcomes! before! and! after! surveys! and!interventions! may! provide! a! tangible! measure! of! success! or! otherwise.! For!example,! the! endophthalmitis! population! study! of! WA! involved! a! survey! of!Australian! ophthalmologists! to! characterise! current! cataract! surgery! practice!including!use!of!chemoprophylaxis! for!endophthalmitis.305!Another!example! is!the! Practice! Styles! and! Preferences! Survey! of! the! American! Cataract! and!Refractive! Surgery! (ACRS)! membership! that! has! been! conducted! yearly! by!Leaming!since!1985!until!2012.306!
4.1.2. Quality!of!life!The! term! ‘quality! of! life’! conveys! “an! overall! sense! of! wellHbeing,! including!aspects!of!happiness!and!satisfaction!with!life!as!a!whole.”307!While!conceptually!this!has!meaning!to!most!people,!it!is!also!entirely!subjective!and!so!challenging!to! measure.! Understanding! and! measuring! healthHrelated! quality! of! life! goes!beyond!the!traditional!health!measures!of!morbidity!and!mortality,!which!treats!health!as!a!rather!uniHdimensional!construct!defined!by!the!presence!or!absence!of!disease.!While!health!has!an!impact!on!quality!of!life!other!aspects!of!life!may!have!even!greater!impact!e.g.!social!situation,!relationships,!religion!and!culture.!Quality!of!life!measures!attempt!to!broaden!our!concept!of!health!to!include!the!physical!and!mental!wellbeing!of!the!population.!In!ophthalmology!research,!standardised!healthHrelated!quality!of!life!measures!are! being! increasingly! used! to! support! clinical! decisionHmaking.! These! valueHbased!measures!allow!the!impact!of!eye!diseases!and!treatment!outcomes!to!be!
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quantified! taking! into! account! patient! perceptions! that! are! not! available! in!routine!health!administrative!databases.308!!That!the!measurement!of!quality!of!life!is!complex!is!reflected!in!the!countless!healthHrelated! quality! of! life! instruments! developed! over! the! years.!Many! are!disease!specific!and!designed!to!reflect! the!unique! impact!of!a!specific!disease!upon! a! patients’! health.! In! ophthalmology,! a! commonly! used! vision! specific!questionnaire! is! the! 25Hitem! visual! function! questionnaire! developed! by! the!National!Eye! Institute! (NEIHVFQ25)!as! a! reliable! and!well! validated! shortened!version!of!their!larger!51Hitem!questionnaire.309!This!questionnaire!attempts!to!measure!the!impact!of!vision!on!multiple!dimensions!of!disease!including!social!functioning! and! emotional! wellbeing.! In! Australia! the! impact! of! vision!impairment!(IVI)!questionnaire!was!developed!as!a!validated!32Hitem!tool!that!assesses!the!impact!of!vision!dysfunction!across!5!functional!domains!–!leisure,!household,!social,!mobility!and!emotional.310!Utilities! values!offer! an! alternative! to! function!based! assessments! such! as! the!VFQH25! in! deriving! quality! of! life! measures.! They! attempt! to! measure! of! a!person’s! preference! for! a! given!health! state,!which!may!be! interpreted! as! the!quality!of!life!associated!with!that!health!state.!A!utility!value!is!conventionally!defined!on!a!continuum!from!0.0!to!1.0;!whereby!0.0!reflects!the!poorest!health!state!e.g.!death,!and!1.0! the!best!e.g.!perfect!health.!Thus! the!poorer! the!given!health!state!the!closer!it!is!to!0.0.!Utility!values!allow!the!impact!of!disease!and!intervention!on!quality!of! life! to!be!compared!across! the!health!spectrum!and!not! just! ophthalmology.311,312! Utility! values! also! allow! the! calculation! of! the!qualityHadjusted!life!year!(QALY)!(calculated!by!multiplying!the!utility!value!for!a!given!health!state!by!the!number!of!years!spent!at!that!health!state).!Attaching!a!dollar!value! to!QALYs!allows!one! to! attach!a!dollar!value! to! an! intervention!and!guide!expenditure!of!limited!resources.313,314!!Two!main!methods!of!calculating!utility!values!are!the!time!tradeHoff!(TTO)!and!standard!gamble!methods.!Both!require!the!respondent!to!make!a!sacrifice!for!a!given! health! state.! The! TTO!method! asks! the! participant! with! a! given! health!state! to!consider! their!remaining!years!of! life!and!then!to!state! the!number!of!years! of! their! remaining! they! would! be! willing! to! give! up! to! achieve! perfect!
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health.! The! proportion! of! their! remaining! life! they! are! willing! to! ‘trade’! for!perfect!health!is!subtracted!from!1.0!to!give!the!utility!value.!For!example,!a!60!yearHold!man!with!advanced!glaucoma!who!expects!to!live!until!90!is!willing!to!give!up!10!years!(or!30%)!of!his!remaining!life!to!be!glaucoma!free,!the!utility!value! is! 0.7! (1.0H0.3).314! The! standard! gamble! differs! conceptually! in! that! it!requires! the! participant! to! consider! a! gamble! that! converts! them! to! a! perfect!health!state!or!immediate!death.!They!are!asked!to!consider!a!health!state!and!then! give! the! risk! of! immediate! death! they!would! accept! to! achieve! a! perfect!health!state,!this!risk!is!subtracted!from!1.0.!For!example,!a!blind!participant!is!willing!to!accept!a!45%!chance!of!immediate!death!to!achieve!perfect!vision!i.e!the!utility!value!is!0.55.314!
4.1.3. Project!overviews!The! following! is! a! background! overview! of! each! of! the! projects! that! were!undertaken!that!together!augment!or!supplement!the!information!contained!in!health! administrative! databases! to! these! specific! research! areas.! Detailed!methods! are! discussed! in! the! papers! relevant! to! each! of! the! research! areas.!While!each!of! the!above!projects!are!distinct! in! their!own!right,! together! they!add! to! the! knowledge! of! ophthalmic! service! outcomes! for!major! blinding! eye!diseases!in!WA.!
PostCmarketing!surveillance:!arterial!thromboembolic!events!after!antiCVEGF!for!ARMD!This!WA!study!evaluated!the!risk!of!arterial!thromboembolic!events!after!antiHVEGF! treatment! for! ARMD.! ARMD! is! the! leading! cause! of! blindness! in! the!developed! world! thanks! mostly! to! increased! life! expectancy.315! It! is!characterised! by! photoreceptor! and! retinal! pigmented! epithelium! (RPE)!atrophy!at! the!macula! leading! to! loss!of! central!vision!There!are! two! forms:!a!nonHexudative! (‘dry’)! form,! where! central! vision! loss! is! gradual;! and! a! neoHvascular!(‘wet’)!form,!where!vision!loss!is!typically!rapid.316!Left!untreated!the!prevalence!of!blindness!is!as!high!as!11.8%!for!ARMD!patients!over!80!years.315!Dry!ARMD!treatment!is!currently!limited!to!vitamin!supplementation,!which!has!a! small! effect! in! slowing! progression.316! The! development! of! monoclonal!antibody! drugs! that! target! VEGF! has! revolutionised! the! treatment! of!
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neovascular! ARMD!where! no! treatment! that! could! improve! vision! previously!existed.317!The! two!antiHVEGF!agents! initially! introduced,! ranibizumab!and!bevacizumab,!have!been!used! in!Australia! for! the! treatment!of! the!neovascular!ARMD!since!2005.!PhaseHIII!RCTs!(ANCHOR18!and!MARINA19)!demonstrated!that!intravitreal!ranibizumab!improves!vision!and!visionHrelated!qualityHofHlife! in!patients!with!wetHAMD! when! compared! to! photodynamic! therapy! (ANCHOR)! and! sham!injection!(MARINA).!Ranibizumab!is!currently!the!only!antiHVEGF!agent!licenced!for! use! in! neovascular! ARMD! in! Australia.! Prior! to! ranibizumab! becoming!available,! bevacizumab!was! initially! used! offHlabel! prior! the! as! an! intravitreal!treatment! for! neovascular! AMD! based! on! the! support! of! several! case!series.318,319! It! is! also! used! as! an! alternative! to! ranibizumab! in! circumstances!where! patients! do! not! fulfil! the! criteria! for! treatment! under! the! Australian!pharmaceutical!benefits!scheme.!Two!RCTs!subsequently!published!in!2011!and!2012!(the!CATT320 and!IVAN!trials321)!confirmed!bevacizumab!and!ranibizumab!are!equivalent!in!effectiveness!in!reducing!subretinal!fluid!and!improving!visual!acuity.!!Although! the! antiHVEGF! agents! have! shown! promising! results,! clinical! trials!have! suggested! they! are! possibly! associated! with! the! incidence! of! systemic!arterial! thromboembolic! events! (eg,! acute! myocardial! infarction! (AMI)! and!stroke).!In!the!ANCHOR!trial,!the!incidence!of!AMI!at!12!months!was!2.1%!in!the!VEGFHinhibitor! treatment! group! compared! with! 0.7%! in! the! control! group,18!while! stroke! occurred! in! 0.7%!of! both! the! treatment! and! control! groups.18!At!two!years!of!followHup,!the!MARINA!trial!reported!an!incidence!of!1.3%!for!AMI!and! 2.5%! for! stroke! after! intravitreal! ranibizumab,! compared!with! 1.7%! and!0.8%! for! AMI! and! stroke! respectively! in! controls.19! The! risk! of!arteriothrombotic!adverse!events!was!between!2H3%!in!CATT!trial!and!<2%!in!IVAN! the! IVAN! trial,! both! trials! found! there! was! no! significant! difference!between! ranibizumab! and! bevacizumab! in! the! risk! of! arteriothrombotic!events.320,321 !!However,! to! date,! no! populationHbased! investigation! of! the! possible!thromboembolic! risk! associated!with! either! ranibizumab! or! bevacizumab! has!
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been! undertaken.! Given! the! sharp! initial! increase! in! utilisation! of! this!treatment,317!research!of!this!nature!is!needed.!!As! bevacizumab! continues! to! be! used! offHlabel,! it! is! not! recorded! in! available!administrative!datasets.!Additionally,!bevacizumab!may!also!be!given!for!other!indications!including!diabetic!maculopathy!and!retinal!vein!occlusion,!which!is!also!not!recorded!in!administrative!datasets.!This!study!highlights!the!utility!in!linking! disease! specific! databases! and! registries! with! other! health!administrative! databases.! It! required! this! information! be! obtained! from!alternative!sources!–!namely! the! intravitreal! injection!databases!and! logbooks!from!the!individual!retinal!clinics!performing!these!injections!in!WA.!Linkage!of!injection!logbook!data!with!the!HMDC!allowed!analysis!of!the!risk!of!subsequent!arterial!thromboembolic!events!via!hospital!admissions.!
The!Epidemiology!of!Blinding!Eye!Disease!study!(EBEDS)!Blindness! is! a! crippling! disability! resulting! in! misery,! loss! of! employment,!economic!loss!and!premature!death.!!It!is!estimated!that!around!50,000!(0.57%)!Australians! are! known! to! be! blind,322! with! an! incidence! 4.5! times! higher!amongst!indigenous!groups.323!Blindness!rates!are!predicted!to!rise!markedly!in!the! next! 20! years,! owing! largely! to! the! ageing! of! the! developed! world’s!population.324!Currently,!no!accurate!or!validated!population!data!on!blindness!exists!anywhere!in!the!world.325!Existing! prevalence! of! blindness! data! in! the! population! is! based! on! small!population!samples,325!or!voluntary!blindness!registries.326!Trends!in!blindness!incidence! are! only! derived! from! blind! registries! but! there! are! the! attendant!problems!of!case!ascertainment!and!diagnostic!inaccuracy.324,325!Measurements!of!voluntary!registration!rates! in!the!United!Kingdom!indicate!that!about!70%!of! legally! blind! persons! are! registered.327!More! recent!work! there! found! that!68%!were! registered! but! 34%!of! the! registered! blind!were! in! fact! not! legally!blind!when!reHexamined.328!
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There!are!a!number!of!methods! to!determine! the! total! burden! of!disease! in! a! community.! ! A! simple!combination! of! multiple! lists! with!details! of! the! disease! in! question!may! obtain! prevalence! data.!However,! this! is! prone! to!underestimating! true!prevalence.329! Sequential!populationHbased! sampling!techniques! have! previously! been!attempted! but! this! is! very!expensive,! labour! intensive!and!requires!a!stable!and!consistent!population.!A!principal! fault! is! that! any! results! cannot! be! extrapolated! to! the! whole!population! since! an! isolated! sample!population! is! rarely! representative!of! the!whole! population.! Capture! –! recapture! techniques!may! be! used! to! accurately!determination! of! disease! prevalence! in! a! relatively! efficient! and! inexpensive!way.! Others! have! used! this! technique! to! measure! prevalence! of! stroke,330!dementia,331!and!varicella!zoster332.!CaptureHrecapture!involves!measuring!the!dilution!of!a!target!population!within!the!broader!population.!The!acquisition!of!two!or!more!independent!sources!of!disease! registration! within! the! one! population! is! required,! and! then! dilution!mathematics! is!used! to!calculate!prevalence!and!confidence! intervals.!Because!no! two! lists! can! be! truly! independent! three! lists! are! preferred! to! allow! the!calculation!of!dependence!between!lists.333,334!In!the!case!of!diabetes,!the!three!list!captureHrecapture!approach! found!that!prevalence!was!100%!greater! than!that!calculated!by!list!summation.334!During! EBEDS! the! diagnostic! accuracy! of! the!WA! blind! register! (held! by! the!Association!for!the!blind!of!WA!(ABWA))!in!determining!legal!blindness1!and!its!cause!was!validated.!Subsequently!captureHrecapture! techniques!were!used! to!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!Legal!blindness!in!Australia!is!defined!as!having!a!best!corrected!visual!acuity!of!LogMAR!greater!than!1!(Snellen!less!than!6/60)!or!a!visual!field!restriction!of!less!than!10!degrees!from!central!fixation!or!a!combination!of!reduced!visual!acuity!and!field!loss!resulting!in!an!equivalent!level!of!disability!in!the!better!eye.!
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calculate!a!populationHbased!prevalence!of!blindness!in!WA.!Three!capture!lists!were! generated! in! this! study! to! calculate! blindness! prevalence! in!WA! (Figure!4H1).!The!first!(A)!was!derived!from!the!blind!register.!The!second!list!(B)!was!generated! over! a! defined! period! and! comprised! all! legally! blind! patients!attending!routine!appointments,!either!at!public!hospital!outpatient!eye!clinics,!or!at! selected!ophthalmologists!and!optometrists! clinics.!The! final! list! (C)!was!generated! over! a! separate! defined! period! and! comprised! all! legally! blind!patients! attending! either! a! tertiary!hospital! outpatient! eye! clinic,! a! consultant!ophthalmologist’s! rooms,! or! selected! general! medical! practitioner! clinics.!Relationships! between! the!3! lists!were! analysed!using! logHlinear!modelling! in!which!the!logarithm!of!the!expected!frequency!is!expressed!as!a!linear!function!of! effects! and! interaction! terms.335,336! Detailed! statistical! methodology! is!presented!in!the!published!papers.!Once! a! validated! list! of! blindHregistered! people! in!WA!was! created,! then! data!integration! techniques! allowed! the! study! of! health! outcomes! of! the! validated!ABWA! registered! blind! cohort! through! linkage! to! hospital! administrative! and!mortality!data!using!the!WADLS.!
Aboriginal!eye!health!The! Aboriginal! communities! in! the! eastern! Goldfields! region! of! WA! are!extremely! isolated! with! poor! access! to! health! care! (Figure! 4H2).337! This!remoteness,! combined! with! cultural! barriers! to! health! care,! means! there! are!potentially! a! large! proportion! of! the! Aboriginal! community! who! are! not!captured! in! hospital! administrative! datasets! until! late! in! the! disease! process!when!hospital! care! is! inevitable.! They! represent! an! important! and! vulnerable!population! that,! due! to! their! lack! of! access! to! health! care! facilities,! is! not!adequately!represented!in!the!WADLS.!!Eye!health! among!Aboriginal!Australians! first! gained!national! attention! in! the!midH1970s! as! a! result! of! The! National! Trachoma! and! Eye! Health! Program!(NTEHP).338! It! found! that! the! prevalence! of! eye! disease! among! Aboriginal!Australians! was! up! to! tenHtimes! greater! than! the! nonHAboriginal! Australian!population!and!that!blindness!was!up!to!twice!as!common,!with!the!majority!of!this!vision!loss!being!due!to!preventable!or!treatable!conditions.339!More!recent!
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studies! show! that! vision! loss! in! Aboriginal! people! is! still! the! result! of!preventable!or! easily! treated! conditions! such!as! cataract,! diabetic! retinopathy!(DR),!uncorrected!refractive!error,!trachoma!and!trauma.340,341!They!tend!to!be!more!common!and!severe!in!regional!communities!where!factors!such!as!access!to!health!care,!poor!housing,!poor!diet!and!poor!sanitation!may!play!a!role.342!!The!Goldfields!Eye!Health!Survey!examined!trends!in!diabetic!retinopathy!and!causes! of! vision! loss.! Clinical! and! demographic! data! from! ophthalmic!examinations!performed!during!yearly!clinics!in!Aboriginal!communities!of!the!Eastern! Goldfields! region! of! WA! were! collated! into! a! clinical! database.! This!registry!formed!a!comprehensive!dataset!of!Aboriginal!eye!health!in!the!region!over! a! 12Hyear! period! not! available! through! the! HMDC.! This! study! highlights!how! survey! methodologies! may! be! used! to! fill! in! the! gaps! in! knowledge!regarding! the! health! of! itinerate! and! isolated! populations! who! are! underHrepresented! in! health! administrative! databases.! The! data! from! such! surveys!may! be! linked! to! administrative! datasets! in! outcomes! studies! e.g.! Busselton!health!study.66!
Diabetic!retinopathy!screening!and!management!practices!Diabetic!retinopathy!is!a!national!health!priority.!It!is!the!fourth!major!cause!of!blindness! in! the! Australian! community! and! one! of! the! most! common!complications! of! diabetes.10! The! contribution! of! diabetic! retinopathy! to! the!burden!of!blindness!in!the!Australian!community!is!expected!to!worsen!as!the!number!of!Australians!with!diabetes!doubles!over! the!next! two!decades.343H345!
Figure!4N2!The!Eastern!Goldfields!Eye!Health!Survey!area,!Western!Australia!(reprinted!with!permission)!
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Fortunately!vision!loss!from!diabetic!retinopathy!is!preventable!in!up!to!98%!if!detected! early! and!managed! appropriately.346! The! predicted! rising! burden! of!diabetes!and!diabetic!retinopathy!therefore!needs!to!be!met!with!improvement!in! early!detection!and!appropriate!management! if! significant! visual!burden! in!the!community!is!to!be!minimised.!The!Australian!National!Health!and!Medical!Research!(NH&MRC)!guidelines!for!diabetic!retinopathy!screening!and!management!provide!a!comprehensive!and!prescriptive!outline!for!best!practice,347!yet!only!half!of!diabetics!are!adequately!screened.348H352!The! reasons! for! this! aren’t! immediately! apparent.!Perhaps! the!link!between!early!detection!through!screening!and!prevention!of!blindness!due!to! diabetes! is! not! adequately! emphasised! so! people! with! diabetes! aren’t!motivated! to! attend! regular! eye! checks.!Alternatively,! eye! care!providers!may!not!refer! their!patients!as!regularly!as! they!report.!These!questions!cannot!be!evaluated!using!administrative!datasets.!This! study! involved! a! national! survey! of! ophthalmologists,! optometrists! and!general! practitioners! (GP)! regarding! their! diabetic! retinopathy! screening! and!management! practices.! The! survey! questionnaire! (Appendix! 2)! was!administered!during!November!2007!and!February!2008!to!a!random!selection!of!ophthalmologist,! optometrist! and!GPs.!This! survey!was! conducted!after! the!release! of! the! NH&MRC! guidelines! for! diabetic! retinopathy! screening! and!management,! with! the! aim! of! measuring! their! impact! by! comparison! with!similar! surveys! done! prior.353H358! The! results! were! collated,! analysed! and!reported!by!the!coHauthors!under!the!candidates!close!guidance.!
Quality!of!life!after!postCoperative!endophthalmitis!and!in!the!severely!visionCimpaired!Quality!of!life!was!explored!across!two!separate!studies.!The!first!explored!the!impact! of! a! major! blinding! event,! postoperative! endophthalmitis,! on! patient!quality! of! life.! While! visual! acuity! is! the! most! commonly! reported! outcome!measure! in! studies! investigating! postoperative! endophthalmitis,272,293,359,360! it!cannot!describe!the!impact!of!endophthalmitis!upon!a!patients!overall!quality!of!life!where! social! interaction,!mental! health,! dependency! and! functional! ability!play! an! important! role.! By! determining! the! quality! of! life! in! patients! with!endophthalmitis,! the! personal! burden! imposed! by! this! condition! can! be!
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estimated!including!a!more!accurate!estimate!of!the!true!cost!(in!a!dollar!sense)!of!endophthalmitis!beyond!simply!the!cost!to!the!health!care!system.!Quality! of! life!was! evaluated! in! this! study!using! three! validated!quality! of! life!questionnaires.! The! first! was! the! National! Eye! Institute’s! VFQH25!questionnaire,309! which! measures! self! reported! patient! perceptions! of! vision!and!healthHrelated!quality!of!life.!The!second!was!the!EuroQol!EQH5D!(EQH5D)361!questionnaire!that!measures!general!healthHrelated!quality!of!life;!and!the!final!tool!was!the!TTO!method!to!allow!calculation!of!utility!values.362!In! EBEDS,! quality! of! life! associated! with! severe! vision! impairment! was!described! using! the! IVI! questionnaire! and! TTO! methodology.! The! questions!were!administered!in!an!interview!conducted!during!the!validation!clinics!held!to! validate! the! blind! register.! The! study! coordinator,! Ms! Julie! Crewe,!administered!all!questionnaires!to!maintain!consistency!across!responses.!!
4.2. Research!output!
Published!manuscripts!This! chapter! includes! 10! papers! published! in! the! peerHreviewed! literature!addressing!the!research!areas!discussed!above:!one!paper!describes!the!risk!of!arterial! thromboembolic! events! after! antiHVEGF! treatment;! 4! papers! describe!the! findings! from! EBEDS;! one! paper! describes! trends! in! diabetic! retinopathy!and! the!causes!of!vision! loss! in!Aboriginals! from!the!Eastern!Goldfields;! three!papers!describe! the!diabetic! retinopathy!screening!and!management!practices!of! Australian! ophthalmologists,! optometrists,! and! GPs! respectively;! and! two!paper! describe! quality! of! life! in! postHoperative! endophthalmitis! and! severe!vision!impairment!respectively.!
Research!Translation!Research!findings!arising!from!this!chapter!were!presented!at!local!and!national!conferences.!The! study! evaluating! thromboembolic! events! after! antiHVEGF! treatment! has!formed!a!pilot!project!for!a!large!national!postHmarketing!surveillance!study!to!fully! assess! the! systemic! safety! of! intravitreal! antiHVEGF! treatment! –the! fight!retinal!blindness!(FRB)!project.363! !
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MYOCARDIAL INFARCTION AFTER
INTRAVITREAL VASCULAR ENDOTHELIAL
GROWTH FACTOR INHIBITORS
A Whole Population Study
ANNA KEMP, PHD,*† DAVID B. PREEN, PHD,* NIGEL MORLET, FRANZCO,‡
ANTONY CLARK, MBBS,‡§ IAN L. MCALLISTER, FRANZCO,‡¶ TOM BRIFFA, PHD,**
FRANK M. SANFILIPPO, PHD,** JONATHON Q. NG, MBBS, PHD,†† CHARLOTTE MCKNIGHT, MBBS,‡¶
WAYNE REYNOLDS, MBBS,‡ MARK C. GILLES, FRANZCO, PHD‡‡
Purpose: To determine the risk of thromboembolic and gastrointestinal bleeding events
in the 12 months after injections of bevacizumab or ranibizumab compared with
photodynamic therapy and a nontreated community sample.
Methods: Hospital and death records were examined for 1,267 patients treated with
vascular endothelial growth factor inhibitor and 399 patients treated with photodynamic
therapy attending Western Australian eye clinics from 2002 to 2008, and 1,763 community
controls, aged $50 years. Hospital records from 1995 to 2009 were analyzed for history of
myocardial infarction (MI), stroke, and gastrointestinal bleeding before treatment. Records
were searched for evidence of these events in the 12 months after treatment.
Results: The 12-month MI rate was higher for vascular endothelial growth factor inhibitor
patients than photodynamic therapy patientsand the community group (1.9/100 vs. 0.8 and
0.7, respectively). No differences were observed between patients treated with bevacizu-
mab and ranibizumab. The adjusted MI rate was 2.3 times greater than the community
group (95% confidence interval, 1.2–4.5) and photodynamic therapy rate (95% confidence
interval, 0.7–7.7). The 12-month MI risk did not increase with the number of injections
administered (hazard ratio, 0.9; 95% confidence interval, 0.5–1.5). Stroke and gastrointes-
tinal bleeding did not differ between any exposure groups.
Conclusion: Although all the adverse events examined were rare, patients treated with
vascular endothelial growth factor inhibitors were significantly more likely to experience fatal
or nonfatal MI than the community group. This increased risk may be related to the underlying
age-related macular degeneration or vascular endothelial growth factor inhibitor use itself.
RETINA 33:920–927, 2013
The vascular endothelial growth factor (VEGF)inhibitor drugs, bevacizumab and ranibizumab,
are effective in treating neovascular age-related macular
degeneration (AMD), with many patients experiencing
improvements in vision and quality of life.1–4 Use of
these therapies has grown rapidly in recent years5 and is
used for AMD treatment in the United States and else-
where.5–7 These medications are known to increase the
risk of arterial thromboembolic events (e.g., myocardial
infarction [MI] and stroke) when used systemically,6
but much smaller doses are administered through local-
ized intravitreal injection for neovascular AMD,7 and it
is unknown whether this would increase the risk of
thromboembolic events for patients with, or without,
a history of these events.7
The MARINA1 and ANCHOR4,8 Phase III trials
investigating the efficacy of VEGF inhibitors for neo-
vascular AMD reported a small trend toward increased
arterial thromboembolic events in patients treated with
ranibizumab.1,4,8 In the ANCHOR trial, the incidence
of acute MI at 24 months was 2.2% in the VEGF
inhibitor treatment group compared with 1.4% in the
control group,8 whereas stroke occurred in 1.1% and
1.4% of the treatment and control groups, respec-
tively.9 At 2 years of follow-up, the MARINA trial
reported an incidence of 1.3% for MI and 2.5%
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for stroke after intravitreal ranibizumab treatment
compared with 1.7% and 0.8% for MI and stroke,
respectively, after placebo10 When 12-month data
from 3 trials (MARINA, ANCHOR, and PIER) were
combined, the overall incidence of arterial thrombo-
embolic events was higher for patients treated with
ranibizumab (2.5%) compared with controls (1.1%).5
Photodynamic therapy (PDT), a commonly used
treatment for neovascular AMD before 2006, is not
known to increase the risk of arterial thromboembolic
events.5,10 Gastrointestinal (GI) bleeding was reported
in 0.8 per 100 patients treated with ranibizumab com-
pared with no events among PDT patients.9,11 Those
clinical trials individually had insufficient power to
statistically evaluate low-incidence events, leading
researchers to comment that the clinical significance
of the noted adverse events is unclear and requires
further attention.4,12
A retrospective study of 146,942 Medicare beneficia-
ries in the United States observed patients for 12 months
after treatment with ranibizumab, bevacizumab, pegapta-
nib, or PDT.5 After statistical adjustment, patients treated
with ranibizumab were found to have a reduced risk of
MI compared with PDT patients (hazard ratios [HR],
0.78; 95% confidence interval [CI], 0.62–0.98).5 No dif-
ferences in MI rates were observed between any other
exposure groups, and no differences in rates of stroke or
GI bleeding were reported between groups.5
To date, no study has compared the risk of thrombo-
embolic eventsafter these therapies with that in the
general population or examined the effect of previous
thromboembolic events on risk after VEGF inhibitor
treatment. Such comparisons are important, given the
mixed evidence for underlying risk of thromboembolic
events in patients with AMD13–17 and in the large
number of patients using these therapies.5 We used
whole population–linked medical/health data to deter-
mine whether AMD patients treated with intravitreal
injections of bevacizumab or ranibizumab had an
increased risk of thromboembolic events compared
with AMD patients treated with PDT and a community
sample without neovascular AMD. Our study may be
viewed as a Phase IV pharmacovigilance method of
evaluating the thromboembolic adverse effects of
VEGF inhibitors in a real-world population.
Methods
A matched multiple-comparison cohort was retro-
spectively studied using whole-population routinely
collected health/medical data to determine the risk of
thromboembolic events after intravitreal treatment
with bevacizumab or ranibizumab. Ethical approval
was provided by the University of Western Australia
(WA) and the WA Department of Health.
Exposure Groups
Three groups of individuals aged$50 years fromWA
were examined: 1) VEGF inhibitor patients, 2) PDT
patients, and 3) a community comparison group without
neovascular AMD. All VEGF inhibitor patients were
treated for AMD between January 1, 2006, and December
31, 2008. All of the PDT group also had AMD and
were treated from January 1, 2002, to December 31,
2007. The PDT group was identified over an earlier
and longer time period because of the diminishing use
of this treatment in recent years.5 The VEGF inhibitor
and PDT groups were identified from routinely
recorded treatment information maintained by the four
eye clinics providing these treatments in WA during
the study period. We tested the null hypothesis of no
difference between groups using separate one-way
comparisons for each of the outcomes of interest.
The community group was randomly selected from
a pool of eligible adults (aged $50 years) listed on the
WA Electoral Roll who had no record of treatment
with ranibizumab, bevacizumab, or PDT from 2002
to 2008. People in the eligible pool were matched
to the VEGF inhibitor group by gender, 5-year age
group, and socioeconomic status and residential loca-
tion, both of which were based on geocodes.
Outcome Ascertainment
Eye clinic records were linked to health outcome
data through the WA Data Linkage System (WADLS),
maintained by the WA Department of Health.18 The
WADLS combines eight core data sets including
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hospital admissions, deaths and Electoral Roll registra-
tions, dating back variously to 1966.18 The system is
updated continuously, and the quality of linkage has
been assessed by comparison of routine linkage to
clerical investigation, with average proportions of
invalid links (false positives) and missed links (false
negatives), both estimated at 0.11%.18 Hospital data
were linked for all individuals from January 1, 1995,
to December 31, 2009. Demographic information (i.e.,
age, sex) and data relating to primary and coexisting
diagnoses were extracted from the hospital data
set. Geocodes available in the hospital and mortality
data sets were used to attach social disadvantage
(Socio-Economic Indexes for Areas) and geo-
graphic remoteness (Accessibility/Remoteness Index
of Australia) to all records.19,20
The outcomes of interest were MI, stroke, and GI
bleeding listed in the principal discharge diagnosis
field of a hospital admission record (nonfatal) or as the
cause of death identified using the International
Classification of Diseases version 10 with Australian
Modifications (ICD-10-AM: MI I21.0–I22.9, stroke
I163.0–I163.9, GI bleeding K92.2).21 To be consistent
with other studies, we examined the rates of admission
and death for 12 months after the treatment for all
individuals.5,22
Follow-up for VEGF inhibitor and PDT patients
commenced on the first (index) recorded date for
treatment. Individuals who received both PDT and
VEGF inhibitors (n = 126) (in all instances, use of these
two treatments was consecutive rather than concomi-
tant) were considered VEGF inhibitor–only patients if
their VEGF inhibitor treatment commenced before
PDT (n = 3) or their first PDT treatment was within
12 months of subsequently commencing VEGF inhib-
itor treatment (n = 37). Patients first treated with PDT
and with a minimum of 12 months between their
index PDT date and index VEGF inhibitor date were
considered to be both VEGF inhibitor and PDT
patients, with separate follow-up periods used in each
instance (n = 86). The community group were ran-
domly assigned index dates in accordance with the
index treatment dates of the VEGF inhibitor group.
This method, used elsewhere,23 ensured a comparable
12-month period for the community group to observe
MI, stroke, and GI bleeds. Follow-up ended at 12
months after the index date, death, or the date of the first
recorded admission, whichever occurred first. Follow-up
was censored if the outcomes of interest, fatal or non-
fatal, did not occur by the end of the follow-up period.
Individuals with prior MI, stroke, GI bleed, or
diabetes were identified from International Classifica-
tion of Diseases codes of these conditions in any of the
discharge diagnosis fields in the hospital data set
during the period from January 1, 1995, to the index
treatment.
Statistical Analyses
Patients’ demographic characteristics at index treat-
ment were compared for all groups. Chi-squared and
one-way analysis of variance tests were used to com-
pare the differences between groups for categorical
and continuous variables, respectively.
The 12-month rate of fatal or nonfatal MI, stroke,
and GI bleeding was calculated for all groups using
person-time at risk as the denominator. We also
separately calculated the rates for patients treated with
bevacizumab or ranibizumab. Given the low number
thromboembolic events, two-tailed Fisher exact tests
were used to compare groups. The patients treated
with bevacizumab and ranibizumab were subsequently
analyzed as one VEGF inhibitor group because no
differences in events were detected between patients
treated with these drugs. No further analyses were
conducted for stroke or GI bleeding because the Fisher
exact test did not identify any differences between the
groups. In addition, there were too few stroke or GI
bleed events to undertake regression modeling,24 espe-
cially when adjusting for covariates.
Cox proportional hazards regression was used to
calculate the hazard (“risk”) of MI in the 12 months
after treatment with VEGF inhibitors or PDT and the
equivalent observation period for the community
group. Models were adjusted for sex, age, and history
of MI or diabetes. Survival time to fatal or nonfatal MI
for the community group was compared with survival
for VEGF inhibitor patients. For each variable in the
Cox models, the proportional hazards assumption was
tested visually using Kaplan–Meier curves and
by examining a plot of −log(−log(survival time))
against (log)time.
Number needed to harm (NNH) analysis was
performed to quantify any increased risk of MI
in patients treated with VEGF inhibitors compared
with PDT patients and the community group.
The NNH estimates and 95% CIs were calculated
as the inverse of the absolute risk increase
(NNH ¼ 1%MI VEGF inhibitor group−%MI community group).25
All analyses were performed using PASW (formerly
SPSS) version 17.0.26
Results
Characteristics of the study participants are shown
in Table 1. The groups were generally well matched,
but the community group was 2 years younger, on
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average, than the VEGF inhibitor patients (P , 0.001)
and PDT controls and was more likely to have a history
of stroke (7.5% vs. 4.7% and 4.8%, respectively; P =
0.002). PDT patients were treated over a longer period
than VEGF inhibitor patients (244 days vs. 199 days,
P , 0.001) and had an additional 25 days between
treatments on average (P , 0.001). Vascular endothe-
lial growth factor inhibitor patients received slightly
more treatments, on average, than PDT patients.
The rate of adverse events among treated groups is
shown in Table 2. Stroke and GI bleeding rates
across groups were very low, and rates for MI were
low (stroke: 0.3–0.8/100, GI bleeds: 0.0–0.6/100,
MI: 0.7–2.1/100 patients). The rates for stroke and
GI bleeding did not differ between treated groups,
and no significant differences were observed
between patients with bevacizumab and ranibizu-
mab. The difference between the MI rate for VEGF
inhibitor patients and the community group was sig-
nificant (1.9 vs. 0.7/100, P = 0.01). The rate for PDT
patients, however, did not differ significantly from
that in the VEGF inhibitor group (0.8 vs. 1.9/100,
P = 0.14).
Patients treated with VEGF inhibitors had approxi-
mately 2.3 to 2.5 times the risk of MI than the
community group in the unadjusted model (95% CI,
1.3–4.9) and after adjustment for prior MI, diabetes, sex,
and age (95% CI, 1.2–4.5) (Table 3). Similar HRs were
found for VEGF inhibitor patients compared with the
PDT group; however, these were not significant in the
unadjusted (HR, 2.3; 95% CI, 0.7–8.1) or adjusted mod-
els (HR, 2.4; 95% CI, 0.7–7.7). In the VEGF inhibitor
group, risk of MI did not increase with each additional
treatment received (HR, 0.9; 95% CI, 0.5–1.5, not
shown).
For every 93 patients treated with VEGF inhibitors,
an additional MI would occur over and above the
community rate (Table 3). Survival time to MI for the
VEGF inhibitor and community groups is shown in
Figure 1. Although the difference in survival curves
was statistically significant (HR, 2.3; 95% CI, 1.2–
4.5), this represented a small difference in survival
probability at 12 months.
Discussion
By using whole-population routinely collected health/
medical data from an Australian state of 2.3 million
people,27 we determined the risk of thromboembolic
Table 1. Demographic and Treatment Characteristics of Patients Treated with Intravitreal Injections of Bevacizumab and
Ranibizumab, PDT Patients, and Community Controls
VEGF Inhibitor PDT Community P
Total number 1,267 399 1,763 —
Male, % 40 48 45 0.083
Age at index, years* 79.1 (8.0) 78.7 (8.4) 77.0 (9.6) ,0.001†
SEIFA score‡ 6.9 (2.2) 7.0 (2.2) 6.9 (2.1) 0.684
Residence, %
Major cities 61 62 58 0.587
Inner regional 28 28 30
Outer regional 8 7 8
Remote 3 3 4
History, %
Diabetes 15.2 12.8 12.1 0.052§
MI 5.5 3.3 6.0 0.203
Stroke 4.7 4.8 7.5 ,0.001¶
GI bleed 4.3 2.3 4.3 0.139
Index date Jan 20, 2006, to
Dec 24, 2008
Jan 11, 2002, to
Aug 24, 2007
Jan 17, 2006, to
Dec 24, 2008**
—
Treatment duration
days
199 (218) 244 (231) — 0.001
Days between
treatments
39 (40) 64 (51) — ,0.001
No. treatments 4.1 (2.8) 3.2 (1.7) — 0.001
Bevacizumab 792 — — —
Ranibizumab 475
*Values are represented as mean (SD).
†The community group was significantly younger than VEGF inhibitor patients (P , 0.001) and PDT patients (P = 0.003).
‡Socio-Economic Indices For Areas, range 0 (high disadvantage) to 10 (low disadvantage).
§History of diabetes was more common in the VEGF inhibitor patients compared with the community (P = 0.017).
¶History of stroke was more common in the community group than in VEGF inhibitor patients (P = 0.002).
**Pseudo-dates (see the “Methods” section).
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events in the 12 months after treatment with VEGF
inhibitors compared with PDT patients and a non-
treated community group. The 12-month rate for MI,
stroke, and GI bleed was low in all exposure groups,
consistent with rates in the general population for
$50-year-olds (MI: 1.1/100 person-years,28 stroke:
0.2/100 person-years,29 GI bleeds: 0.1/100 person-
years).30 We observed no significant differences in
the rates of MI, stroke, or GI bleeding between
patients treated with bevacizumab or ranibizumab
(1.6 and 2.1 events/100 persons, respectively). No dif-
ferences in the 12-month rate of stroke or GI bleeding
were found between groups.
Previous studies reported no differences in stroke or
bleeding between VEGF inhibitor and PDT patients
but did report significantly lower MI incidence (1.1 vs.
1.3/100 person-years) for ranibizumab compared with
PDT.5 The reported incidence of MI was similar to
that in our study; however, Curtis et al did not adjust
for socioeconomic differences between exposure
groups. Their study was conducted in the United
States where ranibizumab is more expensive than
PDT. The authors suggest that socially disadvantaged
patients may have been more likely to receive PDT,
accounting for the difference in rates of MI.5 Such
differences between exposure groups did not occur
in our study, as the exposure groups were well
matched for socioeconomic status and costs were sim-
ilar across groups.31,32 During the study period, rani-
bizumab was available to social security recipients for
A$4.90 and to other Australian residents for $30.70.
Bevacizumab was not publically subsidized during the
study period and cost approximately $50 per treat-
ment. PDT was fully subsidised for social security
Table 2. Number of Adverse Events in the 12 Months After Index Treatment for Bevacizumab and Ranibizumab Patients,
PDT Patients, and the Community Group
Bevacizumab Ranibizumab
VEGF
Inhibitor
(Total) PDT* Community Fisher Exact Test (P)
MI, n (%)
Nonfatal 8 (1.0) 8 (1.7) 16 (1.3) 3 (0.8) 9 (0.5) Bevacizumab vs.
ranibizumab (0.66)
Fatal 5 (0.6) 2 (0.4) 7 (0.6) 0 (0.0) 4 (0.2) VEGF inhibitor vs.
photodynamic (0.14)
Total 13 (1.6) 10 (2.1) 23 (1.9) 3 (0.8) 13 (0.7) VEGF inhibitor vs.
community (0.01)
Stroke, n (%)
Nonfatal 2 (0.3) 2 (0.4) 4 (0.3) 3 (0.8) 8 (0.5) Bevacizumab vs.
ranibizumab (0.63)
Fatal 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) VEGF inhibitor vs.
photodynamic (0.37)
Total 2 (0.3) 2 (0.4) 4 (0.3) 3 (0.8) 8 (0.5) VEGF inhibitor vs.
community (0.77)
GI bleed, n (%)
Nonfatal 4 (0.5) 3 (0.6) 7 (0.6) 0 (0.0) 7 (0.4) Bevacizumab vs.
ranibizumab (0.53)
Fatal 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) VEGF inhibitor vs.
photodynamic (0.21)
Total 4 (0.5) 3 (0.6) 7 (0.6) 0 (0.0) 7 (0.4) VEGF inhibitor vs.
community (0.59)
MI or stroke, n (%)
Total 15 (1.9) 12 (2.5) 27 (2.1) 6 (1.5) 21 (1.2) Bevacizumab vs.
ranibizumab (0.29)
VEGF inhibitor vs.
photodynamic (0.29)
VEGF inhibitor vs.
community (0.03)
MI, stroke or GI bleed
Total, n (%) 19 (2.4) 15 (3.2) 34 (2.7) 6 (1.5) 28 (1.6) Bevacizumab vs.
ranibizumab (0.26)
VEGF inhibitor vs.
photodynamic (0.12)
VEGF inhibitor vs.
community (0.03)
*Photodynamic therapy.
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recipients and cost approximately $50 for other
patients.31,32
Although MI was rare, we observed statistically
significant differences between treated groups. Com-
pared with the community group, patients receiving
VEGF inhibitors were 2.3 times more likely to have
a MI. This equates to an additional MI for every 93
patients treated, over and above the community rate.
Two explanations may account for the increased MI
rate we observed, namely MI risk may be increased
by VEGF inhibitors themselves (i.e., a drug effect)
or the underlying condition (i.e., AMD). If AMD
were associated with MI,14 both VEGF inhibitor and
PDT patients should have higher MI rates than the
community group. We found a significantly increased
MI hazard for VEGF inhibitor patients than the com-
munity group but not for PDT patients. If VEGF
inhibitors themselves increased MI, a higher hazard
among VEGF inhibitor patients than both the commu-
nity and PDT groups would be expected. Although
significant differences existed between the VEGF
inhibitor and community groups, none were found
between VEGF inhibitor and PDT patients.
Despite including all PDT patients in WA over 7
years, the number of patients in this group was
comparatively small (n = 399). A minimum PDT sam-
ple of 1,200 is required to detect the small rate differ-
ence in MI between PDT and VEGF inhibitor patients
Table 3. Results from Cox Proportional Hazards Regression Comparing Risk (and 95% CIs) of MI in the 12 Months After
Index Treatment and Number Needed to Harm for Bevacizumab and Ranibizumab Patients, PDT Patients, and the
Community Group
Exposure Groups Unadjusted HRs Adjusted HRs*
Number Needed to
Harm
VEGF inhibitors vs.
community
2.47 (1.25–4.87) 2.29 (1.16–4.54) 93 (52–414)
P = 0.01 P = 0.02
VEGF inhibitors vs. PDT 2.44 (0.73–8.14) 2.32 (0.70–7.74) 97 (52–N)†
P = 0.15 P = 0.17
PDT vs. community 1.02 (0.29–3.58) 0.97 (0.28–3.43) 6,896 (142–N)
P = 0.89 P = 0.96
*Models included age, sex, history of MI, and history of diabetes.
†The CIs spanning infinity indicate nonsignificant estimates for number needed to harm.25
Fig. 1. Results from Cox pro-
portional hazards regression:
cumulative survival for MI
admission or death in patients
treated with intravitreal in-
jections of bevacizumab or ra-
nibizumab and the community
(models included age, sex, his-
tory of MI, and history of dia-
betes). Risk of MI for patients
treated with VEGF inhibitors
compared with the untreated
community group, adjusted HR,
2.29 (95% CIs, 1.16–4.54; P =
0.02).
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(0.8% vs. 1.9%), with 70% power. Consequently, our
statistical comparisons for PDT analyses were under-
powered. Likewise, there was insufficient power to
detect differences between patients treated with beva-
cizumab and ranibizumab because of the few events in
each group. However, our finding of no differences in
thromboembolic events for patients treated with these
drugs is consistent with recent findings from the
CATT and IVAN studies.33 Pooling of data across
jurisdictions will be required to obtain a larger group
for further analysis, and we are currently collaborating
with national and international groups to address this.
We found that the risk of MI admission or death did
not increase with the number of VEGF inhibitor
injections received. Our data suggested that patients
receiving multiple treatments did not differ from those
receiving only one or two in terms of their age, sex,
residential location, socioeconomic status, or diabetes
history. Myocardial infraction admission did not
always signal the end of VEGF inhibitor treatments,
suggesting that this was not a simple survivor bias for
all. Evidence of a dose–response relationship usually
suggests a causal relationship34; however, other stud-
ies have reported that adverse effects from VEGF in-
hibitors are idiosyncratic rather than dose-related.35,36
We accessed all hospital and death records for the
study participants but did not have details of medica-
tion use, family history, or lifestyle and behavioral
factors that might affect the risk of MI, stroke, and GI
bleeding for individual patients. Only serious episodes
of GI bleeding and diabetes requiring hospitalization
would have been identified, so it is likely we have
underestimated their risk or prevalence, respectively.
The strength of our study was that it was a popula-
tion-based, Phase-IV “real-world” study. We used the
data that are highly representative of the Australian
population27,37 and had complete follow-up for admis-
sions and death for MI, stroke, and GI bleeding within
12 months of the index treatment. The comparison
groups were well matched for sex, socioeconomic sta-
tus, residential location, and prior MI, and we were able
to adjust for diabetes and age. Finally, we had access to
treatment records for every patient receiving intravitreal
VEGF inhibitors and PDT inWA over the study period.
Conclusion
Given the expansive growth in VEGF inhibitor
treatment for AMD and other eye conditions, the issue
of increased MI risk is important. We found that the
12-month rate for MI after treatment with VEGF
inhibitors was low but elevated compared with the
community. It remains unclear whether the increased
risk to VEGF inhibitor patients is associated with
AMD itself or its treatment with bevacizumab or
ranibizumab. The seriousness of this adverse event
warrants further investigation of the possible associa-
tion between the use of VEGF inhibitors and MI, with
pooling of data to increase statistical power.
Key words: adverse events, age-related macular
degeneration, bevacizumab, choroidal neovasculariza-
tion, postmarketing surveillance, ranibizumab.
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ABSTRACT
Background: To validate the accuracy of clinical oph-
thalmic information held on the West Australian
blind register.
Design: Community-based cross-sectional study.
Participants: Legally blind or severely vision-impaired
people were selected randomly from the Association
for the Blind of Western Australia register.
Methods: Individuals were reviewed by one of two
consultant ophthalmologists.
Main Outcome Measures: The positive predictive
value (ppv), sensitivity and specificity for legal blind-
ness status and diagnostic causes of vision loss were
calculated using data extracted from the Association
for the Blind of Western Australia blind register.
Results: 273 blind or near blind people were reviewed
from the register total of 4271 individuals. Therewere
more women (57%) than men, median age 81 years.
For legal blindness status the ppv was 0.88 (95%
confidence interval [CI] 0.82–0.92), sensitivity 0.75
(95%CI 0.74–0.84) and specificity 0.6 (95%CI 0.46–
0.73). The ppv for the diagnostic causes of blindness
were: age-related macular degeneration = 0.95 (95%
CI 0.91–0.97), retinitis pigmentosa ppv = 1 (95% CI
0.81–1.0), diabetic retinopathy ppv = 0.9 (95% CI
0.57–0.99), optic neuropathies ppv = 0.77 (95%
CI 0.51–0.92) and glaucoma ppv = 0.87 (95%CI 0.7–
0.96). Forty individuals (15%) had treatable condi-
tions contributing to their vision loss.
Conclusions: The blind register diagnoses and legal
blindness status are of high accuracy. This informa-
tion allows useful linkages to other databases for
studies of blindness interactions. A regular updating
mechanism would improve the future accuracy of
this valuable regional asset. The presence of
untreated cataract suggests that regular follow up
and appropriate treatment may help optimize vision
in blind patients.
Key words: blindness, blind register, positive predictive
value, validation.
INTRODUCTION
Our understanding, treatment and provision of
support services for the vision-impaired and blind are
enhanced by having an accurate clinical database or
register of those affected. In Western Australia (WA),
the Association for the Blind of Western Australia
(ABWA) client database forms the blind register, and
the aim of this study was to validate the clinical
ophthalmic information described in this register.
Western Australia occupies a third of the Austra-
lian continent, and has about 10% (2.24 million) of
the Australian population, most of whom reside in
the Perth urban region (1.95 million). The WA demo-
graphics reflect those of the national population,
with the indigenous population comprising 3% of
the WA population, 78% are Caucasian, 18% are
from South and East Asia and 1% are African or
Hispanic in origin.1
Vision-impaired individuals were referred to
ABWA for support and rehabilitation services by
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general practitioners, optometrists, ophthalmologists
or by self-referral. At registration, clinical details
supplied by an ophthalmologist or optometrist are
recorded on the ABWA database. The patient will
then be contacted by ABWA and reviewed in a low
vision clinic by an optometrist or orthoptist who
documents their functional vision. A weakness of
this voluntary register is that it is incomplete.
Despite this, as the sole service provider in this
region of Australia, the ABWA holds the largest
repository of data on the blind and vision-impaired.
In September 2009, the ABWA register had 4271
listed individuals. Of these, 1612 (38%) were
recorded as being legally blind and were confirmed
to be alive at the end of the study period (November
2009). This was made possible by linking data
records of the WA state register of deaths with the
study cohort. Only 17 (1%) of ABWA-registered
legally blind people were recorded as being Aborigi-
nal or Torres Strait Islanders.
METHODS
Individuals were randomly selected from the ABWA
register database. We selected all those who were
deemed to be severely vision-impaired having a best
corrected visual acuity (BCVA) LogMAR !0.7 (6/30
or worse) or who had <20° diameter of visual field in
their better eye. These individuals were invited to
join the study. Invites were sent to the last known
residential address recorded in the ABWA register.
Each person was subsequently contacted by tele-
phone, by a single researcher (JC), who explained
the study aims and objectives. Individuals who were
interested and able to travel to a clinical appraisal
received a complete ophthalmic review – performed
by one of two consultant ophthalmologists (WM,
NM) where the medical and ophthalmic history and
examination results were recorded without reference
to ABWA clinical records.
Legal blindness status was defined as having a
BCVA of LogMAR >1 or <10° diameter of visual field,
or a combination of both reduced visual acuity and
field restriction, resulting in an equivalent level of
vision loss, in the better eye. Individuals found to be
not legally blind were termed near blind for the
purposes of this study. Prioritized causes of vision
loss as determined by the ophthalmologist, previous
ophthalmic surgery, BCVA and field restriction were
recorded for each eye separately. Demographic
details, date of most recent ophthalmic appointment,
and any reported comorbid conditions were recorded
for each individual person. Clinical information from
the review was recorded in a Microsoft Access data-
base ver.2007.
The blind register recorded clinical information
provided by optometrists and ophthalmologists. His-
torically, clinical information relating to the diag-
noses and causes of vision loss were recorded for
each person, rather than for individual eyes. Where
more than one pathology was found to relate to loss
of vision, the diagnoses were listed rather than
ranked. The ABWA records were transposed into
Microsoft Access relational tables for comparison
with the findings of the clinical review assessment.
The positive predictive value (ppv) for legal
blindness status and for each of the causes of blind-
ness were calculated using person data rather than
for separate eyes; that is, if the clinical review
recorded glaucoma as the primary cause in one eye
and age-related macular degeneration (AMD) in the
contra lateral eye and the register recorded both
glaucoma and AMD for this person, this would be
considered to have a totally accurate record of
diagnoses. But if the register showed only AMD for
the same individual, then the diagnoses would be
considered accurate for AMD and incomplete for
glaucoma.
SPSS v17 (SPSS Inc., Chicago, Illinois, USA) and
Stata v10 (StataCorp LP, Texas, USA) were used to
analyse the data.
This study had Curtin University Human Research
Ethics Committee approval and all participants gave
written consent for the use of the de-identified col-
lated data.
RESULTS
From the ABWA register 1367 individuals were ran-
domly selected, of which 716 had a BCVA LogMAR
!0.7 (Fig. 1). Of those, 17% (n = 122) had been lost
to follow up, 50 (7%) had died since last contact, and
263 (37%) were either not well enough, not able to
attend or not interested in attending the clinics.
We reviewed 273 severely vision-impaired or
legally blind individuals which represented 12% of
all the individuals listed on the register. The age and
gender demographics of the cohort are shown in
Table 1. There were more women (n = 155) than
men (n = 118) and the median age was 81 (range
3–99) years.
Legal blindness
We found that 217 (79%) of the 273 reviewed indi-
viduals met the criteria for legal blindness status
having either a BCVA LogMAR >1 or a retinal field
restriction of <10° or a combination of both a reduced
visual acuity and field loss resulting in the same
level of disability, in the better eye. However, 54
(20% of the total number reviewed) were not
recorded on the register as being legally blind, and
22 others (8%) who were registered as legally blind
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were found to be near blind/vision-impaired at
review. So the ppv of the register legal blindness
categorization for the actual legal blindness status, as
determined by the clinical review, was calculated as
0.88 (Table 2).
The age and gender demographics of the 56 near
blind individuals (found to not be legally blind in
the review clinics) did not differ significantly from
those of the group who were confirmed as legally
blind (Table 1).
Data collated from the review clinics found that
most of the vision loss and blindness in this cohort
was caused by AMD (65%). More eyes were affected
by neovascular AMD (36.1%) than atrophic AMD
(28.9%). Glaucoma was found in 14.6%, congenital
retinal dystrophies including retinitis pigmentosa,
Stargardts, Ushers and others in 9.5%, optic atrophy
in 6.2%, other congenital conditions in 4% and dia-
betic retinopathy in 3.7%.
Diagnoses
The ppv, sensitivity and specificity of each of the
causes of blindness in this cohort are shown in
Table 2. After the review of 546 eyes of 273 individu-
als we found that 26 individuals (9.4%) had conflict-
ing variations in their diagnoses compared with the
diagnoses recorded in the register. Fourteen of these
were considered minor discrepancies being due
mainly to missing, unavailable or unknown diag-
noses in the register (Table 3).
Age-related macular degeneration was found
to cause bilateral vision loss in 177 (65%) individu-
als at review. Seven of these people were found to
have a primary diagnosis of AMD contributing to
vision loss that was not included in their registered
diagnoses. A total of 188 eyes were found to be
affected by neovascular AMD and 159 by atrophic
AMD. Of these 177 individuals, 133 (75%) were
legally blind. The register listed 178 individuals
with a diagnosis of AMD but eight people were not
confirmed to have AMD at review giving a ppv of
0.95 (95% confidence interval [CI] 0.91–0.97).
Glaucoma had a ppv of 0.87 (95% CI 0.70–0.96).
Of the 33 people registered with a diagnosis of glau-
coma relating to their vision loss, four were not con-
firmed at review. The review clinics found 66 eyes
with glaucoma contributing to vision loss in 40 indi-
viduals (26 bilateral, 14 unilateral). Eleven of these
people (nine bilateral, two unilateral) were not
listed as having glaucoma at all on the register.
Retinal dystrophies were relatively accurately
recorded by the register (ppv = 0.92, 95% CI 0.71–
0.98). This group included retinitis pigmentosa
(n = 12 individuals), Stargardt’s disease (n = 6),
Ushers syndrome (n = 1), rod-cone dystrophy (n = 1),
choroidal dystrophy (n = 1) and macular dystrophy
(n = 1). All were bilaterally affected and all were
legally blind. There were three additional individu-
als not registered with a retinal dystrophy but who
were confirmed in the review clinics; as bull’s eye
maculopathy (n = 2), and one case of Leber’s con-
genital amaurosis. These had registered diagnoses
of AMD ¥2 and missing diagnostic information
(respectively).
Optic neuropathy was diagnosed in 17 people
(14 bilateral and three unilateral). Fourteen of these
were registered as such by the ABWA. Additionally,
four others on the register had this diagnosis, but
were not confirmed at review. The ppv was 0.77
(95% CI 0.51–0.92).
Diabetic retinopathy was identified as the
primary cause of vision loss in 10 people (20 eyes),
seven were legally blind and three near blind. All
Randomly selected
from ABWA records
1307
BCVA LogMAR ≥ 0.7
or field <20°
Invited 716
Volunteered&
Consented
281
BCVA LogMAR <0.7
591 
Not well enough
Transport problems
Not interested
Not able to attend
107
73
68
15 
Lost to follow up 122
Died 50
DNA                8
Ophthalmic reviewed
273
Figure 1. Flow chart of patient selection from the whole regis-
ter of the Association for the Blind of Western Australia (ABWA)
through to the review clinics. Registered clients were initially
selected randomly, and then sub-selected for those having a best
corrected visual acuity (BCVA) LogMAR !0.7 or visual field loss
<20° and finally invited to attend an ophthalmic review clinic.
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were accurately registered by the ABWA. One addi-
tional individual registered with diabetic retinopa-
thy was not confirmed at review. For that patient,
bilateral central retinal vein occlusion was the
cause of the vision loss. The ppv was 0.90 (95% CI
0.57–0.99).
Retinal vascular occlusions were found in eight
patients (11 eyes, 10 central retinal vein occlusions
and one retinal artery occlusion). Five people were
legally blind and three near blind. Five of these eight
people were registered as having a retinal vascular
occlusion. A further four people were registered with
vascular occlusions but these were not confirmed at
review. The ppv was 0.55 (95% CI 0.22–0.84).
Forty (15%) people were found to have a treatable
condition which could lead to an improvement
in their vision. These included 54 cataracts in 29
individuals, eight posterior capsular opacities in
seven individuals, two pterygia and two people with
reactivation retinal haemorrhaging which may
respond to anti-vascular endothelial growth factor
treatments.
There was a significant difference in the mean
length of time since the last visit to an ophthalmolo-
gist between men (24.1 months, SD 32.3) and
women (17.4 months, SD 18.5) (mean difference =
6.6, 95% CI 0.3–12.9, P = 0.04) and also between
people who were legally blind (22.4 months, SD
27.6) and those who were near blind (13.3 months,
SD 15.8) (mean difference = 9.1, 95% CI 1.4–16.8,
P = 0.02) (Table 1).
Most of this cohort of severely vision-impaired
and legally blind people had at least one self-
reported comorbid condition (n = 214, 78%), with
almost half (46%) having two or more additional
health issues. The most commonly (35%) reported
comorbidity was hypertension.
DISCUSSION
The legal blindness status recorded on the WA blind
register was found to be relatively precise, making
the register a useful resource for further linked
health-care studies. The review clinics identified an
additional 54 individuals (20%) who would also
satisfy the criteria for legal blindness but who were
registered only as vision-impaired. Other studies2,3
have found that up to 33% of eligible legal blind
individuals were not registered appropriately for
support and rehabilitation.
The sensitivity of the register was moderately
good (0.75, 95% CI 0.74–0.84) when recording legal
blind status and the specificity was modest (0.6, 95%
CI 0.46–0.73). These results may be explained by the
fact that the ABWA register under-records legal
blindness. This happens when individuals are ini-
tially registered as vision-impaired but who progress
to legal blindness at a later date. The progression to
legal blindness may not always be communicated to
the ABWA, leading to delays in data revision and a
reduction in the specificity of the register. A system
for regularly updating the register would greatly
improve the quality of the data and the research
outcomes derived from them.
Conversely we found that 8% of individuals who
were registered as legally blind were near blind or
partially sighted on the day of assessment. There is a
recognized test–retest variability in determining
visual acuity of !0.18 (in terms of 95% ranges), so
that those individuals with a registered visual acuity
Table 1. Demographics (gender and age) of the study cohort separated into those who were legally blind or near blind on the register
and those confirmed as legally blind or near blind in the review clinics
Total Review clinic legally blind Review clinic near blind
Registered legally blind (n) 184 163 21
Registered near blind (n) 89 54 35
Male Female Male Female
Registered legally blind (n) 184 74 89 9 12
Mean age (years) (SD) 72 (20.0) 77 (16.6) 76 (13.3) 83 (10.2)
Median age (years) 79 82 82 84
Range (years) 8–94 6–98 50–88 61–95
Previous review, mean
months (SD)
25 (33.1) 18 (19.5) 26 (25.6) 13 (12.8)
Registered near blind (n) 89 19 35 16 19
Mean age (years) (SD) 61 (33.8) 74 (22.3) 66 (27.1) 71 (26.1)
Median age (years) 80 81 79 81
Range (years) 3–99 5–97 5–89 7–89
Previous review, mean
months (SD)
29 (29.4) 22 (20.4)* 11 (14.9) 9 (8.3)*
Total (n) 273
SD, standard deviation. *Independent t-test significant difference P < 0.05.
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of close to LogMAR = 1.0 could, by chance, be found
over or under the legal blindness cut-off mark on the
day of review.4 Additionally, Snellen charts are
widely used by those submitting the registration
forms to the ABWA, and this could also lead to
greater variability in the recorded visual acuity mea-
surement in the register data.5
A UK study found that after review of blind reg-
istration forms (BD8 forms), 6% of those recorded as
legally blind were vision-impaired.6 In Scotland,
17% of patients were re-categorized after review of
registration forms from blind to partially sighted7
and in the West Midlands UK, 34%were found to be
inappropriately registered as legally blind after a
retrospective chart review.3
Patients volunteered to attend these review clinics
and therefore this study cohort may not truly be
representative of the overall WA population of
severely vision-impaired and blind people.
However, we found the proportions of each of the
primary causes of vision loss in this cohort were
broadly similar to those of the group who did not
attend and also similar to those previously reported
for WA (Fig. 2).8
Western Australia is a geographically vast region,
so this sample cohort may also have underrepre-
sented the number of blind people with debilitating
comorbid conditions, especially conditions that
make travelling difficult or impossible. These condi-
tions will have a greater impact on people living in
rural and remote regions of WA.
We found retinal dystrophies and AMD were the
most accurately diagnosed and registered causes of
blindness. On the other hand, retinal vascular occlu-
sions and glaucoma were the diagnoses that were
possibly overlooked, misdiagnosed or inaccurately
recorded at registration. The diagnosis of retinal vas-
cular occlusion may not necessarily be evident years
after the event, and may not have been detectable at
review, in all cases. The relative contribution of glau-
coma to the overall blindness may be difficult to
assess, particularly in the presence of other problems
such as AMD.
Three Aboriginal persons were randomly selected
and reviewed in the study clinics. They were all
found to be legally blind. Taylor et al.9 have recently
estimated that up to 1.9% of Aboriginal persons
were likely to be legally blind, which suggests in
WA, about 639 of 71 000.10 Clearly, very few of these
are currently registered with ABWA for assistance
(n = 17), highlighting an area of great need. The issue
of how to identify and provide appropriate services
for blind and vision-impaired Aboriginal persons
requires urgent attention.
An accurate clinical database of the changing pat-
terns of the causes and extent of blindness in the
community, will allow for better planning, treatmentTa
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and delivery of health services for the severely
vision-impaired.
By monitoring changes in disease incidence and
prevalence, we can better understand the impact
brought about by targeted programmes or treatments
for blinding eye disease.
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Table 3. Summary of variations found in the diagnoses in the review clinic (two left hand columns for right and left eyes, respectively),
compared to the diagnoses on the register (two right hand columns for first and second listed diagnoses, respectively)
Review clinic Review clinic ABWA ABWA
Right primary diagnosis Left primary diagnosis Diagnosis 1 Diagnosis 2
Major variations
1 Macular dystrophy Macular dystrophy Lebers optic atrophy Lebers optic atrophy
2 Retinal detachment AMD AMD Br. retinal vein occl.
3 AMD Trauma AMD Br. retinal vein occl.
4 AMD AMD Stargardts Stargardts
5 AMD AMD Stargardts Cataract
6 Homonymous hemianopia Homonymous hemianopia AMD Cataract
7 Myopic macular degen. Myopic macular degen. AMD Optic neuropathy
8 Retinal vein occlusion Retinal vein occlusion Diabetic retinopathy Optic neuropathy
9 Choroideraemia Choroideraemia Glaucoma Cataract
10 Amblyopia Endog. endophthalmitis Glaucoma n/a
11 Congenital falciform folds Congenital falciform folds Glaucoma Cataract
12 Hysterical blindness Hysterical blindness Glaucoma n/a
Minor variations
13 AMD Corneal decompensation AMD n/a
14 AMD Retinal detachment AMD n/a
15 AMD AMD IOL n/a
16 AMD AMD n/a n/a
17 Glaucoma AMD AMD n/a
18 AMD Glaucoma Glaucoma n/a
19 Bull’s eye maculopathy Bull’s eye maculopathy AMD n/a
20 Failed PK Failed PK Keratitis Corneal opacity
21 Macula oedema/
epiretinal membrane
Trauma Macular degeneration Trauma
22 Optic neuropathy No vision loss Tumour n/a
23 Optic neuropathy Optic neuropathy n/a n/a
24 Lebers congen. amaurosis Lebers congen. amaurosis n/a n/a
25 Bull’s eye maculopathy Bull’s eye maculopathy AMD Cataract
26 Myopic macular degen. Glaucoma Glaucoma Cataract
Minor discrepancies were generally cases where data was missing, unavailable or unknown. Major differences were judged, by the
ophthalmologists, to be clinical errors. ABWA, Association for the Blind of Western Australia; AMD, age-related macular degeneration;
IOL, intraocular lens; n/a, not available; PK, penetrating keratoplasty.
AMD
Glaucoma
Vascular occlusion
Diabetic
retinopathy
Retinal
detachment
Optic neuropathy
0 20 40
% of sample population
60 80
Yong et al. WA 1984–2002 [8]
Non-attendees 2008–2009
Review cohort 2008–2009
Figure 2. Comparative frequen-
cies of the major causes of blind-
ness in this study cohort, in those
who did not attend and in a previ-
ous Western Australian (WA) blind
register incidence report.8 AMD,
age-related macular degeneration.
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ABSTRACT
Aim To determine the prevalence of blinding eye disease
in Western Australia using a capture and recapture
methodology.
Methods Three independent lists of residents of
Western Australia who were also legally blind were
collated during the capture periods in 2008e9. The first
list was obtained from the state-wide blind register.
A second list comprised patients routinely attending
hospital outpatient eye clinics over a 6-month period in
2008. The third list was patients attending
ophthalmologists’ routine clinical appointments over
a 6-week period in 2009. Lists were compared to identify
those individuals who were captured on each list and
those who were recaptured by subsequent lists.
Log-linear models were used to calculate the best fit and
estimate the prevalence of blindness in the Western
Australian population and extrapolated to a national
prevalence of blindness in Australia.
Results 1771 legally blind people were identified on
three separate lists. The best estimate of the prevalence
of blindness in Western Australia was 3384 (95% CI
2947 to 3983) or 0.15% of the population of 2.25 million.
Extrapolating to the national population (21.87 million)
gave a prevalence of legal blindness of approximately
32 892 or 0.15%.
Conclusion Captureerecapture techniques can be used
to determine the prevalence of blindness in whole
populations. The calculated prevalence of blindness
suggested that up to 30% of legally blind people may not
be receiving available financial support and up to 60%
were not accessing rehabilitation services.
The prevalence of blindness is a fundamental
measure required effectively to target intervention
programmes and to provide hard data against
which progress can be evaluated. Most information
on the prevalence of blindness is derived from blind
registers or sampling surveys.1 2 The conventional
approach to creating blind registers is by voluntary
referrals from general practitioners and ophthal-
mologists. Reports have shown that underreporting
of eligible patients was a significant problem
particularly when there was no evaluation of the
degree of ascertainment.3 4 Alternative methods for
determining the prevalence of blindness have
required sampling surveys of communities or
complete population census data collection.5 6
Captureerecapture techniques were initially
developed to estimate animal populations but have
more recently been used and validated by epide-
miologists to estimate the prevalence of medical
conditions such as postoperative joint infections,
brain injury, diabetes and pertussis in infants.7e11
The method utilises overlapping incomplete lists of
affected individuals collated during repeated
‘capture’ exercises to estimate the size of the
unsampled portion of the population. It also assess
the degree of undercounting.
Our aim was to use captureerecapture method-
ology to determine the true prevalence of blindness
in Western Australia. The results will enable us to
improve the referral process by which people who
are vision impaired are directed to support service
providers, to monitor interventions and to predict
future healthcare needs and costs.
METHODS
Legal blindness in Australia is defined as having
a best corrected visual acuity of LogMAR greater
than 1 or a visual field restriction of less than 108
from central fixation or a combination of both
reduced visual acuity and field loss resulting in the
equivalent level of disability in the better eye.
In this study three separate ‘capture’ lists of
people who were legally blind and resident in
Western Australia (lists A, B and C), were collated
over an 18-month period between April 2008 and
September 2009. Western Australia has four
tertiary-level hospitals including a paediatric
hospital, each with public ophthalmology clinics,
which contributed cases to the study. Both urban
and rural-based consultant ophthalmologists,
general practitioners and an optometrist enrolled
patients in the study. Optometrists or ophthalmic
nurses determined the level of vision loss. The
diagnostic cause of vision loss and legal blindness
status were determined by consultant ophthal-
mologists using full clinical notes, in all cases.
This study was approved by the human research
ethics committees of Curtin University and
participating hospitals.
List A was derived from the blind register held by
the Association for the Blind of Western Australia.
This recorded all individuals who were vision
impaired or legally blind who were either self-
referred, or referred by ophthalmologists, optome-
trists or healthcare providers from anywhere
within the state. It is a voluntary system of referral
and has high diagnostic accuracy with a positive
predictive value of 0.88 for legal blindness status.12
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List B was collated over the 6-month period April to
September 2008. It consisted of patients who were legally blind
attending routine appointments at either public hospital
outpatient eye clinics or selected consultant ophthalmologists’
clinics or who were assessed by an optometrist.
Patients were not enrolled within a 7-day postoperative period.
There were no age limits on being listed as legally blind. Listed
patients gave consent for their identifiers (first name, middle
name, last name, gender and date of birth) to be utilised for the
specific purposes of this study. Patients were enlisted using
standardised forms to record the level and cause of vision loss.
The third data list (C) was collected over a 6-week period
AugusteSeptember 2009. Eligible patients comprised those who
were legally blind and attending either a tertiary hospital
outpatient eye clinic or a consultant ophthalmologist’s rooms or
selected general medical practitioners’ clinics. The methodology,
selection and inclusion criteria were identical for this list as those
for list B and were confirmed by ophthalmologists in all cases.
Deterministic unique matching with clerical review between
lists (A, B and C) was achieved using available identifier fields: date
of birth, gender, first and last names. All legally blind individuals
listed on the blind register (list A) at 30 September 2009, with
residential post codes within Western Australian state boundaries
(post codes 6000e6999) were selected. Individuals with a matched
identity on the state register of deaths, with a date of death before
the end of the collection period were excluded. This facility was
made possible by the Western Australian data linkage unit and
permitted the accurate calculation of outmigration due to deaths
in the blind register population.
Following the identification of the total number of individuals
contained in the three lists and the matches identified between
lists, the data were classified into seven cells of a three-way
contingency table. The table has eight cells (23) with the eighth
cell corresponding to blind individuals who were absent from all
three lists. The data are illustrated in a Venn diagram (figure 1) and
in an incomplete contingency table (table 1). Incomplete contin-
gency tables were used to estimate the number of individuals in
the missing cell of the table using log-linear modelling.13 14
Log-linear modelling
The logarithm of the count in each cell of the table was
modelled as a linear function of terms indicating the presence or
absence on each dimension (list). Pair-wise dependence of lists
can be modelled as interaction terms between the relevant lists.
Explicitly: the log-linear model may be expressed using the
following notation (following Chao et al):14
LogðMa;b;cÞ ¼ u þ uðaÞ þ uðbÞ þ uðcÞ þ uða;bÞ þ uða;cÞ þ uðb;cÞ
Where Ma,b,c represents the expected number of people identified
in the combination of lists given by the indices a, b and c; as the
‘intercept’ term in the linear model, u represents the logarithm
of the number not captured; other terms in the model represent
the influence of relevant list membership (or ‘joint’ membership
for interaction terms) on the expected number in that list (or
combination of lists). It must be assumed that no three-way
interaction term is present, so that the final (unknown) cell can
be determined from the estimates of the main effects and two-
way interaction terms in the model. Seven models were fitted to
the data: one with no interactions (indicating that memberships
of lists were independent of each other), three models with one
two-way interaction term, and three models with two two-way
interaction terms. Models fitted are shown in supplementary
table 2, available online only.
The simplest model (least number of estimated parameters) in
which the deviance indicated an adequate fit (p>0.05, c2
statistic with the appropriate degrees of freedom) was selected
as the best model. The purpose of fitting the model was to
estimate the number of people who were not captured in any of
the lists. This number was estimated for each model, and was
added to the number of people who were present in at least one
list, to obtain an estimate of the total population of blind
people. The 95% CI for the number not captured provide an
indication of the reliability of the final population prevalence
estimate.
Dependencies between source lists appear as statistically
significant interaction terms in the log-linear model. The inter-
action term in the model attempts to correct for any dependence,
and results in a model that fits the observed data better. The
influence of this dependence on the estimate of people not listed
is difficult to predict. However, more confidence can be placed in
estimates that are derived from models that describe the data
well. The interaction terms were included when they provide
a significant improvement to the goodness of fit of the model.
The model coefficients were estimated using the ‘Genmod’
procedure, SAS software program, version 9.1. Other analyses
were carried out using PASW Statistics v18, (Microsoft).
Previous studies of the prevalence of blindness in Australia
have been age restricted (50 years or more) in which blindness is
more frequent.5 15 To compare the estimate of this study with
previous estimates we recalculated the captureerecapture prev-
alence estimates, using the same matrices and models, after
selecting only those people who were blind and aged 50 years or
more, in each of the three collated lists.
All Australian adults who are legally blind are eligible for
financial support in the form of a government pension. For the
Figure 1 Venn diagram showing the distribution of 1771 individuals
who were legally blind, to illustrate the overlap between the number of
people who were blind and identified on each of the three lists: A, blind
register; B, individuals attending routine hospital outpatient eye clinics
2008; and C, individuals attending ophthalmologist or general
practitioner appointments 2009.
Table 1 Contingency table showing the distribution of 1771 individuals
who were legally blind, between three lists
Recapture (C) present Recapture (C) absent
Capture (B)
present
Capture (B)
absent
Capture (B)
present
Capture (B)
absent
Blind register (A) present 5 68 47 1466
Blind register (A) absent 6 79 100 e
A, blind register; B, individuals attending routine hospital outpatient eye clinics 2008; and C,
individuals attending ophthalmologist or general practitioner clinical appointments 2009.
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purposes of validation and comparison, we compared the esti-
mated prevalence of blindness with the total number of blind
pension recipients in the state, during the periods of data
collection for this study. These de-identified data were made
available by the Australian federal government offices of the
Department of Families and Housing, Community Services and
Indigenous Affairs.
RESULTS
This study identified 1771 individuals resident in Western
Australia who were legally blind. There were 721 male and 1050
female individuals ranging in age from 1 year to 106 years at the
end of the data collection period in 2009.
The blind register (list A) contained 1586 individuals who
were confirmed as being alive and resident in the state of
Western Australia. Eleven people on the blind register had
recorded dates of death that could not be confirmed by the state
register of deaths, and all were included in the analysis. Eight
people from list B and one from list C died before the end of the
study period (October 2009), and were not included in the final
analysis. After clerical checking, 46 people on the blind register
were excluded as they had no known residential post code in
Western Australia (6000e6999) and were lost to follow-up.
The mean incidence of people who were legally blind added to
the blind register over the previous 5 years (2004e8) was 320 per
year or a cumulative incidence of 16 per 100 000 population per
year (figure 2A). The combined incidence of legally blind over
the previous 24 years is shown in figure 2B.16
The distribution of people across the three ‘capture’ lists is
shown in figure 1. List B had 158 people who were blind, of
which 100 were not present on either of the other lists (A and
C). Thirty-seven were nursing home residents and of these, five
were matched to people on list A. List C contained 158 people
who were blind, of whom 79 were not present on either list A or
list B. No nursing home residents were identified on list C. Five
people were present on all three lists and six were present on
both list B and list C.
Using log-linear modelling the simplest model, with no
interactions between the three lists, led to a poor fit with the
data (p¼0.021). The model with one interaction term (3)
showed the best fit (deviance 2.63, p¼0.268). The calculated
estimate of the ‘uncaptured’ portion of the blind population was
1613. Together with the previous 1771 ‘captured’, this provided
a best estimate of the total state population of legally blind in
2009 as 3384 (95% CI 2947 to 3983) (see supplementary table 3,
available online only).
An age restricted (50 years or more) population prevalence
estimate was also calculated in the same way (see supplemen-
tary figure 3, available online only). Using the same model (3)
with a single interaction and the best fit (p¼0.142), we obtained
an estimate of the number of people who were blind to be 2859
(95% CI 2470 to 3408) or 0.43% of the state population aged
50 years or more (n¼666 009)17 (see supplementary table 4,
available online only).
Extrapolating these results to a national level, the prevalence
of legal blindness in Australia in 2009 was 32 892 (95% CI 28 645
to 38 715) equivalent to 0.15% of the national population of 21.9
million. The age restricted ($50 years) prevalence of blindness
was 0.4% (95% CI 0.37% to 0.51%).
The estimated prevalence of people who were blind in
Western Australia exceeded both the total number of recipients
of the blind pension (n¼2244) and the number registered for
support with the Association for the Blind of Western Australia
(see supplementary figure 4, available online only).
DISCUSSION
This is the first study that we are aware of to use capture and
recapture mathematics to calculate the prevalence of blindness
in a whole population. We estimated that 3384 (95% CI 2947 to
3983) or 0.15% of the Western Australia population of 2.25
million were legally blind at the end of September 2009. This is
higher than either the number receiving the government blind
pension or those registered for support from the Association for
the Blind of Western Australia.
Comparing this prevalence estimate with previous cross-
sectional Australian studies, we found that the results were
remarkably similar. Both the Melbourne Visual Impairment
Project18 and the Blue Mountains Eye Study5 reported a preva-
lence of legal blindness of 0.5% in the population aged 50 years
or more. This suggests that the captureerecapture technique is
a valid and highly cost-effective method compared with tradi-
tional cross-sectional, population-based surveys for determining
disease prevalence.
The strengths of this study are the moderately stable and
relatively isolated population. It was recently shown that the
Western Australian population is representative of the Austra-
lian population as a whole.19 Therefore, data from this study can
reasonably be extrapolated to the national population of
Australia. All individuals who were legally blind were included in
this estimate, with no age restrictions. A prevalence estimate has
been obtained from a disparate and low prevalence population
Figure 2 (A) Incidence in Western Australia (WA) of individuals who
were registered as legally blind each year and the number of deaths in
this population 2003e8. (B) Incidence of individuals who were legally
blind registered annually in Western Australia per 100 000 population over
24 years. Data from a previous study, Yong et al16 and from this study.
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that is comparable to previous published estimates derived from
large population sampling surveys.
The study was limited by two of the four assumptions of
captureerecapture estimations: equal capture probabilities and
a closed population (no births, deaths or migration). It is
commonly accepted that this later assumption can rarely be
fulfilled in human applications.20 The provision of medical
services in rural Western Australia (geographical area 2.65
million km2) is limited, and as a result data collection from the
very remote regions of the state was low, but not zero. In
addition, people living in residential nursing care facilities,
although not specifically excluded, were less likely to attend
hospital or other clinical appointments and therefore the prob-
ability of being ‘captured’ was not equal when compared with
others in the community. As remotely isolated people and
nursing home residents were previously found to have a higher
prevalence of blindness than the general population6 21e23 this
would result in an underestimation of the true blind population.
These results have shown that relevant government and
community agencies are unaware of many people who are
legally blind. While it is possible that people who are blind may
choose not to claim income support, may be financially inde-
pendent or may not wish to be identified as legally blind, these
results suggest that there may be up to 35% more people who
are legally blind and eligible for financial support than are
currently in receipt of a blind pension in Western Australia. We
also found that only one third of individuals who are legally
blind have ever been referred to or have visited the only provider
of support services in the state, leaving 60% of individuals
without rehabilitation support. Understanding the full extent of
the burden of blindness will help to improve the targeting of
appropriate rehabilitation programmes with special emphasis on
psychological issues, increasing mobility and social connectivity.
This captureerecapture study has shown that it is a relatively
efficient and cost-effective method for the accurate estimation of
the prevalence of legal blindness.
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ABSTRACT
Background: To evaluate the impact of blindness on
hospitalization rates of children.
Design: Matched cohort study.
Participants: Children confirmed as legally blind
(2003–2009), age- and gender-matched to control
cohort of normally sighted children from the state
register of births.
Methods: The rates and reasons for admission to
hospital were compared using hospital morbidity
records. The association of blindness with rates of
admission and length of stay in hospital, 2003–2010,
were estimated using multivariate negative binomial
regression models.
Main Outcome Measures: Descriptive statistics, inci-
dent rate ratios, and predicted means for hospital
separations and length of stay.
Results: Fifty-nine blind and 59 control children had
a combined total of 107 separations accounting for
237 bed days in hospital after the index date of legal
blindness. The median age at the index date was 8
years. Over 90% of separations and 92% of bed days
were incurred by 22 blind children. Blind children
had four (95% confidence interval 1.9–9.3) times
more hospital separations and stayed in hospital six
(95% confidence interval 1.9–17.5) times longer
than the control cohort children. There were more
than 40 times as many comorbidities recorded by the
blind children (n = 201) compared with the control
children (n = 5). A third of the blind children were
hospitalized for respiratory conditions.
Conclusions: Children who are born or become blind
in childhood have more and longer periods in hos-
pital than sighted children likely because of complex
comorbid health problems. There was a dispropor-
tionate incidence of comorbid respiratory diseases in
the blind children.
Key words: blind, children, hospitalization, respiratory.
INTRODUCTION
Very little information exists on the health and well-
being of children who become blind during child-
hood. Although there are data on the incidence and
prevalence of different types of childhood blindness
or vision loss,1–5 there is no information on the health
outcomes, hospitalization characteristics or comor-
bidities of children who become blind.
Blindness in the general community has a low
prevalence (0.15%) and 0.02% in those aged less
than 18 years.6,7 Childhood blindness carries a high
financial cost for the community as well as a high
individual cost8 that impacts, in particular, normal
motor, language and social development, all com-
pounded when the child enters the education
system.9
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This matched cohort study examined the extent of
hospital utilization by children who were legally
blind during the period from 2003 to 2010. We com-
pared the number of hospital separations and bed
days attributed to the children who were blind and
compared with a cohort of normally sighted children
taking into account the various causes of vision loss,
socioeconomic status and residential remoteness.
METHODS
Blind children were identified from the voluntary
register of the Association for the Blind of Western
Australia and from paediatric ophthalmologists’
clinics. The index date for the blind children was the
date of first confirmation or registration as legally
blind that occurred between May 2003 and Sep-
tember 2009. Legal blindness was confirmed in all
cases by a specialist ophthalmologist. Blindness
was defined as having a best-corrected visual acuity
of logMAR >1 or <10° diameter of visual field, or a
combination of both reduced visual acuity and field
restriction, resulting in an equivalent level of vision
loss in the better eye. Children whose clinical fea-
tures were consistent with blindness (could not fix
or follow light), but whose acuity could not be
measured were also included. The blind register
contained demographic details and previously vali-
dated clinical data on the causes and extent of vision
loss.10
The children who were blind were age- and
gender-matched in a 1:1 ratio with normally sighted
control children from the state register of births. All
hospital morbidity records from the earliest hospital
admission through to 2010 for both the blind and
sighted children were de-identified and collated.
Each control child was attributed the same ‘index
date’ as their blind-matched child to ensure an equi-
table length of follow up.
The data were analysed to compare the hospital
separation rates, the number of bed days occupied,
the diagnoses at separation and comorbidities that
occurred after the index date. The number of separa-
tions post-index date was determined after exclud-
ing interhospital transfers. The length of stay (LOS)
(the number of bed days) was defined as the separa-
tion date minus the admission date plus one. An
Index of Relative Socioeconomic Disadvantage was
assigned to each child based on residential address
at the time of last hospital separation. This rating
was based on aggregated household and individual
attributes within the Australian Bureau of Statistics
collector districts using 2006 census data. The Index
of Relative Socioeconomic Disadvantage was used to
divide the population into quartiles of disadvantage
(1 most disadvantaged to 4 least disadvantaged).11
The Accessibility and Remoteness Index of Australia
(ARIA+) was used to describe geographical accessi-
bility at the time of hospital separation. ARIA+
measures access in terms of physical distance from
services and is divided in to four broad levels of
remoteness: major cities, inner regional, outer
regional, remote and very remote regions of Aus-
tralia.12 ARIA+ categories were assigned to cases
using the Australian Bureau of Statistics collector
districts of the residential address at the time of last
hospital separation.
The matching, linkage and extraction of state-
wide administrative health records were carried out
by the West Australian Data Linkage System. Inter-
national Statistical Classification of Diseases and
Related Health Problems, 10th revision, Australian
Modification codes were used to identify primary
and comorbid diagnoses associated with each hospi-
tal separation. Significance of association between
rates of separation and LOS, and categorical factors
were determined by chi-squared tests or by compari-
son of means for continuous variables using t-tests,
with the level of significance set at 0.05. Negative
binomial regression analysis was carried out to esti-
mate the mean number of hospital separations and
LOS after adjusting for blind status, gender, socio-
economic status, remoteness index and cause of
blindness where appropriate. A purposeful back-
ward stepwise selection of variables was performed
to generate the most parsimonious regression
models. Analysis was carried out using IBM PASW
v18 (IBM Corporation, Armonk, NY, USA) and Stata
v12 (StataCorp LP, College Station, TX, USA).
This study was approved by Curtin University
Human Research Ethics Committee and by the
Department of Health of Western Australia, Human
Research Ethics Committee. We certify that all appli-
cable institutional and governmental regulations
concerning the ethical use of human volunteers were
followed during this research.
RESULTS
The matched cohort consisted of 59 legally blind
children and 59 age- and gender-matched normally
sighted control children. None of the control children
appeared on the blind register or had any hospital
primary diagnosis or comorbidity coding for blind-
ness or ophthalmic-related problems and were pre-
sumed to be normally sighted. The median age at the
index date of legal blindness was 8.2 years (standard
deviation [SD] ! 4.2, range 0.2–16 years). Of the 59
children who were blind (54% male), 22 (37%) had
at least one hospital stay after the index date of
blindness (range 1–19) compared with 9 (15%) of
the control children (range 1–2). Two blind children
(14%) had a comorbidity code (H54.0) specifically
mentioning their blind status. The characteristics,
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number of separations and days spent in hospital for
the blind and control cohorts are shown in Table 1.
Cause of blindness
Retinal pathologies were the most common cause
of blindness affecting 26 (44%) blind children
(Table 2). Five children were blind, but the cause of
vision loss was not sufficiently specified to classify
them (e.g. Marfans syndrome-related). All condi-
tions causing blindness in this cohort had a bilateral
impact on vision resulting in legal blindness.
The mean age at the index date was not signifi-
cantly different for children with either optic nerve
damage (n = 14, mean age 9.8 years), retinal patholo-
gies (n = 26, mean age 9.0 years) or cortical blindness
(n = 4, mean age 6.2 years). However, children with
blindness as a consequence of developmental abnor-
malities were significantly younger at the index date
of blindness (n = 8, mean age 4.9 years, SD = ! 3.3
years) than children with either retinal pathologies
(t-test P = 0.01, 95% confidence interval [CI] 1.0–7.3)
or optic nerve blindness (P = 0.01, 95% CI 1.5–8.4).
The mean age at the index date was the same for
males (8.1 years) and females (8.4 years) (P = 0.70).
The cause of blindness in the children without
hospital separations (n = 15) were broadly similar to
those of children with hospital separations, although
they were significantly older (mean 10.9 years, SD
4.0) (t-test, P = 0.004, 95% CI 1.2-5.8) than those
hospitalized (mean 7.4 years, SD 3.8). There was no
significant difference in the mean age of the control
cohort children with (n = 25, 7.5 years, SD 4.4) or
without (n = 34, 8.6 years, SD 4.1) hospital separa-
tions at the assigned index date (P = 0.30).
Hospital separations
The blind children had 97 hospital separations after
the index date of blindness compared with just 10
separations by the normally sighted control children.
Thirty-seven per cent of the blind children were
admitted as emergency cases. Both blind and con-
trols groups had just one admission each for a single
day to ICU. All causes of blindness were associated
with an increased number of hospital separations
compared with the normally sighted controls. Chil-
dren with blindness relating to a developmental con-
dition (n = 8) had the greatest number of hospital
separations (37, mean 4.6, SD 6.9) compared with
admissions by the control children (n = 59) (10,
mean 0.2, SD 0.4, P < 0.001). Cortical blindness
was also associated with a higher mean rate of hos-
pital separations; four affected children having 11
separations (mean 2.7, SD 2.7) had eight times more
hospital separations than the control children
(P < 0.001).
Table 1. Demographics, hospital separation and bed days of
the matched cohorts of blind and control children after the
index date
Controls Blind Total P value
Gender (%)
Male 32 (54) 32 (54) 64 1.0
Female 27 (46) 27 (46) 54
Children with hospital
admission (%)
Yes 9 (15) 22 (37) 31 0.007
No 50 (85) 37 (63) 87
Hospital admissions (%) 10 (9) 97 (91) 107 –
Bed days in hospital (%) 19 (8) 218 (92) 237 –
Admission type (%)
Emergency 2 (20) 36 (37) 38 0.3
Elective 8 (80) 61 (63) 69
Comorbidities
Admissions with
comorbidities (n)
1 (6) 72 (201) 73 –
Admissions with no
comorbidities (n)
9 25 34 –
Legally blind and
registered (%)
Yes 0 50 (85) – –
No 59 (100) 9 (15) – –
–, not available.
Table 2. Principal cause of blindness in blind cohort (n = 59)
by gender
Male Female Total %
Retinal problems
Retinal dystrophy 7 5 12
Albinism 4 4 8
Retinopathy of prematurity 3 2 5
Norrie’s disease 1 0 1
Subtotal 26 44
Optic nerve problems
Optic atrophy 2 6 8
Optic nerve hypoplasia 4 1 5
Glaucoma 0 1 1
Subtotal 14 24
Developmental problems
Congenital ocular malformation 4 0 4
Coloboma (including
CHARGE syn.)
1 3 4
Subtotal 8 14
Cortical blindness 2 2 4
Subtotal 4 7
Neoplasms
Retinoblastoma 1 0 1
Glioma, optic chiasm 0 1 1
Subtotal 2 3
Other
Marfans syndrome 1 0 1
Nystagmus 2 1 3
Not specified, amblyopia 0 1 1
Subtotal 5 8
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The most frequently recurring primary diagnosis
group was musculoskeletal problems (n = 16). Only
children who were blind were admitted to hospi-
tal for musculoskeletal problems (16 admissions),
congenital (12 admissions), ophthalmic (5 admis-
sions), infections (5 admissions), neurological (4
admissions), endocrine (3 admissions) or genito-
urinary (1 admission) diagnoses (Fig. 1).
There were more than 40 times as many comor-
bidities recorded by the children who were blind
(n = 201) compared with the control children (n = 5)
during these hospital stays.
A negative binomial regression analysis of hospi-
tal separations that accounted for the variable length
of follow up estimated that the children who were
blind had an incident rate ratio 4.2 times greater
(95% CI 1.9–9.3) than the control children (Table 3).
The model predicted a mean of 1.2 separations (95%
CI 0.7–1.6) for each blind child compared with 0.3
separations (95% CI 0.1–0.4) for control children.
Socioeconomic status and residential remoteness
were not significantly associated with the number of
hospital separations.
LOS
The 22 blind and 9 control children with hospital
separations after the index date of blindness spent
a total of 237 bed days in hospital during the study
Genito-urinary
Circulation
Endocrine
Neurological
Digestive system
Injuries
Congenital
Symptoms
Eyes/Ears
Infections
Musculoskeletal
Respiratory
Blind Number of hospital separations
0 5 10 15 20
Controls
Others
Figure 1. Hospital separations, by primary diagnosis groups,
for blind children after confirmed blind or for control children
after their assigned index date.
Table 3. Negative binomial regression and predicted means: number of hospital separations and number of bed days after legal
blindness was confirmed
Admissions IRR P value 95% CI Predicted mean
separations/period
95% CI
Vision
Controls 1 – – 0.3 0.1–0.5
Blind 4.2 <0.001 1.9–9.3 1.2 0.7–1.6
Respiratory infections
No 1 – – – –
Yes 3.0 <0.001 1.6–5.7 – –
Cause of blindness
Controls 1 – – 0.2 0.1–0.4
Retinal 3.4 0.003 1.5–7.8 0.7 0.2–1.3
Optic nerve 8.3 <0.001 3.2–21.3 1.8 0.6–3.0
Cortical 18.1 <0.001 3.5–91.7 3.9 -1.7–9.4
Developmental 7.6 0.001 2.4–24.0 1.6 0.1–3.1
Neoplasms n/a – – – –
Length of stay (days) IRR P value 95% CI Predicted mean
bed day/period
95% CI
Vision
Controls 1 – – 0.5 0.0–1.0
Blind 5.8 0.002 1.9–17.5 2.8 1.3–4.3
Respiratory infections
No 1 – – – –
Yes 4.1 0.002 1.7–9.9 – –
Cause of blindness
Controls 1 – – 0.5 0.0–0.9
Retinal 2.4 0.06 1.0–5.9 1.1 0.4–1.8
Optic nerve 11.6 <0.001 3.7–36.4 5.4 0.4–10.3
Cortical 37.7 <0.001 6.8–208.1 17.5 -8.4–43.5
Developmental 7.0 0.01 1.6–31.2 3.3 -0.8–7.3
Neoplasms n/a – – – –
CI, confidence interval; IRR, incident rate ratio; n/a insufficient data to calculate effect; –, not available.
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period (2003–2010). The majority (92%) of days
spent in hospital were occupied by the blind chil-
dren (Fig. 2). The primary diagnoses accounting
for the most bed days (25%) were for respiratory
problems (54 days), musculoskeletal (32 days) and
infections (22 days).
Children with blindness caused by developmen-
tal abnormalities spent the greatest number of days
in hospital (94 bed days) having five times more
days in hospital than controls (19 bed days). The
mean number of bed days spent in hospital by all
children who were blind (3.7 bed days) was signifi-
cantly greater than the mean number of bed days of
the normally sighted controls (0.3 bed days) (P =
0.007, 95% CI 1.0–5.8). Of the blind children, those
with cortical blindness had the highest mean LOS
per admission (34 days, mean 3.1 per admission, SD
3.3), and this was not significantly different from the
control children’s mean LOS (P = 0.33).
A regression analysis of factors affecting the LOS
after the index date of blindness adjusting for the
variable length of follow up found that the incident
rate ratio of bed days was 5.8 times greater (95% CI
1.9–17.5) for the blind children compared with the
control children (95% CI 0.0–1.0) (Table 3). The LOS
was not associated with either the socioeconomic
status or the residential remoteness index.
DISCUSSION
The hospitalization records of children who were
blind illustrate a picture of extensive and complex
health issues requiring significant periods of care in
tertiary level hospitals. We did not anticipate that
respiratory problems would incur the most bed days
by this cohort of children, nor that respiratory prob-
lems requiring hospitalization were almost entirely
among the blind children, affecting a third of all the
blind children and accounting for a quarter of all
days spent in hospital. This is made more significant
because others have reported high mortality rates
among blind children and that these deaths were
largely caused by respiratory diseases.13 In that
study, Blohmé and Tornqvist reported that three
quarters of deaths were due to pneumonia and that
the deaths occurred in adolescence or early adult-
hood, predominantly in the children who had had
additional disabilities combined with their blind-
ness. In our study cohort, we had limited informa-
tion on other health-related factors. It should also be
noted that although there were no recorded deaths in
the blind cohort (mean age of 8.2 years), the blind
children were survivors up to this age. Children who
were blind and died prior to blind registration were
not included here.
The distribution of conditions resulting in child-
hood blindness in our study were broadly similar
to those reported by Rudanko and Laatikainen who
surveyed a larger cohort of full-term babies who
developed either vision impairment or blindness in
Finland.14 Retinal dystrophies were the most fre-
quent cause of childhood blindness in this cohort,
followed by albinism and optic neuropathies. Our
finding that males were overrepresented in the blind
cohort compared with the population gender ratio of
male to female children was consistent with other
studies of childhood blindness in Europe.5,13–15
The strengths of this study were that it included
all the legally blind children listed on the blind
register in Western Australia in mid-2009, plus an
additional nine unregistered blind children who
were identified through paediatric ophthalmology
clinics. The combined blind cohort represented
approximately half of the estimated total population
of blind children in Western Australia at the time
and would therefore be broadly representative of the
whole population of blind children.6 The study was
also strengthened by a previous validation assess-
ment of clinical data contained in the Western Aus-
tralian blind register.10
We restricted the analysis of hospital admissions
to those events that occurred only after the children’s
blind status had been confirmed so that a compara-
tive level of vision impairment was achieved across
all the children in the blind cohort. This methodol-
ogy excluded bias in the data arising from extended
periods spent in hospital by a small number of pre-
mature babies or those born with severe perinatal
problems.
The limitations of this study include the small
sample size due to the low prevalence of childhood
blindness. Despite this, we were able to demonstrate
significant differences in the hospitalization rates
compared with normally sighted control children
and between the different causes of childhood blind-
ness. Small subgroup population sizes, however,
Genito-urinary
Circulation
Endocrine
Neurological
Digestive system
Injuries
Congenital
Symptoms
Eyes/Ears
Infections
Others
Musculoskeletal
Respiratory
Blind Number of bed days
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Controls
Figure 2. Length of stay, as bed days, by primary diagnosis
groups after blindness was confirmed, or for the control children,
after their assigned index date.
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limited the possibilities of drawing conclusions on
separate entities. Although matched cohort studies
in a one-to-one ratio have been published recently,
this study may have benefited from increasing the
number of control children two or three times that of
the children who were blind.16
Clinical and hospital morbidity records on which
this study relied may not be totally comprehensive.
Vision loss or blindness was only recorded in the
hospital morbidity records of two of these children
admitted to hospital as a comorbid condition. The
clinical details of the causes and levels of vision
loss in children listed on the blind register were
also occasionally non-specific, incomplete or out of
date.
We found that blindness in childhood was associ-
ated with frequent and extended periods in tertiary
hospital care and presents a significant public health
issue. We found that blindness was rarely recorded
as a comorbid condition. The incidence of respiratory
illness in the blind children was unexpected and a
cause for concern as it may lead to serious morbidity
and mortality in these children. Further study of
the relationship between respiratory illness and
blindness in children is warranted. Cooperative and
complementary relations between ophthalmologi-
sts, paediatricians and support service providers are
required to ensure best practice health service provi-
sion for children who are blind.
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ABSTRACT
Aim Determine whether blindness in people aged
18–65 years was associated with increased rates of
mortality, hospitalisation and length of stay.
Methods A retrospective matched cohort study of
legally blind people and normally sighted controls, aged
18–65 years, comparing mortality rates and hospital
morbidity records.
Results Together, 419 blind and 419 controls
accumulated 12 258 hospital separations over the
11-year study period. The blind had an age-specific
mortality rate seven times greater (12/1000 person years)
than the general population (1.8/1000 person years)
(p<0.001). Blindness was recorded as a comorbid
condition for 76 (22%) blind individuals, on just 255
(2.3%) hospital separation records. Psychiatric, mental
or behavioural conditions were the most frequently
recorded diagnoses, after dialysis and endocrine conditions.
After adjusting for comorbidities, the blind cohort had 1.5
times more hospital separations (p=0.007, 95% CI 1.1 to
2.0) and 2.2 times more bed days (p=0.016, 95% CI 1.4
to 4.1) compared with the control cohort.
Conclusions Recognition and acknowledgement of
in-patients’ blind status may assist in understanding the
frequent and extended health service utilisation rates.
Encouraging and promoting the uptake and access to
rehabilitation support services would be measures that
may reduce the health service burden of blindness, the
incidence of depression and other mental health problems.
INTRODUCTION
The impact of blindness is widely studied and
acknowledged as one of the most severe of disabil-
ities; decreasing personal independence and mobil-
ity, often leading to social isolation and depression,1
adversely impacting quality of life, susceptibility to
injury and the financial status of individuals.2–6
Blindness in Australia and in other developed coun-
tries is a condition normally associated with older
aged groups.7 There is, however, very little informa-
tion on the health and well-being of people of
working-age, who are blind.8 9
This study identified a large cohort of legally blind
people aged less than 65 years from the state register
of people with vision impairments. Australia does not
currently have a national database of people with
vision impairments. In Western Australia (WA), there
is a single service provider; the Association for the
Blind of Western Australia (ABWA), and registration
with ABWA is voluntary. We have previously validated
the accuracy of the register as a data resource;10 the
completeness of the register was also assessed using a
capture and recapture method.7 This study cohort
was estimated to include more than half of the blind
population of adults aged 18–65 years in WA. We
subsequently linked these cohorts, at the individual
person level, to the state-wide Hospital Morbidity
Data System (HMDS) via the West Australian Data
Linkage System.11 12
We present an examination of the impact of blind-
ness on mortality and general health using data
linkage and hospital morbidity records of hospitals
throughout the state.
METHODS
Using a matched cohort study design, we examined
the frequency of admission to and time spent in hos-
pital due to acute disease and increased comorbidity
burden, combined with non-acute vision loss, the
socioeconomic status and accessibility to services of
people aged 18–65 years.
Study data were obtained from the WA state blind
register and the WA Data Linkage System following
approval from the Curtin University Human Research
Ethics Committee and by the Department of Health of
Western Australia Human Research Ethics Committee.
The study adhered to the tenets of the Declaration of
Helsinki.
Blind cohort: All adults listed on the state blind
register, aged between 18 and 65 years at the index
date of registration, were included in the cohort of
blind individuals. Legal blindness was confirmed by
a specialist ophthalmologist and was defined as
having a best-corrected visual acuity of LogMAR
>1 or a visual field restriction of <10° from central
fixation, or a combination of both reduced visual
acuity and field loss resulting in an equivalent level
of disability, in the better eye.
Control cohort: A random selection of normally
sighted, age-matched (±2 years) and gender-matched
adults was derived from the state electoral role of
WA (where voting is compulsory for all adults).
Matching was provided in a ratio of 1:1 blind to con-
trols. A de-identified extract of all hospital morbidity
records from the WA Hospital Morbidity Data collec-
tion and any death records from the death register
pertaining to individuals in the two cohorts were
obtained. Matching, linkage and de-identification of
all in-patient hospital morbidity and mortality
records were carried out by the Data Linkage Branch
of the Department of Health, WA.
This study compared the frequency of hospital
separations and cumulative length of stay (LoS) in
hospital over an 11-year period, or to the date of
death if earlier. A same-day hospital separation was
considered as a LoS of 1 day. The total number of
hospital separations and cumulative number of days
in hospital excluded any inter-hospital or nested
transfers.
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The Accessibility and Remoteness Index of Australia (ARIA+)
at the time of hospital separation was divided into four broad
levels of remoteness: major cities, inner regional, outer regional,
and remote and very remote regions of Australia.13 An Index of
Relative Socio-economic Disadvantage (IRSD) was assigned to
each person’s residential address at the time of last hospital sep-
aration. The IRSD had four categories dividing the population
into quartiles of disadvantage (one most disadvantaged to four
least disadvantaged).
Charlson’s comorbidity index was used to adjust for the effects
of comorbid conditions on the number of separations and LoS.14
This index consisted of 17 separate diagnosis codes, weighted
according to the mortality risk as described elsewhere.15 The total
weighted index was divided into four discrete intervals of increas-
ing morbidity (0, nil comorbidities; 1, 1–2 comorbidities; 2, 3–4
comorbidities; and 3, ≥5 comorbidities).
Descriptive statistics were used to compare mortality rates,
separation rates and LoS of the blind and control cohorts. To
account for any similarity (lack of independence) between cases
and their matched control, generalised estimating equations
assuming a negative binomial distribution were used to estimate
incident rate ratios (IRR) after accounting for the variable
length of the follow-up periods for each individual. A purpose-
ful backward step-wise selection of variables was performed to
generate the most parsimonious regression models. Variables
tested for inclusion were gender, age, socioeconomic status,
remoteness index and comorbid conditions. Analysis was
carried out using IBM PASW V.18 (IBM Corporation, Armonk,
New York, USA) and Stata V.12 (StataCorp LP, Texas, USA).
RESULTS
The matched cohorts consisted of 419 legally blind adults, 210
males and 209 females (median age 50.3, range 18–65 years) and
419 age-matched and gender-matched controls. When combined,
Table 1 Demographics of blind and control cohorts
Controls Blind Total p Value
Gender
Male 210 210 420
Female 209 209 418
Total 419 419 838
Age at index date (years)
18–29 52 55 107
30–39 67 69 136
40–49 85 80 165
50–59 121 132 256
60–65 90 82 172
Employment status (%)
Employed 166 (40) 92 (22) 258 χ2
Unemployed 10 (2) 19 (4) 29 0.002
Pensioner 12 (3) 88 (21) 100
Other, student,
home duties, retired
122 (17) 79 (19) 201
Missing 109 (26) 141 (34) 250
Marital status (%)
Never married 55 (18) 106 (31) 161
Divorced or separated 18 (6) 32 (9) 50
Married 223 (72) 183 (54) 406
Residential geographic region (%)
Major city 217 (52) 266 (64) 483
Inner regional 36 (9) 40 (9) 76
Outer regional 37 (9) 21 (5) 58
Remote and very remote 18 (4) 14 (3) 32
Unknown 111 (26) 78 (19) 189
Mean socioeconomic index t test
938.5 828.2 880.6 <0.001
p Value, probability.
Table 2 Hospital separations and length of stay (days) of blind and control cohorts during the study period (mid-1999 to mid-2010)
Controls Blind Total p Value
People with any hospital discharge (%)
Yes 310 (47) 343 (53) 653 –
No 109 (59) 76 (41) 185 0.006*
Admission type (%)
Emergency 214 (15) 1244 (85) 1458 –
Elective 1027 (9) 9873 (91) 10 900 <0.001*
Hospital separations (%)
Before index date legal blindness 645 (14) 4049 (86) 4694 –
After index date legal blindness 596 (8) 7068 (92) 7664 <0.001*
Total 1241 11 117 12 358
Total bed days (%)
Before index date legal blindness 1769 (12) 13 376 (88) 15 145 <0.001†
After index date legal blindness 1562 (11) 12 758 (89) 14 320 <0.001†
Total 3331 (11) 26 134 (89) 29 465 <0.001†
Psychiatric care
People receiving psychiatric care (%) 5 (18) 22 (82) 27 0.001*
Separations for psychiatric care (%) 24 (3) 675 (97) 699 <0.001*
Total days of psychiatric care (%) 117 (8) 1262 (92) 1379 0.23†
Mean length of each stay (SD) 8 (8) 4 (9) – 0.07†
Mean days per person (SD) 23 (31) 57 (110) – 0.23†
*χ2 test.
†t test.
p Value, probability.
1580 Crewe JM, et al. Br J Ophthalmol 2013;97:1579–1585. doi:10.1136/bjophthalmol-2013-303993
Clinical science
 group.bmj.com on March 19, 2014 - Published by bjo.bmj.comDownloaded from 
the cohorts accumulated 12 258 hospital separations for a total
of 29 465 bed days during the 11-year study period (1999–
2010). The median length of follow-up was 10.9 years (range
4.5–11 years). None of the controls appeared on the blind regis-
ter or had any hospital comorbidity coding for blindness and
were presumed to be normally sighted. Demographic characteris-
tics are shown in table 1, and hospitalisation events are shown in
table 2.
Of the study population, 28 died between the index date and
the study end date, with significantly more deaths in the blind
cohort (n=25, 6%) compared with the control cohort (n=3,
1%) (χ2, p<0.001). The mean length of time from the index
date to death was 2.3 years (SD 1.8, range 0.2–6.1 years). The
age-standardised mortality rate was ten times greater for the
blind cohort (12/1000 person years, 95% CI 6.3 to 16.9) than
the control cohort 1.2/1000 person years (95% CI 0 to 2.8).
The WA population mortality rate (aged 18–65 years in 2011)
was 1.8/1000 person years (95% CI 1.8 to 1.9)16 (figure 1).
In this cohort of adults of working age, there were significantly
fewer blind people (n=92) who were employed compared with
the control group (n=166, χ2 p=0.002). Almost twice as many
blind males (n=57) were employed compared with blind women
(n=35), which was disproportionate compared with the control
cohort employed (males=95, females=71).
Cause of blindness
Almost 30% of blindness in this cohort resulted from a congeni-
tal retinal dystrophy (retinitis pigmentosa n=83, Stargardt’s
n=15, Usher’s n=7, rod/cone dystrophies n=6 and unspecified
dystrophies n=15). Diabetic retinopathy, glaucoma and optic
nerve pathologies each accounted for more than 10% of cases
(table 3). The age at the index date of blindness illustrates the
rapid development of blindness due to diabetic retinopathy in
those aged over 40 years (figure 2).
Comorbidity
Blindness was recorded as a comorbid condition in the HMDS
records of just 76 (22%) blind individuals admitted to hospital
and on just 255 (2.3%) hospital separation records. In total, 41
of the 76 patients coded as being blind in their hospital records
were identified prior to the index date of blind registration.
Twenty-eight blind (7%) and three controls (<1%) had a
Charlson comorbidity index of five or greater. Most (80%)
people with diabetic retinopathy had comorbidity scores of 1 or
greater (figure 3).
Hospital separations
Overall, the blind cohort had more than seven times as many
hospital separations compared with the matched control cohort.
However, 64% (n=7748) of separations were for renal dialysis
alone, incurred by just 25 individuals who were blind.
Forty-three blind individuals were admitted to intensive care
units (ICUs) for 54 separations in contrast to just 15 controls
having 20 ICU separations over the study period.
Figure 1 Age-standardised mortality rates as deaths per thousand
person years for blind, controls and the Western Australian population.
Table 3 Major contributing causes of blindness for those in the blind cohort, with and without hospital separations and median age at the
index date of blindness
Cause of blindness
People with nil
hospital separations,
n (%)
People with ≥1 hospital
separations,
n
Total
n Per cent of cohort
Median age at the
index, years
Retinal dystrophies 37 (31) 84 121 28.9 47
Diabetic retinopathy 3 (6) 48 51 12.2 56
Glaucoma 1 (2) 45 46 11.0 52
Cataract 3 (9) 31 34 8.1 55
Other macular/retinal 7 (21) 26 33 7.9 57
Optic atrophy 6 (19) 26 32 7.6 57
Optic neuropathies 3 (10) 26 29 6.9 49
Age-related macular degeneration 6 (22) 22 27 6.4 57
Congenital or familial 4 (20) 16 20 4.8 55
Cerebral vascular accident 0 16 16 3.8 51
Cornea 1 (9) 10 11 2.6 51
Neoplasms 0 10 10 2.4 53
Retinal detachments 1 (14) 6 7 1.7 48
Retinal vascular disease (occlusions) 0 6 6 1.4 63
Trauma/surgery 0 2 2 0.5 45
Other or missing 45 10.7
Subtotal of causes of blindness 463
Total number of blind individuals 419 100 50
Cumulative total exceeds the total number of individuals (n=419) as more than one causal factor may have contributed to blindness.
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The blind cohort had more hospital separations than controls
for all the major diagnostic groups, except for neoplasms (blind
n=41, controls n=54) and obstetric problems (blind n=34,
controls n=73). Forty-four blind people (10%) were hospita-
lised with a primary diagnosis of ‘care involving rehabilitation
procedures’ compared with just two controls (0.5%). Four times
as many blind people (n=22) were hospitalised for periods of
psychiatric care compared with controls (n=5). The blind indi-
viduals had 20 times as many separations from psychiatric care
facilities (n=296) than controls (n=14) (figure 4).
After adjusting for comorbidities and accounting for the
length of follow-up, the blind cohort had 1.5 times more hos-
pital separations (p=0.007, 95% CI 1.1 to 2.0) than controls.
This equated to a mean of 16 separations (95% CI 12.3 to
19.0) for each blind person compared with 10 separations (95%
CI 7.2 to 13.4) for controls over the study period. Increasing
comorbidity scores were also associated with significantly
greater IRR (table 4A).
Eight per cent (844) of all hospital separations in this cohort
of working-age blind people resulted in a transfer to a nursing
home compared with just 0.2% (3) in the control cohort.
Length of stay
During the study period, the blind cohort accrued 26 134 bed
days compared with 3331 by the control cohort. However, 25
blind individuals receiving renal dialysis accounted for more
than a quarter of all the bed days occupied (7860 bed days).
Blind people occupied more bed days in every primary diag-
nostic group compared with controls. The primary diagnoses
accounting for the greatest number of days in hospital, other
than renal dialysis, were endocrine problems (2973 days), fol-
lowed by mental or behavioural problems (1794 days), circula-
tory problems (1709 days), ‘other conditions’ (including
follow-up after neoplasms, adjusting implants and devices,
rehabilitation and transition to appropriate accommodation)
and injuries resulting from burns or poisoning (1274 days).
Although blind individuals were admitted to hospital for oph-
thalmic conditions over 300 times, the number of bed days
accumulated for ophthalmic treatments (n=794 days) was con-
siderably less than other major diagnostic causes (figure 4).
Excluding admissions that were for dialysis only, the
unadjusted median LoS for people who were blind (5 days, SD
12.3) was twice as long as the median LoS for controls
(2.6 days, SD 4.8) (p<0.001, 95% CI −3.5 to −2.1). After
adjusting for comorbidities and dialysis, this relationship
remained significantly greater (p=0.016) (table 4B).
More than three times as many blind people (n=30) com-
pared with controls (n=9) were admitted to hospital for the
treatment of mental or behavioural conditions. Of these, 22
(73%) blind and 5 (55%) controls also had periods of psychi-
atric care. The blind cohort accrued 1262 days and controls
296 days as in-patients of psychiatric care units.
DISCUSSION
In this relatively young and blind cohort, we found a strong
association between blindness, the frequency of admission and
LoS in acute care hospitals in WA. The blind also had a
Figure 4 (A) The total number of bed days (excluding dialysis)
accumulated over the 11-year study period for the most frequent
primary diagnosis groups. (B) The number of hospital separations over
the same period for the same diagnostic groups.
Figure 2 Age at the index date of blind registration and the number
of people affected by the four principal causes of blindness, n=250
(60% of study cohort).
Figure 3 Percentage of people with a comorbidity index score of zero
or ≥1: controls or people blind due to one of the four main causes of
blindness. Comorbidity index scores: Charlson’s weighted scores.
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significantly higher mortality rate compared with the
age-standardised population mortality rate. The study cohort
was estimated to include at least half of all the legally blind
people aged 18–65 years at the time in WA and, as such, was
broadly representative of the working-age blind population as a
whole.7 17
Rahi et al did not find an association between severe vision
impairment and the self-reported hospitalisation events in a UK
birth cohort (aged 50 years), which included 0.3% (n=29) indi-
viduals who were severely vision impaired or blind. However,
the authors acknowledged that the study was underpowered to
detect any such associations.9 The current study has shown that
young people who became blind during their working life were
more frequently admitted to ICUs as emergency admissions and
experienced more frequent and prolonged periods of in-patient
psychiatric care.
The predicted mean number of days in hospital per year for
the blind was double that of the controls. This finding was con-
sistent with that of Morse et al,18 who analysed US health insur-
ance data of a large cohort described as ‘primarily legally blind’
but where the visual acuity was not tested and the hospital case
mix was somewhat different.
The strengths of this study are the ability to combine large
health-related data sets at the individual person level across the
whole state population, thereby avoiding bias limitations asso-
ciated with analysis of single-centre studies. This study is also
Table 4 Negative binomial regression analysis and predictive margin: (A) number of separations and (B) length of stay (days)
IRR p Value 95% CI Predictive margin 95% CI
A. Discharges
Vision
Controls 1 10.3 7.2 to 13.4
Blind 1.5 0.007 1.1 to 2.0 15.6 12.3 to 19.0
Dialysis
No 1
Yes 24.4 0.000 16.6 to 35.7
Comorbidity score
0 1
1 2.2 0.002 1.3 to 3.7
2 2.2 0.000 1.5 to 3.3
3 3.3 0.000 2.3 to 4.7
Remoteness score
Major city 1
Inner regional 0.8 0.17 0.6 to 1.1
Outer regional 0.8 0.31 0.6 to 1.2
Remote and very remote 0.8 0.25 0.6 to 1.1
Socioeconomic score
Most disadvantaged 1
More disadvantaged 1.2 0.12 0.9 to 1.5
Less disadvantaged 1.3 0.18 0.9 to 2.1
Least disadvantaged 1.1 0.49 0.8 to 1.4
B. Length of stay (days)
Vision
Controls 1 24.6 8.2 to 40.9
Blind 2.2 0.016 1.4 to 4.1 53.5 36.8 to 70.2
Dialysis
No 1
Yes 9.2 0.000 5.3 to 16.2
Comorbidity score
0 1
1 4.8 0.019 1.3 to 18.0
2 3.6 0.000 2.0 to 6.7
3 6.5 0.000 3.6 to 11.9
Remoteness score
Major city 1
Inner regional 0.8 0.22 0.5 to 1.2
Outer regional 0.7 0.11 0.5 to 1.1
Remote and very remote 0.7 0.05 0.5 to 1.0
Socioeconomic score
Most disadvantaged 1
More disadvantaged 1.4 0.08 1.0 to 2.1
Less disadvantaged 1.3 0.26 0.8 to 2.0
Least disadvantaged 1.1 0.79 0.6 to 1.8
IRR, incident rate ratio; p value, probability.
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strengthened by having the level of vision loss defined and con-
firmed in all cases by a qualified ophthalmologist. Similarly, the
blind register was validated in an earlier study by two independ-
ent ophthalmologists.10 However, by selecting the blind cohort
from the register of a service provider, it is likely that the indivi-
duals in the blind cohort would have accessed a range of rehabili-
tation services in contrast to blind people who have never been
registered or received support services. This may result in an
underestimation of the full extent of the healthcare burden of
blindness in WA.
Vision impairment and blindness have previously been linked
to an increased risk of death.19 20 Eighty years ago, a life insur-
ance company in the USA reported that blind clients had a mor-
tality rate more than double that of non-blind clients.21 In the
current study, the age-specific mortality rate of this younger blind
cohort was seven times greater than that of the normally sighted
controls and also of the state population aged 18–65 years. While
we did not have details of the specific causes of death, we did
note that most of the blind people who died in this cohort had
been hospitalised for either diabetes with multiple comorbid con-
ditions or were admitted for treatment of problems of the circula-
tory system.
It was disappointing to note that 75% of legally blind patients
admitted to hospital did not have their blind status recorded as
a comorbid condition in their hospital records. These data,
together with an earlier report,22 suggest that hospital clinicians
and/or coding staff did not recognise vision loss at the level of
legal blindness to be a relevant or significant comorbidity con-
tributing to the health and well-being of patients.
While only a small proportion of individuals in the blind
cohort were admitted to hospital for the treatment of mental or
behavioural problems, the majority of these cases went on to
receive extended periods of in-patient psychiatric care. These
data support the more widely reported incidence of mental
illness and depression estimated to affect up to a third of
severely vision impaired and blind people.23 Depression per se
would not be generally treated in an acute care hospital setting,
and therefore data available in this study would not accurately
reflect the extent of depression in either the blind cohort or
control cohort. Rather, the in-patient treatment of people with
mental or psychiatric problems could be viewed as the extreme
end of this spectrum of illnesses, which include depression,
behavioural, mental and psychiatric conditions. Rehabilitative
care was prescribed to just 10% of blind people in this cohort.
The current study did not take into account the personal
impact of blindness on quality of life24 nor the economic
burden of reduced productivity where less than a quarter were
employed and so the full extent of the burden of blindness is
only partially reflected in these hospitalisation rates. However,
we conclude that legal blindness contributes to an increased fre-
quency of admission to and extended LoS in hospital. The spe-
cific reasons for these extended periods in hospital may be a
consequence of poorer mobility skills, confusion or disorienta-
tion in the hospital setting, leading to issues of health and
safety. Hospital stays maybe extended to accommodate surgical
or medical follow-up for blind patients with transport difficul-
ties or there may be concerns regarding the discharge of blind
patients with revised or new medication regimens.
Recognition and acknowledgement of in-patients’ blind status
may assist in understanding the frequent and extended health
service utilisation rates. Encouraging and promoting the uptake
and access to rehabilitation support services would be measures
that may reduce the health service burden of blindness, the inci-
dence of depression and other mental health problems. A better
understanding of the specific needs of patients who are blind
could reduce additional days in acute care hospitals and there-
fore also healthcare costs.
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ABSTRACT
Purpose: To report on diabetic retinopathy (DR) and
the major causes of vision loss and blindness in
Aboriginals in the Eastern Goldfields region of
Western Australia between 1995 and 2007.
Methods: Aboriginals (>16 years old) diagnosed with
diabetes or eye problems from 11 communities in
the Eastern Goldfields region of Western Australia
were examined annually from 1995 to 2007. Data
collected from prospective clinical examination
included; visual acuity (VA), causes of vision loss,
and whether DR was present. Severity of DR was
graded according to the Early Treatment of Diabetic
Retinopathy Study modified Airlie House grading
system.
Results: A total of 920 Aboriginals underwent 1331
examinations over the study period. There were 246
eyes with vision loss (best-corrected VA < 6/12) in
159 Aboriginals, of whom five were bilaterally blind.
The four major known causes of vision loss were
cataract (n = 53, 30.1%), DR (n = 44, 25.0%), uncor-
rected refractive error (n = 31, 17.6%) and trauma
(n = 19, 10.8%). Aboriginals who had diabetes were
far more likely to have vision loss (odds ratio = 8.5,
95% confidence interval 5.7–12.6, P < 0.0001). Of
the 329 Aboriginals with diabetes, 82 (24.9%)
had DR, and 32 (9.7%) had vision-threatening
retinopathy. Of those with diabetes, 94 (42.5%)
returned for follow-up examination on an average of
3.2 visits with a median time between visits of
2 years.
Conclusion: The four major causes of vision loss in
Aboriginals from the Eastern Goldfields are largely
preventable and/or readily treated. DR and other
diabetes-related eye conditions are a major cause of
vision loss in Aboriginals, representing a significant
health challenge for health services and clinicians
into the future.
Key words: Aboriginal Australian, blindness, diabetic
retinopathy, epidemiology, low vision.
INTRODUCTION
The National Trachoma and Eye Health Program
(NTEHP) brought awareness to Australian Aborigi-
nal eye health in the mid 1970s.1 They reported the
prevalence of eye disease among Aboriginal Austra-
lians compared with the general population was up
to 10 times more common and blindness twice
as common, and that the majority of vision loss was
due to preventable or treatable conditions.2 Recent
studies have shown little has changed and that
vision loss in Aboriginal people is still due to pre-
ventable or treatable conditions including cataract,
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diabetic retinopathy (DR), uncorrected refractive
error, trachoma and trauma.3–8
The inclusion of DR as an important cause of
vision loss in Aboriginal communities is new since
the NTEHP when no cases were reported.1 Diabetes
has become particularly concerning for eye health in
Australian Aboriginals due to its dramatic rise in
prevalence in recent decades. Up to 20% of Austra-
lian Aboriginals have diabetes compared with 7% in
the general community,9,10 with 25% having some
signs of DR.11 The implications for Aboriginal eye
health are significant not only due to the expected
increase in DR but also due to the increase in
other diabetes-related eye conditions, for example,
cataract, retinal vascular disease and neovascular
glaucoma.
Most data on Australian Aboriginal eye health
have been derived from short-lived cross-sectional
surveys of remote communities.7,8,12–15 One major dif-
ficulty of these surveys is variable ascertainment due
to the transient nature of remote Aboriginal people.
The Goldfields Eye Health Survey (GEHS) began in
1992 as a yearly public health screening initiative to
evaluate and manage eye health problems, namely
trachoma, in Aboriginal communities in the Gold-
fields region of Western Australia (WA) (Fig. 1).16 We
realized that repeated examinations of these remote
communities, whose population is highly mobile,
would allowmore complete ascertainment of various
diseases over time. In 1995, DR screening was com-
menced and DR grades recorded for all Aboriginals
with diabetes examined. After 16 years, the GEHS is
the longest running Aboriginal eye health survey in
Australia. The aim of this paper is to report on data
collected in the GEHS on DR and the major causes of
vision loss over 12 years in Aboriginals from the
Eastern Goldfields region of WA.
METHODS
The goldfields eye health survey
All residents of the Eastern Goldfields communities
visited in each year were eligible to attend the visit-
ing eye clinics. The communities visited are isolated
and scattered across the region and included Kal-
goorlie, Coolgardie, Norseman, Coonana, Cosmo
Newberry, Laverton, Leonora, Menzies, MtMargaret,
Tjuntjunjarra and Wiluna (Fig. 1). The average resi-
dent Aboriginal population in the region over the
study period was 3980 (range 3645–4372) of which
1384 resided in remote communities (Epidemiology
Branch, Health Information Collection, Department
of Health of Western Australia).
The visiting ophthalmology team comprised an
ophthalmologist, a training ophthalmology registrar
and a nurse. Local community nurses and Aboriginal
Health Workers (AHW) also assisted during each
visit. Those who had an eye complaint, vision
problem or who were diabetic were particularly
sought out by the visiting team and were transported
to the local community health centre to be examined.
Figure 1. The Eastern Goldfields Eye Health Survey Area, Western Australia.
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Those unable to attend, such as the frail or elderly,
were seen in their homes.
Where possible all subjects had their visual acuity
(VA) measured (with current spectacles if they were
worn); and dilated indirect and direct ophthalmos-
copy was performed to examine the posterior
segment and ocular media. Those with a VA worse
than 6/12 were refracted before dilation.
The logistics of ensuring maximal service delivery
are significant given the size of the area and tran-
sience of the local Aboriginal population. The visit-
ing team worked very closely with the regional
Public Health Department and community AHWs
and nurses to select the most suitable time to visit.
Precise timing was chosen closer to each visit to
avoid local ceremonies or cultural events that were
likely to diminish the Aboriginal population avail-
able for screening.
Data collection
Clinical information was recorded prospectively
between 1995 and 2007 inclusive, except 2000 when
no survey was conducted for logistical reasons. In
2003, clinical information was entered into an elec-
tronic database and all subsequent survey visits
were recorded on this database. This allowed people
diagnosed with diabetes in the communities to
be identified in subsequent visits and a review
initiated. Approval was obtained from local Aborigi-
nal Community Councils in the region for the use,
analysis and reporting of the data collected.
Definitions
The presenting VA was that defined as that measured
at the time of each visit on a standard Snellen chart.
If spectacles were worn then the VA with the current
correction was recorded. Vision impairment (VI) was
defined as a presenting VA worse than 6/12. Blind-
ness was defined as a presenting VA worse than
6/60. VI was attributed to refractive error if the best-
corrected VA was better than or equal to 6/12. Simi-
larly, blindness was attributed to refractive error if
the best-corrected VA was better than or equal to
6/60.
The cause of vision loss in eyes was attributed to
the major disease present. Where two or more dis-
eases were present the cause was attributed to that
which was felt to be the greatest contributor to vision
loss.
The simplified World Health Organization tra-
choma grading scheme was used to grade trachoma.17
DR was graded according to the Early Treatment of
Diabetic Retinopathy Study modified Airlie House
grading system.15 Peripheral DR was graded as
‘mild’, ‘moderate’ or ‘severe’ non-proliferative retin-
opathy, and proliferative DR (PDR). Diabetic macu-
lopathy was graded as Grade 1 (hard exudates
within 1 disc diameter of the centre of the macula),
Grade 2 (hard exudates or retinal thickening within
500 microns of the centre of the macula) or Grade 3
(hard exudates or retinal thickening beneath the
centre of the macula). For clinical simplicity, Grade
1 maculopathy was categorized as diabetic macu-
lar oedema not significant, and Grades 2 and 3 con-
sidered together as clinically significant macular
oedema (CSME). Patients were considered to have
vision-threatening retinopathy (VTR) if severe non-
proliferative retinopathy, PDR or CSMEwas present.
Communities visited were grouped into remote
and non-remote on the basis of their distance from
Kalgoorlie (the major centre within the Goldfields
region). We considered communities outside a radius
of 250 km from Kalgoorlie as remote, whereas all
others were considered non-remote.
Data analysis
Data were analysed using Stata (Release 10; Stata
Corporation, College Station, TX, USA). Population
characteristics and the major causes of VI were sum-
marized using simple descriptive statistics. Categori-
cal variables were compared using the chi-squared
statistic, and Fisher’s exact test where categories
were less than five. Mean ages at initial visit were
compared using the Student t-test. Trends over time
in DR severity and the median time to follow-up
were assessed using the Spearman rank correlation
coefficient.
RESULTS
Study population characteristics are summarized in
Table 1. There were 1331 examinations performed
on 920 Aboriginals between 1995 and 2007 includ-
ing 592 examinations on 329 people with diabetes.
The mean age of all participants at their first visit
was 42 years (range 16–89 years), with males
being slightly older than females (Mean difference
2.4 years, 95% confidence interval [CI] 0.02–4.9,
P < 0.05) and diabetics significantly older than non-
diabetics (Mean difference 10.7 years, 95% CI 9.72–
14.10, P < 0.001.
There were 159 Aboriginals who had one or more
VI or blind eyes (246 eyes), of whom five had bin-
ocular blindness (Table 2). In 70 eyes (28.4%) the
causes of VI or blindness was unknown or not
recorded and were excluded from analysis. Impor-
tantly, we found no significant difference in the
age or sex distribution of this group of patients com-
pared with those whose diagnosis was known.
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Aboriginals who had diabetes accounted for 76.1%
of patients with vision loss and were significantly
more likely to have vision loss compared with those
who did not have diabetes (odds ratio = 8.5, 95% CI
5.7–12.6, P < 0.001).
The major causes of vision loss are summarized in
Table 2. Cataract (28.6%, 95% CI 20.7–35.3), DR (28.
6%, 95% CI 20.7–35.3), uncorrected refractive error
(21.1%, 95% CI 14.4–27.6) and trauma (5.4%, 95%
CI 1.8–9.0) made up the top four causes. There were
only three vision impaired eyes due to trachoma.
There was no significant difference in the causes of
vision loss for men and women.
Trauma accounted for 13 blind eyes (31.0%, 95%
CI 16.1–43.9) and was the second most common
cause of blindness after cataract (18 eyes, 38.1%,
95% CI 23.3–52.7). DR accounted for seven blind
eyes (16.7%, 95% CI 4.9–27.1). There was one blind
eye due to trachoma seen in 1997 and none found
since that time. In those five people who had bin-
ocular blindness; two were due to bilateral cataracts,
one due to cataract and DR, and one due to trauma in
one eye and cataract in the other. The cause of bin-
ocular blindness in the last person was not recorded.
The severity of DR in diabetic Aboriginals seen in
each year is summarized in Table 3. Over one-third
(35.8%, 95% CI 32.7–38.9) of all patients examined
had diabetes, with 82 (24.9%, 95% CI 20.3–29.6)
showing signs of DR and 32 (9.7%, 95% CI 6.5–2.9)
signs of VTR at least once since 1995. The trend in
the proportion who had DR, VTR and CSME showed
no significant change over time (Spearman Rank
P > 0.1) (Fig. 2). Two cases of PDR were seen in
1995, and one case in 1997 and 2006. At their first
visit, 18% (95% CI 14.1–22.4) of diabetics had DR,
whereas 7% (95%CI 4.2–9.8) had VTR. Two patients
had PDR at their first visit.
Ninety-four (42.5%, 95% CI 36.0–49.0) Aborigi-
nal diabetics from remote communities returned for
follow-up examination at least once over the study
period, on an average of 3.2 occasions. Follow-up
time varied across the years (Fig. 3) with the overall
median time between examinations being 2.0 years
(0.7–10.3 years). Less than half (47.9%) of follow-up
examinations occurred within 2 years of the previous
exam.
DISCUSSION
There is a relative paucity of recent data regarding
the causes of vision loss in Aboriginal Australians.
Table 1. Characteristics of Aboriginals (>16 years) seen in the Eastern Goldfields Eye Health Survey 1995–2007
All participants
(n = 920)
Diabetics
(n = 329)
P-value†
Examinations (n) 1331 592
Age (years)‡
Male (mean ! SD) 43.1 ! 15.0 48.5 ! 12.2 <0.001
Female (mean ! SD) 40.7 ! 14.7 47.7 ! 13.4 <0.001
Female n, (%) 500 (54.4) 195 (59.3) 0.05
Remote community n, (%) 520 (56.5) 221 (67.2) <0.001
Vision loss n, (%)§ 159 (17.3) 121 (36.8) <0.001
Monocular vision impairment 88 70
Monocular blindness 24 22
Binocular vision impairment 79 57
Binocular blindness 5 5
†P-values are derived from Student’s t-test for continuous variables and chi-squared test for categorical variables comparing the
diabetic to non-diabetic population. ‡Age was only available for 595 participants. §Persons may contribute to more than one category
over the study period.
Table 2. Known causes of blind and VI eyes in Aboriginals
examined in the Eastern Goldfields Eye Health Survey 1995–
2007†
Cause VI eyes
n (%)
Blind eyes
n (%)
Total eyes‡
n (%)
Cataract 42 (28.6) 16 (38.1) 53 (30.1)
Diabetic retinopathy 42 (28.6) 7 (16.7) 44 (25.0)
Refractive error 31 (21.1) 0 (0.0) 31 (17.6)
Trauma 8 (5.4) 13 (31.0) 19 (10.8)
Other 10 (6.8) 3 (7.1) 12 (6.8)
Trachoma 3 (2.0) 1 (2.4) 4 (2.3)
Pterygium 4 (2.7) 0 (0.0) 4 (2.3)
Amblyopia 2 (1.4) 1 (2.4) 3 (1.7)
Retinal detachment 2 (1.4) 0 (0.0) 2 (1.1)
Retinitis pigmentosa 2 (1.4) 0 (0.0) 2 (1.1)
Secondary glaucoma 0 (0.0) 1 (2.4) 1 (0.6)
Surgical complication 1 (0.7) 0 (0.0) 1 (0.6)
Total 147 (100) 42 (100) 176 (100)
†The cause of vision loss was not recorded for 70 eyes (three
VI eyes, and 68 blind eyes). ‡Eyes may contribute to more than
one category over the study period, for example, VI eyes that
have progressed to blindness. VI < 6/12,"6/60; blind < 6/60. VI,
vision impaired.
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Figure 2. Trend in the propor-
tion of adult Aboriginals with dia-
betes with diabetic retinopathy
seen in the Eastern Goldfield
Eye Health Survey 1995–2007. ( ),
any diabetic retinopathy; ( ),
vision-threatening retinopathy. (No
survey was conducted in 2000.)
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Figure 3. A Box and whisker plot
showing the trend in follow-up time
in Aboriginals with diabetes from
remote communities in the Eastern
Goldfields Eye Health Survey 1995–
2007. Whiskers mark the upper
and lower 5% values; ( ) outliers.
Table 3. Severity of DR in Aboriginals with diabetes seen in the Eastern Goldfields Eye Health Survey 1995–2007 (n; %)
Period n DR Severity of diabetic retinopathy
Macula Oedema NPDR
VTRCSME DMENS Mild Mod Severe PDR
1995–1997 152 44 (28.9) 14 (9.2) 7 (4.6) 21 (13.8) 13 (8.6) 4 (2.6) 3 (2.0) 21 (13.8)
1998–2001 156 24 (15.4) 6 (3.8) 6 (3.8) 11 (7.1) 6 (3.8) 2 (1.3) 0 (0.0) 8 (5.1)
2002–2004 131 29 (22.1) 2 (1.5) 7 (5.3) 20 (15.3) 3 (2.3) 4 (3.1) 0 (0.0) 6 (4.6)
2005–2007 118 19 (16.1) 7 (5.9) 2 (1.7) 7 (5.9) 6 (5.1) 4 (3.4) 1 (0.8) 12 (10.2)
Whole period 329 82 (24.9) 27 (8.2) 20 (6.1) 49 (14.2) 24 (7.3) 13 (4.0) 3 (0.9) 32 (9.7)
At presentation 329 60 (18.2) 19 (5.8) 8 (2.4) 31 (9.4) 15 (4.6) 6 (1.8) 2 (0.6) 23 (7.0)
CSME, clinically significant macular oedema; DMENS, diabetic macular oedema not significant; DR, diabetic retinopathy; NPDR,
non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; VTR, vision-threatening retinopathy (CSME or severe NPRD
or PDR).
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Ours is the first study to report on the major causes of
vision loss and blindness in an Australian Aborigi-
nal population since 1994 and is the first to have
collated these data over a period greater than
10 years.
The major causes of VI and blindness in Aborigi-
nals in the Goldfields region differ from previous
reports between 15–40 years ago.2,4,12 In particular,
we found a greater association of vision loss with
diabetes and a lesser association with trachoma.
Some similarities remain especially concerning cata-
ract, which is a significant cause of vision loss,
accounting for nearly one-third of VI eyes and con-
tributing substantially to blindness (38%). Although
this is an improvement from previous reports, where
40–50% of all blindness was due to cataract,2,4 it is
still over twice that reported in the wider Australian
population.18 These findings reinforce the impor-
tance of continuing cataract surgery delivery to these
communities where significant barriers to attending
surgery are known to exist.19,20
It was encouraging that we found few cases of
vision loss due to trachoma given its prevalence in
previous studies and that it is still endemic in many
remote Australian communities,2–4,12,16,21–23 We have
not seen any new blind eyes due to trachoma since
1997, and saw few vision impaired eyes. This repre-
sents a significant improvement since the 1970s
NTEHP where nearly 10% of Aboriginals had tra-
chomatous monocular or binocular blindness.2 This
is perhaps a reflection of an improvement in living
conditions, better community education regarding
hygiene and improved access to antibiotics in the
region.16
Trauma accounted for a significant proportion of
blind eyes examined (>1/3) and changed little over
the study period. Our findings indicate an improve-
ment from those of Mann who found trauma was the
second most common cause of blindness in eyes
seen in the Eastern Goldfields region in 1954.12
However, it is higher than reports from other
regions, where approximately one-quarter of blind
eyes were due to trauma,2,4 and may be reflective
of increased interpersonal violence reported in
Aboriginal communities.24,25
Our study confirms the importance of diabetes as a
major health issue among Australian Aboriginals.
We found over 75% of Aboriginals from the Eastern
Goldfields with vision loss also had diabetes, and
that having diabetes was associated with an 8.5-fold
increase in risk of vision loss from any cause. In
terms of DR, a quarter of Aboriginals with diabetes
had signs of DR, which contributed to VI in 20%
of eyes. This is higher than previously reported in
other Aboriginal communities (Table 4) and is sig-
nificantly higher than in the general Australian
population.7,8,13–15,18 Our observation of 10% with
signs of VTR at least once over the study period is
similar to that seen in other communities. It is con-
cerning that almost 20% diabetics had signs of DR
and a third had VTR at their first visit to the eye
clinic. These findings strongly reinforce the need for
early and regular ophthalmic review of all diabetics
in remote Aboriginal communities.
Less than half of all diabetic patients returned for
follow-up and, among those who did, only half were
seen within the recommended 2 years.26 This was
despite efforts to recall all diabetic patients using our
clinical database. It is possible that these people
chose not to attend or were elsewhere at the time the
clinic visited. The mobile nature of Aboriginal popu-
lations is well described,27 whether those who
weren’t in the community at the time of each survey
engaged health services elsewhere is not known.
Although we found the use of a clinical database to
initiate patient recall was a useful tool, as it allowed
better monitoring of known diabetic patients, the
implementation of such a system on a larger scale
could further assist clinicians and health workers in
monitoring patients across different health services.28
Interestingly, there were no cases of primary open
angle closure glaucoma or age-related macular
degeneration (ARMD). This compares favourably
with the wider Australian community where
glaucoma and ARMD contribute significantly to
blindness.29,30 It could be explained by the relatively
young study population and the reduced life expect-
ancy of Aboriginal Australians,31 although it sug-
gests that there may be reduced susceptibility to
glaucoma and ARMD among Aboriginals.
Table 4. Proportion of diabetics seen with DR and VTR in other Aboriginal communities
Author Location Year DR VTR
Durkin et al.11 Remote, South Australia 1999–2004 21% 12%
Murray et al.12 Kimberly region, Western Australia 1999–2004 21% 3.5%
Diamond et al.13 Pilbara region, Western Australia 1997 23% –
Jaross et al.9,10 Katherine region, Northern Territory 1996 21% 8.5%
1993 18% 6.7%
Our study Goldfields region, Western Australia 1995–2007 25% 9.7%
DR, diabetic retinopathy; VTR, vision-threatening retinopathy.
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Some study limitations exist. We examined 920
(~23%) of the approximately 3980 Aboriginals resi-
dent in the WA communities visited. Our ascertain-
ment of cases was unlikely to be complete at every
visit since our assessment relied upon voluntary
attendances. The mobility of the Aboriginal commu-
nities may have also diminished our ability to
capture the total population at risk.27 The data pre-
sented may also be subject to selection bias since
Aboriginal people who had diabetes or had vision
problems were specifically targeted. Therefore, our
data may over estimate the contribution of diabetes-
related eye disease (e.g. cataract and DR). For these
reasons, questions regarding prevalence and trends
over time for the major causes of vision loss could not
be properly answered from our data. However, the
repeated annual surveys over 12 years and the use of
local community health workers to find and bring
patients have likely maximized case ascertainment
within each community.
Our findings reinforce those of previous cross-
sectional Aboriginal eye health surveys indicating
the main causes of vision loss in Aboriginal eyes are
still treatable or preventable. There is a clearly a need
to assess ophthalmic services provide to these com-
munities given readily treated conditions, such as
cataract and refractive error, remain important causes
of vision loss. We are particularly concerned by the
threat of diabetes to Aboriginal eye health because of
the strong association with vision loss and that no
demonstrable improvement in retinopathy was seen,
even with large local efforts to encourage review
examinations. However, it is encouraging to see
significantly reduced rates of trachoma associated
vision loss compared with reports from 15 or more
years ago.1,2,4,12
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ABSTRACT
Background: To compare the self-reported manage-
ment of diabetic retinopathy by Australian ophthal-
mologists with the 1997 National Health and
Medical Research Council (NHMRC) guidelines.
Methods: Self-reported cross-sectional survey of pat-
terns of practice. Questionnaires were sent to all
Australian ophthalmologists, comprising questions
regarding professional details, diabetic retinopathy
screening attitudes/practices and specific hypotheti-
cal management scenarios. Data were analysed using
Chi-squared and adjusted logistic regression.
Result: 480 of the 751 (64%) eligible Australian oph-
thalmologists participated. The majority (80%,
n = 376) reported they consistently reviewed
patient’s glycaemic control, but only 55% and 41%
regularly reviewed blood pressure and serum choles-
terol control, respectively. Ophthalmologists gener-
ally adhered to NHMRC-recommended screening
intervals, although only 38% agreed with the guide-
lines relating to screening of pre-pubertal diabetic
patients. Fluorescein angiogram was used more than
recommended, especially for mild non-proliferative
diabetic retinopathy where 45% of respondents used
this investigation. Practice duration >15 years was
associated with more regular fluorescein angiogram
use (OR = 3.74; 95% CI: 2.53–5.53, P < 0.001). In
the clinical scenarios where clinically significant
macular oedema was concurrently present with
cataract or proliferative diabetic retinopathy, >26%
referred to retinal subspecialists for management;
85% of the remaining ophthalmologists performed
macular laser first. Respondents with practice dura-
tion >15 years were 7.8 times (P = 0.001) more likely
to perform cataract surgery first.
Conclusion: Diabetic retinopathy management guide-
lines were generally well followed by Australian
ophthalmologists. However, areas of practice varia-
tion existed including frequent use of fluorescein
angiogram. Significant proportion of practitioners
referred diabetic patients to retinal subspecialists,
who were more likely to adhere to guideline
recommendations. Ophthalmologists with greater
experience (>15 years) were more likely to employ
practices differing from NHMRC recommendations.
Key words: clinical guideline, diabetic retinopathy,
management survey.
INTRODUCTION
Blindness from diabetic retinopathy (DR) is largely
preventable.1 Despite readily available screening
services and treatment facilities in Australia, DR
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remains the leading cause of blindness among
working-aged Australians2 and is a significant
economic burden to the Australian health system.3
Hoping to improve the management of DR, the
National Health and Medical Research Council
(NHMRC) released the original Clinical Practice
Guidelines: Management of Diabetic Retinopathy in
1997.4
The impact of these guidelines and their imple-
mentation were evaluated through national surveys
conducted between 1997 and 2000 by the Centre of
Eye Research Australia (CERA) to determine the
practice patterns of ophthalmologists before and
after the guidelines’ publication.5–7 Those surveys
found that although the NHMRC guidelines were
well received among ophthalmologists, there were
few significant changes to management practices
towards its recommendations.7
A revised version of the NHMRC DR management
guidelines was released in late 2008.8 As nothing is
known about ophthalmologist’s use of NHMRC
guidelines since 2001, we re-examined the contem-
porary DR management patterns in the present
study. Our aim was to identify any changes in man-
agement trends over the last decade and provide
information to guide the implementation of the
revised guidelines, as well as establishing baseline
data for future evaluation.
METHODS
The present study was a cross-sectional survey of
currently practising Australian ophthalmologists.
A self-administered two-page questionnaire was
mailed to all Australian Fellows of the Royal Aus-
tralian and New Zealand College of Ophthalmo-
logists (RANZCO) (n = 751) in November 2007.
Further mail-out of surveys to non-respondents was
conducted twice in January and February 2008 to
help maximize responses. The University of Western
Australia Human Research Ethics Committee
approved this study.
Questions in this survey were adapted from the
previous survey with the assistance of CERA, allow-
ing a direct comparison of results. The questions
were related to general professional and practice
details; DR screening attitudes and practices (fre-
quency of DR screening and reviewing risk factors,
use of reminder notice, confidence in detecting signs
of sight-threatening DR and the desire to participate
in community DR screening activities); and several
specific management scenarios (the use of fluorescein
angiography [FA], treatment order for patients with
clinically significant macular oedema [CSME] and
concurrent cataract or early proliferative diabetic ret-
inopathy [PDR] [see copy of questionnaire in appen-
dix 1 for detail]).
Responses were analysed using SPSS version 15.0
(SPSS, Chicago, IL, USA) with significance set at
P < 0.05 for all analyses. Relationships between cat-
egorical variables such as retinal specialty, location
of practice, specialist experience and DR manage-
ment practices were examined using Chi-squared
analysis except when the expected frequencies of
cells was less than five, in which case Fisher’s exact
tests were used. Multivariate logistic regression
analyses were used to explore independently signifi-
cant factors affecting ophthalmologists’ adherence to
NHMRC recommendations. All regression analyses
were adjusted for retinal subspecialty, location of
practice, country of medical training, duration of
practice and percentage of patients with diabetes.
RESULTS
The questionnaire was sent to 762 ophthalmologi-
sts of whom 11 (1.4%) were unable to be located
because they had retired, died or moved practice. Of
the remaining 751 eligible ophthalmologists, 480
(63.9%) completed and returned the questionnaire.
Ophthalmologists characteristics
The professional characteristics of respondents are
summarized in Table 1. The number of years practis-
ing as a specialist ophthalmologist among respon-
dents ranged from 1 to 55 years (mean 17.0 years,
SD 11.2 years, median 15 years) and the majority
(82.2%) were trained in Australia. The average prac-
tice saw approximately 400 patients per month with
the majority of practices (77.7%, n = 369) reported to
have !5% of their patient with diabetes. One
hundred and one respondents (23.1%) indicated that
they had a retinal subspecialty interest and 33.9% of
respondents had practices in a rural location.
Current practice and attitudes to DR
management
A large majority of ophthalmologists (80%, n = 376)
always asked patients with diabetes about their
blood glucose control although only 54.8% (n = 260)
and 41.3% (n = 194) respondents sought this infor-
mation for blood pressure and blood cholesterol
control, respectively. Just over half of respondents
53.5% (n = 251) consistently advised patients about
the importance of risk factor control in delay-
ing retinopathy. In multivariate logistic regression
analyses, compared with others the retinal subspe-
cialists were 2.28 (95% CI: 1.38–3.76, P = 0.001) and
1.62 (95% CI: 1.01–2.61, P = 0.045) times more likely
to always review patients’ blood pressure and blood
cholesterol control, respectively; and 1.93 (95% CI:
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1.18–3.16, P = 0.009) times more likely to routinely
advise their patients the importance of risk factor
control in delaying retinopathy.
Regarding ophthalmologists’ confidence in detect-
ing clinical signs of sight-threatening DR, the major-
ity of respondents (89.6%, n = 421) reported being at
least ‘often confident’ in detecting new blood vessels
away from the optic disc (new vessels elsewhere,
NVE) and moderate thickening near the macula
(87.2%, n = 408). Retinal subspecialists were more
likely to report a higher level of confidence for both
NVE (95.5%, n = 106 vs. 87.7%, n = 315; P = 0.02)
and macular thickening (97.3%, n = 108 vs. 84.2%,
n = 308; P = 0.01) than others. After controlling for
retinal subspecialty, clinician confidence for detect-
ing macular thickening was 4.94 times greater
in ophthalmologists with practice experience less
than 15 years compared with those with >15 years
practice duration (OR = 4.94, 95% CI: 2.52–9.68,
P < 0.001).
Overall, 49.3% (n = 236) of respondents indicated
a moderate or strong desire to more active participa-
tion in community DR screening, although retinal
subspecialists were 2.37 times (95% CI: 1.45–3.88;
P = 0.001) more likely to report this desire than
others. Around half of the ophthalmologists (53.4%,
n = 253) indicated that they routinely send recall
notices to remind diabetic patients to return for eye
examination.
Hypothetical patient scenarios
management
Screening interval
Reported screening recommendations for the hypo-
thetical diabetic patients of varying ages and diabetic
control, without signs of DR on initial examination
are shown in Table 2. As the duration of diabetes
increased and glycaemic control worsened, there was
a general trend for ophthalmologists to shorten the
screening interval to within 1 year even if patients
have no retinopathy signs. For the hypothetical
7-year-old child, only 38.3% (n = 181) of ophthal-
mologists agreed with the 1997 NHMRC guidelines’
recommendation to commence screening at puberty.
Even though retinal subspecialists were significantly
more likely to adhere to recommended practice than
others (48.6%, n = 54 vs. 35.2%, n = 127, P = 0.011),
Table 1. General characteristics of respondent Australian oph-
thalmologists and their practice details (n = 480)
Characteristics Results (number [%])
Specialist practice
duration (years)
Range: 1–55 years (mean = 17.0,
SD = 11.2, median = 15)
!5 86 (18.0%)
6–10 81 (16.9%)
11–15 77 (16.1%)
16–20 76 (15.9%)
21–25 50 (10.5%)
26–30 56 (11.7%)
>30 52 (10.9%)
Country of ophthalmic
training
Australia 393 (n = 82.2%)
Other 85 (n = 17.8%)
Practice size Range: 1–3000 patients/month
(mean = 428, SD = 286.3,
median = 400)
"1 rural practice location 160 (n = 33.9%)
% of patients with diabetes
<1% 165 (3.4%)
1–5% 90 (18.9%)
5–10% 155 (32.6%)
10–15% 113 (23.8%)
>15% 101 (21.3%)
Subspecialist interest
None 152 (31.7%)
Vitreo-retinal 44 (9.2%)
Medical retinal 67 (14.0%)
Anterior segment 94 (19.6%)
Oculo-plastic 37 (7.7%)
Other 86 (17.9%)
Table 2. Percentage of responses for the screening interval of patients with DM of varying ages and diabetic control who have no signs
of diabetic retinopathy on initial examination
Patient type Refer
elsewhere
Screening intervals
Begin screening
in 5 years
Review in
2 years
Review in
1 year
Review in
6 months
7-year-old child with new type 1 DM 11.7 38.3† 29.4 16.7 3.8
18-year-old with new type 1 DM 5.7 11.2 45.9† 30.0 7.2
60-year-old with new diet-controlled DM 4.2 2.1 68.4† 23.9 1.3
60-year-old with new oral hypoglycaemic-controlled DM 3.6 0.6 51.5† 41.4 3.0
60-year-old with 10 years of well oral hypoglycaemic-controlled DM 3.6 0.4 44.5 49.6† 1.9
60-year-old with 10 years of well insulin-controlled DM 2.9 0.6 29.9 61.3† 5.3
60-year-old with 10 years of poor insulin-controlled DM 3.2 0.8 7.4 48.1† 40.5
†Indicates the NHMRC-recommended practice. DM, diabetes mellitus; NHMRC, National Health and Medical Research Council.
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51.4% (n = 57) of them commenced screening of the
pre-pubertal child earlier than recommended by the
NHMRC.
Use of fluorescein angiography
Responses to the patient scenario regarding the use
of FA in patients with varying retinopathy severity
are summarized in Table 3. Almost all ophthalmo-
logists (90.2%, n = 422) indicated they would not
use FA when there were no signs of retinopathy,
although 44.5% (n = 210) would at least occasionally
use FA for patients with mild non-proliferative dia-
betic retinopathy (NPDR), contrary to the 1997
NHMRC guidelines. There was no significant differ-
ence in FA use among respondents until the hypo-
thetical patient had severe NPDR, where retinal
subspecialists were 1.72 times (95% CI: 1.08–2.73,
P = 0.022) more likely to perform FA on such
patients than others. In all degrees of DR, there was
a consistent trend of more frequent use of FA among
ophthalmologists who received their specialty train-
ing in the earlier years. In particular, ophthalmolo-
gists with >15 years practice duration were 3.12
(95% CI: 1.55–6.27, P = 0.001) and 3.74 (95% CI:
2.53–5.53, P < 0.001) times more likely to perform
FA in patients with none or mild NPDR, respec-
tively; and 2.23 times (95% CI: 1.48–3.37, P < 0.001)
more likely to always perform FA in patients with
severe NPDR than those with shorter practice
duration.
Concurrent CSME with cataract or
early PDR
Responding to a complex case where a patient with
coexistent CSME and cataract that would make the
former difficult to treat, 26% (n = 95) of ophthal-
mologists indicated that they would refer such a
patient to retinal subspecialist for management.
Those with rural practice were less likely to refer
than metropolitan-only ophthalmologists (13.9%,
n = 17 vs. 32.2%, n = 77, P < 0.001). Excluding those
who refer, most ophthalmologists (94.2%, n = 356)
would treat the CSME first. Only 5.8% (n = 22)
were contrary to the NHMRC guidelines and would
delay macular laser therapy until cataract surgery
had been performed. From the multivariate logistic
regression analysis, ophthalmologists with duration
of practice >15 years were 7.8 times (95% CI: 2.23–
27.36, P < 0.001) more likely to perform cataract
surgery first. There was no significant difference in
the order of treatment between retinal subspecial-
ists and others.
Table 3. Percentage of responses for the frequency of fluorescein (FA) use in patients with varying signs of non-proliferative diabetic
retinopathy (The NHMRC only recommends FA use in selected cases of severe non-proliferative diabetic retinopathy)
Presence of clinical signs Frequency of performing FA
Never Occasionally Often Always Refer
No signs of diabetic retinopathy
Overall 90.2 7.5 0.6 0.2 1.5
Retinal specialty
Retinal 89.0 10.1 0.0 0.9 0.0
Non-retinal 90.5 6.7 0.8 0.0 1.9
Years in practice**
!15 95.0*** 4.6* 0.0 0.0 0.4
>15 85.0*** 10.6* 1.3 0.4 2.6
Mild non-proliferative diabetic retinopathy
Overall 49.3 34.4 7.6 2.5 6.2
Retinal specialty
Retinal 50.5 39.6 5.4 2.7 1.8
Non-retinal 48.9 32.8 8.3 2.5 7.5
Years in practice ***
!15 65.0*** 28.4** 2.5*** 0.4** 3.7*
>15 32.5*** 40.8** 13.2*** 4.8** 8.8*
Severe non-proliferative diabetic retinopathy
Overall 4.5 20.0 25.1 31.4 19.1
Retinal specialty***
Retinal 4.5 26.1 27.0 39.6* 2.7***
Non-retinal 4.4 18.1 24.4 28.9* 24.2***
Years in practice ***
!15 6.6* 28.8*** 25.9 23.5*** 15.2*
>15 2.2* 10.5*** 24.1 39.9*** 23.2*
*P < 0.05, **P ! 0.01, ***P ! 0.001. FA, fluorescein angiography; NHMRC, National Health and Medical Research Council.
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With the second complex case, a patient with
CSME and early PDR, 45.9% (n = 169) of ophthal-
mologists would refer the patient to retinal subspe-
cialists for further management. Those with rural
practice were again less likely to refer than
metropolitan-only ophthalmologists (32.8%, n = 40
vs. 51.9%, n = 125, P = 0.001). Excluding those who
refer, 1.9% (n = 9) of all surveyed ophthalmologists
reported performing pan-retinal photocoagulation
first, 55.6% (n = 266) would perform macular photo-
coagulation first, and 6.5% (n = 31) would perform
both procedures together. The likelihood of adhering
to NHMRC’s recommendation of performing focal
laser first in such patient did not differ by subspe-
cialty, experience, practice location or the country of
training.
Management of retinopathy
The responses for the management of patients with
varying severity of retinopathy are shown in
Table 4. The 1997 NHMRC recommended
follow-up intervals for patients with signs of retin-
opathy (annual review for patients with isolated
peripheral micro-aneurysm and three to six
monthly reviews for patients with moderate to
severe retinopathy) were followed by the majority
(>80%) of ophthalmologists. There was no signifi-
cant difference in follow-up practice between
retinal subspecialists and others. In the patients
with moderate and severe NPDR, ophthalmologists
with >15 years practice experience were again more
likely to perform FA and/or photocoagulation than
others (16.5%, n = 38 vs. 3.3% n = 8; P < 0.001 for
moderate NPDR, 44.6% n = 103 vs. 31.3% n = 77;
P < 0.001 for severe NPDR).
Compared with the previous survey
To evaluate the long-term effects of the 1997 DR
guidelines on clinician’s practice, the published
figures from previous surveys performed by CERA
were compared with results of the current study
(see Tables 5, 6). Possible improvements towards
recommended practice included reduction in the
proportion of ophthalmologists using FA in
patients with mild NPDR and performing cataract
surgery prior to treating CSME. Other positive
changes included a greater confidence in detecting
macular oedema and the increasing use of patient
reminder notices. Reminders for patients has been
shown to improve compliance to clinical guide-
line’s recommendations.9
In contrast to these improvements, our findings
also suggest that there were some negative changes
in DR management by Australian ophthalmologists.
For example, there was a reduction in the desire to
participate in community DR screening and in the
Table 4. Percentage of responses for the management of patients with varying signs of retinopathy
Presence of
clinical signs
Follow-up interval/management
Refer
Review in
2 years
Review in
1 year
Review in
6 months
Review in
3 months Angiogram ! laser
Mild NPDR 3.8 13.0 67.0 14.3 1.7 0.2
Mod NPDR 11.5 0.4 18.7 49.1 10.7 9.6†
Severe NPDR 17.4 0.0 3.4 17.4 24.1 37.7†
†Ophthalmologists with >15 years practice experience were again more likely to perform fluorescein angiography and/or photoco-
agulation than others (16.5%, n = 38 vs. 3.3%, n = 8; P < 0.001 for moderate NPDR, 44.6%, n = 103 vs. 31.3%, n = 77; P < 0.001 for severe
NPDR). NPDR, non-proliferative diabetic retinopathy.
Table 5. Comparison of respondents’ attitude and practices in diabetic retinopathy management recorded during the baseline, first
follow-up and current survey5,6
Questions Percentage of response
Baseline
(1997)
First follow up
(1998) Current
Often or always advise about importance of risk factor control 96.8 97.3 92.6
Use of recall notices 16.7 22.4 53.4
Often to always feel confident in detecting NVE 94.1 93.5 89.6
Often to always feel confident in detecting moderate retinal thickening near the macular 80.2 79.1 87.2
Moderate to strong perceived need for further education in diabetic retinopathy 58.9 52.0 46.9
Moderate to strong desire to participate in community diabetic retinopathy screening 60.2 56.4 49.3
NVE, new vessels elsewhere.
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proportion of ophthalmologists who consistently
advise patients regarding the importance of risk
factor control.
DISCUSSION
We found the majority of ophthalmologists adhered
to most of the 1997 NHMRC DR management guide-
lines, but there were several areas of difference.
These included: (i) frequency of advice regarding DR
risk factor control (including blood pressure and
serum cholesterol); (ii) when to screen for retinopa-
thy in the pre-pubertal patients with diabetes; and
(iii) use of FA in patients with no or early DR.
In keeping with the increasing trend of subspe-
cialization within ophthalmology,10,11 we found that
many ophthalmologists referred complex DR cases to
retinal specialists for further management (up to
45.9%). Rural ophthalmologists were however sig-
nificantly less likely to refer, perhaps because of
logistic difficulties with follow up as a result of geo-
graphical separation. Retinal subspecialists were
more likely to follow the NHMRC guidelines, had a
greater desire to participate in screening and had
more confidence detecting sight-threatening retin-
opathy than others. Although subspecialization may
introduce problems in the planning and organization
of clinical services,10 some found better clinical out-
comes when certain conditions, such as retinal
detachment and corneal grafting, were managed by
subspecialists rather than generalists.10,11 No study,
however, has compared clinical outcomes from the
management of DR by retinal subspecialists with
those by generalists.
We found that ophthalmologists with longer prac-
tice duration (>15 years) were more likely to differ
from the NHMRC recommendations in several
aspects of DR management. They were up to 3.7
times more likely to use FA in patients with mild
NPDR and were nearly eight times more likely to
treat cataract first prior to macular laser for patients
with CSME and cataract. This discrepancy may
reflect the evolution in recommended practice that
has occurred over time. Ophthalmologists who were
qualified earlier may have received teaching that was
different from the current guidelines. This group of
ophthalmologists may benefit from additional tar-
geted continual medical education activities that are
more effective in encouraging a shift towards current
best evidence-based practices.12
In recent times treatment for DR and maculopathy
using intravitreal injection of triamcinolone (IVTA)
and anti-angiogenic agents has increased.13 Anecdot-
ally, a number of ophthalmologists noted that they
would perform IVTA at the time of cataract surgery
for the hypothetical patient with both CSME and
cataract. Several respondents also commented that
they would combine IVTA or anti-angiogenic drugs
with laser therapy for the patient with CSME and
PDR. The revised 2008 guidelines suggest that IVTA
may be considered for selected cases where macular
oedema persists after focal/grid laser treatment.8
Because the study design and the questionnaire
used in the current study was similar to previous
surveys by CERA, it was possible to compare results
between different survey time-points to identify pos-
sible trends in DR management practice. However, it
is noted that the current study had a lower response
rate than previous CERA surveys (64% vs. 82%),
increasing the susceptibility of this study to response
bias. Nevertheless, the comparisons identified a few
modest changes in DR management practices among
Australian ophthalmologists towards NHMRC rec-
ommendations, in particular, regarding FA use in
patients with mild NPDR and the treatment order for
concurrent cataract andCSME.On the other hand, the
consistency in advising about risk factors control and
the interest in community DR screening may have
declined. Substantial resources are invested in the
development and revision of clinical guidelines such
as that produced by NHMRC for DR management.14
It is therefore important to consider the cost-
effectiveness of such undertaking. Previous studies
have demonstrated that the process of merely provid-
Table 6. Comparison of percentages of ophthalmologists whose responses to the hypothetical scenarios were contrary to the NHMRC
guideline recommendations5,6
Scenario Percentage practice against recommended practice
Baseline
(1997)
First follow up
(1998) Current
Diabetic retinopathy screening for a 7-year-old child 53.0 46.5 49.9
Fluorescein angiogram for patient with nil retinopathy 7.6 10.6 8.3
Fluorescein angiogram for patient with mild NPDR 53.3 52.1 44.5
Recommended treatment order for patient with CSME and cataract 15.9 11.9 4.6
Recommended treatment order for patient with CSME and PDR 10.3 7.6 8.4
CSME, clinically significant macular oedema; NHMRC, National Health and Medical Research Council; NPDR, non-proliferative diabetic
retinopathy; PDR, proliferative diabetic retinopathy.
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ing information through passive dissemination of the
clinical guidelines alone without appropriate imple-
mentation strategies is rarely sufficient to stimulate
corresponding changes in practice.15 Hence, other
avenues of communication that supplement or
surpass clinical guidelines in producing change in
specialist practice should be further explored.
In conclusion, although the overall adherence to
the guidelines by Australian ophthalmologists was
good, we found several areas for improvement. Oph-
thalmologists with longer practice duration were
more likely to employ some DR management prac-
tices differing from that recommended. Retinal sub-
specialists, however, were more likely to follow the
guidelines and many other ophthalmologists prefer
to refer complex diabetic cases to them for further
management.
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ABSTRACT
Background: To survey the current diabetic retinopa-
thy screening and management practices of Austra-
lian optometrists following the release of the 1997
National Health Medical Research Council Diabetic
Retinopathy Management Guidelines.
Design: Cross-sectional national survey, primary care
setting.
Participants: 1000 Australian optometrists across dif-
ferent states.
Methods: A self-administered questionnaire was sent
to 1000 optometrists across all states during 2007/
2008.
Main outcome measures: Use of retinal camera,
screening practices/attitudes and behaviour in dia-
betic retinopathy management.
Results: 568 optometrists (57%) responded to the
survey. Patients’ unpreparedness to drive post dila-
tion (51%) and the fear of angle closure glaucoma
(13%) were the two main barriers to optometrists
not performing dilated ophthalmoscopy. Those who
had strong desire to screen for diabetic retinopathy
were more likely to use a retinal camera (p < 0.005).
Use of a retinal camera was significantly associated
with an increased confidence in detecting clinical
signs of diabetic retinopathy including macular
oedema (P < 0.001). Optometrists who read the
guidelines at least once were 2.5-times (P < 0.001)
more likely to have confidence in detecting macular
oedema than those who had never read the
guidelines. Although they may be confident in diag-
nosis, and may use retinal cameras for screening,
nearly 60% of optometrists would not refer patients
with macular oedema to an ophthalmologist.
Conclusions: Despite their self-reported desire for
involvement in diabetic retinopathy, the manage-
ment of macular oedema by Australian optometrists
needs improvement. The use of retinal cameras and
promotion of the 2008 NHMRC guidelines should be
encouraged to improve overall optometric diabetic
retinopathy management, particularly with macular
oedema.
Key words: diabetes, diabetic retinopathy, screening,
survey.
INTRODUCTION
The prevalence of diabetes mellitus is growing
rapidly worldwide.1 In 2000, there were approxi-
mately 941 000 Australians living with diabetes, and
it is estimated that by 2030, this will rise to 1.6
million.1 Diabetic retinopathy (DR) occurs in 25% of
patients with diabetes in Australia.2 As 98% of
visual impairment secondary to DR can be prevented
by timely treatment, early detection is crucial.3
As the primary eye care providers, the optom-
etrists and general practitioners play an enormous
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role in DR screening in the community. As part of
routine DR screening, the National Health and
Medical Research Council (NHMRC) guidelines4
recommended that all examiners should assess
patients’ best-corrected visual acuity and perform
dilated fundus examination at time of diagnosis of
diabetes. Alternately, the dilated fundus examina-
tion may be replaced by retinal photography. Addi-
tional information such as HbA1c (glycosylated
haemoglobin), blood pressure profile, lipid profile,
smoking status and other diabetes-related complica-
tions may also help in determining the urgency for
referrals.
Australian optometrists have previously been
surveyed in 1999 and 20015,6 following the release
of the original 1997 NHMRC guidelines on DR
management.7 A revised version of these guidelines
was released in late 2008.4 However, to date no
published studies have examined the long-term
impact of these guidelines on DR screening
and management practices among Australian
optometrists.
Our aimwas to identify any changes in DR screen-
ing and management practices that have occurred
over the last decade following the release of these
national guidelines. This will provide information
that will guide the implementation of the revised
guidelines, as well as establishing updated data for
future evaluation.
METHODS
We conducted a cross-sectional survey of currently
practising Australian optometrists. A random sample
of 1000 optometrists was selected from the Optom-
etrists Association of Australia membership database
(4414 members). A self-administered two-page
questionnaire, an information pamphlet about the
objectives of this study and a postage-paid return
envelope were mailed to each selected optometrist in
November 2007. A repeat mail-out of surveys to non-
respondents was conducted after 3 months to maxi-
mize responses. The University of Western Australia
Human Research Ethics Committee approved this
study.
The questionnaire used for this study was adapted
from two previous surveys conducted by McCarty
et al.5,6 to allow temporal comparison regarding DR
management practices by Australian optometrists.
The survey instrument comprised questions relating
to general professional and practice details, and DR
screening attitudes and practices (e.g. perceived bar-
riers and estimated frequency of performing dilated
fundoscopy on diabetic patients, confidence in
detecting sight-threatening DR, desire to participate
in community screening and perceived need for
further education on DR).
Optometrists were surveyed about their manage-
ment practices using 12 hypothetical clinical scen-
arios. The first seven scenarios involved patients of
different ages (7, 18 and 60 years of age), varying
diabetic treatment (diet alone, oral hypoglycaemic
agent or insulin) and who had no DR detected at
their first visit. The last five scenarios focused upon
DR management following the detection of microa-
neurysms, retinal haemorrhages, new vessels forma-
tion and macular oedema. Optometrists were given
five choices of performing dilated fundoscopy in less
than 6 months, 1 year, 2 years, 5 years or prompt
referral to an ophthalmologist.
All participants remained anonymous throughout
data collection and analyses. Responses were analy-
sed using Stata 10.0 (StataCorp, College Station, TX,
USA) with significance set at P < 0.05 for all
analyses. Descriptive statistics were calculated for all
continuous variables. Relationships between cat-
egorical variables were explored using Pearson
c2-tests. Multivariate logistic regression models were
used where appropriate to explore outcomes of inter-
est (such as the use of a retinal camera and confi-
dence of detecting DR signs and diabetic macular
oedema) while controlling for possible confounding
factors of practice location, place of training and
years of practice.
RESULTS
A total of 568 (57%) optometrists currently practising
in Australia responded to the survey. Demographic
characteristics of the respondent optometrists are
shown in Table 1. Our sample size was 13% of the
total optometrists practising in Australia (total
optometrists = 4414), and the percentage of state and
urban/rural distribution of the respondent optom-
etrists was reasonably comparable to the data pub-
lished by the Australian Institute of Health and
Welfare (AIHW) in 2006.8 More than 80% reported
receiving a copy of the 1997 NHMRC guideline, and
only 65% reported having read them at least once.
Of the ophthalmic equipment used by optom-
etrists to examine patients with diabetes, the direct
ophthalmoscope was most frequently used (72%),
followed by slit-lamp biomicroscopy (65%), binocu-
lar indirect ophthalmoscope (56%) and retinal
camera (51%). Almost 15% of optometrists never
performed direct ophthalmoscopy whereas 55% of
optometrists used a retinal camera in their practices
on more than half of their diabetic patients.
Table 2 shows the perceived barriers to optom-
etrists not performing dilated ophthalmoscopy.
Patients’ unpreparedness to drive (51%) and a fear of
precipitating angle closure glaucoma (13%) post
dilation were the two leading reported ‘moderate’ to
‘major’ barriers. Only a small number of optometrists
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reported a lack of confidence in detecting changes
(2%) and uncertainty about DRmanagement (1%) as
moderate to major barriers to performing dilated
fundoscopy.
Table 3 summarizes reported current practices,
examinations procedures and routine enquiry of risk
factors by optometrists. About 90% of optometrists
reported either ‘often’ or ‘almost always’ performing
dilated fundoscopy on patients with known diabe-
tes, and only 23% would routinely perform dilated
fundoscopy on patients without any history of dia-
betes or glaucoma. Two-thirds always questioned
about a positive diagnosis of diabetes in patients
older than 40 years. As part of routine follow up for
patients with diabetes, 95% of optometrists ‘often’ or
‘almost always’ enquired about blood glucose level,
as well as factors such as assessment of blood pres-
sure, cholesterol level, smoking status and impor-
tance of risk factors control to prevent diabetes
complications (Table 3).
Almost all optometrists reported being ‘often’ or
‘always’ confident in detecting microaneurysms
(93%) and retinal haemorrhages (97%), but fewer
were confident in detecting new vessel formation
(85%). More than 50% of the optometrists were
‘often’ or ‘always’ unsure in detecting macular
oedema.
Table 1. Demographics of the optometrists responding to a
survey on diabetic retinopathy screening
Total number (%)
State or Territory of practice – 566
New South Wales 195 (34%)
Victoria 160 (28%)
Queensland 97 (17%)
Western Australia 44 (7%)
South Australia 42 (7%)
Tasmania 20 (4%)
ACT 7 (1%)
Northern Territory 1 (<1%)
Number of years of practice
0–10 42 (7%)
11–20 169 (30%)
21–30 260 (46%)
>30 97 (17%)
Location of practices
Metropolitan 359 (64.1%)
Rural 170 (30.4%)
Metropolitan and rural 31 (5.5%)
Location of training
Australia 520 (92%)
UK 25 (4%)
South Africa 9 (2%)
New Zealand 8 (1%)
USA 2 (<1%)
Canada 1 (<1%)
Table 2. Barriers to optometrists performing dilated fundoscopy
Barriers Not a barrier Minor barrier Moderate barrier Strong barrier
Patients’ unpreparedness to drive 68 (12%) 205 (37%) 179 (32%) 107 (19%)
Worry of angle closure glaucoma 305 (55%) 185 (33%) 48 (9%) 22 (4%)
Time consuming 297 (53%) 195 (35%) 61 (11%) 9 (2%)
Lack of dilating drops 539 (97%) 9 (2%) 2 (<1%) 8 (1%)
Lack of ophthalmoscopes 545 (98%) 3 (1%) 3 (1%) 6 (1%)
Lack of confidence in detecting changes 468 (84%) 76 (14%) 11 (2%) 1 (<1%)
Unsure of diabetic retinopathy management 514 (92%) 37 (7%) 6 (1%) 1 (<1%)
Table 3. Current optometrists’ management and attitudes to diabetes and diabetic retinopathy
Screening questions and examinations Almost never Sometimes Half the time Often Almost always
On patients >40 years
1 Routine questioning about diagnosis of diabetes 20 (4%) 56 (10%) 21 (4%) 80 (14%) 389 (69%)
2 Routine dilated fundoscopy without history of diabetes
or glaucoma
102 (18%) 258 (46%) 73 (13%) 56 (10%) 74 (13%)
3 Routine of dilated fundoscopy with history of diabetes 13 (2%) 27 (5%) 22 (4%) 58 (10%) 448 (79%)
Frequency of risk factors enquiries
Blood sugar control 2 (<1%) 3 (<1%) 21 (4%) 95 (17%) 446 (79%)
Blood pressure control 10 (2%) 15 (3%) 77 (14%) 185 (33%) 279 (49%)
Blood cholesterol control 14 (3%) 53 (9%) 121 (21%) 167 (30%) 211 (37%)
Smoking status 48 (9%) 116 (21%) 161 (28%) 140 (25%) 102 (18%)
Advice regarding complications 11 (2%) 33 (6%) 98 (17%) 221 (39%) 202 (36%)
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Most optometrists (95%) used a recall system to
follow up patients with diabetes for examination.
However, only half reported that more than 70% of
their patients would return to see them within the
suggested time frame. When patients were referred
to ophthalmologists, the majority (83%) of referring
optometrists reported that more than 70% of their
patients would see their ophthalmologist within the
suggested time frame. The percentage of optometrists
expressing ‘moderate’ to ‘strong’ desire to screen for,
and receive further education regarding DRwas 78%
and 72%, respectively.
Changes in reported management
since 19995
The percentage of optometrists performing dilated
fundoscopy on diabetic patients has increased sig-
nificantly from 75% in 1999 to 89% in 2009 (P <
0.001). In addition, the confidence in detecting sight-
threatening DR changes (new vessels elsewhere and
macular oedema) improved significantly from 1999
to 2009 (new vessels elsewhere: 75–85%, P < 0.01;
macular oedema: 33–47%, P < 0.001). Significantly,
more optometrists reported using a recall system in
2009 (95%) compared with 1999 (83%). From 1999
to 2009, there were no significant changes in the
potential perceived barriers such as fear of inducing
angle closure glaucoma post dilation (1999: 17%;
2009: 13%), lack of confidence in detecting DR
changes (1999: 4%; 2009: 2%), uncertainty about DR
management (1999: 2%; 2009: 1%) and the desire to
screen for DR (1999: 84%; 2009: 78%). In contrast,
there was significantly less desire for further educa-
tion about DR diagnosis and management from 1999
to 2009 (84% to 72%, P < 0.0001).
Responses to the hypothetical
clinical scenarios (Table 4)
Only 11% of optometrists reported that they would
perform dilated fundoscopy on a 7-year-old child
newly diagnosed with diabetes in 5 years, and 17%
would refer this child to an ophthalmologist.
Optometrists would still recommend a 12-month
examination for diabetic patients with good glycae-
mic control with no signs of DR compared with the
2-year follow up recommended by the NHMRC
guidelines (Table 3). Nonetheless, the overall per-
centage of optometrists following the NHMRC-
recommended management practices (dilated
fundoscopy within 1 or 2 years of diagnosis, or refer-
ral to an ophthalmologist) was greater than observed
in 1999. In 2009, the majority of optometrists
reported that they would refer patients with severe
non-proliferative DR (NPDR) (90%) and prolifera-
tive DR (PDR) (98%) to an ophthalmologist.
However, only 42% would refer patients with
macular oedema to an ophthalmologist for prompt
investigation and treatment.
From multivariate logistic regression analyses,
optometrists who had a strong desire to screen for
DR were almost twice as likely to ‘often’ or
‘almost always’ use a retinal camera to examine
patients with diabetes after controlling for previous
training location, duration and location of
current practice (OR = 1.98, 95% CI = 1.27–3.10,
P < 0.005).
Table 4. Optometrists’ management of hypothetical clinical scenarios and specific signs of DR
Case scenarios Referral to
ophthalmologists
Review in
5 years
Review in
2 years
Review in
1 year
Review in
<6 months
If no signs of DR at baseline examination
7-yo – newly diagnosed diabetic 95 (17%) 63 (11%)† 125 (22%) 183 (33%) 96 (17%)
18-yo – newly diagnosed with DM 40 (7%) 16 (3%) 141 (25%)† 255 (45%) 113 (20%)
60-yo with good HbA1c control – diet alone 5 (1%) 1 (<1%) 211 (37%)† 290 (51%) 58 (10%)
60-yo, 10-year diabetes, commenced on OHA 9 (2%) 0 (0%) 86 (15%)† 374 (66%) 98 (17%)
60-yo, 10-year diabetes with good HbA1c on OHA 10 (2%) 1 (<1%) 72 (13%)† 417 (74%) 65 (12%)
60-yo, 10-year diabetes with good HbA1c on insulin 21 (4%) 0 (0%) 31 (6%)† 409 (72%) 105 (19%)
60-yo, poorly controlled HbA1c despite insulin 79 (14%) 0 (0%) 2 (<1%) 127 (22%)† 360 (63%)
DR signs
Occasional microaneurysms on peripheries 43 (8%) 14 (3%) 297 (53%) 167 (30%)† 44 (8%)
Macular oedema (not clinically significant) 234 (41%)† 6 (1%) 43 (8%) 138 (25%) 139 (25%)
Peripheral microaneurysms and retinal haemorrhages 224 (40%) 0 (0%) 81 (14%) 169 (30%) 93 (16%)†
Extensive microaneurysms, retinal haemorrhages
and occasional cotton wool spots all located peripherally
509 (90%)† 0 (0%) 4 (1%) 18 (3%) 36 (6%)
New vessel formation 557 (98%)† 0 (0%) 0 (0%) 1 (<1%) 10 (2%)
†Recommended time frame suggested by National Health and Medical Research Council guidelines in 1997. DM, diabetes mellitus;
DR, diabetic retinopathy; HbA1c, glycosylated haemoglobin; OHA, oral hypoglycaemic agents; yo, year-old.
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When controlled for reading the guidelines, pre-
vious training location, duration and location of
practice, optometrists who ‘often’ and ‘always’ used
a retinal camera were more confident in detecting
retinal diabetic changes such as microaneurysms
(OR = 5.29, 95% CI = 2.22–12.40, P < 0.001), new
vessels formation elsewhere (OR = 4.62, 95% CI =
2.56–8.34, P < 0.001) and macular oedema (OR =
2.49, 95% CI = 1.51–4.12, P < 0.001).
Reading the guidelines at least once was also
associated with increased confidence in detecting
macular oedema (OR = 2.49, 95% CI = 1.51–4.12,
P < 0.001). However reading the guidelines did not
improve referrals for patients with macular oedema
(OR = 1.04, 95% CI = 0.65–1.65, P = 0.88). Likewise
confidence in detecting macular oedema after con-
trolling for other factors such as previous training
location, duration and location of practice and use of
a retinal camera was not associated with optometric
referrals of patients with macular oedema to an
ophthalmologist (OR = 0.99, 95% CI = 0.71–1.39,
P = 0.97).
DISCUSSION
Our results indicate that DR management practices
of Australian optometrists have improved since the
release of NHMRC guidelines in 1997.7 Compared
with the two national surveys conducted in 1999 and
2001,5,6 more optometrists now perform dilated fun-
doscopy on diabetic patients, use recall notices and
had greater confidence in detecting and managing
DR changes in their patients. Additionally, nearly
80% of optometrists had ‘moderate’ to ‘strong’ desire
to screen for DR. This could significantly reduce the
waiting period of diabetic patients to see an ophthal-
mologist in the public setting and may triage the
urgency of ophthalmic review by severity, especially
for patients with sight-threatening DR. We also
found an approximate 10% rise in the use of recall
notices over the last decade. This helps to ensure
regular eye screening of patients, as a patient
reminder system was reported to be an effective way
of enforcing and increasing the patients’ adherence
to clinical guidelines.9
Both the 1997 and 2008 NHMRC guidelines6,7 rec-
ommend that screening of diabetic children should
start at the time of puberty, with the screening inter-
val determined by the clinical findings. Those with
moderate to severe NPDR, PDR or macular oedema
warrant prompt referrals to an ophthalmologist.
We found that optometrists generally reviewed dia-
betic patients with no signs of DR more frequently
than recommended.7 The optometrists should be
encouraged to read the guidelines more frequently
in order to review the patients with diabetes in an
appropriate time frame to reduce their unnecessary
financial burden.
The responses we obtained regarding the manage-
ment of diabetic macular oedema by Australian
optometrists were of concern. More than 50% of
optometrists reported that they lacked confidence in
detecting macular oedema and only 40% would
refer patients with macular oedema to an
ophthalmologist.
Although both the use of a retinal camera and
reading the guidelines were significantly associated
with increased confidence in detecting macular
oedema, they were not associated with appropriate
referral of patients with macular oedema to an
ophthalmologist. Confidence in detecting macular
oedema was also not associated with referrals to an
ophthalmologist.
In other words, the optometrists were not likely
to refer patients with macular oedema to an oph-
thalmologist despite having read the guidelines,
being confident in detecting macular oedema and
using a retinal camera. Given macular oedema is a
major cause of significant visual impairment,
optometrists need to improve their management
(confidence to detect and referrals) of this condition
to ensure prompt laser treatment for patients with
diabetic maculopathy. Although early stages of
macular oedema may be difficult to detect with-
out indirect ophthalmoscopy, any reduction in
visual acuity should raise suspicion and prompt a
referral.
Concern about use of dilating drops inducing
angle closure glaucoma seems unwarranted as it is a
rare event (1 in 20 000).10 Promoting the use of non-
mydriatic fundus cameras may help. We found there
was a strong association between the frequency of
retinal camera use and the desire to screen, as well as
confidence in detecting DR changes. Others have
found non-mydriatic retinal camera fundus photog-
raphy yielded a reasonable sensitivity (95%) and
specificity (99%).11
The present study provides an overview of DR
management by Australian optometrists, which has
improved over the last decade following the release
of 1997 NHMRC guideline.7 Given that macular
oedema causes significant visual impairment in
patients with diabetes, further education about the
detection and referral of subjects with macular
oedema is important. The use of retinal cameras
and promotion of the new 2008 NHMRC guide-
lines7 should be encouraged to improve the overall
optometric DR management and reduce the inci-
dence of this preventable blinding disease in the
future. A further survey may help assess the impact
of the new 2008 NHMRC guidelines, especially the
management of diabetic macular oedema by Aus-
tralian optometrists.
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ABSTRACT
Purpose: The aim of this study is to determine if post-
operative endophthalmitis adversely affects quality of life
after cataract surgery.
Methods: We compared quality of life in patients who
developed endophthalmitis after cataract surgery between
1 January and 31 December 2003 with those who had
uncomplicated surgery. The National Eye Institute VFQ-25
(VFQ-25) and EuroQol EQ-5D (EQ-5D) questionnaires
and time trade-off utility scores were used to compare
self-perceived general health and vision-related quality of life
between groups. Linear regression was used to model
differences between groups after adjusting for age, gender
and visual acuity in the better eye.
Results: Nineteen postoperative endophthalmitis cases were
compared with 30 who had uncomplicated cataract surgery.
Following surgery the mean composite VFQ-25 score was
13.5% (95% confidence interval [CI]: 6.0–26.4, P < 0.01)
lower in endophthalmitis cases. Endophthalmitis patients
reported significantly lower (P < 0.05) general vision, near
vision, peripheral vision, mental health and role difficulties
subscales scores after adjusting for age, sex and visual acuity.
No significant differences were found in other subscales.
Mean time trade-off utility and all EQ-5D scores were similar
except for mobility (95% CI: 0.04–0.68, P < 0.05).
Conclusions: Endophthalmitis after cataract surgery nega-
tively impacts on self-perceived vision-related quality of life,
resulting in poorer psychological well-being and ability to
maintain a role in daily life.
Key words: adverse event, cataract surgery, postoperative
endophthalmitis, quality of life.
BACKGROUND
Cataract extraction surgery is the most commonly performed
operation in the developed world.1,2 Although sight-
threatening complications are uncommon, endophthalmitis
occurs in approximately one out of every 500 cataract opera-
tions performed in Australia.1,3 Despite improvements in pre-
vention and treatment, endophthalmitis remains a serious
complication, often resulting in severe long-term visual
impairment and significant morbidity.3,4
Visual acuity (VA) is the most commonly reported
outcome measure in studies investigating postoperative
endophthalmitis.3,4 However, VA is unable to describe the
impact of endophthalmitis upon a patient’s perceived quality
of life (QOL) where social interaction, mental health, depen-
dency and functional ability likely play an important role.
Visual impairment has been repeatedly reported to limit
social interaction, psychological well-being and indepen-
dence; and increases morbidity resulting in a poorer QOL.5–8
Although it is generally assumed that postoperative endoph-
thalmitis reduces QOL owing to its detrimental effects
on visual outcomes, this has not yet been empirically
demonstrated.
There is a growing trend in ophthalmology towards the
use of standardized health-related QOL measures to
support clinical decision making since they allow the
impact of eye diseases and treatment outcomes to be quan-
tified from predominantly values-based measures.9 In the
case of postoperative endophthalmitis, quantification of the
personal burden imposed is an important consideration in
determining its overall cost. Given the enormous cost asso-
ciated with routine chemoprophylaxis to prevent relatively
few postoperative endophthalmitis cases,10 QOL analysis
is an essential consideration to properly assess and justify
the costs and benefits of alternative chemoprophylaxis
regimes.
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We assessed the impact of postoperative endophthalmitis
on patients’ self-reported perceptions of vision and health-
related QOL measured using the National Eye Institute’s
VFQ-25 (VFQ-25)11 questionnaire, the EuroQol EQ-5D
(EQ-5D)12 questionnaire and time trade-off (TTO) utility
values.13
METHODS
Self-perceived health and vision-related quality of life
(VRQOL) was compared between patients who developed
endophthalmitis after cataract surgery (cases) with those
who had uncomplicated cataract surgery (‘controls’).
Study population
Patients who had postoperative endophthalmitis were
recruited prospectively between 1 January and 31 December
2003 from three teaching hospitals in Western Australia
where the vast majority of cases of endophthalmitis in the
State are treated.3 They were defined as patients who had a
clinical diagnosis of postoperative endophthalmitis within
one month following cataract surgery. The associated
cataract operation was not necessarily performed at the
endophthalmitis-treating hospital. Each eligible patient was
approached and invited to participate in the study. Of the 30
potential cases of postoperative endophthalmitis identified,
19 (63%) consented to participate.
Controls were randomly selected from all cataract opera-
tions performed in two of the teaching hospitals over the
study period. Fifty-one patients were approached to partici-
pate in the study, of which 30 (59%) consented to do so.
Tools
The VFQ-25 measures the influence of visual disabilities and
visual symptoms on generic health domains such as emo-
tional well-being and social functioning, and task-oriented
domains related to visual functioning. It consists of 12 sub-
scales: general health, general vision, near activities, distance
vision, driving, peripheral vision, colour vision, ocular pain,
role limitation, dependency, social function and mental
health.11 For each subscale, there is choice of five possible
answers. The responses to questions within each subscale are
converted to a score out of 100, with zero representing the
worst possible score. A composite score provides an average
of all 12 subscales.
The EQ-5D measures generic health-related QOL across
five domains: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression.12 Each question has three
possible answers (1 = ‘no problem’, 2 = ‘some problem’ and
3 = ‘severe problem’). A summary score is derived from con-
version of the five scores, where 1 is the maximum score and
indicates best health status. A visual analogue scale is also
included in this instrument in which general health status is
a score out of 100.
Utility values for cases and controls were calculated using
the TTOmethod. A score is generated by asking participants
to state the maximum number of years of their remaining life
they would be willing to give up or ‘trade’ to receive perfect
vision. This fraction is then subtracted from 1.0 to give
a utility value between 1.0 and 0, where 1.0 represents a
perfect health state and 0 is death.
Data collection
The VFQ-25 and EQ-5D questionnaires and the TTO utility
question were administered to cases via interview and were
self-administered by the control group. To avoid bias in
participant responses, interview questions were asked verba-
tim according to thewritten instructions provided to controls.
Questionnaires were administered to cases and controls
12 months following cataract surgery to ensure results were
more reflective of the long-term impact of endophthalmitis
rather than the acute effect of the disease. Clinical informa-
tion was obtained directly from participants and through
review of the hospital medical record. Details recorded
included age, sex, best-corrected VA, comorbidity (recorded
as a Charlson Index of Comorbidity14) and level of function in
activities of daily living (recorded using the Modified Barthel
Index15). Best-corrected VA was that recorded in the medical
record nearest the time of data collection.
Statistical analysis
Analysis was performed using Stata version 9.2 (Statacorp,
College Station, TX, USA). Univariate analysis of categori-
cal data for both cases and controls were compared using
Fisher’s exact test, and for continuous variables using inde-
pendent t-test. The groups were further divided based on the
best-corrected VA; those with a VA < 6/12 in their best eye
were regarded as vision impaired, whereas those with a
VA ! 6/12 were regarded as having no visual impairment.
Linear regression was used to compare differences in mean
VFQ-25, EQ-5D and TTO utility scores between groups,
adjusted for age, sex and visual acuity. Results were consid-
ered to be statistically significant at the P < 0.05 level.
Ethics approval
Written informed consent was obtained from all study
participants. Ethics committee approval for this study was
obtained from The University of Western Australia, Royal
Perth Hospital, Sir Charles Gairdner Hospital and Fremantle
Hospital and Health Service.
RESULTS
Patient characteristics are summarized in Table 1. No signifi-
cant differences existed between patient groups with regard
to age, gender, Charlson Index of Comorbidity and Barthels
Index of Activities of Daily Living. Whereas a comparable
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proportion of patients were vision impaired in either group,
those who had postoperative endophthalmitis were more
likely to have at least unilateral visual impairment (53%
vs. 17%, P = 0.009). Best-corrected distance VAs in operated
and non-operated eyes in both groups are compared in
Table 2. The proportion of postoperative endophthalmitis
patients with VA < 6/12 in their operated eye was signifi-
cantly more than the comparison group (P = 0.01).
Mean VFQ-25 subscale scores are summarized in Table 3.
The age and sex-adjusted mean composite score, which
combines all measured subscales included in the VFQ-25,
was 13.5% lower for cases (95% confidence interval: 6–26.4,
P < 0.01). The mean scores for the general vision, near activi-
ties, mental health, role difficulties and peripheral vision
subscales were all significantly lower in cases after adjusting
for age, sex and visual acuity in the better eye. No significant
differences were found for the other subscales.
Subgroup analysis comparing VFQ-25 subscale scores
between groups with and without visual impairment
(VA < 6/12 in at least one eye) showed that endophthalmitis
cases without recorded visual impairment had lower scores in
all but the driving subscale (Table 4). Similarly, among visu-
ally impaired participants, cases had consistently lower mean
scores than controls in all subscales. None of these differ-
ences were found to be statistically significant for either
group.
EQ-5D subscale scores are summarized in Table 5. Post-
operative endophthalmitis patients reported poorer QOL in
all domains of the EQ-5D compared with controls. The
difference in summary score, which provides an overall
average of each of the domains, though lower for endoph-
thalmitis patients, was not significant. Only the difference
found in the mobility domain (1.63 vs. 1.27) remained sig-
nificant (P=0.03). Mean TTO utility values were slightly, but
not significantly, lower for postoperative endophthalmitis
patients (0.90 vs. 0.96, P = 0.12).
Table 1. Comparison of patient characteristics between those who had postoperative endophthalmitis following cataract surgery (cases) and
those who had uncomplicated cataract surgery (controls)
Cases Controls P-value
(n = 19) (n = 30)
Age (mean! SD) 81.2! 8.5 76.60! 11.5 0.14*
Sex distribution
Male 6 (32) 8 (27) 0.48**
Female 13 (68) 22 (73)
Degree of vision loss
No visual impairment 9 (47) 25 (83)
Unilateral visual impairment 9 (47) 3 (10) 0.009**
Bilateral visual impairment 1 (6) 2 (7)
General disability (mean! SD)
Charlson Index of Comorbidity Score 1.26! 1.2 1.20! 1.6 0.95*
Modified Barthels Index Score 103.7! 11.8 106.2! 7.4 0.25*
*Two-tailed independent t-test. **Fisher’s exact test. Numbers in brackets are percentages.
Table 2. Comparison of postoperative visual acuity between
patients who had postoperative endophthalmitis following cataract
surgery (case) and those who had uncomplicated surgery (controls)
in operated and non-operated eyes
Post-op VA Operated eye Non-operated eye
Cases Controls Cases Controls
"6/6 5 15 6 18
6/9 5 11 6 6
6/12 1 1 4 2
6/18 2 1 1 2
6/24 2 – – 1
6/36 – 1 1 –
6/60 – – 1 1
<6/60 4 1 – –
P-value* 0.01 1
*Fisher’s exact test comparing the proportion of eyes with post-
operative distance visual acuity"6/12 and <6/12 between cases and
controls.
Table 3. Comparison of mean NEI VFQ-25 Subscale Scores in
patients who had postoperative endophthalmitis (cases) following
cataract surgery with those who did not (controls)
NEI VFQ-25 Subscale Cases
(n = 19)
Controls
(n = 29)
P-value*
General health 55.0! 19.2 65.1! 23.3 0.13
General vision 64.2! 17.2 77.2! 20.0 0.01
Eye pain 79.6! 23.3 83.2! 22.0 0.44
Near activities 69.0! 32.5 85.8! 17.2 0.008
Distance activities 76.6! 26.2 86.0! 15.1 0.05
Social function 86.2! 27.0 93.0! 14.0 0.13
Mental health 69.7! 32.3 85.5! 22.3 0.02
Role difficulties 71.7! 32.3 87.3! 16.9 0.02
Driving† 64.6! 42.1 70.8! 32.1 0.91
Colour vision 90.8! 20.8 96.5! 14.5 0.17
Peripheral vision 69.4! 36.9 86.6! 22.0 0.02
Composite score 74.3! 22.7 85.9! 15.5 0.01
*Adjusted for age, sex and visual acuity. †Controls (n = 16) and
cases (n = 6). All values are given as mean! SD.
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DISCUSSION
Our findings suggest that postoperative endophthalmitis
following cataract surgery results in poorer patient perceived
VRQOL compared with uncomplicated cataract surgery.
Participants who had postoperative endophthalmitis were
more likely to report difficulties in a range of vision-related
activities involving near, distance, peripheral and general
vision. They were also more dependent upon others, felt
their vision limited the activities they could engage in and
more likely to feel frustrated and worried because of their
poor vision. However, no significant effect upon general
health-related QOL was found.
Our findings of reduced VRQOL using the VFQ-25 were
independent of VA in the better eye. This may have been
because postoperative endophthalmitis patients were more
likely to have unilateral vision loss, and although VRQOL is
found to correlate most strongly with VA in the better eye,
the presence of unilateral visual impairment in known to
cause poorer VRQOL.7,8,16 When we restricted the compari-
son to those with no visual impairment in either eye and then
compared mean VFQ-25 subscale scores, those with post-
operative endophthalmitis still reported a lower QOL in all
subscales except driving. Although these differences were
not found to be significant in our study, it suggests that
factors other than visual acuity may be affecting QOL in
these patients.
Similar findings were reported in a study examining the
effect of central retinal vein occlusion (CRVO) on QOL.17
CRVO is similar to postoperative endophthalmitis in that it
is an acute and predominantly unilateral complication result-
ing in sudden and severe vision loss. The VFQ-25 was used
to measure VRQOL in 51 patients who had CRVO and who
were compared with patients with normal vision and those
with diabetic retinopathy. The authors found that patients
with CRVO had significantly lower scores on several sub-
scales in the VFQ-25 which also persisted after adjusting for
VA of the better eye.
This contrasts previous studies that have found the impact
of an eye disease on QOL is primarily dependent upon its
effect on vision and independent of the underlying
condition.18 However, these studies involved chronic, slowly
progressive eye diseases, unlike postoperative endophthalmi-
tis, which tends to be an acute complication resulting in
sudden and severe vision loss.3,19 It also requires intensive and
prolonged inpatient treatment, often with multiple proce-
dures, and frequent and prolonged outpatient review.
Patients are often independent and relatively healthy before
developing postoperative endophthalmitis, and the impact
of such a sudden and severe change in their perceived health,
in addition to the sudden disruption to their life in order to
treat it, is conceivably far greater than in a chronically pro-
gressive eye condition that allows greater time for the patient
to adapt.
Table 4. Mean NEI VFQ-25 Subscale Scores in patients who had postoperative endophthalmitis following cataract surgery (cases) with those
who did not (controls) according to presence of visual impairment (visual acuity <6/12) in either eye
NEI VFQ-25 Subscale No visual impairment P-value* Visual impairment P-value*
Cases
(n = 9)
Controls
(n = 24)
Cases
(n = 10)
Controls
(n = 5)
General health 56.7! 18.9 62.6! 23.7 0.50 53.5! 20.3 77.0! 18.9 0.17
General vision 70.6! 19.1 79.0! 15.2 0.19 58.5! 20.0 69.0! 25.3 0.84
Eye pain 75.0! 27.2 80.2! 23.0 0.53 83.8! 19.6 97.5! 5.6 0.11
Near activities 78.8! 31.6 87.2! 14.4 0.20 60.2! 32.3 79.4! 28.6 0.46
Distance activities 80.1! 29.3 86.3! 14.9 0.32 73.4! 24.3 84.5! 17.8 0.69
Social function 87.0! 27.0 92.9! 14.1 0.29 85.4! 28.4 93.3! 14.9 0.81
Mental health 76.0! 33.3 88.1! 17.4 0.14 64.0! 31.9 73.0! 38.8 0.92
Role difficulties 79.2! 32.3 87.2! 16.4 0.27 65.0! 32.4 87.5! 21.2 0.49
Driving† 79.2! 36.1 68.6! 34.8 0.99 50.0! 50.0 80.6! 17.3 0.80
Colour vision 88.9! 25.3 99.0! 5.1 0.06 92.5! 16.9 85.0! 33.5 0.28
Peripheral vision 80.6! 32.5 88.5! 19.5 0.18 58.3! 39.5 75.0! 35.3 0.87
Composite score 79.2! 26.6 86.6! 14.3 0.21 69.8! 18.9 82.2! 22.2 0.64
*Adjusted for age and sex. †No visual impairment: cases (n = 3) and controls (n = 13); visual impairment: cases (n = 3) and controls (n = 3).
All values are given as mean! SD.
Table 5. Mean EuroQOL EQ-5D Scores comparing patients who
had postoperative endophthalmitis following cataract surgery
(cases) with those who had uncomplicated surgery (controls)
EuroQOL EQ-5D
Subscale
Cases
(n = 19)
Controls
(n = 30)
P-value*
Mobility 1.63! 0.50 1.27! 0.52 0.03
Self-care 1.16! 0.37 1.10! 0.48 0.63
Usual activities 1.47! 0.70 1.20! 0.55 0.16
Pain 1.79! 0.53 1.50! 0.63 0.12
Anxiety and depression 1.47! 0.49 1.33! 0.55 0.35
Summary score 0.66! 0.32 0.81! 0.25 0.08
General health state 68.4! 16.3 78.1! 16.7 0.07
*Adjusted for age, sex and visual acuity. All values are given as
mean! SD.
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We found mean TTO utility and EQ-5D scores were
generally worse among cases and suggests postoperative
endophthalmitis has some impact on self-perceived general
health-related QOL. However, these differences did not
reach statistical significance in our study, despite approach-
ing it on several subscales. This is likely due to a combination
of our small sample size and the relative insensitivity of the
EQ-5D and TTO for detecting more subtle vision-related
impacts on QOL detected by the VFQ-25.20,21 Espallargues
et al., in their study of 209 patients with substantial vision loss
due to age-related macular degeneration, found that the
EQ-5D did not reflect the reductions in health status in terms
of visual impairment and function detected by more specific
vision related measures. They argued that the lack of sensi-
tivity of the EQ-5D relates to the relevance of its descriptive
systems, which fail to capture the impact of daily living
activities that rely upon central vision.21
We identified several potential limitations to this study.
The sample size is relatively small, because of the rarity of
postoperative endophthalmitis in the community, and
limited our ability to assess more subtle changes in QOL
between groups. Reporting bias exists owing to differences
in questionnaire delivery to cases and controls as inter-
viewer bias may have been introduced for cases that was
not present among controls (who were given self-
administered questionnaires). Furthermore, it was also not
possible to know whether the questionnaire was truly self-
administered to controls or whether a family member or
carer aided in its administration. Previous studies show that
proxy respondents tend to over-report problems compared
with patients.22 Should this have occurred in our study, it
would have resulted in a smaller difference between cases
and controls and lead to an underestimation of true QOL
scores.
Our study is strengthened by its population-based design
and its use of widely accepted QOL measurement tools. The
VFQ-25 questionnaire is a scientifically validated, widely
used and easily administered tool for evaluating self-reported
VRQOL in patients with visual impairment from a range of
ages and cultural backgrounds.23–25 It has been used success-
fully to assess the impact of numerous acute and chronic eye
conditions on QOL including diabetic retinopathy,26 age-
related macular degeneration27 and glaucoma.28 The EQ-5D
is used widely in general health-related QOL research,
where its validity is well established;12 however, its utility as
a measure of the impact of vision on health-related QOL is
variable.21,29 Utility analysis is also regarded as a valid
measure of VRQOL30 and is becoming increasingly
important in the study of values-based outcomes in
ophthalmology.31 Studies have shown that TTO utility cor-
relates most strongly with the VA of the better seeing eye.32
Postoperative endophthalmitis remains a severe and
potentially devastating complication of cataract surgery. We
found that postoperative endophthalmitis has a measureable
impact upon the psychological well-being of patients and
their ability to maintain a normal role in daily life beyond its
affect on VA. The measurement of patient perceived QOL as
an additional outcome measure to VA (using reliable and
easily administered questionnaires such the VFQ-25) is a
useful tool for clinicians to provide a more complete under-
standing of the impact of postoperative endophthalmitis and
treatment outcomes on QOL than can be gleaned from VA
alone.
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ABSTRACT
Background: To explore the interaction between
vision impairment, perceived quality of life loss and
willingness to trade remaining life for vision gain.
Design: Community-based cross-sectional study
Participants: Legally blind or severely vision-impaired
people selected randomly from the Association for
the Blind of Western Australia register.
Methods: Individuals were examined by consultant
ophthalmologists and completed the Impact of
Vision Impairment profile quality of life assessment
and a Time Trade-Off evaluation. Vision-related
utility values were calculated. The results were
analysed using univariate and multivariate regres-
sion methods.
Main Outcome Measures: IVI Rasch Logits and TTO
utility values (TTO UV).
Results: 156 people volunteered to contribute to the
study. The median age was 80 (19–97) years, and
56% were female. Being legally blind (logMAR > 1)
(95% CI 1.1 to 5.2, P = 0.003), clinically depressed
(95% CI -11.2 to -1.8, P = 0.007) or more than
40 years of age (95% CI 0.9 to 8.1, P =
0.015) significantly lowered overall impact of vision
impairment scores. The emotional domain of impact
of vision impairment was associated with willingness
to trade part of remaining life. A 5-Logit increase in
impact of vision impairment emotional score
resulted in a 21% (95% CI 10 to 31) decrease in the
odds of being likely to trade life for sight. The Aus-
tralian definition of blindness compared with World
Health Organisation or USA best separates those
with perceived loss and appears useful in identifying
vision loss-related morbidity.
Conclusions: These results suggest that emotional
health and lack of depression are important determi-
nants for quality and value of life.
Keywords: blind, depression, IVI assessment, quality of
life, time trade-off utility value.
INTRODUCTION
A blinding eye condition can be a devastating dis-
ability, leading to depression,1,2 loss of employment,
financial stress3 and premature death.4 The total cost
of vision-related disorders in Australia has been esti-
mated to be $9.85 billion per annum.5,6 We wanted to
explore how visual function, varying diagnoses and
length of onset of severe vision impairment and
blindness affected quality of life. And in particular,
what was the interaction between the subjective
impact of vision impairment (IVI) and time trade-off
utility values (TTO UVs)?
The IVI questionnaire is a well-validated tool
developed in Australia to evaluate self-reported per-
formance of tasks associated with everyday living. It
has three component domains of mobility, reading or
recognition tasks and emotional well-being, which
together combine to give an overall IVI score.7
Time trade-off utility values are used by health
economists to quantify and compare patient
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preferences across a range of diseases and health
states.8 By using TTO UV to evaluate and objectively
assess quality of life, economists can perform a cost–
utility analysis. The UV multiplied by the remaining
years of life gives the ‘quality-adjusted’ life years
(QALYs); an effective intervention that costs less
than about $50 000 per QALY is considered reason-
able value for money.9
METHODS
The Association for the Blind of Western Australia
maintains a register of vision-impaired and legally
blind members (n = 4271). Individuals were ran-
domly selected from the register and then subse-
lected if they were severely vision-impaired or ‘near
blind’ (Fig. 1). For the purposes of this study this
‘near blind ’ was defined as having a previous Asso-
ciation for the Blind of Western Australia clinical
record, as determined by an ophthalmologist or
optometrist, of a best-corrected visual acuity (BCVA)
of logMAR > 0.6 or <20° diameter of field, or a com-
bination of both reduced VA and field restriction, in
the better eye. Legal blindness in Australia is con-
firmed when the better eye has a VA logMAR > 1 or
field of <10° diameter, or a combination of both
visual acuity and field loss that results in the equiva-
lent level of vision loss. Study volunteers were aged
at least 18 years and able to travel to attend the clini-
cal appraisal. Consent was obtained from all partici-
pants after the study aims and purpose were
explained. The research project was approved by the
Human Research Ethics Committee of Curtin
University.
Each individual was clinically reviewed by one of
two consultant ophthalmologists (WM, NM) to
determine the cause of vision loss and establish the
current level of vision loss. Best-corrected distance
VA for each eye was measured using a logMAR chart,
at 6 and 3 m, in standardized lighting conditions. In
this study counting fingers, hand movements, per-
ception of light and no perception of light were
assigned logMAR values of 2, 3, 3.5 and 4,
respectively. Field restriction was mapped using a
Bjerrum screen, with a 10-mm target at 1 m distance,
for each eye. Existing comorbidities were obtained
by self-report during this assessment. Any history of
cognitive or neurological impairment that was
reported by individuals or carers, or individuals who
were unable to understand the questions were
excluded from the study.
A standardized verbal interview was carried out
by a single interviewer (JC), to collect demographic
details. All data were entered and stored in a data-
base created in Microsoft Access (v 2007). We
employed two validated tools to measure the effects
of vision loss; the IVI questionnaire10 and a TTO
question.11–13 Participants unable or unwilling to
complete both IVI and TTO assessments were
excluded from the analysis.
Responses to the IVI questionnaire were selected
from a list of choices, by the patient, as either ‘not at
all’ (3), ‘a little’ (2), ‘a fair amount’ (1) to ‘a lot’ (0).
There was provision for ‘don’t do this for reasons
other than vision loss’ (8). Overall IVI score and
mean IVI score were calculated for each domain:
mobility, emotional effects and reading/recognition
skills. Items rated 8 were excluded from the
calculation. A score conversion based on Rasch
Unavailable
ABWA register VI
and blind
4271
Randomly selected
from register
1307
BCVA > LogMAR 0.6
Invited
716
BCVA < LogMAR 0.6
591
Excluded due to level of vision
Not well enough          105
Transport problems     73
Not interested              68
Not able to attend        15
Died                             50
Lost to follow up          122
Consented
281
DNA                             8
Ophthalmic review
volunteers
273
Q of Life and TTO
assessment
156
Language, age, cognitive
or other problems        117
Figure 1. Flow diagram to describe the cohort selection
process. A total of 1307 vision-impaired people were randomly
selected from the register. Individuals who were ‘near blind’
(n = 716) were invited to be part of the study and 281 agreed
to attend the clinics. Of these, 156 volunteered to complete
the impact of vision impairment and time trade-off assess-
ments. ABWA, Association for the Blind of Western Australia;
BCVA, best-corrected visual acuity; TTO, time trade-off utility; VI,
vision-impaired.
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analysis was performed as described by others.7,14
Student’s t-tests and standard linear regression
models, to account for multiple predictors, were used
to estimate the effect of demographic and clinical
factors on the overall IVI scores and for each of the
three domain scores. The most parsimonious models
were constructed whereby factors not significantly
associated with the dependent variable were
removed.
A TTO question quantifies a person’s preference
for a preferred health status. In this study, the scores
ranged between 0 (total blindness) and 1 (perfect
vision) and represent a measure of global or illness-
specific quality of life.15 UVs have been used to objec-
tively assess quality of life associated with health
states across different medical specialities.8 In the
TTO assessment, participants were asked to quantify
how much, if any, of their own estimate of remaining
life they would be prepared to trade if their sight
could be restored, as described and validated by
others.11–13 This estimate was converted to a percent-
age of their remaining years of life. A TTO UV was
then calculated:
UV years to trade-off years of remaining life= −1 ( / )
Demographic and clinical factors associated with
variations in the TTO UV were investigated using
Tobit regression models to account for the bounded
nature of the dependent variable on the (0, 1) inter-
val showing a truncated normal distribution.
Stata v10 (Stata Corporation, College Station, TX,
USA) and SPSS v17 (SPSS Inc., Chicago, IL, USA)
were used for all analyses.
RESULTS
One thousand three hundred and seven individuals
were randomly selected from the register of blind
and vision impaired in Western Australia. Of these,
716 were considered to be ‘near blind’ and eligible
for inclusion in this study. There were 122 who had
no known contact details and 50 who had died since
last contacted. A further 263 (48%) declined to join
the study being either not well enough, having
transport difficulties, not interested or were unable
to attend. One hundred and fifty-six individuals vol-
unteered for a full ophthalmic review and to com-
plete the IVI and TTO assessments (Fig. 1). The
demographic details of this cohort are shown in
Table 1. There were more female (n = 86) than male
(n = 70), and the age of the cohort ranged from 19 to
97 years (mean 74 years, median 80 years). ‘Legal
blindness’ was found in 82% (n = 128); the remain-
ing 18% (n = 28) were termed ‘near blind’ for the
purposes of this study, having a BCVA of logMAR
0.6–1 with or without field restriction. Age-related
macular degeneration was the primary cause of
vision loss in 60% (n = 94) of the participants; of
these, 62% were neovascular and 38% atrophic. The
remaining causes were: congenital retinal dystro-
phies 15.4% (n = 24), optic neuropathies 5.4%
(n = 8), diabetic retinopathy 4.5% (n = 7), glaucoma
3.2% (n = 5), myopia 2% (n = 3), vein occlusions
1.3% (n = 2), cataract 0.6% (n = 1) and other 7.6%
(n = 12). Only 8% (n = 13) of participants were diag-
nosed with a blinding eye condition in childhood
(aged less than 12 years). More than half had become
legally blind within the last 10 years, range
1–70 years (mean 11 years, median 8 years).
Comorbidities were self-reported by 80%
(n = 124) of individuals, and 46% (n = 71) had two
or more comorbid conditions. Almost half the indi-
viduals with comorbidities had hypertension 42%,
ischaemic heart conditions 17%, diabetes 18%, cere-
brovascular disease 5%, cancer/neoplasm 5% and
depression 3%.
Factors associated with IVI score
outcomes
Univariate analysis indicated that being legally blind
in Australia: having a BCVA logMAR > 1 or field loss
of 10° or a combination of reduced VA and field loss
was associated with a 6-Logit lower mean overall IVI
score (Table 1) compared with IVI scores for people
who were near blind (BCVA logMAR 0.6–1). This
difference remained highly significant (3.1, 95% CI
1.1 to 5.2, P = 0.003) after adjustment for other factors
using multivariate modelling (Table 2). We also
analysed the alternate cut-off points that the World
Health Organisation (WHO) (BCVA logMAR > 1.3)
and USA (BCVA logMAR ! 1) used to define
blindness. The mean difference in overall IVI scores
between near blind and blind was greatest (6 Logits)
using the Australian definition of legal blindness
compared with the WHO (4 Logits) or US definitions
(2 Logits). There was no significant difference in
the mean IVI scores between individuals who
had a BCVA logMAR " 1, with (n = 24) or without
(n = 28) field restriction, nor between legally blind
people who had BCVA logMAR < 1 but with limited
fields (n = 24) and all other legally blind people
BCVA logMAR > 1 (n = 104) (data not shown).
In this study, being ‘legally blind’ rather than
‘near blind’ was associated with a significantly
lower mean overall IVI score (3.1, 95% CI 1.1 to 5.2,
P = 0.003).
Across the IVI domain categories, the single factor
that was most consistently associated with signifi-
cantly lower IVI scores was the presence of depres-
sion as a comorbidity (n = 6). Although this is a
small number in a cohort of 156, the association
remained significant in regression analysis. In
patients with a self-reported diagnosis of depression
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overall mean IVI score was 6.5 Logits worse (95% CI
-11.2 to -1.8, P = 0.007), mean mobility IVI scores
were 11.5 Logits worse (95% CI -20.5 to -2.4, P =
0.013), and emotion IVI scores were 17 Logits worse
(95% CI -30 to -3.8, P = 0.012) compared with those
of people without a diagnosis of depression
(Table 2).
The only other comorbidity that was shown to
impact on overall mean IVI score was any form of
cancer/neoplasm (n = 8). This was associated with
better overall IVI scores, mean 4.5 Logits (95% CI 1.0
to 8.1, P = 0.013).
Patients aged less than 40 years had significantly
better mean overall IVI scores (4.5, 95% CI 0.9 to 8.1,
P = 0.015) and IVI reading/recognition domain
scores compared with those aged more than 40 years
(12.6, 95% CI 5.2 to -20.0, P = 0.001). Regression
analysis demonstrated that better IVI reading/
recognition scores were associated with a higher
level of education completed (5.3, 95% CI 0.9 to 9.7,
P = 0.02).
The completion of a secondary education com-
pared with primary only education was significantly
associated with a higher mean IVI mobility score in
the adjusted regression model (-8.1, 95% CI -14.9 to
-1.3, P = 0.019) (Table 2).
Factors associated with TTO UVs
There were no significant differences in the demo-
graphics or health-related factors (age, gender, age of
onset, years since onset, level of vision loss) of those
who would (n = 107) or would not trade (n = 49)
some years of remaining life for sight restoration.
Nor was there any significant difference in TTO
UV of those people who were legally blind (log-
MAR > 1) (n = 128) and those who were ‘near blind’
(logMAR ! 1) (n = 28).
Because of the bounded nature (0, 1) of the TTO
UVs, a single Tobit regression model found that age
group was the only demographic variable that was
Table 1. Univariate analysis of Rasch adjusted IVI scores and TTO UVs for demographic and vision characteristics, using independent
t-test
n Mean IVI
Overall score " SD Emotion score " SD Reading score " SD Mobility score " SD
Total 156 51 " 12.2 59 " 15.5 52 " 10.9 55 " 10.7
Gender
Male 70 52 " 11.7 58 " 15.1 52 " 11.5 57 " 10.3
Female 86 50 " 12.6 59 " 15.8 51 " 11.5 54 " 10.8
Vision
Australian near blind 28 57 " 12.3* 62 " 13.9 58 " 10.9* 59 " 12.3*
Australian legal blind 128 51 " 11.9* 59 " 15.8 50 " 10.5* 54 " 10.1*
logMAR > 1+ field loss
USA near blind 33 57 " 11.5 59 " 16.2 58 " 12.2† 56 " 11.5
USA legal blind 123 55 " 9.7 59 " 15.4 50 " 9.9† 55 " 10.5
logMAR # 1
WHO near blind 99 57 " 10.1 60 " 15.1 54 " 11.1‡ 56 " 10.7
WHO legal blind 57 53 " 9.8 58 " 16.2 47 " 8.9‡ 54 " 10.5
logMAR > 1.3
Median age = 80
<80 years 76 51 " 12.8 57 " 16.7 53 " 11.5 54 " 10.6
#79 years 80 52 " 11.6 61 " 14.0 51 " 10.3 56 " 10.7
Comorbidities
No 31 55 " 13.6 60 " 15.3 57 " 13.1 57 " 11.2
Yes 125 51 " 11.7 59 " 15.6 51 " 10.4 55 " 10.5
Age of onset
<12 years 13 55 " 10.4 65 " 12.5 55 " 10.2 55 " 9.4
#12 years 143 51 " 12.3 59 " 15.7 52 " 10.9 55 " 10.8
Education
Primary only 9 44 " 10.3 54 " 11.1 45 " 14.0 46 " 8.9*
Secondary 121 51 " 12.2 59 " 16.3 51 " 9.4** 56 " 10.6*
Tertiary 25 55 " 11.9 59 " 12.5 58 " 14.4** 57 " 10.8
Unknown 1
TTO UV
Traders 107 53 " 9.1* 56 " 13.9† 50 " 10.0‡ 54 " 9.4**
Non-traders 49 60 " 11.1* 65 " 16.9† 54 " 12.4‡ 59 " 12.2**
*, **, †, ‡ indicate where significant differences were found between separate data sets P < 0.05. IVI, impact of vision impairment; SD,
standard deviation; TTO UV, time trade-off utility value.
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associated with the TTO UV. Participants aged less
than 40 years (n = 8) had significantly higher mean
TTO UVs (95% CI 0.03 to 0.58, P = 0.03) compared
with older participants (Table 3).
No comorbidities, such as: diabetes, depression,
vascular disease, hypertension, arthritis or joint
problems, any form of neoplasia or the total number
of comorbidities had any significant effect TTO UV
scores in this cohort.
Although vision-specific tools for quantifying
health status UVs are not truly comparable across
diverse medical states,16 others have made this
Table 2. Demographic and clinical factors associated with mean IVI scores as estimated by four separate linear regression models for
total IVI scores and the emotion, reading and mobility domains (n = 156)
Difference in mean IVI scores† 95% CI P-value
Total IVI
Age group (years)
<40 4.5 0.9–8.1 0.015
40–59 -0.2 -3.1–2.7 0.896
60–79 -0.7 -2.4–1.1 0.436
80+ Referent group
logMAR ! 1 3.1 1.1–5.2 0.003
Depression -6.5 -11.2–-1.8 0.007
Neoplasms 4.5 1.0–8.1 0.013
Traders -2.8 -4.5–-1.1 0.001
Emotion IVI
Depression -16.9 -30–-3.8 0.012
Traders -9.2 -14.1–-4.2 0.001
Reading IVI
Age group (years)
<40 12.6 5.2–-20.0 0.001
40–59 3.4 -2.2–9.0 0.227
60–79 1.2 -2.3–4.7 0.489
80+ Referent group
Education
Primary -5.4 -12.1–1.2 0.109
Secondary Referent group
Tertiary 5.3 0.9–9.7 0.020
logMAR ! 1 7.1 3.0–11.2 0.001
Neoplasms -6.5 -11.7–-1.3 0.014
Traders -3.7 -7.1–-0.3 0.032
Mobility IVI
Education
Primary -8.1 -14.9–-1.3 0.019
Secondary Referent group
Tertiary 1.9 -2.4–6.3 0.379
logMAR ! 1 4.5 0.4–8.7 0.031
Depression -11.5 -20.5–-2.4 0.013
Traders -5.6 -9.0–-2.2 0.001
Only variables showing a statistically significant association were included in each of the final models. †Difference in mean score
between those with the variable of interest compared with those without the variable of interest (or the referent group where
appropriate). CI, confidence interval; IVI, impact of vision impairment.
Table 3. Demographic, clinical and IVI factors associated with Time Trade-Off utility value scores as estimated from a single Tobit
regression model that accounts for the bounded nature (0, 1) of the TTO utility values
Variable Difference in mean IVI scores* 95% CI P-value
Age group (years)
<40 0.31 0.03–0.58 0.030
40–59 0.11 -0.07–0.30 0.219
60–79 0.04 -0.08–0.16 0.499
80+ Referent group
Emotion IVI scores (5 Logits) 0.04 0.02–0.06 <0.001
Only variables that were statistically significant at an alpha level of 0.05 are included in the final model.
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comparison.15,17,18 Severe vision loss was rated com-
parable with colon cancer (UV 0.8), a diagnosis of
AIDS (0.79), moderate stroke (UV 0.73) or having a
failed kidney transplant (UV 0.62) (Table 5).15
Combined TTO UV and IVI scores
outcomes
We found that 49 individuals would not consider
trading any years of remaining life for their sight
restoration (TTO UV = 1). The majority (84%) of
these ‘zero traders’ were also legally blind (n = 41).
Using an independent t-test, zero traders had mean
overall IVI Logit score of 60 compared with ‘traders’
(people who were prepared to trade some life for
sight restoration [TTO UV < 1]) who had a mean
overall IVI Logit score of 54 (mean difference =
6.4, 95% CI 3.0 to 9.7, P = 0.000). Zero traders also
had significantly higher scores in the three IVI
subdomains, except for the IVI reading domain in
legally blind individuals (Table 4).
There was a strong association between an indi-
vidual’s TTO UV and IVI emotion domain score,
where every 5-Logit increase in the domain score
increased the TTO UV 4%. However there were no
other demographic or clinical variables associated
with differences in the TTO UVs.
Similarly, when the TTO UV was used to catego-
rize participants as either traders or zero traders, we
found that the odds of being a trader was signifi-
cantly associated with the IVI emotion domain score.
Every 5-Logit increase in the IVI emotion domain
score was associated with a 21% (95% CI 10 to 31)
decrease in the odds of being a trader. Again no other
demographic or clinical factors were associated with
the odds of being a trader or not.
No specific diagnostic cause of vision loss was
associated with any difference in any of the TTO UV
or IVI scores in the multivariate analysis.
DISCUSSION
We found that the cut-off level for legal blindness in
Australia (logMAR > 1) coincided with significant
differences in mean IVI scores when compared with
other visual acuity cut-off points used by WHO and
in other countries. However, in this cohort we did
not find that field restriction made a significant dif-
ference to IVI scores compared with equally vision-
impaired subgroups with no field loss or more
severely blind subgroups. This is consistent with
findings of other research groups who found that
reduced visual acuity rather than visual field loss
was a stronger determinant for reduced daily living
activities.19 In this cohort, people found to be legally
blind at review had significantly worse overall IVI,
mobility and reading/recognition skill scores when
compared with individuals found to be near blind.
The most marked finding in this group was that
people who self-reported a diagnosis of a depressive
illness had significantly lower IVI scores across all
domains. Despite the small numbers, the statisti-
cal effect remained significant after controlling for
other factors and had the strongest impact on the IVI
emotion component. This finding is consistent with
that of others who have reported a strong association
between vision impairment and depressive sym-
ptoms.20–22 These groups reported depression affect-
Table 4. Comparison of mean IVI scores for near blind and legally blind who would (traders) and would not trade (zero traders) some
years of remaining life for sight restoration
n Near blind, mean ! SD n Legally blind, mean ! SD P-value
Total IVI score
Zero traders 8 68 ! 9.8 41 58 ! 10.7 0.02*
Traders 20 56 ! 8.1 87 53 ! 9.2 0.11
P-value 0.003* 0.004*
IVI emotion score
Zero traders 8 70 ! 10.7 41 64 ! 17.9 0.38
Traders 20 58 ! 13.7 87 56 ! 14 0.46
P-value 0.032* 0.002*
IVI reading score
Zero traders 8 64 ! 15.9 41 52 ! 10.7 0.01*
Traders 20 55 ! 7.1 87 49 ! 10.3 0.006*
P-value 0.039* 0.13
IVI mobility score
Zero traders 8 69 ! 12.7 41 57 ! 11.2 0.01*
Traders 20 55 ! 9.9 87 53 ! 9.3 0.43
P-value 0.004* 0.033*
*indicates where significant differences were found for P < 0.05 using independent t test. n is the number in each category. IVI, impact
of vision impairment; SD, standard deviation.
Quality of life with severe vision loss 341
© 2011 The Authors
Clinical and Experimental Ophthalmology © 2011 Royal Australian and New Zealand College of Ophthalmologists
ing larger percentages of the vision-impaired than
found in the present study, which may be because we
did not specifically assess for depression, relying
instead on self-reporting. It is possible that people
with depression may be less likely to volunteer to
attend a study clinic, so were underrepresented in the
present study. Depression compounds the disability
resulting from vision loss, reducing quality of life,
physical and mental functioning, as well as increas-
ing disability.1,2 However depression is treatable,
leading to dramatic improvements in functional
status, disability and quality of life.23
Most people (80%) in this cohort of blind or near
blind individuals had some form of comorbidity,
which is similar to that found by others.24,25 Adverse
outcomes associated with both vision impairment
and comorbidities have been reported by several
groups.2,26 Brody et al.2 reported that the level of
vision loss alone is not an indicator for the onset of
depression, but where vision loss was combined
with any comorbidity, there was a significant risk of
depression.
Those who attended the assessment clinics were
necessarily relatively healthy, mobile and had carer
support, so we may have underestimated the extent
of disability and depression associated with severe
vision loss. Also we relied on self-reporting of
medical comorbidities and did not assess their
severity. Despite these limitations, our findings were
consistent with previous research, indicating that
vision loss and depression are associated with
declines in a range of health indicators.
Interestingly, a diagnosis of cancer or neoplasia
was found to be associated with better overall mean
IVI scores. Others have not reported this effect, to the
best of our knowledge, and the small numbers
affected in this cohort suggest that the results should
be tested in a study suitably powered to detect a
difference. It may indicate a personal re-evaluation
of the impact of vision loss in the context of a life-
threatening condition.
Despite the cohort’s median age (80 years), we
found that the participants had little or no problem
with the concept of the TTOmethodology, contrary to
reports by others.27 The number that would consider
trading some life for restoration of their sight (68%)
was similar to other studies (Table 5).8,15,28,29 The IVI
emotion scores and being aged less than 40 years
were the only variables that had significantly higher
TTO UV scores in a regression analysis (Table 3).
There was no significant difference in TTO UV scores
with any other demographic or clinical factors tested
in this cohort (diagnostic cause or level of vision loss,
education level, rural or urban residency or the pres-
ence of comorbidities). Overall we found that those
who were legally blind did not have significantly
worse TTO UV scores than people who were ‘near
blind’. However we did find that those who were not
prepared to trade any years of remaining life for sight
(zero traders) did have significantly better IVI scores
than the group who were willing to trade life for
sight. In particular, higher IVI emotion scores were
associated with zero traders, implying that they were
coping better with everyday living and its associated
tasks, and that future life had value.
Blinding eye disease is a serious public health
problem endangering personal confidence and inde-
pendence, autonomy and quality of life. We found
that older people with severe levels of vision loss
were most adversely affected by their disability,
especially when depressed. However, we also found
that those with good coping skills were less inclined
to trade life for sight in TTO assessments, strongly
implying that emotional health and lack of depres-
sion are important determinants of quality and value
of life. Whether this relates to successful rehabilita-
tion requires further study.
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107 Traders only 0.62 0.22 0.58–0.67
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nizations and WHO were listed as other potential sources
of financial and technical support.
Although limited in scope, this survey indicates that
eye health promotion is not included in general health
promotion programmes, nor systematically within eye
programmes in WPIC. Despite this, the majority of par-
ticipants indicated interest in, and acknowledged benefits
of including eye health promotion within the services
they deliver. Further, they perceived their Health Promo-
tion Departments would support their eye health promo-
tion efforts. It is likely that context-specific solutions
need to be found to address this apparent disconnect.
Collaboration between eye care personnel, other active
agencies and WPIC Health Promotion Departments may
result in the inclusion of eye health in general health pro-
motion initiatives, as well as support for specific eye
health initiatives. If such collaborations enable eye care
personnel to be more active, and to employ approaches to
health promotion that are more participatory and creative
(e.g. integration into outreach activities, collaboration
with community groups and the use of radio, photo-
novellas or drama), they may contribute to more com-
prehensive eye programmes, preventing problems and
promoting eye health.
Karen Hobday MPH,
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The Fred Hollows Foundation New Zealand,
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Differences in diabetic retinopathy
management by primary eye care
providers in Australia
The number of people with diabetes mellitus across the
globe is expected to double by 2030.1 According to
AusDiab Study in 2003, the prevalence of diabetic retin-
opathy (DR) in Australia was 22% in people with type 2
diabetes and 6.2% in those newly diagnosed.2
The National Health and Medical Research Council
recently updated their evidence-based DR clinical practice
guidelines, encouraging the primary eye care providers
such as the general practitioners (GPs) and optometrists to
play a role in community screening for DR.
During 2007 and 2008, we sent out 3000 self-
administered questionnaires enquiring about routine DR
management practices to a random sample of GPs and
optometrists across all States in Australia.3,4 A total of 429
GPs (21%, n = 429/2000) and 569 optometrists (57%,
n = 569/1000) responded. Both rural (33%) and metropoli-
tan practitioners (67%) were represented in the survey
sample. The results reporting screening barriers and man-
agement with referral are shown in Table 1.
We found nearly 80% of optometrists reported having a
strong desire to screen for DR and only 40% of GPs. Prac-
tical barriers and poor diagnostic confidence may be the
main reason for the lack of enthusiasm among GPs.
Fundoscopy using the direct ophthalmoscope is an
essential basic medical examination skill. In the absence of
retinal photography or a slit lamp, ophthalmoscopy with
dilation is still the optimal method to examine for signs of
DR in the primary eye care setting.
A fear of causing acute angle closure glaucoma with
dilating drops is still a concern despite the exceedingly
low risk (1 in 20 000).5 Even in the rare event that an acute
angle closure glaucoma attack is precipitated, it is readily
treatable and provides the patient with a diagnosis in a
supportive setting. Therefore, such a fear should not be
seen as a barrier.
It is concerning that nearly 60% of optometrists would
not refer patients with diabetic macular oedema (Table 1).3
This warrants a call for action, as diabetic maculopathy
causes most of the significant visual impairment from
diabetes. Although macular oedema may be difficult to
detect with direct ophthalmoscopy or colour fundus pho-
tography, any unexplained drop in visual acuity always
should be suspicious and prompt an early referral to an
ophthalmologist.
Table 1. Management differences between GPs and optom-
etrists who responded to an Australian National Survey
(2008–2009)
Screening barriers GPs Optometrists P-value
(1) Lack of confidence in
detecting changes
using dilated
fundoscopy
86% 2% <0.001
(2) Time limitations 73% 13% <0.001
(3) Patients unprepared-
ness to drive
64% 51% <0.001
(4) Fear of angle closure
glaucoma
44% 13% <0.001
Referral of findings to
ophthalmologists
(1) Severe non-
proliferative DR
99% 90% <0.001
(2) Proliferative DR 99% 98% <0.05
(3) Macular oedema 86% 40% <0.001
The significance of differences was determined by Pearson
c2-test. DR, diabetic retinopathy; GP, general practitioner.
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Iridotomy in Caucasians: a more
conventional angle
Walland and Thomas, in their editorial1 regarding our
paper on the effects of iridotomy in Caucasians,2 emphasize
the central role of gonioscopy in the management of angle
closure. We couldn’t agree more. We perform gonioscopy
for every patient, regardless of the availability of imaging
with anterior segment optical coherence tomography
(AS-OCT). Gonioscopy is a fundamental clinical skill,
remains the gold standard for angle assessment, and
detects potentially management-altering findings such as
peripheral anterior synaechiae and characteristics of angle
pigmentation. The point about variations in AS-OCT find-
ings over small areas is well made. This is a limitation of
the existing technology, which is about to be replaced by
volume scanning of the anterior chamber angles. In an
attempt to mitigate this problem, we took multiple images
(at least six) with AS-OCT in each quadrant in an attempt
to be aware of local regional variations.
We collected data from the eyes that we had identified
as having had laser peripheral iridotomy (PI), and so we
could only comment on these eyes. For our routine clinical
practice we had developed a standardized protocol based
on the best available information available to us, so that
we could manage these patients in a consistent manner.
AS-OCT findings, particularly when the scleral spur was
difficult to localize, are always viewed in the context of the
gonioscopic appearance. Occasionally, widespread adhe-
sion of the anterior iris to the scleral spur and posterior
trabecular meshwork (sometimes referred to as ‘creeping
angle closure’), resembled open angles on AS-OCT when
the spur was unidentifiable. Some of the time, angles
that appeared to stay open on gonioscopy were obviously
occludable in darkness using AS-OCT, as has previously
been described.3 More often, angles that appeared signifi-
cantly closed in darkness on gonioscopy were safely open
in many AS-OCT images of at least two of the cardinal
meridia; so in an eye that was symptomless and otherwise
normal the AS-OCT saved the patient from unnecessary
treatment, if not follow-up. We therefore view anterior
chamber angle imaging as a very useful adjunct; in much
the same way that posterior segment OCT is useful for
assessing macular architecture.
In our cohort of patients, gonioscopic findings sup-
ported the use of PI, independent of the angle imaging
results, 69% of the time. We did not record how many
patients that were thought to require PI on gonioscopy but
subsequently had the need for PI refuted by AS-OCT; this
might be the topic of some future work. In the patients
who had PIs, 59% had gonioscopy performed by the refer-
rer prior to visiting our clinic that substantively agreed
with our gonioscopy findings. In our paper we chose
AS-OCT as a less subjective measure of the effect of laser PI
because of the inherent variability of angle assessment by
gonioscopy, particularly when performed by different
clinicians. Because the gonioscopy findings for the patients
in our study had not been recorded in a standardized
manner, we did not feel that we could include gonioscopy
in the analysis for our report. The importance of gonios-
copy was thus de-emphasized as a result.
We agree that at present, there is no evidence suggesting
that subjects with occludable angles detected only on
AS-OCT but not gonioscopically show significantly higher
rates of glaucomatous progression compared to subjects
without such findings. Our question is thus: what would
you do for such a patient who has confirmed appositional
angle closure on AS-OCT but not on gonioscopy? Would
you really wait until glaucoma progression has occurred or
until gonioscopy demonstrates occludable angles first
before performing PI, thereby incurring the extra costs of
additional follow-up visits and worry for the patient?
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Diabetic retinopathy in Australian
Aboriginal peopleceo_2430_1 185..195
It is with much interest that I read the paper by Antony
Clark and co-workers that reports the findings of multiple
visits to the Eastern Goldfields in Western Australia and
documents their findings over a 12-year period.1 This work
is highly commendable although of course it does miss
many of the Aboriginal communities in the north-eastern
part of their area. Overall, they examined some 920 people
over the age of 16 out of a population in excess of 4000 in
that age range. Nevertheless, their findings are useful and
important.
One area that does need correction is the very clear
statement by the National Health and Medical Research
Council Guidelines on diabetic retinopathy that Aboriginal
and Torres Strait Islander peoplewith diabetes need to have
their eyes examined on an annual basis.2,3 In their paper,
Clark and co-workers misquote this as recommendation to
be seen within 2 years. The biennial examination is the
recommendation for mainstream Australia because of the
much better control of diabetes in mainstream.
Hugh Taylor AC MD FRANZCO
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Diabetic retinopathy in Australian
Aboriginal people: responseceo_2430_2 185..195
We thank Professor Taylor for his comments1 regard-
ing our paper.2 We presented 12 years of data from the
Goldfields Eye Health Survey which consisted of yearly
visits to the Eastern Goldfields Aboriginal communities
between 1995 and 2007. The survey represents one of the
longest running Aboriginal eye health initiatives in Aus-
tralia and allows a unique insight into Australian
Aboriginal eye health over time that cannot be gleaned
from cross-sectional community surveys. Although we
did not examine all of the over 4000 Aboriginal people
living in the region, we do feel that the 920 seen com-
prised at least the major proportion of those with vision
problems or who were diabetic.
Our yearly visits to Aboriginal communities in the
Eastern Goldfields region are in line with the frequency
of eye examination for Aboriginal people with diabetes
recommended in the National Health and Medical
Research Council Guidelines on diabetic retinopathy.3,4
We should clarify that in commenting upon the poor
follow-up of those Aboriginals examined it was our
intention to emphasize this by comparing follow-up
to the minimum standard for the general Australian
population (2 years). That only 47.9% of those with
diabetes were seen again within 2 years falls vastly short
of the minimum recommendation for even the general
Australian population. We did not intend to imply that
the recommended screening interval for Aboriginal and
Torres Strait Islanders be 2 years and appreciate the
opportunity to provide further clarification.
Our data were collected in consistent, low-cost
manner over many years and demonstrates the utility of
creating a prospective Aboriginal eye disease registry.
This is particularly important for diabetes, where
retinal disease grades can be stored and retrieved. A
national or state-wide scheme storing retinal photograph
and/or clinical examination scores, dates and locations
would be a cost-effective way to check individual
follow-up status, disease severity as well as trends in
disease.
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Coordination is the key to the
efficient delivery of eye care
services in indigenous communities
There are some shining examples of the effective delivery
of eye care in Australia. By studying these one can identify
components critical to their success and make sure these
components are incorporated in other programmes to
achieve similar high levels of efficiency.1 The key compo-
nent is good coordination and this needs to occur at mul-
tiple levels. Good coordination improves the experience of
the patient, the community, the health-care provider and
the health system. It is also more efficient as everyone
works together to ensure that the patients actually turn up
and receive the care they need.ceo_2431 186..196
Coordination may mean different things to different
people and it can cover a range of activities such as man-
agement, communication, facilitation, cooperation and
integration. The linkages and inclusive approach that good
coordination provides makes the real impact.
The current model for the provision of eye care
involves Regional Eye Health Coordinators (REHC) that
were introduced after the 1997 Taylor Report.2 The
recommendation for establishing Aboriginal Eye Health
Coordinators was based on two successful models of
regional coordination, one in far north Queensland and
the other in the Pilbara. In each of these cases, there was
a senior, semi-retired nurse who acted as the coordinator
for the surgical visits of patients, the visits of the oph-
thalmologist, optometrist or eye team, and coordinated
these with the Aboriginal Medical Services (AMS). These
people worked at quite a high level and made sure that
the visiting eye services actually worked. The 1997
Report recommended that these regional coordinators
would be jointly responsible to the AMS, the state-run
hospital, the private ophthalmologist and the private
optometrist and ideally, the coordinator would be an
indigenous person. In its implementation this recommen-
dation was modified to provide funding to Aboriginal
Community Controlled Health Services to fund Aborigi-
nal Health Workers (AHW) who became REHC and were
firmly based in the AMS. Each of 37 or so regions was to
have an REHC, although some were never appointed and
at times many positions were vacant.
The roles and expectations for REHC have expanded
enormously and it has become impossible for any single
person to manage all the tasks now encompassed in this
role. In some areas particularly committed and persistent
REHC have selected a limited number of functions from
within this large range and they have done that part of the
job very well and with great dedication. Others have just
quit or have seen their position disestablished. The aboli-
tion of these positions was made even easier when global
funding for the AMS was introduced after a review in
2003. Some REHC spend much of their time in the field as
clerks just filling out Medicare forms and forms for glasses.
In looking at these issues again it becomes clear that the
roles are too broad and they need to be reviewed and
redefined.
The first step in trying sort out the requirements for the
delivery of eye care is to go back to the basics about what
care should be provided where and by whom.
People skilled in primary eye care need to be available
at the community clinic level.
The staff in these clinics include General Practitioners,
nurses, and in many areas AHW who have some clinical
responsibilities. Each of these groups should have an
appropriate understanding of the requirements and their
roles in providing primary eye care.
The second level is the provision of specialist eye care in
a clinic setting. Secondary eye care may be provided by a
visiting eye team or by an existing stationary service, clinic
or practice depending on existing circumstances. Eye care
may be provided by optometrists and ophthalmologists
working together or separately, with or without other
support staff such as orthoptists.
The third level eye care would include cataract, laser
and other surgery. Patients requiring more specialized eye
care would be expected to be referred to a capital city or
regional centre for further management. This level of care
would be provided at the regional level, usually in a public
hospital. Staff would include ophthalmologists, nurses
and theatre staff, technical support staff and many others.
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question the NH&MRC guidelines rather than the optom-
etric practices of Australian optometrists. Member feed-
back suggests the general view of optometrists and many
ophthalmologists is that patients presenting with mild DR
without DME can be managed by optometrists and should
be referred in a timely fashion when the optometrist finds
referral necessary.
The association advises all optometrists to discuss man-
agement of patients with mild NPDR without DME with
their local (or visiting) ophthalmologist and to take advice
as to the appropriate management protocol in these cases.
Jared Slater BOptom and Joe Chakman BSc
Optometrists Association Australia, Melbourne,
Victoria, Australia
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Referral of diabetic macular
oedema by Australian
optometrists: response
We thank Slater and Chakman for their interest in our
survey.1
Given the interest and debate that was generated by our
findings, it is good to see that a further on-line survey has
been conducted. With the relatively low response rate of
26% it would be easy to over interpret their results. None-
theless, it is still worrying that 17% of optometrists would
not always refer a patient with diabetic macular oedema
for further assessment and treatment by an ophthalmolo-
gist even if they only had otherwise minimal non-
proliferative diabetic retinopathy.
This would indicate a critical deficiency of knowledge,
which is further reinforced by the fact that according to
Slater and Chakman, some optometrists may have misin-
terpreted our use of ‘not clinically significant’ as inferring
not needing referral. Further the fact that the National
Health and Medical Research Council guidelines on dia-
betic retinopathy2 had only been read by 65% clearly
demonstrates that more can and should be done to improve
the management and timely referral of patients with
retinopathy.
Like all health professionals, optometrists need to fully
embrace a culture of continuing education and quality
improvement. All relevant stakeholders need to foster con-
tinuing education and work to ensure all professionals
involved with diabetic retinopathy screening are suitably
informed.
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5.1. Key!findings!and!their!clinical!significance!Western!Australia!is! ideal!for!populationHbased!research!that!is!representative!of!Australia.!Despite!its!isolation!and!comprising!only!oneHtenth!of!the!national!population!it!is!among!the!three!jurisdictions!closest!to!the!eightHjurisdictional!average! in!all!but! two!socioeconomic!and!demographic! indicators! (proportion!privately! insured! and! per! capita! health! expenditure).! It! also! has! one! of! the!highest! proportions! of! the! population! who! are! Aboriginal,! making! it! better!suited! than! other! jurisdictions! to! populationHbased! research! involving!Aboriginal! health! issues.! In! comparing! the! population! profiles! of! Australia’s!State! and! Territory! populations,! researchers! are! better! able! to! determine! the!extent!to!which!contextual!issues!concerning!key!socioHdemographic!and!health!economic!indicators!may!affect!the!external!validity!of!research!results!arising!from! any! one! jurisdiction.! These! findings! lend! support! to! the! notion! that! any!key!findings!arising!from!this!thesis!are!externally!valid!to!the!wider!Australian!context.!The! major! projects! presented! in! this! thesis! encompass! six! broad! themes!concerning! blinding! eye! diseases! in! WA! i.e.! cataract! surgical! safety! and!outcomes,!ARMD!medication!safety/postHmarketing!surveillance,!epidemiology!of!blindness,!Aboriginal!and!remote!eye!health,!diabetic!retinopathy!screening!and!management,!and!quality!of!life.!In!carrying!out!these!projects!the!strengths!and! limitations! in!using!hospital! administrative!data! for!health! research!were!explored,!as!well!as!alternative!methodologies!that!may!augment!or!supplement!the! information!available! in! them.!The!major! findings! from!these!projects!will!now!be!discussed.!
Cataract!surgery!complications!A!significant!part!of!this!thesis!was!dedicated!to!understanding!the!trends!and!impact!of!blinding!complications!of!cataract!surgery!in!WA.!Cataract!surgery!is!one!of!the!most!common!operations!performed!in!WA!and!rates!have!increased!linearly! over! the! study! period.! Patients! may! continue! to! be! reassured! that!cataract! surgery! is! safe! H! less! than!1%!of!procedures! result! in!a! serious!sightHthreatening! complication! in!WA.! The! trend! is! towards! improving! safety! since!
103!
the! transition! to! phacoemulsification! from! ECCE,! where! the! rate! of!postoperative!complications!has!declined!by!over!70%!over!21!years.!!Retinal! detachments! are! the! most! common! serious! complication! (5Hyear!cumulative! incidence! 0.63%)! and! have! not! been! affected! adversely! by! the!transition! to! phacoemulsification! from! ECCE! (RR=1.00,! 95%! CI! 0.82H1.23).!Significant! populationHbased! risk! factors! for! the! occurrence! of! retinal!detachment!after!phacoemulsification!in!particular!were!male!gender,!younger!age,!and!anterior!vitrectomy!being!performed!during!cataract!surgery.!!!Wound! dehiscence! is! predictably! far! less! common! since! the! introduction! of!small! incision!phacoemulsification! surgery!with! rates!nearly!oneHtenth!of! that!seen! in! ECCE! (RR=0.12.! 95%! CI! 0.08H0.18).! Dropped! nucleus! is! still! rare! but!increased!significantly!when!phacoemulsification!was!introduced!(IRR=1.74!for!each!5!year!period! since!1990!95%CI!1.16H2.63)! for!both!phacoemulsification!and!ECCE.!While! IOL!dislocations!were!uncommon,!rates!have!almost!doubled!during! 1985! to! 2001! (0.17! to! 0.30! per! 1,000! procedures),! which! warrants!further! scrutiny.! Pseudophakic! corneal! oedema! is! very! uncommon! and! has!declined!significantly.!The!rate!of!complicated!cataract!surgery!needing!anterior!vitrectomy!has!also!declined!since! the!1980s!and! is!a!good! indication!of! improved!surgical! safety.!Major! risk! factors! for! its! occurrence!were!older! or! younger! age,!male! gender,!and! surgery! performed! in! public! and! rural/remote! hospitals.! The! risk! for!serious! sightHthreatening! complications! is! increased! significantly! if! it! occurs,!particularly!for!retinal!detachment!and!IOL!dislocations.!The!degree!to!which!these!serious!complications!may!impact!quality!of!life!was!explored! in! postoperative! endophthalmitis! patients! and! was! one! of! the! first!studies!to!do!so.!Postoperative!endophthalmitis!causes!a!significant!reduction!in!quality! of! life! across! multiple! domains! in! three! validated! quality! of! life!instruments.! This! most! significant! in! the! National! Eye! Institute! VFQH25! tool!where!patients!reported!a!significant! impact!on!general!vision,!near!activities,!mental! health,! role! difficulties! and! peripheral! vision.! This! information! is!particularly! important! since! it! demonstrated! the! added! burden! of! serious!
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adverse!cataract!surgery!outcomes!beyond!what!can!simply!be!reported!using!health!administrative!data.!!!The!body!of!knowledge!regarding!cataract!surgery!complications!generated!in!this!PhD!arms!ophthalmic!surgeons!in!WA!and!wider!afield!with!the!information!to! appropriately! counsel! their! patients! regarding! the! likely! risk! of! a! serious!complication! during! and! following! their! cataract! surgery.! It! also! supports!clinical!decision!making!by!allowing!them!to!identify!which!of!their!patients!are!at!particularly!high!risk!for!a!serious!complication!during!and!following!surgery!(like! retinal! detachment)! and! to! monitor! those! patients! accordingly! in! the!postoperative!period.!While!serious!complications!are!rare!and!becoming!even!more! so,! large! numbers! of! surgeries! mean! even! rare! complications! have! the!potential!to!cause!significant!visual!morbidity!in!the!community.!It!is!therefore!imperative! to! continue! to!monitor! and! improve! the! safety! of! cataract! surgery!(particularly! with! the! advent! of! new! technologies! into! the! future)! if! this!morbidity!is!to!be!minimised.!
PostCmarketing!surveillance:!antiCVEGF!for!ARMD!While! procedures! such! as! cataract! operations! are! well! coded! in! hospital!administrative! databases,! offHlabel! medications! are! not.! This! study!demonstrated! the! utility! of! adhoc! linkage! of! clinic! electronic!medical! records!and! registries! to! administrative!data! to! study! rare! adverse!outcomes!of!novel!treatments.!The! introduction! of! intravitreal! antiHVEGF! for! WA! patients! with! neovascular!ARMD!has!revolutionised!their!care!without!having!a!major!impact!on!their!risk!of! thromboembolic! events.! The! risk! of! stroke! or! gastrointestinal! bleeding!associated!with! intravitreal! antiHVEGF! use! is! not! significantly!more! than! that!seen! in! the! community! and,! while! the! rate! of! myocardial! infarction! is! over!double!seen!in!community,!the!absolute! increase!in!risk!remains! low!(1.9%!vs!0.7%).!On!a!wholeHpopulation!level,!the!widespread!uptake!of!antiHVEGF!treatment!for!neovascular! ARMD! (and! more! recently! for! vein! occlusion! and! diabetic!maculopathy)! has! the! potential! to! produce! a! significant! additional! burden! for!the!WA!health!system!due!to!the!increased!number!of!myocardial!infarcts.!This!
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must! be! weighed! against! its! effectiveness! as! the! only! treatment! to! slow! or!prevent! blindness! that,! on! an! individual! level,! potentially! outweighs! the!relatively! small! increased! risk! of! heart! attack.! However,! as! newer! agents! are!developed,!then!comparing!the!risk!of!adverse!thromboembolic!events!between!these!agents!will!become!more!important!in!guiding!patient!safety.!
The!epidemiology!of!blinding!eye!disease!EBEDS! has! taught! us! a! great! deal! about! blindness! in! WA.! CaptureHrecapture!methodology!has!proven! itself! to!be!useful! in!providing!a! reasonably! efficient!and!costHeffective!way!to!estimate!blindness!prevalence!in!the!community.!We!estimated! 3,384! (95%! CI! 2,247! to! 3,983)! or! 0.15%! of! the! population! were!legally! blind! in!WA! at! 30th! September! 2009.! Our! results! were! comparable! to!those!from!other!Australian!populationHbased!surveys!H!the!Blue!Mountains!Eye!Study! and! the! Melbourne! Vision! Impairment! Project,! which! found!approximately!0.5%!of!those!aged!50!years!or!older,!were!blind.13,15!!These!findings!demonstrate!that!government!and!community!support!agencies!are! unaware! of! a! significant! proportion! of! those!who! are! legally! blind! in! the!community.!Our!number!exceeded! the!number!of!people! in!WA!registered! for!the!blind!pension!or!registered!with!the!Association!for!the!Blind!(ABWA)!–!the!states! only! provider! of! vision! rehabilitation! and! support! services.! ABWA!maintains!a!large!(n=4,272)!dataset!of!vision!impaired!and!legally!blind!people!in!WA!that!is!reasonably!precise!for!identifying!legal!blindness!(sensitivity!75%,!specificity!60%)!and!with!reasonable!diagnostic!accuracy.!Yet!only!40%!of!those!legally! blind! are! registered!with! the! service,! leaving! 60%! of! the! legally! blind!community! in!WA!without! rehabilitation! support.! Aboriginals! were! even! less!likely!to!be!represented!with!only!17!actually!registered!despite! large!surveys!suggesting!1.9%!of!the!Aboriginal!population!are!likely!to!be!legally!blind.323!Blindness! is! important! since! we! found! that! it! results! in! more! hospital!admissions;! longer! hospital! stays,! and! increased! mortality! for! those! children!and!working!age!people!in!WA!who!are!blind.!Blindness!is!also!associated!with!a!significant!reduction!in!quality!of! life!with!the!greatest!reduction!at!the!cutHoff!to!legal!blindness!(logMAR!>1).!!
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The!development!of!a!validated!blind!register!that!is!inclusive!of!the!majority!of!blind! people! in!WA! is! a! future! goal! and!would! provide! a! useful! resource! for!further! linked! data! studies.! Ongoing! linkage! with! the! WADLS! would! allow! a!hard!endpoint!be!identified!in!blinding!eye!diseases!and!also!the!study!of!health!outcomes! of! the! blind! cohort.! This! would! have! particular! relevance! to! the!evaluation!of!rehabilitation!services!provided!by!ABWA!and!others!for!the!blind!and!vision!impaired.!
Australian!Aboriginal!Eye!Health!EBEDS!taught!us!that!the!blind!Aboriginal!population!are!poorly!represented!in!the!ABWA!register!and,!even!with!captureHrecapture!methods;! the!vastness!of!WA! makes! identifying! them! difficult.! Data! collected! during! the! clinics! of! the!eastern! Goldfields! eye! health! survey! provided! a! unique! opportunity! to! better!understand! the! causes! and! patterns! of! vision! loss! in! these! communities,! and!particularly! diabetic! retinopathy.! The! results! indicated! that! the! state! of! eye!health!in!Aboriginals!from!the!remote!eastern!Goldfields!region!of!WA!remains!a!concern.! !The!top!three!causes!of!vision! loss! in!these!communities!(cataract,!diabetic! retinopathy,! and! refractive! error)! are! preventable! and/or! readily!treated.! We! should! not! still! be! seeing! cataractHrelated! blindness! (30%! of! all!blind! eyes! in! the! survey),!which! combined!with! high! rates! refractive! error! in!these! communities! points! to! significant! barriers! in! access! to! ophthalmic! care.!Diabetes! in! particular! has! a! significant! association! with! vision! loss! and!blindness,!yet!screening!of!diabetics!in!these!communities!remains!suboptimal.!Of!some!reassurance!in!this!survey!was!the!low!level!of!trachomaHrelated!vision!loss!–!although!this!particular!survey!didn’t!capture!the!current! level!of!active!trachoma!in!the!community.!Findings! from! this! survey!were! presented! to! local! ophthalmologists! and! also!nationally!and!supported!the! impetus!for!change.!Since!publication,!significant!changes! to! the! delivery! of! ophthalmic! care! have! occurred! culminating! in! the!development!of!the!Lions!Outback!Vision!initiative!in!2010.!This!initiative!was!established! in! response! to! the! recognised! inadequacy!of! eye! care!provision! in!remote! WA! indigenous! communities! with! the! specific! aim! to! address! the!
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“unique! challenges! of! delivering! quality! specialist! eye! health! care! to! regional,!remote!and!Indigenous!communities!across!the!state”.364!!
Diabetic!retinopathy!screening!and!management!practices!This! national! survey! provided! important! insights! into! the! state! of! eye! care!provided!by!ophthalmologists,!optometrists!and!GPs!across!the!country!for!the!rapidly!growing!population!of!diabetics!Australia.!There!is!a!declining!trend!in!the! desire! of! ophthalmologists! and! GPs! to! participate! in! community! diabetic!retinopathy! screening.! GPs! lack! the! confidence! to! detect! signs! of! diabetic!retinopathy!and!don’t!have!the!time!to!perform!a!dilated!retinal!exam,!despite!a!good! level! of! knowledge! regarding! appropriate! screening! and! management!protocols.!Optometrists!demonstrated!the!greatest!motivation!for!screening,!are!better! equipped! than!GPs! in! being! able! to! provide! this! service,! and! are!more!confident!in!detecting!signs!of!diabetic!retinopathy.!However,!further!education!is!needed!to!improve!knowledge!among!optometrists!since!overHscreening!and!underHreferral! is! an! issue.! Of! most! concern! was! that! the! majority! of!optometrists! aren’t! confident! in! detecting! macular! oedema! and! a! significant!proportion! reported! they! (inappropriately)! do! not! refer! macular! oedema! for!ophthalmology!review.!Ophthalmologists!generally!adhere!well!to!best!practice!guidelines! for! screening! and! management! of! diabetic! retinopathy.! Areas! for!improvement!included!overHscreening!of!preHpubertal!diabetics!and!overHuse!of!fluorescein! angiography.! Those! who! were! further! from! their! training! years!were!most!likely!to!deviate!from!best!practice!guidelines.!Feedback!of!these!findings!to!the!optometry,!ophthalmology!and!GP!community!included!publication! in!national!medical! journals,! presentation!at! the!national!ophthalmology! college! congress,! and!media! releases! in! the! optometry! and!GP!communications.! The! optometry! findings! in! particular! stimulated! discussion!within! the! optometry! community! where! there! was! consideration! for! further!education.!
5.2. Strengths!and!limitations!The!strengths!and!limitations!specific!to!the!individual!studies!are!discussed!in!greater! detail! in! the! discussion! section! of! each! of! the! papers.! The! following!
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provides! a! discussion! of! the! broad! strengths! and! limitations! of! the! work!presented!in!this!thesis.!A! significant! portion! of! this! research! was! populationHbased,! using! large!administrative! databases! from! a! stable,! isolated! population! that! is!representative! of! Australia.! This! ensured! large! sample! sizes,! almost! complete!case!ascertainment!with!minimal!loss!to!followHup!within!the!state,!and!findings!that! were! externally! valid! to! the! widerHAustralian! context.! The! large! sample!sizes!were!essential!for!studying!rare!events!i.e.!cataract!surgery!complications!and! thromboembolic! events! after! antiHVEGF! treatment! particularly! when!multiple! risk! factors!were! examined.! They! allowed! large!multivariate!models!that! controlled! for! multiple! risk! factors! and! potential! confounders!simultaneously.!The! limitations! of! studies! using! administrative! databases! relate! to! their!retrospective! observational! design,! the! effect! of! confounding! by! variables! not!present! in! the!databases! or! not! accounted! for! in! the! analysis! (e.g.!medication!use,!lifestyle!factors,!ocular!biometry)!and!issues!with!quality!data.!These!issues!were!discussed!in!greater!detail!in!Chapter!1.!Perhaps!the!greatest!limitation!of!administrative!databases!are!the!lack!of!clinical!detail!in!the!variables!recorded,!which!severely!limits!the!scope!of!clinical!questions!that!may!be!answered.!This!was! demonstrated! by! the! fact! that! both! projects! in! this! thesis! that! used!administrative!databases!required!some!form!of!data!validation!(e.g.!confirming!laterality)!or!additional!data!be!sought!(e.g.!type!of!antiHVEGF!given!or!cataract!surgery! operative! details).! This! also! slows! research! considerably,! particularly!when!chart!review!is!required.!The!cataract!surgery!complications!project!took!several!years!before!data!validation!was!complete!due! to! the!sheer!volume!of!charts!that!needed!manual!review.!To!strengthen!and!broaden!the!scope!of!the!clinical!story!of!eye!care!outcomes!in! WA! beyond! what! could! be! provided! in! administrative! data,! other!epidemiological!methods!were!explored.!Understanding!the!impact!on!quality!of!life! of! a! serious! complication! of! cataract! surgery,! such! as! postoperative!endophthalmitis! and! of! severe! vision! impairment,! is! essential! if! were! are! to!accurately! quantify! its! importance! beyond! a! fairly! superficial! focus! on! health!
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outcomes!as!they!relate!to!cost!and!health!service!utilisation.!Loss!of!quality!of!life! is! costly! and! through! calculation! of! utility! values! and!qualityHadjusted! life!years,!can!be!quantified.!!The! unique! survey! of! blind! and! near! blind! people! in! WA! allowed! the!development!of!a!well!validated!group!upon!which!to!conduct!further!studies!of!their! health! outcomes! and! service! utilisation.! The! captureHrecapture!methodology! used! to! provide! an! estimate! of! prevalence! of! blindness! in! WA!compared!favourable!with!results!from!large!Australia!crossHsectional!surveys.!It! demonstrated! this!methodology! to! be! an! efficient! and! cost! effective!way! to!estimate!blindness!prevalence.!!Clinical! surveys! also! offered! greater! insight! into! clinician! knowledge,! and!attitudes! regarding! diabetic! retinopathy! screening! and!management.! There! is!concern!among! some! that! the! focus!on!health!outcomes!as! a!driver!of!quality!care! neglects! the! ‘art’! of! medicine,! ignoring! the! inherent! uncertainty! and!vagaries! of! disease! that! clinicians! are! presented! on! a! daily! basis.365! Focusing!purely! on! research! utilising! administrative! databases! will! tell! us! what! was!actually!done!(to!an!extent)!but!tells!us!nothing!regarding!the!‘why’!or!‘why!not’;!nor! does! it! inform! us! about! a! clinicians! level! of! knowledge! or! understanding!that! underpins! their! practice.!While! we!may! easily! discover! where! there! are!deficiencies!in!care,!without!this!knowledge!it!is!not!possible!to!know!where!or!how!changes!could!be!made.!The!major!limitations!in!this!survey!were!selection,!reporting!and!recall!bias!that!limits!external!validity.!This!was!a!particular!issue!in! surveys! sent! to!general!practitioners!where! response! rates!were!very!poor!(21%).!Similarly,! data! from! the! clinical! register! of! the! eastern! Goldfields! eye! health!survey!provided!a!comprehensive!overview!of!the!state!of!diabetes!and!burden!of! vision! impairment! in! an! isolated,! vulnerable! population! otherwise! not!captured!in!routine!hospital!administrative!databases!in!WA.!The!long!duration!of!the!eye!health!survey!meant!that!those!with!vision!problems!and/or!diabetes!should! have! been! captured! at! least! once,! unlike! in! previous! crossHsectional!studies!in!Australia.!
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5.3. Research!translation!
5.3.1. Dissemination!of!research!findings!Research! arising! from! this! thesis! has! been! the! subject! of! a! comprehensive!dissemination! strategy! at! a! local,! national! and! international! level.! At! a! local!level,!this!has!involved!reporting!of!research!findings!to!WA!ophthalmologists!at!hospital! clinical! meetings! as! well! as! WA! Royal! Australian! College! of!Ophthalmologists! (RANZCO)! clinical! meetings.! In! addition! to! being! a! training!ophthalmologist!myself,! the! clinical! advisory! team!on! the! projects! comprising!the!thesis!are!local!ophthalmologists.!This!meant!there!was!a!direct!feedback!of!research! findings! to! the! local! clinical! ophthalmology! community! and! thus! a!direct!translation!into!clinical!practice.!This!has!facilitated!an!effective!and!rapid!completion!of!the!research!feedback!loop.!!At! a! national! level,! the! findings! from! these! projects! were! presented! at! the!RANZCO! annual! scientific! congresses! in! the! form! of! talks! and! poster!presentations.! Publication! of! these! findings! in! the! national! medical! journals!ensured! feedback! to! the! wider! Australian! medical! community.! While!internationally,!research!findings!were!presented!at! the!World!Ophthalmology!Congress!in!Hong!Kong!as!well!as!in!highHranking!international!ophthalmology!journals.!
5.3.2. Future!projects!The!expertise!developed! in! this! thesis! and! the! antiHVEGF!project! in!particular!will! support! a! new! study! to! evaluate! the! benefit! in! delaying! the! progressing!from! vision! impairment! to! blindness! associated! with! the! introduction! of! the!antiHVEGF! treatments! for! ARMD.! Linking! blind! registration! data!with! hospital!morbidity!and!mortality!data!will! allow! the! impact!of! treatment! for!ARMD!on!patient!morbidity!(e.g.!hospital!admissions,!falls)!and!mortality!to!be!measured.!In! doing! so,! the! cost! savings! produced! by! the! reduction! in! new! blind!registrations!can!be!quantified.!Other! promising! populationHbased!projects! that! have! arisen! as! a! result! of! the!knowledge! and! expertise! generated! through! this! thesis! include! studies! of!glaucoma!and!crash!risk!through!linkage!of!automated!perimetry!(visual!field)!
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data!with!hospital!morbidity!and!road!traffic!datasets;!trends!in!eye!care!service!utilisation! through! the! linkage! of! outpatient! eye! clinic! attendance! data! with!hospital! attendances;! and! the! populationHbased! risk! for! retinal! detachment! in!WA.!An!exciting!and!promising!application!of!data! linkage! techniques! is! the!use!of!Australia’s! Commonwealth! health! datasets! for! health! research.! Two! major!datasets! include! the!Pharmaceutical!benefits! scheme!(PBS),!which! includes!all!prescriptions!funded!by!the!federal!government;!and!Medicare,!which!includes!patient! attendances! to! general! practice! and! specialist! clinics! outside! of! public!hospitals.! Three!major! projects!were! initially! conceived! as! part! of! this! thesis:!one! project! to! identify! and! describe! the! WA! glaucoma! population! and! their!treatment!trends!using!prescriptions!for!eye!drops!and!admissions!for!surgery;!another! to! describe! the! use! and! adequacy! of! diabetic! retinopathy! screening!using!Medicare!attendances!to!ophthalmologists!and!other!eye!care!providers;!and! the! third! to! characterise! the! trends! in! eye! care! services! utilisation! using!Medicare! data! from! attendances! to! eye! care! providers.! However,! despite! a!memorandum! of! understanding! being! in! place! between! the! WALDS! and! the!Commonwealth!agencies!involved,!there!were!lengthy!delays!and!eventually!an!inability!of!the!Commonwealth!to!supply!the!data!for!these!projects,!and!so!they!could!not!be!completed.!These! projects! still! represent! important! health! priority! areas! for! ophthalmic!research! in!Australia.!There! is!also! the!potential! to! support!a!vast!program!of!ophthalmic! research! through! data! integration! processes! into! areas! that!determine!social!and!economic!determinants!of!health!such!as!educational!and!welfare!records.!The!impact!of!ophthalmic!disease!on!other!health!outcomes!e.g.!injury!and!mental!health!may!be!usefully!assessed!with!data!integration.!!The!expertise!in!populationHbased!health!research!developed!during!this!thesis!along!with! the!establishment!of! the!PHRN! is! a!promising! step! towards! seeing!these!projects!to!fruition.!!
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5.3.3. Automating!data!collection!and!extraction!
The!electronic!cataract!audit!tool!(eCAT)!The! ability! to! undertake! populationHbased! research! that! supports! realHtime!monitoring!of!adverse!outcomes!and!trends!in!disease!in!a!timely!manner!is!an!exciting! reality! for! the! future!of!health! research.!This! can!be!attributed! to! the!methodologies! developed! to! analyse! very! large! preHexisting! datasets.! The!implementation!of!the!eCAT!system!(Appendix!3)!in!hospitals!across!WA!will!be!instrumental! in! facilitating! populationHbased! monitoring! of! cataract! surgery!outcomes!in!a!timely!fashion!by!facilitating!the!collection!of!more!accurate!and!complete! cataract! surgery! data.! Automated! integration! with! the! WADLS! is!envisioned! for! the! future! and! will! eliminate! the! time! and! costs! required! for!chart! review! and! pave! the! way! for! outcomes! research! that! is! more!contemporary!and!thus!more!relevant!for!the!ophthalmology!community.!The! system! is! currently! available! for! use! in! all! public! hospitals! (the! major!tertiary!hospitals!have!mandated! its!use)!and!a!major!private! facility! in!Perth!has! also! adopted! the! system.! The! next! phase! of! the! project! will! be! the!development!of!preH!and!postHoperative!modules!that!will!add!further!utility!to!the!system.!Its!success!has!lead!to!interest!from!clinicians!in!subHspeciality!areas!to!develop! similar!modules! to! address!operations! in! their! areas!e.g.! glaucoma!surgery!or!retinal!detachment!surgery!since!the!eCAT!system!is!flexible!enough!that!it!can!feasibly!be!adapted!to!any!ophthalmic!procedure.!The! future! vision! for! the! eCAT! system! is! to! provide! real! time! reporting! of!complication! risk! and!monitoring! of! risk! events! for! timely! surgeon! feedback.!Analysis! already! undertaken! on! cataract! surgery! complications! in! WA! since!1980! provides! a! robust! dataset! that! allows! calculation! of! prior! probabilities!upon!which!Bayesian! techniques!may!be! applied! to! generate! risk!models! and!upon!which!real!time!reporting!of!complication!risk!may!be!achieved.366!
Clinical!registries!Purpose! built! clinical! registries! aggregated! by! scraping! data! from! electronic!health! records! (EHR)! offers! a! practical! and! efficient! solution! to! address!limitations!in!hospital!administrative!data!and!traditional!clinical!registries.!For!example,!the!American!Academy!of!Ophthalmology’s!newly!commissioned!IRIS!
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Registry! (Intelligent! Research! in! Sight)! offers! the! promise! of! a! national!comprehensive!eye!disease!register.!It!is!designed!to!assist!in!delivering!quality!patient!care!through!measuring!and!reporting!outcomes!and!benchHmarking.367!A!breakthrough!in!the!design!of!the!registry!was!its!integration!with!physician!EHR!that!avoids!disruption!of!physician!workflow!and!duplicate!data!entry!that!are! major! barriers! to! the! implementation! and! ongoing! success! of! clinical!registries.367! In! Australia,! there! needs! to! be! a! greater! political! imperative!coupled!with!improved!design!and!ergonomics!of!EHR’s!to!see!their!use!expand!throughout! the! wider! ophthalmic! community! and! achieve! what! is! being!attempted!in!the!US.!Methods!are!also!required!to!utilize!the!existing!information!held!electronically!as!text!files!outside!modern!HER,!as!there!is!a!huge!amount!of!legacy!data!stored!since!the!advent!of!wordHprocessors!(e.g.!consultation!letters).!That!information!would! provide! further! important! historical! data! to! assess! trends! in! diagnosis!and! management.! Such! techniques! may! also! enable! integration! of! written!reports!from!other!areas!such!as!pathology!and!radiology.!
The!‘Big!Data’!revolution!As! more! data! sources! are! created! and! data! integration! process! allows! the!linkage!of!multiple!data!sources,!then!the!volume!of!data!available!for!research!will!continue!to!grow.!This!begs!the!question!H!how!do!you!then!deal!with!such!massive! amounts! of! data! so! called! “Big! data”.! Big! data! methodologies! being!developed!allow! the! efficient! study!of! large!databases!using!machine! learning!algorithms!that!offer!the!promise!of!better!predictive!models,!the!ability!to!deal!with! nonHvalidated! ‘dirty’! data! without! the! need! for! comprehensive! data!cleaning,!and! faster!computing!with!more!data.368! It!offers!a!practical!solution!that!best!capitalises!on!the!vast!volume!of!data! likely!to!be!generated!as!more!EHR! and! clinical! registries! come! online.! Developing! greater! expertise! in! this!area!for!health!will!be!imperative!if!we!are!to!take!full!advantage!of!the!benefits!that!may! be! delivered! through! big! data! trends! currently! occurring! outside! of!health.!
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5.4. Personal!and!professional!development!
5.4.1. Professional!development!This!PhD!programme!has!equipped!me!with!the!skills!and!maturity!necessary!to!go!on!to!further!develop!my!interests!in!clinical!research.!On!a!practical!level!I!have! gained! expertise! in! developing! comprehensive! research! protocols! and!proposals,!interacting!with!human!research!ethics!bodies!to!ensure!research!is!carried! out! in! an! ethical! way,! performing! complex! analysis! of! large!administrative!datasets,!and!the!development!of!grant!applications!for!funding!of!ongoing!research.!I!also!undertook!several!courses!to!assist!in!my!statistical!analysis! skills! including! introductory! and! advanced! courses! in! the! analysis! of!linked! health! data,! a! unit! in! biostatistics,! and! a! course! in! data! management!using!SAS!software.!!
5.4.2. Clinical!training!During!the!PhD!programme!I!completed!my!clinical!training!in!ophthalmology.!The! knowledge! gained! through! the! projects! comprising! this! PhD! has! helped!shaped!my!clinical!practice!by!providing!the!evidence!base!necessary!to!support!my! dayHtoHday! clinical! decisions.! For! example,! using! knowledge! of! cataract!surgery!complications!in!WA!I!am!better!able!to!inform!patients!regarding!their!specific! risk! for! adverse! events;! while! I! have! a! better! understanding! of! the!unique!eye!health!challenges! facing!our!blind!and!our! local! remote!Aboriginal!populations.!Similarly,!the!clinical!knowledge!developed!during!clinical!training!has! contributed! to! shaping! the! thesis,! particularly! in! my! understanding! of!cataract! surgery! outcomes! and! in! contextualising! the! importance! of! the!research.!For!example,!‘dropped!nucleus’!is!not!simply!a!word!in!a!table,!for!me!it!is!an!88HyearHold!grandmother!of!15!with!pseudoexfoliation!who!spent!many!days!of!her!life!in!an!ophthalmology!clinic,!undergoing!multiple!procedures!due!to! her! complicated! cataract! operation! that! left! her! legally! blind.! Through!my!clinical!work!I!am!also!better!able!to!identify!the!gaps!in!our!clinical!knowledge!and!thus!direct!my!future!research!interests.!
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5.4.3. Vision!for!the!future!As!I!write!the!final!words!in!this!thesis!I!look!towards!a!new!phase!in!my!career.!I! have! commenced! a! yearHlong! clinical! fellowship! in! glaucoma! and! anterior!segment! surgery! in! Toronto,! Canada;! and! will! follow! this! with! another! in!paediatric! ophthalmology.! My! vision! is! to! continue! on! with! my! research!interests! in!ophthalmic!epidemiology!and!outcomes!research!whilst! in!Canada!and!foster!collaborative!links!with!researchers!in!Canada!that!I!may!nurture!on!return!to!Australia.!While!I!will!maintain!my!strong!commitment!to!clinical!ophthalmology!I!would!like!to!see!my!clinical!practice!complemented!and!rounded!off!with!a!productive!research! portfolio.! This! would! include! working! within! the! framework! of! our!current! collaborative! research! team! in! WA! as! part! of! the! eye! and! vision!epidemiology! research! group! (EVER! group).! I! can! envision! the! EVER! group!developing! further! as! an! enthusiastic! group! of! engaged! clinicians! and!researchers!interested!in!ophthalmic!epidemiology.!I!would!like!to!support!the!EVER! group! collaboration! develop! further! into! a! research! body! that! supports!research! fellows,!higher!degree!by!research!students!and!other!clinicians!with!an! interest! in! epidemiology;! while! allowing! it! to! be! productive! in! securing!competitive! research! grants! that! allow! us! to! undertake! internationally!competitive!research.!I!see!a!real!need!for!ongoing!research!into!surgical!outcomes!in!ophthalmology!and! in! particular! the! development! of! realHtime! monitoring! of! outcomes! and!adverse!events.!We! rely! too!heavily!on!published! studies,! often!of! events! that!have!occurred!years!ago!somewhere!else.!The!future!of!health!is!in!EHR!and!we!in! WA! are! well! placed! to! take! advantage! of! this! changing! tide,! particularly!through!the!work!we!have!already!achieved!in!this!area.!I!would!personally!like!to!see!a!future!whereby!surgeons!are!able!to!understand!exactly!where!they!are!in!terms!of!their!surgical!outcomes!within!a!legal!and!political!framework!that!fosters!a!‘noHblame’!policy!and!supports!reflective!selfHimprovement.!To!achieve!this! in! ‘realHtime’,! simply! at! the! touch! of! a! button! is! now! a! more! achievable!reality! with! big! data! techniques.! I! suspect! the! greatest! challenge! won’t! be! in!
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developing! the! appropriate! techniques! and! infrastructure,! but! rather! in!developing!the!legal!and!political!framework!that!supports!it.!This!thesis!has!only!explored!the!tip!of!a!very!large!iceberg!that!represents!the!future!possibilities!for!big!data!in!ophthalmic!research.!I’m!excited!to!be!a!part!of!the!drive!that!will!see!us!make!best!use!of!existing!data!for!outcomes!research!that!will!improve!our!dayHtoHday!clinical!practice!in!a!meaningful!way.! !
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HUMAN RESEARCH ETHICS COMMITTEE (DOHWA HREC) AHEC EC00422 
Postal Address: 
Executive Officer    
DOHWA HREC ph: (08) 9222 4278 
1st Floor ‘C’ Block fax: (08) 9222 4236 
189 Royal Street  e-mail: HREC@health.wa.gov.au  
EAST PERTH  WA  6004  http://www.health.wa.gov.au/healthdata/hrec/ 
 
 
Prof James Semmens  
Curtin University Innovation Research Institute 
Curtin University of Technology 
GPO Box U1987 
PERTH WA 6845 
 
 
Dear Prof Semmens 
 
Project #2011/18 
Endophthalmitis and the Complications of Cataract Surgery 1980 to 2008 
 
Date of commencement: 01/03/2011 
Date of completion: Ongoing 
Research Team: Prof James Semmens Dr Antony Clark 
 Dr Nigel Morlet  Dr Jonathon Ng 
 Dr Katrina Spilsbury  Ms Julie Crew 
 Ms Patricia Barett  Mr Syed Mukhtar 
 Delia Hendrie  Dr William Tjhin 
 Emily Stanton  A/Prof Bill Morgan 
 Dr Tina Khanam  Dr Daniel Ting 
 Dr Charlotte McKnight Dr Wayne Reynolds 
DOH data required: Yes  
Data linkage required: Yes 
Datasets to be accessed: Hospital Morbidity;  Mortality 
Date of Ethical Review: 13/04/2011 
Ethics approval validity: 13/04/2015 (4years) 
 
I am pleased to advise that the Committee has granted ethical approval for this project.  
 
This letter constitutes Ethics Approval only; you will not receive the data requested for 
your project until approval for the release of these data is signed by the Department of 
Health WA Director General's delegate.  
 
This approval is subject to your continued compliance with the following conditions: 
! DOHWA HREC holds the Principal Investigator responsible for the ethical conduct of the 
project and the security of the personal health information therefore he/she must – 
1. Report anything which might warrant review of ethical approval of the project in 
the specified format including: 
" Any serious or unexpected adverse events. 
" Unforeseen events that might affect the continued ethical acceptability of the 
project. 
" Submit for approval any changes or amendments to the research protocol, 
including methodology, data required, duration of the project and any changes 
to the approved data storage arrangements. 
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DOHWA HREC is constituted and operates in accordance with the National Health and Medical Research Council’s 
(NHMRC) ‘National Statement on Ethical Conduct in Human Research’. Applications are also reviewed for 
compliance with the Department of Health WA ‘Practice Code for use of personal health information’. 
2. Advise if the project is discontinued or withdrawn before the expected date of 
completion and give reasons for this action. 
3. Provide an annual progress report to the HREC and a final report at the completion 
of the project. 
4. Advise any changes of personnel in the research team, and provide a DOHWA 
Confidentiality Agreement/Confidentiality Acknowledgement form for any addition 
to the research team. 
 
We wish you well with your project. 
 
Yours sincerely 
 
 
 
 
 
 
Dr Judyth Allen 
Chair 
Department of Health WA Human Research Ethics Committee 
 
19 April 2011 
 
Cc   Dr Antony Clark  
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Research Ethics 
Research Services 
M459 
 
35 Stirling Highway, Crawley, WA  6009 
Telephone:  (08) 6488 3703 
Facsimile:    (08) 6488 8775 
Email:  kkirk@admin.uwa.edu.au 
http://www.research.uwa.edu.au/human_ethics 
 
 
Our Ref. RA/4/1/2217 10 December 2008 
 
 
Dr D Preen 
School of Population Health - M431 
UWA 
 
 
HUMAN RESEARCH ETHICS COMMITTEE 
 
 
Project: Does treatment of age-related macular degeneration with intravitreal 
injection of vascular endothelial growth factor inhibitors increase arterial 
thromboembolic events? 
 
 
Please be advised that ethical approval of the above project has been granted by the Human 
Research Ethics Committee. 
 
The Committee is bound by NHMRC Guidelines to monitor the progress of all approved projects 
until completion to ensure that they continue to conform to approved ethical standards. 
 
The committee requires that all Chief Investigators report immediately anything that might affect or 
impact upon ethical approval of the project, including adverse events affecting subjects. 
 
Approval should be sought in writing in advance for any amendments to the original application.  
You are also required as a condition of this approval to inform the Committee if for any reason the 
research project is discontinued before the expected date of completion. 
 
A report form for completion will be sent to you twelve months from this date or one month after your 
indicated completion date. 
 
Please note that approval has been granted for a period of four years.  Initial approval is for a 
period of one year, and, thereafter for future periods of one year at a time subject to the 
receipt of satisfactory annual reports.  At the end of the four-year period you will be required to 
complete a new "Application to Undertake Research Involving Human Subjects" should you wish to 
continue with your research.  However, in special circumstances, the Chair has the authority to 
extend the approval period in order to complete a project.  Failure to submit a final report may 
result in delays for future applications. 
 
Please quote Project No RA/4/1/2217 all correspondence associated with this study. 
 
Yours sincerely 
 
 
KATE KIRK 
Executive Officer 
(Human Research Ethics Committee)
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HUMAN RESEARCH ETHICS COMMITTEE (DOHWA HREC) AHEC EC00422 
Postal Address: 
Executive Officer    
DOHWA HREC ph: (08) 9222 4278 
1st Floor ‘C’ Block fax: (08) 9222 4236 
189 Royal Street  e-mail: HREC@health.wa.gov.au  
EAST PERTH  WA  6004  http://www.health.wa.gov.au/healthdata/hrec/index.cfm  
 
 
Dr David Preen 
Director, Centre for Health Services Research 
School of Population Health (M431) 
The University of Western Australia 
35 Stirling Highway 
CRAWLEY   WA  6008 
 
 
Dear Dr Preen  
 
RE: Project #EC 2009/7 
Vascular Endothelial Growth Factor Inhibitors and Cardiovascular Events in 
Treatment of Neovascular Age-Related Macular Degeneration (VICE) 
 
Date of commencement: 01/02/2009 
Date of completion: 31/12/2011 
Research Team: Dr David Preen  Prof James Semmens 
 Dr Frank Sanfilippo  Dr Tom Briffa 
 Dr Antony Clark  A/Prof Nigel Morlet 
 Dr Jonathon Ng  Dr Alexandra Bremner 
 Dr Tina Khanam  Dr Charlotte McKnight 
 Dr Wayne Reynolds 
Data linkage required: Yes 
Datasets to be accessed:  Hospital Morbidity Data Collection 
 Electoral Roll 
 Mortality 
Date of Ethical Review: 11/02/2009 
Ethics approval validity: 11/02/2013 (4years) 
 
I am pleased to advise that the Committee has granted ethical approval for this project.  
 
Please note there was discussion amongst the Committee about whether patients are made 
aware of potential adverse effects of prescribed drugs. In the light of this discussion the 
Committee would like to know how the researchers intend to disseminate and communicate 
their findings (National Statement on Ethical Conduct in Human Research [Section 1.3(d)]. 
 
This letter constitutes Ethics Approval only; you will not receive the data requested for your 
project until approval for the release of these data is signed by the Department of Health WA 
Director General's delegate.  
 
This approval is subject to your continued compliance with the following conditions: 
! DOHWA HREC holds the Principal Investigator responsible for the ethical conduct of the 
project and the security of the personal health information therefore he/she must – 
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DOHWA HREC is constituted and operates in accordance with the National Health and Medical Research Council’s 
(NHMRC) ‘National Statement on Ethical Conduct in Human Research’. Applications are also reviewed for 
compliance with the Department of Health WA ‘Practice Code for use of personal health information’. 
1. Report anything which might warrant review of ethical approval of the project in 
the specified format including: 
! Any serious or unexpected adverse events. 
! Unforeseen events that might affect the continued ethical acceptability of the 
project. 
! Submit for approval any changes or amendments to the research protocol, 
including methodology, data required, duration of the project and any changes 
to the approved data storage arrangements. 
2. Advise if the project is discontinued or withdrawn before the expected date of 
completion and give reasons for this action. 
3. Provide an annual progress report to the HREC and a final report at the completion 
of the project. 
4. Advise any changes of personnel in the research team, and provide a DOHWA 
Confidentiality Agreement/Confidentiality Acknowledgement form for any addition 
to the research team. 
 
We wish you well with your project. 
 
Yours sincerely 
 
 
 
 
 
 
Dr Judyth Watson 
Chair 
Department of Health WA Human Research Ethics Committee 
 
13 February 2009 
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Research Ethics 
Research Services 
M459 
 
35 Stirling Highway, Crawley, WA  6009 
Telephone:  (08) 6488 3703 
Facsimile:    (08) 6488 8775 
Email:  kkirk@admin.uwa.edu.au 
http://www.research.uwa.edu.au/human_ethics 
 
 
Our Ref. RA/4/1/2266 22 April 2009 
 
 
Dr D Preen 
School of Population Health - M431 
UWA 
 
 
HUMAN RESEARCH ETHICS COMMITTEE 
 
 
Project: Monitoring cataract surgery outcomes in Western Australia:  establishing a 
State-wide cataract surgery register 
 
 
Please be advised that ethical approval of the above project has been granted by the Human 
Research Ethics Committee. 
 
The Committee is bound by NHMRC Guidelines to monitor the progress of all approved projects 
until completion to ensure that they continue to conform to approved ethical standards. 
 
The committee requires that all Chief Investigators report immediately anything that might affect or 
impact upon ethical approval of the project, including adverse events affecting subjects. 
 
Approval should be sought in writing in advance for any amendments to the original application.  
You are also required as a condition of this approval to inform the Committee if for any reason the 
research project is discontinued before the expected date of completion. 
 
A report form for completion will be sent to you twelve months from this date or one month after your 
indicated completion date. 
 
Please note that approval has been granted for a period of four years.  Initial approval is for a 
period of one year, and, thereafter for future periods of one year at a time subject to the 
receipt of satisfactory annual reports.  At the end of the four-year period you will be required to 
complete a new "Application to Undertake Research Involving Human Subjects" should you wish to 
continue with your research.  However, in special circumstances, the Chair has the authority to 
extend the approval period in order to complete a project.  Failure to submit a final report may 
result in delays for future applications. 
 
Please quote Project No RA/4/1/2266 all correspondence associated with this study. 
 
Yours sincerely 
 
 
KATE KIRK 
Executive Officer 
(Human Research Ethics Committee)
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8.Appendix*2:*Diabetic*retinopathy*
screening*and*management*survey*
questionnaires*
Diabetic Retinopathy National Questionnaire Ophthalmologists 
  
PLEASE TURN OVER PAGE 
1. How many years have you been practicing ophthalmology? (exclude training years): __________________ 
 
2. Where did you complete your medical training?  
! Australia   ! New Zealand  ! United Kingdom   !Other (specify): ________________ 
 
3. In which State/Territory do you currently practice? 
! NSW ! VIC ! ACT ! TAS ! QLD ! WA ! NT 
 
4. For each location where you practice please indicate whether it is a rural/metropolitan practice and estimate the monthly 
number of patients you would normally see (include public hospital outpatient clinics): 
Practice 1: ! Rural  ! Metropolitan Number of Patients per month: ___________________________________ 
Practice 2: ! Rural  ! Metropolitan Number of Patients per month: ___________________________________ 
Practice 3: ! Rural  ! Metropolitan Number of Patients per month: ___________________________________ 
 
5. If you have a sub-specialty interest, is it: 
! Vitreo-retinal surgery ! Medical retina ! Anterior segment  ! Oculo-plastics ! Other sub-specialty 
 
6. Please select which of the following describes your current practice most accurately:  
! General ophthalmologist ! Minor sub-specialty interest ! Mostly sub-specialist ! Exclusively sub-specialist 
 
7. Please estimate the percentage of your patients who have diabetes: 
! Less than 1% ! 1-5% ! 5-10% ! 10-15% ! More than 15% 
 
8. Please estimate how many times you have either ordered or performed the following procedures and tests for patients with 
diabetes in the last 12 months: 
 Less than once a 
month 
Up to 10 per 
month 
10 to 20 per 
month 
20 to 30 per 
month 
More than 30 
per month  
Focal or Grid Macular Photocoagulation: ! ! ! ! ! 
Pan Retinal Photocoagulation: ! ! ! ! ! 
Optical Coherence Tomography: ! ! ! ! ! 
Retinal Photography: ! ! ! ! ! 
 
9. How would you rate your confidence in clinically determining either the presence or absence of the following signs? 
 Always unsure Often unsure Often confident Always confident 
New Vessels away from the disc: ! ! ! ! 
Moderate retinal thickening near the macula: ! ! ! ! 
 
10. Consider how you would normally manage patients who have diabetes: 
 Never Every 2 years Yearly 6 monthly 
More than 6 
monthly 
How often do you ask about sugar control? ! ! ! ! ! 
How often do you ask about blood pressure? ! ! ! ! ! 
How often to you ask about blood cholesterol? ! ! ! ! ! 
How often do you review smoking status? ! ! ! ! ! 
How often do you advise about the importance of 
the above factors in delaying complications? 
! ! ! ! ! 
 
11. Do you send recall notices to your patients who have diabetes to remind them to return for examination? 
!  No ! Yes 
 
12. When you advise your patients with diabetes to return to your clinic for retinopathy examination, what percentage would 
return within a reasonable time of the suggested follow up visit? 
! less than 30% ! 30 to 50% ! 50-70% ! 70-90% ! 90 to 100% 
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*** END OF SURVEY – THANK YOU FOR YOUR CONTRIBUTION *** 
19. How strong is your desire to play more of a role in community screening for diabetic retinopathy? 
! No Desire ! Small Desire ! Moderate Desire ! Strong Desire 
20. How strong is your need to learn more about diagnosis and/or management of diabetic retinopathy? 
! No Need ! Small Need ! Moderate Need ! Strong Need 
 
21. Consider the following patients with poorly controlled diabetes and normal vision. You are confident that they do not have 
any macula oedema. How often would you order a fluorescein angiogram at their initial presentation if you detected the 
following signs: 
 Almost never Sometimes Often Almost always I’d  refer elsewhere 
No retinopathy: ! ! ! ! ! 
Mild Non-Proliferative Retinopathy: ! ! ! ! ! 
Severe Non-proliferative Retinopathy: ! ! ! ! ! 
 
22. You see a patient with diabetes. They have a cataract that requires surgery and also have clinically significant macular 
oedema. The cataract will make it difficult but not impossible to perform laser therapy to the macula. Which would you 
normally aim to do? (tick one option) 
! Refer Elsewhere ! Delay macular laser therapy until after cataract 
surgery 
! Delay cataract surgery until after macular laser 
therapy  
 
23. You see a patient with diabetes who requires Pan-Retinal Photocoagulation (PRP) for early proliferative diabetic 
retinopathy and Focal Macular Photocoagulation for clinically significant macular oedema. How would you normally 
manage them? (tick one option) 
! Refer 
Elsewhere 
! Perform PRP and wait until a later 
date to perform macular 
photocoagulation 
! Perform macular photocoagulation 
and wait until a later date to 
perform PRP 
! Perform both 
procedures together 
 
24. The following patients have no signs of retinopathy and no ophthalmic problems at your baseline examination. Assume that 
they are compliant with your follow up instructions. How would you manage them? 
 Refer elsewhere for 
regular eye 
screening 
Advise regular 
eye screening in 
about 5 yrs 
Review in 
2 yrs 
Review in 1yr 
Review in 
6 months or 
less 
A 7yr old child recently diagnosed with diabetes ! ! ! ! ! 
An 18 yr old recently diagnosed with diabetes ! ! ! ! ! 
A 60 yr old recently diagnosed with very mild diabetes (“a 
touch of sugar”) well controlled by dietary means alone 
! ! ! ! ! 
A 60 yr old recently diagnosed with diabetes and 
commenced on oral medications 
! ! ! ! ! 
A 60 yr old with a 10 yr history of diabetes, achieving good 
glycaemic control with oral medications 
! ! ! ! ! 
A 60 yr old with a 10 yr history of diabetes, achieving good 
glycaemic control but requiring insulin 
! ! ! ! ! 
A 60 yr old with a 10yr history of diabetes, requiring insulin 
but still poorly controlled 
! ! ! ! ! 
 
25. The following patients are all 60 years old and have a 10 year history of diabetes, well controlled with oral medications. You 
have detected the following signs and are confident that there is no macular oedema and no other signs or problems. 
Assume that vision is normal, that there are no other eye problems and that the patients are compliant. How would you 
normally manage them? 
 Refer 
elsewhere 
Review in 
2 yrs 
Review in 
1 yr 
Review in 
6 months 
Review in 
3 months, no 
angiogram 
Angiogram 
± Laser 
Occasional microaneurysms located outside the macula ! ! ! ! ! ! 
Numerous, widespread microaneurysms and retinal 
haemorrhages, all located outside the macula 
! ! ! ! ! ! 
Numerous, widespread microaneurysms and retinal 
haemorrhages with venous bleeding in 2 quadrants, all 
located outside the macula 
! ! ! ! ! ! 
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PLEASE TURN OVER PAGE 
1. How many years have you been practicing optometry?(exclude training years): ____________________ 
 
2. In which State/Territory do you currently practice? 
! NSW ! VIC ! ACT ! TAS ! QLD ! WA ! NT 
 
3. Where did you complete your medical training?  
! Australia   ! New Zealand   ! United Kingdom ! Other (specify): _______________   
 
4. For each location where you practice please indicate whether it’s rural/metropolitan and estimate the monthly number of 
patients you would normally see (include public hospital outpatient clinics): 
Practice 1: ! Rural  ! Metropolitan Number of Patients per month: ____________________________________ 
Practice 2: ! Rural  ! Metropolitan Number of Patients per month: ____________________________________ 
Practice 3: ! Rural  ! Metropolitan Number of Patients per month: ____________________________________ 
 
5. Regarding  the NHMRC Guidelines for the Management of Diabetic Retinopathy published in 1997: 
Do you receive a copy? ! Yes ! No (skip to question 6) 
Have you read them? ! Not at all ! Partially ! Once entirely ! Several times 
 
6. Please estimate the percentage of your patients who are diabetic: 
! Less than 1% ! 1-5% ! 5-10% ! 10-15% ! More than 15% 
 
7. Consider new patients over 40 years old. How often do you ask specifically whether or not they have been diagnosed with 
diabetes? 
! Almost never ! Sometimes ! About half the time ! Often  ! Almost always 
 
8. Consider new patients over 40 years old who do not have a narrow angle or a history that is specifically suggestive of diabetes, 
glaucoma or a retinal problem. How often would you perform dilated ophthalmoscopy on them?  
! Almost never ! Sometimes ! About half the time ! Often ! Almost always 
 
9. Among new patients who you know have diabetes, how often do you perform dilated ophthalmoscopy? (assume they are not 
receiving dilated exams elsewhere) 
! Almost never ! Sometimes ! About half the time ! Often ! Almost always 
 
10. How would you rate the following as barriers to you performing dilated ophthalmoscopy on patients with diabetes? 
 Not a barrier Minor barrier Moderate barrier Major barrier 
Time consuming to dilate ! ! ! ! 
Patients don’t want to be dilated ! ! ! ! 
Worried you will precipitate angle closure glaucoma ! ! ! ! 
Patients are unprepared eg need to drive after ! ! ! ! 
Not confident in detecting changes ! ! ! ! 
Unsure what to do if changes are detected ! ! ! ! 
Lack of dilating drops in the practice ! ! ! ! 
Lack of ophthalmoscope in your practice ! ! ! ! 
 
11. How often do you use the following instrument when you examine patients with diabetes? 
 Almost never Sometimes Half the time Often Almost always 
Direct ophthalmoscope: ! ! ! ! ! 
Monocular Indirect Ophthalmoscope: ! ! ! ! ! 
Binocular Indirect Ophthalmoscopy: ! ! ! ! ! 
Slit lamp fundus viewing lens: ! ! ! ! ! 
Retinal camera: ! ! ! ! ! 
 
12. How would you rate your confidence in clinically determining either the presence or absence of the following signs? 
 Always unsure Often unsure Often confident Always confident 
Microaneurysms: ! ! ! ! 
Hard Exudates: ! ! ! ! 
New Vessels away from the disc: ! ! ! ! 
Moderate retinal thickening near the macula: ! ! ! ! 
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***END OF SURVEY – THANK YOU FOR YOUR CONTRIBUTION*** 
13. Consider how you would normally manage patients who have diabetes: 
 Never Every 2 years Yearly 6 monthly More than 6 
monthly 
How often do you ask about blood sugar control? ! ! ! ! ! 
How often do you ask about blood pressure control? ! ! ! ! ! 
How often to you ask about blood cholesterol control? ! ! ! ! ! 
How often do you review smoking status? ! ! ! ! ! 
How often do you advise about the importance of the 
above factors in delaying complications? 
! ! ! ! ! 
 
14. Do you send recall notices to your patients who have diabetes to remind them to return for examination? 
!  No ! Yes 
 
15. When you advise you patients with diabetes to return to your clinic for retinopathy examination, what percentage would 
return within a reasonable time of the suggested follow up visit? 
! less than 30% ! 30 - 50% ! 50 - 70% ! 70 - 90% ! 90 - 100% 
 
18. What do you think is the rate of compliance with your instructions for patients with diabetes to visit ophthalmologists? 
! less than 30% ! 30 - 50% ! 50 - 70% ! 70 - 90% ! 90 - 100% 
 
19. How strong is your desire to play more of a role in community screening for retinopathy among people with diabetes? 
(under current Medicare arrangements) 
! No Desire ! Small Desire ! Moderate Desire ! Strong Desire 
 
20. How strong is your need to learn more about diagnosis and/or management of retinopathy among people with diabetes? 
! No Need ! Small Need ! Moderate Need ! Strong Need 
 
21. The following patients have no signs of retinopathy and no ophthalmic problems at your baseline examination. Assume that 
they are compliant with your follow up instructions. How would you manage them? 
 
Refer to an 
ophthalmologist 
Advise regular 
dilated eye exams 
in about 5 yrs 
Dilate in 
2 yrs 
Dilate in 
1yr 
Dilate in 
6 months 
or less 
A 7yr old child recently diagnosed with diabetes ! ! ! ! ! 
An 18 yr old recently diagnosed with diabetes ! ! ! ! ! 
A 60 yr old recently diagnosed with very mild diabetes (“a 
touch of sugar”) well controlled by dietary means alone 
! ! ! ! ! 
A 60 yr old recently diagnosed with diabetes and 
commenced on oral medications 
! ! ! ! ! 
A 60 yr old with a 10 yr history of diabetes, achieving good 
glycaemic control with oral medications 
! ! ! ! ! 
A 60 yr old with a 10 yr history of diabetes, achieving good 
glycaemic control but requiring insulin 
! ! ! ! ! 
A 60 yr old with a 10yr history of diabetes, requiring insulin 
but still poorly controlled 
! ! ! ! ! 
 
22. The following patients are all 60 years old and have a 10 year history of diabetes, well controlled with oral medications. You 
have detected the following signs and are confident that there is no macular oedema and no other signs or problems. Assume 
that vision is normal, that there are no other eye problems and that the patients are compliant. How would you normally 
manage them? 
 
Refer to an 
ophthalmologist 
Review in 
2 yrs 
Review in 
1 yr 
Review in 
6 months 
Review in 
3 months 
Occasional microaneurysms located peripherally: ! ! ! ! ! 
Macular oedema that is not clinically significant: ! ! ! ! ! 
Peripheral microaneurysms plus occasional retinal 
haemorrhages: 
! ! ! ! ! 
Extensive microaneurysms and retinal haemorrhages and 
occasional cotton wool spots, all located peripherally: 
! ! ! ! ! 
Proliferative retinopathy: ! ! ! ! ! 
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PLEASE!TURN!OVER!PAGE!
1. How(many(years(have(you(been(practicing(medicine?((exclude(training(years):(__________________yrs(
(
2. Where(did(you(complete(your(medical(training?!(
!!Australia!!( !!New!Zealand!( !!United!Kingdom!!( !Other!(specify):!________________(
(
3. In(which(State/Territory(do(you(currently(practice?(
! NSW! ! VIC! ! ACT! ! QLD!! ! WA! ! NT!!! ! TAS!
(
4. Are(you(in(a(rural/remote(or(metropolitan(practice?( !!Rural/Remote!!( !!Metropolitan(
(
5. Regarding(guidelines(for(managing(diabetic(retinopathy:(
Did!you!receive!a!copy!of!the!1997!NHMRC!Guidelines!for!the!Management!of!Diabetic!Retinopathy?!
! Yes! ! No!(skip!to!question!5)!
Have!you!read!them?! ! Not!a!all! ! Partially! ! Once!entirely! ! Several!times!
Do!you!refer!to!other!published!guidelines!when!managing!your!diabetic!patients?! ! No! ! Yes!(specify):!!___________!
(
6. Consider(how(you(would(normally(manage(patients(who(have(diabetes:(
( Never( Every(2(years( Yearly( 6(monthly(
More(than(6(
monthly(
How!often!do!you!measure!glycosylated!haemoglobin?! !! !! !! !! !!
How!often!do!you!measure!blood!pressure?! ! ! ! ! ! 
How!often!to!you!measure!blood!cholesterol?! ! ! ! ! !!
How!often!do!you!review!smoking!status?! ! ! ! ! !!
How!often!do!you!advise!about!the!role!of!the!above!
factors!in!developing!complications?!
! ! ! ! ! 
(
7. What(proportion(of(your(diabetic(patients(would(you(examine(for(diabetic(retinopathy?(
! None!(skip!to!question!10)! ! Less!than!half! ! About!half! ! More!than!half! ! All!
(
8. On(average(how(often(do(you(examine(your(diabetic(patients(for(retinopathy?(
! More!than!annually! ! Annually! ! Every!2!years! ! Every!3\5!years! ! Less!than!5!yearly!
(
9. When(you(examine(patients(for(diabetic(retinopathy(do(you:(
! Never( Rarely( Sometimes( Usually( Always(
Measure!visual!acuity?! !! !! !! !! !!
Perform!fundoscopy!without!dilating!eye!drops?! ! ! ! ! ! 
Perform!fundoscopy!with!dilating!eye!drops?! ! ! ! ! !!
(
10. How(often(do(you(feel(confident(in(being(able(to(detect(clinical(signs(of(diabetic(retinopathy?(
! Almost!never! ! Sometimes! ! About!half!the!time! ! Often! ! Almost!always!
(
11. How(would(you(rate(the(following(as(barriers(to(you(performing(dilated(ophthalmoscopy(on(patients(with(diabetes?(
! Not(a(barrier( Minor(barrier( Moderate(barrier( Major(barrier(
Time!consuming!to!dilate! !! !! !! !!
Patients!don’t!want!to!be!dilated! ! ! ! ! 
Worried!you!will!precipitate!angle!closure!glaucoma! ! ! ! ! 
Patients!are!unprepared!eg!need!to!drive!after! !! !! !! !!
Not!confident!in!detecting!changes! ! ! ! ! 
Unsure!what!to!do!if!changes!are!detected! ! ! ! ! 
Lack!of!dilating!drops!in!the!practice! !! !! !! !!
Lack!of!ophthalmoscope!in!your!practice! ! ! ! !!
(
12. How(often(would(you(refer(your(diabetic(patients(to(the(following(eye(care(professionals?(
!
6(monthly( Annually( Every(2nd(year( Every(5(years(
Only(if(visual(symptoms(
present( Never(
Ophthalmologist! !! !! !! !! !! !!
Optometrist! ! ! ! ! ! !!
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(
13. What(proportion(of(your(diabetic(patients(do(you(think(are(compliant(with(your(instructions(to(visit(an(ophthalmologist?(
! less!than!30%! ! 30!to!50%! ! 50\70%! ! 70\90%! ! 90!to!100%!
(
14. Consider(the(following(scenarios(that(relate(to(a(60(year(old(patient(with(a(10(year(history(of(type(2(diabetes(mellitus(well(
controlled(on(oral(medication.(Assume(that(vision(is(normal,(there(are(no(other(eye(problems(and(the(patient(is(100%(
compliant(with(your(management.(How(would(you(manage(them(given(you(have(found(the(following(signs?:(
! Refer(to(an(
ophthalmologist(
within(a(week(
Refer(to(an(
ophthalmologist(
within(a(month(
Refer(to(an(
ophthalmologist(
within(a(year(
Do(not(refer,(
review(later!
Occasional!microaneurysms!with!normal!vision! !! !! !! !!
Hard!exudates!near!the!macula!with!normal!
visual!acuity! ! ! ! ! 
Peripheral!microaneurysms!plus!occasional!
peripheral!retinal!haemorrhages! !! !! !! !!
Extensive!microaneurysms,!retinal!
haemorrhages!and!occasional!cotton!wool!
spots,!all!located!peripherally!!
! ! ! ! 
New!vessels!covering!an!area!of!about!half!that!
of!the!optic!disc!and!normal!visual!acuity! !! !! !! !!
(
15. The(following(patients(have(no(signs(of(retinopathy(and(no(ophthalmic(problems(at(your(baseline(examination.(Assume(that(
they(are(compliant(with(your(follow(up(instructions.(How(would(you(manage(them?(
! Refer(elsewhere(for(
regular(eye(
screening(
Advise(regular(
eye(screening(in(
about(5(yrs(
Review(in(
2(yrs(
Review(in(
1yr(
Review(in(
6(months(or(
less(
A!7yr!old!child!recently!diagnosed!with!diabetes! !! !! !! !! !!
An!18!yr!old!recently!diagnosed!with!diabetes! ! ! ! ! ! 
A!60!yr!old!recently!diagnosed!with!very!mild!diabetes!
(“a!touch!of!sugar”)!well!controlled!by!dietary!means!
alone!
!! !! !! !! !!
A!60!yr!old!recently!diagnosed!with!diabetes!and!
commenced!on!oral!medications! ! ! ! ! ! 
A!60!yr!old!with!a!10!yr!history!of!diabetes,!achieving!
good!glycaemic!control!with!oral!medications! !! !! !! !! !!
A!60!yr!old!with!a!10!yr!history!of!diabetes,!achieving!
good!glycaemic!control!but!requiring!insulin! !! !! !! !! !!
A!60!yr!old!with!a!10yr!history!of!diabetes,!requiring!
insulin!but!still!poorly!controlled! ! ! ! ! ! 
!
!
!
!
!
***END!OF!SURVEY!–!THANK!YOU!FOR!YOUR!CONTRIBUTION!***!
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
Im
pl
em
en
te
d 
bu
t b
et
a 
te
st
in
g 
in
 
pr
og
re
ss
. 
Si
r C
ha
rle
s 
G
ai
rd
ne
r 
9

Fr
em
an
tle
 H
os
pi
ta
l a
nd
 H
ea
lth
 S
er
vi
ce
 
9

  Pe
rip
he
ra
l H
os
pi
ta
ls
 
O
sb
or
ne
 P
ar
k 
H
os
pi
ta
l 
܆
 
Aw
ai
tin
g 
fin
al
 c
ha
ng
es
 to
 b
e 
m
ad
e 
in
 re
sp
on
se
 to
 b
et
a 
te
st
in
g 
at
 th
e 
Te
rti
ar
y 
ho
sp
ita
ls
. A
nt
ic
ip
at
e 
im
pl
em
en
ta
tio
n 
w
ith
in
 3
 m
on
th
s.
 
Sw
an
 D
is
tri
ct
s 
H
os
pi
ta
l 
܆
 
Be
nt
le
y 
H
os
pi
ta
l 
܆
 
  Pr
iv
at
e 
H
os
pi
ta
ls
 
Th
e 
Ey
e 
Su
rg
er
y 
Fo
un
da
tio
n 
(E
SF
) 
9

Be
ta
 te
st
in
g 
co
m
m
en
ce
d.
 
Li
on
s 
Ey
e 
In
st
itu
te
 
܆
 
Im
pl
em
en
ta
tio
n 
to
 c
om
m
en
ce
 w
he
n 
ES
F 
be
ta
 te
st
in
g 
su
cc
es
sf
ul
ly
 
co
m
pl
et
ed
. 
St
 J
oh
n 
of
 G
od
 S
ub
ia
co
 
܆
 
St
 J
oh
n 
of
 G
od
 B
un
bu
ry
 
܆
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 Be
ta
 te
st
in
g 
of
 th
e 
eC
AT
 w
eb
-b
as
ed
 c
at
ar
ac
t s
ur
ge
ry
 s
of
tw
ar
e 
sy
st
em
 b
y 
cl
in
ic
ia
ns
 is
 w
el
l 
un
de
rw
ay
 i
n 
th
e 
m
aj
or
 m
et
ro
po
lit
an
 t
er
tia
ry
 h
os
pi
ta
ls
 i
n 
Pe
rth
 (
R
oy
al
 P
er
th
 H
os
pi
ta
l, 
Si
r 
C
ha
rle
s 
G
ai
rd
ne
r 
H
os
pi
ta
l a
nd
 F
re
m
an
tle
 H
os
pi
ta
l &
 H
ea
lth
 S
er
vi
ce
s)
. B
et
a 
te
st
in
g 
is
 a
ls
o 
un
de
rw
ay
 a
t 
th
e 
W
A 
Ey
e 
Su
rg
er
y 
Fo
un
da
tio
n 
(E
SF
) 
an
d 
w
e 
ar
e 
cu
rr
en
tly
 a
dd
re
ss
in
g 
im
po
rta
nt
 n
et
w
or
k 
an
d 
IT
 in
fra
st
ru
ct
ur
e 
co
m
pa
tib
ilit
y 
is
su
es
 a
ss
oc
ia
te
d 
w
ith
 it
s 
in
st
al
la
tio
n 
at
 
th
is
 in
st
itu
tio
n.
  
It 
is
 e
xp
ec
te
d 
th
at
 im
pl
em
en
ta
tio
n 
at
 th
e 
ES
F 
w
ill 
be
 c
om
pl
et
ed
 b
y 
O
ct
ob
er
 
31
st
 
 
20
09
, 
an
d 
th
e 
pr
oc
es
se
s 
em
pl
oy
ed
 
at
 
th
e 
ES
F 
w
ill 
fo
rm
 
th
e 
fra
m
ew
or
k 
fo
r 
im
pl
em
en
ta
tio
n 
of
 th
e 
eC
AT
 s
ys
te
m
 in
to
 th
e 
ot
he
r p
riv
at
e 
ho
sp
ita
ls
 (L
io
ns
 E
ye
 In
st
itu
te
, a
nd
 
St
 J
oh
n 
of
 G
od
 S
ub
ia
co
 a
nd
 B
un
bu
ry
). 
Th
e 
in
iti
al
 im
pl
em
en
ta
tio
n 
an
d 
be
ta
 t
es
tin
g 
of
 t
he
 e
C
AT
 s
ys
te
m
 in
to
 T
er
tia
ry
 h
os
pi
ta
l s
ite
s 
ge
ne
ra
te
d 
a 
gr
ea
t 
de
al
 
of
 
fe
ed
ba
ck
 
re
ga
rd
in
g 
sy
st
em
 
ne
tw
or
k 
is
su
es
, 
ar
ea
s 
fo
r 
im
pr
ov
em
en
t 
an
d 
re
qu
es
te
d 
ad
di
tio
ns
. W
e 
fe
lt 
it 
w
as
 im
po
rta
nt
 t
o 
ad
dr
es
s 
th
es
e 
ch
an
ge
s 
ea
rly
 o
n 
w
ith
in
 th
e 
te
rti
ar
y 
se
tti
ng
 p
rio
r t
o 
fu
rth
er
 ro
ll-
ou
t. 
Th
is
 h
as
 in
vo
lv
ed
 a
n 
un
an
tic
ip
at
ed
 
in
cr
ea
se
d 
co
m
m
itm
en
t 
in
 t
im
e 
an
d 
re
so
ur
ce
s,
 w
hi
ch
 w
e 
fe
lt 
to
 b
e 
es
se
nt
ia
l 
if 
w
e 
ar
e 
to
 
en
su
re
 w
id
es
pr
ea
d 
us
er
 a
cc
ep
ta
bi
lit
y 
of
 th
e 
sy
st
em
 a
cr
os
s 
th
e 
St
at
e 
as
 it
 is
 ro
lle
d-
ou
t. 
 
 Th
er
ef
or
e,
 im
pl
em
en
ta
tio
n 
of
 th
e 
eC
AT
 s
ys
te
m
 in
to
 th
e 
ot
he
r 
pu
bl
ic
 h
os
pi
ta
l s
ite
s 
(O
sb
or
ne
 
Pa
rk
 H
os
pi
ta
l, 
Sw
an
 D
is
tri
ct
s 
H
os
pi
ta
l, 
an
d 
Be
nt
le
y 
H
os
pi
ta
l) 
ha
s 
be
en
 d
el
ay
ed
 u
nt
il 
th
e 
ch
an
ge
s 
re
qu
ire
d 
ha
ve
 b
ee
n 
fu
lly
 i
m
pl
em
en
te
d 
an
d 
te
st
ed
 i
n 
th
e 
Te
rti
ar
y 
se
tti
ng
. 
It 
is
 
ex
pe
ct
ed
 th
at
 im
pl
em
en
ta
tio
n 
th
ro
ug
h 
th
es
e 
in
st
itu
tio
ns
 w
ill 
be
 o
n 
an
 a
cc
el
er
at
ed
 tr
aj
ec
to
ry
 
as
  
im
pe
di
m
en
ts
 a
re
 r
ec
tif
ie
d,
 a
nd
 w
e 
an
tic
ip
at
e 
co
m
pl
et
io
n 
by
 J
an
ua
ry
 2
01
0.
 S
im
ila
rly
, w
e 
ha
ve
 e
le
ct
ed
 t
o 
im
pl
em
en
t 
th
e 
sy
st
em
 in
 o
nl
y 
on
e 
pr
iv
at
e 
he
al
th
 s
ite
 -
 T
he
 E
ye
 S
ur
ge
ry
 
Fo
un
da
tio
n 
(E
SF
) 
- 
an
d 
ha
ve
 d
el
ay
ed
 i
m
pl
em
en
ta
tio
n 
in
 t
he
 o
th
er
 p
ro
po
se
d 
pr
iv
at
e 
ho
sp
ita
ls
 u
nt
il 
th
e 
sy
st
em
 is
 fu
lly
 te
st
ed
 a
nd
 fu
lly
 o
pe
ra
tio
na
l i
n 
th
e 
pu
bl
ic
 h
os
pi
ta
ls
 a
nd
 E
SF
.  
Th
e 
Li
on
s 
Ey
e 
In
st
itu
te
 h
as
 a
sk
ed
 to
 d
el
ay
 in
st
al
la
tio
n 
an
d 
be
ta
 te
st
in
g 
at
 th
ei
r 
si
te
 a
s 
th
ey
 
ar
e 
cu
rre
nt
ly
 u
pg
ra
di
ng
 t
he
ir 
da
ta
 b
as
e 
m
an
ag
em
en
t 
to
ol
s,
 a
nd
 i
t 
is
 n
ot
 e
ffi
ci
en
t 
to
 
un
de
rta
ke
 th
e 
pr
og
ra
m
m
in
g 
to
 a
llo
w
 th
e 
ol
d 
ve
rs
io
n 
to
 c
om
m
un
ic
at
e 
w
ith
 th
e 
eC
AT
 s
ys
te
m
, 
th
en
 to
 h
av
e 
to
 m
ak
e 
al
te
ra
tio
ns
 to
 a
cc
om
m
od
at
e 
th
e 
ne
w
 s
ys
te
m
.  
 In
st
al
la
tio
n 
at
 th
e 
tw
o 
St
 J
oh
n 
of
 G
od
 h
os
pi
ta
ls
 in
 t
he
 p
ilo
t g
ro
up
, 
Pe
rth
 a
nd
 B
un
bu
ry
, 
w
ill
 
al
so
 n
ee
d 
ad
di
tio
na
l p
ro
gr
am
m
in
g 
to
 a
llo
w
 th
e 
eC
AT
 s
ys
te
m
 to
 in
te
rfa
ce
 w
ith
 th
ei
r d
at
ab
as
e 
m
an
ag
em
en
t 
to
ol
s.
 T
hi
s 
is
 c
ur
re
nt
ly
 b
ei
ng
 a
dd
re
ss
ed
 a
s 
be
ta
 t
es
tin
g 
an
d 
ev
al
ua
tio
n 
co
nt
in
ue
s 
at
 th
e 
ot
he
r s
ite
s.
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 Fe
ed
ba
ck
 
 W
e 
ha
ve
 b
ee
n 
ve
ry
 p
ro
ac
tiv
e 
in
 o
ur
 d
es
ire
 to
 r
ec
ei
ve
 fe
ed
ba
ck
 o
n 
th
e 
eC
AT
 S
ys
te
m
 fr
om
 
cl
in
ic
ia
ns
 a
nd
 o
th
er
 s
en
io
r 
cl
in
ic
al
 a
nd
 a
dm
in
is
tra
tiv
e 
ho
sp
ita
l s
ta
ff 
w
ho
 h
av
e 
be
en
 in
vo
lv
ed
 
w
ith
 b
et
a 
te
st
in
g 
of
 t
he
 s
ys
te
m
 a
t 
ea
ch
 o
f 
th
e 
cu
rr
en
t 
te
st
 s
ite
s.
 T
he
 f
ee
db
ac
k 
w
e 
ha
ve
 
so
ug
ht
 s
o 
fa
r h
as
 b
ee
n 
fro
m
 fa
ce
-to
-fa
ce
 c
on
ta
ct
 a
nd
 s
ur
ro
un
ds
 s
ev
er
al
 a
re
as
 in
cl
ud
in
g:
 
1.
 
Vi
ew
s 
on
 m
an
da
to
ry
 r
ec
or
di
ng
 r
eq
ui
re
m
en
ts
 i.
e.
 e
st
ab
lis
hi
ng
 a
 u
ni
ve
rs
al
ly
 a
gr
ee
d 
m
in
im
um
 d
at
a 
se
t. 
2.
 
In
di
vi
du
al
 r
ep
or
tin
g 
re
qu
ire
m
en
ts
 f
or
 e
ac
h 
he
al
th
 s
ite
 in
 t
er
m
s 
of
 r
eq
ui
re
m
en
ts
 f
or
 
op
er
at
io
n 
re
po
rts
, m
ed
ic
al
 re
co
rd
s 
an
d 
di
sc
ha
rg
e 
su
m
m
ar
ie
s.
  
3.
 
Ad
eq
ua
cy
 o
f t
he
 u
se
r i
nt
er
fa
ce
 a
nd
 m
en
u 
op
tio
ns
. 
4.
 
Id
en
tif
yi
ng
 h
ar
dw
ar
e 
re
qu
ire
m
en
ts
 t
o 
fa
ci
lit
at
e 
eC
AT
 i
nt
eg
ra
tio
n 
in
to
 o
pe
ra
tin
g 
th
ea
tre
s.
 
5.
 
Id
en
tif
yi
ng
 p
er
ce
iv
ed
 b
ar
rie
rs
 to
 s
ur
ge
on
s 
in
 u
si
ng
 th
e 
eC
AT
 s
ys
te
m
 o
ng
oi
ng
. 
 W
e 
ha
ve
 a
ls
o 
de
ve
lo
pe
d 
a 
su
rv
ey
 t
oo
l 
(A
pp
en
di
x 
2)
 t
ha
t 
w
ill 
be
 a
dm
in
is
te
re
d 
to
 a
ll 
cl
in
ic
ia
ns
 w
ho
 h
av
e 
be
en
 u
si
ng
 th
e 
eC
AT
 s
ys
te
m
 o
nc
e 
it 
is
 fu
lly
 im
pl
em
en
te
d 
in
 th
e 
pu
bl
ic
 
sy
st
em
. T
he
 p
ur
po
se
 o
f t
hi
s 
ev
al
ua
tio
n 
is
 to
:  
 
• P
ro
vi
de
 u
se
rs
 th
e 
op
po
rtu
ni
ty
 to
 g
ui
de
 s
of
tw
ar
e 
de
ve
lo
pm
en
t b
y 
id
en
tif
yi
ng
 a
re
as
 in
 
w
hi
ch
 im
pr
ov
em
en
ts
 m
ay
 b
e 
m
ad
e 
to
 m
ax
im
is
e 
en
d-
us
er
 u
pt
ak
e;
 a
nd
  
 • 
As
ce
rta
in
 e
nd
-u
se
r 
at
tit
ud
es
 t
o 
es
ta
bl
is
hi
ng
 a
 c
at
ar
ac
t 
su
rg
er
y 
cl
in
ic
al
 r
eg
is
te
r 
in
 
W
A 
in
cl
ud
in
g 
pe
rc
ei
ve
d 
be
ne
fit
s 
(e
.g
. 
as
si
st
an
ce
 w
ith
 p
er
so
na
l 
cl
in
ic
al
 a
ud
it,
 
pu
bl
ic
 h
ea
lth
 g
ai
ns
, 
gr
ea
te
r 
ef
fic
ie
nc
y 
in
 d
is
ch
ar
ge
 p
la
nn
in
g 
pr
oc
es
s)
, 
an
d 
ris
ks
 
(e
.g
. p
riv
ac
y,
 le
ag
ue
 ta
bl
es
). 
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 Im
pr
ov
em
en
t 
 Th
e 
eC
AT
 s
ys
te
m
 h
as
 u
nd
er
go
ne
 s
ig
ni
fic
an
t c
ha
ng
es
 o
ve
r 
th
e 
la
st
 1
2 
m
on
th
s 
in
 r
es
po
ns
e 
to
 fe
ed
ba
ck
 fr
om
 c
lin
ic
ia
ns
 a
nd
 o
ur
 d
es
ire
 to
 e
ns
ur
e 
it 
co
m
pl
ie
s 
w
ith
 A
us
tra
lia
n 
N
at
io
na
l e
-
H
ea
lth
 s
ta
nd
ar
ds
.2
,3
1.
1.
 
An
 u
pg
ra
de
 o
f t
he
 d
at
a 
en
try
 p
ro
to
co
l a
nd
 s
ec
ur
ity
 fe
at
ur
es
 to
 m
ee
t A
us
tra
lia
n 
St
an
da
rd
 A
S 
50
17
-2
00
6 
H
ea
lth
 C
ar
e 
C
lie
nt
 Id
en
tif
ic
at
io
n,
 A
us
tra
lia
n 
St
an
da
rd
 
AS
 4
84
6-
20
04
 H
ea
lth
 C
ar
e 
Pr
ov
id
er
 I
de
nt
ifi
ca
tio
n 
an
d 
th
e 
ne
w
 N
at
io
na
l 
E
-
H
ea
lth
 T
ra
ns
iti
on
 A
ut
ho
rit
y 
(N
EH
TA
) 
In
te
ro
pe
ra
bi
lit
y 
Fr
am
ew
or
k 
Ve
rs
io
n 
2.
0 
(N
EH
TA
 0
13
0:
20
07
) 
st
an
da
rd
s 
fo
r 
el
ec
tro
ni
c 
da
ta
 c
ol
le
ct
io
n.
 T
he
se
 s
ys
te
m
 
m
od
ifi
ca
tio
ns
 w
er
e 
ex
te
ns
iv
e 
ye
t 
es
se
nt
ia
l 
to
 e
ns
ur
e 
th
e 
sy
st
em
 m
ee
ts
 t
he
 
m
os
t c
ur
re
nt
 s
ec
ur
ity
 a
nd
 e
-h
ea
lth
 re
qu
ire
m
en
ts
 a
t a
 n
at
io
na
l l
ev
el
. 
 A
re
as
 o
f 
im
pr
ov
em
en
t 
fo
r 
th
e 
eC
AT
 S
ys
te
m
 t
ha
t 
ha
ve
 s
ub
se
qu
en
tly
 
be
en
 a
dd
re
ss
ed
 in
cl
ud
e:
 
1.
2.
 
A 
ne
w
 “
M
ai
nt
en
an
ce
” 
se
ct
io
n 
ha
s 
be
en
 b
ui
lt 
in
to
 t
he
 w
eb
-b
as
ed
 s
ys
te
m
 t
o 
al
lo
w
 in
di
vi
du
al
 in
st
itu
tio
ns
 t
o 
ea
si
ly
 m
ak
e 
ch
an
ge
s/
ad
di
tio
ns
 v
ar
io
us
 f
ea
tu
re
s 
to
 s
ui
t t
he
ir 
pa
rti
cu
la
r c
on
te
xt
. T
hi
s 
in
cl
ud
es
: 
1.
1.
 
C
us
to
m
is
ab
le
 s
ys
te
m
 m
en
us
 (
e.
g.
 th
e 
ad
di
tio
n 
of
 p
ar
tic
ul
ar
 in
tra
oc
ul
ar
 
le
ns
 ty
pe
s,
 o
r a
 p
ar
tic
ul
ar
 ty
pe
 o
f p
ha
co
em
ul
si
fic
at
io
n 
m
ac
hi
ne
). 
1.
2.
 
C
us
to
m
is
ab
le
 p
er
io
pe
ra
tiv
e 
m
ed
ic
at
io
ns
 s
ec
tio
n.
 
1.
3.
 
C
us
to
m
is
ab
le
 o
pe
ra
tiv
e 
di
ffi
cu
lti
es
 s
ec
tio
n.
 
1.
4.
 
C
us
to
m
is
ab
le
 o
pe
ra
tio
n 
re
po
rts
 f
or
 p
rin
tin
g 
in
to
 t
he
 p
at
ie
nt
 n
ot
es
, 
di
sc
ha
rg
e 
su
m
m
ar
ie
s 
an
d 
G
P 
le
tte
rs
. 
1.
5.
 
Th
e 
ab
ilit
y 
fo
r e
ac
h 
he
al
th
 s
ite
 to
 c
on
tro
l t
he
ir 
ow
n 
us
er
-le
ve
l a
cc
es
s.
 
1.
3 
  T
he
 id
en
tif
ic
at
io
n 
an
d 
re
so
lu
tio
n 
of
 s
ys
te
m
 “b
ug
s”
 (A
pp
en
di
x 
3)
 
1.
4 
C
ha
ng
es
 t
o 
th
e 
m
an
da
to
ry
 r
ep
or
tin
g 
re
qu
ire
m
en
ts
 a
nd
 ‘
te
m
pl
at
ed
’ 
ite
m
s 
to
   
   
im
pr
ov
e 
ef
fic
ie
nc
y 
of
 d
at
a 
en
try
 a
nd
 d
ec
re
as
e 
th
e 
tim
e 
re
qu
ire
d 
to
 c
om
pl
et
e 
th
e 
op
er
at
io
n 
re
po
rt.
 
Th
is
 
re
pr
es
en
te
d 
a 
si
gn
ifi
ca
nt
 
is
su
e 
ra
is
ed
 
by
 
pa
rti
ci
pa
tin
g 
su
rg
eo
ns
, a
nd
 w
as
 r
eq
ui
re
d 
to
 b
e 
fu
lly
 a
dd
re
ss
ed
 to
 e
ns
ur
e 
up
ta
ke
 a
nd
 c
om
pl
ia
nc
e 
of
 th
e 
Sy
st
em
 b
y 
cl
in
ic
ia
ns
. 
D
oc
um
en
ta
tio
n 
 W
e 
ha
ve
 b
ee
n 
w
or
ki
ng
 h
ar
d 
to
 d
ev
el
op
 a
 c
om
pr
eh
en
si
ve
 ‘e
C
AT
 U
se
r R
ef
er
en
ce
 M
an
ua
l’ 
to
 
as
si
st
 c
lin
ic
ia
ns
 a
t 
al
l h
ea
lth
 s
ite
s 
m
an
ag
e 
th
e 
eC
AT
 s
ys
te
m
 in
de
pe
nd
en
tly
 in
to
 t
he
 f
ut
ur
e 
(A
pp
en
di
x 
4)
. 
Ad
di
tio
na
lly
, 
w
e 
ar
e 
w
or
ki
ng
 t
ow
ar
ds
 d
ev
el
op
in
g 
an
 ‘
eC
AT
 M
ai
nt
en
an
ce
 
M
an
ua
l’ 
(A
pp
en
di
x 
4)
 t
o 
ou
tli
ne
 t
he
 p
ro
to
co
ls
 t
ha
t 
sh
ou
ld
 b
e 
fo
llo
w
ed
 b
y 
al
l p
ar
tic
ip
at
in
g 
he
al
th
 s
ite
s 
us
in
g 
th
e 
eC
AT
 s
ys
te
m
. 
 D
ue
 t
o 
th
e 
m
ul
ti-
si
te
 n
at
ur
e 
of
 t
he
 p
ro
po
se
d 
eC
AT
 
sy
st
em
 a
nd
 it
s 
hi
gh
 d
eg
re
e 
of
 c
us
to
m
is
at
io
n 
to
 s
ui
t i
nd
iv
id
ua
l h
ea
lth
 s
ite
s 
an
d 
cl
in
ic
ia
ns
, i
t i
s 
es
se
nt
ia
l t
ha
t a
 c
om
m
on
 p
ro
to
co
l f
or
 d
at
a 
en
try
 a
nd
 s
ys
te
m
 a
lte
ra
tio
ns
 b
e 
de
ve
lo
pe
d 
so
 a
s 
to
 e
ns
ur
e 
st
an
da
rd
is
at
io
n 
of
 a
ll 
da
ta
 in
 th
e 
sy
st
em
 a
cr
os
s 
th
e 
di
ffe
re
nt
 h
ea
lth
 s
ite
s.
  
     
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
2  S
ta
nd
ar
ds
 A
us
tra
lia
 e
-h
ea
lth
 [o
nl
in
e]
, A
va
ila
bl
e 
at
: h
ttp
://
w
w
w
.e
-h
ea
lth
.st
an
da
rd
s.o
rg
.a
u 
[A
cc
es
se
d 
10
 S
ep
te
m
be
r 2
00
9]
 
3  N
at
io
na
l E
-H
ea
lth
 T
ra
ns
iti
on
 A
ut
ho
rit
y 
[o
nl
in
e]
, A
va
ila
bl
e 
at
: h
ttp
://
w
w
w
.n
eh
ta
.g
ov
.a
u 
[A
cc
es
se
d 
10
 S
ep
te
m
be
r 2
00
9]
 
N
at
io
na
l E
ye
 H
ea
lth
 In
iti
at
iv
e:
 E
ye
 H
ea
lth
 D
em
on
st
ra
tio
n 
G
ra
nt
s 
Fi
na
l R
ep
or
t 
C
en
tre
 fo
r H
ea
lth
 S
er
vi
ce
s 
R
es
ea
rc
h,
 S
ch
oo
l o
f P
op
ul
at
io
n 
H
ea
lth
, U
ni
ve
rs
ity
 o
f W
es
te
rn
 A
us
tra
lia
 | 
2 
 Pr
oj
ec
t D
iff
ic
ul
tie
s 
 As
 o
ut
lin
ed
 i
n 
pr
ev
io
us
 p
ro
je
ct
 p
ro
gr
es
s 
re
po
rts
, 
a 
nu
m
be
r 
of
 d
iff
ic
ul
tie
s 
ha
ve
 b
ee
n 
ex
pe
rie
nc
ed
 in
 th
e 
co
nd
uc
t o
f t
hi
s 
pi
lo
t p
ro
je
ct
 to
 d
at
e 
th
at
 h
av
e 
le
ad
 to
 s
ig
ni
fic
an
t d
el
ay
s 
in
 
ac
hi
ev
in
g 
ou
r p
ro
je
ct
 o
bj
ec
tiv
es
. T
he
se
 in
cl
ud
e:
 
 St
af
fin
g 
 D
ue
 to
 th
e 
co
m
pe
tit
iv
e 
W
A 
em
pl
oy
m
en
t m
ar
ke
t e
ar
ly
 in
 th
e 
pr
oj
ec
t, 
th
er
e 
w
as
 d
iff
ic
ul
ty
 w
ith
 
th
e 
im
m
ed
ia
te
 e
m
pl
oy
m
en
t 
of
 a
n 
ap
pr
op
ria
te
ly
 s
ki
lle
d 
ca
nd
id
at
e 
fo
r 
th
e 
po
si
tio
n 
of
 p
ro
je
ct
 
co
or
di
na
to
r. 
Th
is
 le
ad
 t
o 
a 
de
la
y 
of
 a
 n
um
be
r 
of
 m
on
th
s 
in
 c
om
m
en
ce
m
en
t 
of
 t
he
 p
ro
je
ct
 
an
d 
in
 im
pl
em
en
ta
tio
n 
of
 th
e 
eC
AT
 s
ys
te
m
 in
 th
e 
pi
lo
t h
os
pi
ta
ls
. S
ub
se
qu
en
tly
, t
he
 p
ro
je
ct
 
ex
pe
rie
nc
ed
 a
 c
ha
ng
e 
in
 p
er
so
nn
el
 a
s 
th
e 
or
ig
in
al
 p
ro
je
ct
 c
oo
rd
in
at
or
 e
m
pl
oy
ed
 f
or
 t
hi
s 
pr
oj
ec
t 
re
si
gn
ed
 f
ro
m
 t
he
 p
os
iti
on
 d
ue
 t
o 
he
al
th
 r
ea
so
ns
 in
 M
ay
 2
00
9.
 I
n 
ad
di
tio
n 
to
 t
he
 
de
la
y 
w
ith
 r
ec
ru
itm
en
t, 
su
bs
ta
nt
ia
l 
tim
e 
w
as
 r
eq
ui
re
d 
fo
r 
tra
in
in
g 
of
 t
he
 n
ew
 p
ro
je
ct
 
co
or
di
na
to
r. 
 
 IT
 is
su
es
/s
ys
te
m
 m
od
ifi
ca
tio
ns
 
 As
 o
ut
lin
e 
ab
ov
e,
 s
ig
ni
fic
an
t 
m
od
ifi
ca
tio
ns
 w
er
e 
re
qu
ire
d 
to
 b
e 
m
ad
e 
to
 t
he
 d
at
a 
en
try
 
pr
ot
oc
ol
s 
fo
r 
th
e 
eC
AT
 s
ys
te
m
 t
o 
en
su
re
 c
om
pa
tib
ilit
y 
w
ith
 r
ec
en
tly
 r
el
ea
se
d 
N
EH
TA
 
st
an
da
rd
s.
 T
he
 m
ov
e 
to
w
ar
ds
 a
 n
at
io
na
l e
H
ea
lth
 s
ta
nd
ar
ds
 w
as
 u
ne
xp
ec
te
d 
at
 th
e 
tim
e 
of
 
pr
oj
ec
t 
co
m
m
en
ce
m
en
t, 
bu
t 
es
se
nt
ia
l 
fo
r 
th
e 
fu
tu
re
 
lo
ng
ev
ity
 
of
 
th
e 
eC
AT
 
Sy
st
em
.  
Ad
di
tio
na
lly
, 
an
d 
as
 a
 r
es
ul
t 
of
 fe
ed
ba
ck
 f
ro
m
 c
lin
ic
al
 e
nd
-u
se
rs
 o
f 
th
e 
Sy
st
em
, 
si
gn
ifi
ca
nt
 
m
od
ifi
ca
tio
ns
 t
o 
th
e 
eC
AT
 f
or
m
 w
er
e 
re
qu
ire
d 
to
: 
a)
 i
nc
re
as
e 
us
er
 a
cc
ep
ta
bi
lit
y;
 a
nd
 b
) 
im
pr
ov
e 
de
fic
ie
nc
ie
s 
id
en
tif
ie
d 
in
 th
e 
pr
oc
es
s 
of
 b
et
a 
te
st
in
g 
th
e 
sy
st
em
. T
he
re
fo
re
, w
e 
ha
ve
 
be
en
 h
ig
hl
y 
re
lia
nt
 u
po
n 
ho
sp
ita
l I
T 
se
rv
ic
es
 in
 o
rd
er
 t
o 
m
ak
e 
th
e 
ch
an
ge
s 
re
qu
ire
d 
an
d 
al
lo
w
 b
et
a 
te
st
in
g 
to
 m
ov
e 
fo
rw
ar
d.
 T
he
se
 s
er
vi
ce
s 
w
er
e 
no
t 
bu
dg
et
ed
 f
or
 in
 t
he
 p
ro
je
ct
 
bu
dg
et
 a
nd
 o
ur
 r
el
ia
nc
e 
on
 t
he
 g
oo
dw
ill 
of
 o
ur
 I
T 
se
rv
ic
es
 t
o 
m
ak
e 
th
es
e 
ch
an
ge
s 
ha
s 
re
su
lte
d 
in
 s
ig
ni
fic
an
t a
dd
iti
on
al
 d
el
ay
s.
 
 W
he
n 
w
e 
be
ga
n 
lo
ok
in
g 
at
 i
ns
ta
lla
tio
n 
at
 t
he
 p
riv
at
e 
si
te
s,
 i
ni
tia
lly
 t
he
 E
ye
 S
ur
ge
ry
 
Fo
un
da
tio
n 
(E
SF
), 
w
e 
en
co
un
te
re
d 
di
ffi
cu
lti
es
 in
 a
cc
es
si
ng
 th
e 
th
ea
tre
 li
st
 fr
om
 th
e 
pr
iv
at
e 
ho
sp
ita
l 
du
e 
to
 t
he
 d
iff
er
en
t 
da
ta
ba
se
 m
an
ag
em
en
t 
to
ol
s 
us
ed
 a
t 
th
e 
pr
iv
at
e 
si
te
s.
 F
or
 
ex
am
pl
e,
 t
he
 e
C
AT
 s
ys
te
m
 u
se
d 
SQ
L 
Se
rv
er
 a
s 
th
e 
da
ta
ba
se
 m
an
ag
em
en
t 
to
ol
, 
an
d 
th
e 
ES
F 
us
es
 m
yS
Q
L.
 T
he
 e
C
AT
 s
ys
te
m
 is
 a
cc
es
se
d 
vi
a 
th
e 
th
ea
tre
 li
st
, w
hi
ch
 is
 s
to
re
d 
on
 th
e 
ho
sp
ita
l 
si
te
’s
 s
ys
te
m
. 
Th
er
ef
or
e 
th
e 
eC
AT
 s
ys
te
m
 n
ee
ds
 t
o 
be
 a
bl
e 
to
 i
nt
er
ro
ga
te
 t
he
 
pr
iv
at
e 
si
te
’s
 d
at
ab
as
e 
in
 o
rd
er
 to
 a
cc
es
s 
th
e 
pa
tie
nt
 n
am
es
 o
n 
th
e 
th
ea
te
r 
lis
t. 
Th
is
 m
ea
nt
 
ex
tra
 p
la
nn
in
g 
an
d 
co
m
pu
te
r p
ro
gr
am
m
in
g 
tim
e 
to
 m
ak
e 
th
is
 p
os
si
bl
e 
at
 th
e 
pr
iv
at
e 
si
te
s.
 A
s 
ea
ch
 s
ite
 u
se
s 
a 
di
ffe
re
nt
 d
at
ab
as
e 
m
an
ag
em
en
t 
to
ol
, 
th
e 
pr
og
ra
m
m
in
g 
ne
ed
s 
to
 b
e 
re
-
w
or
ke
d 
fo
r e
ac
h 
pr
iv
at
e 
si
te
.  
         
N
at
io
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l E
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at
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 H
ea
lth
 D
em
on
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ra
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G
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nt
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l R
ep
or
t 
C
en
tre
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r H
ea
lth
 S
er
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s 
R
es
ea
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 S
ch
oo
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io
n 
H
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lth
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f W
es
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  Fu
tu
re
 P
ro
gr
es
s 
 Th
e 
eC
AT
 s
ys
te
m
 is
 c
ur
re
nt
ly
 b
ei
ng
 u
se
d 
su
cc
es
sf
ul
ly
 in
 a
ll 
of
 P
er
th
’s
 T
er
tia
ry
 h
os
pi
ta
ls
 to
 
re
co
rd
 c
at
ar
ac
t 
su
rg
er
y 
da
ta
 a
nd
 g
en
er
at
e 
a 
co
m
pr
eh
en
si
ve
, 
an
d 
cl
in
ic
al
ly
 u
se
fu
l c
at
ar
ac
t 
su
rg
er
y 
po
st
-o
pe
ra
tiv
e 
re
po
rt.
 W
e 
en
vi
si
on
 f
ur
th
er
 r
ol
l-o
ut
 o
f 
th
e 
eC
AT
 s
ys
te
m
 t
o 
ot
he
r 
pu
bl
ic
 h
os
pi
ta
ls
 w
ill 
be
 a
 r
el
at
iv
el
y 
sm
oo
th
 p
ro
ce
ss
 s
in
ce
 t
he
 n
et
w
or
ki
ng
/IT
 i
nf
ra
st
ru
ct
ur
e 
re
qu
ire
d 
fo
r e
C
AT
 a
t t
he
se
 s
ite
s 
is
 a
lre
ad
y 
in
 p
la
ce
. F
ur
th
er
m
or
e,
 th
e 
cl
in
ic
ia
ns
 w
ho
 o
pe
ra
te
 
in
 t
he
se
 h
os
pi
ta
ls
 a
ls
o 
op
er
at
e 
in
 t
he
 t
er
tia
ry
 s
et
tin
g 
an
d 
so
 w
ill 
al
re
ad
y 
be
 f
am
ilia
r 
w
ith
 
eC
AT
. 
Im
pl
em
en
ta
tio
n 
w
ith
in
 t
he
se
 i
ns
tit
ut
io
ns
 i
s 
ex
pe
ct
ed
 t
o 
be
 c
om
pl
et
ed
 b
y 
Ja
nu
ar
y 
20
10
.  
 Fo
rm
al
 c
on
su
lta
tio
n 
ha
s 
be
en
 h
el
d 
w
ith
 th
e 
O
ph
th
al
m
ol
og
y 
H
ea
d 
of
 D
ep
ar
tm
en
t a
t e
ac
h 
of
 
th
e 
pr
op
os
ed
 p
riv
at
e 
ho
sp
ita
l s
ite
s 
(S
JO
G
 B
un
bu
ry
 a
nd
 S
ub
ia
co
, 
LE
I) 
an
d 
al
l i
ns
tit
ut
io
ns
 
ha
ve
 a
gr
ee
d 
to
 im
pl
em
en
t t
he
 e
C
AT
 s
ys
te
m
. I
m
pl
em
en
ta
tio
n 
of
 th
e 
eC
AT
 s
ys
te
m
 in
 P
er
th
’s
 
m
aj
or
 p
riv
at
e 
ho
sp
ita
ls
 w
ill 
re
qu
ire
 a
dd
iti
on
al
 s
up
po
rt 
fro
m
 e
ac
h 
fa
ci
lit
y’
s 
IT
 s
er
vi
ce
 s
in
ce
 th
e 
ne
tw
or
ki
ng
 in
fra
st
ru
ct
ur
e 
at
 e
ac
h 
si
te
 is
 d
iff
er
en
t. 
H
ow
ev
er
, 
us
in
g 
th
e 
le
ss
on
s 
ga
in
ed
 fr
om
 
im
pl
em
en
tin
g 
th
e 
sy
st
em
 in
 th
e 
ES
F 
w
e 
ar
e 
be
tte
r a
bl
e 
to
 a
nt
ic
ip
at
e 
po
ss
ib
le
 d
iff
ic
ul
tie
s,
 a
nd
 
it 
is
 e
xp
ec
te
d 
th
at
 im
pl
em
en
ta
tio
n 
w
ith
in
 t
he
se
 p
riv
at
e 
ho
sp
ita
ls
 w
ill 
be
 a
ch
ie
ve
d 
by
 J
un
e 
20
10
. 
 As
 y
et
, w
e 
ha
ve
 n
ot
 y
et
 n
ee
de
d 
to
 u
se
 a
ny
 o
f t
he
 h
ar
dw
ar
e 
bu
dg
et
 a
s 
th
e 
pu
bl
ic
 h
os
pi
ta
ls
 
an
d 
th
e 
Ey
e 
Su
rg
er
y 
Fo
un
da
tio
n 
ha
ve
 th
ei
r 
ow
n 
pr
in
te
rs
 th
at
 w
e 
w
er
e 
ab
le
 to
 a
cc
es
s.
 It
 is
 
an
tic
ip
at
ed
 th
at
 w
he
n 
th
e 
sy
st
em
 is
 im
pl
em
en
te
d 
at
 th
e 
sm
al
le
r 
pu
bl
ic
 h
os
pi
ta
ls
 a
nd
 p
riv
at
e 
si
te
s 
th
es
e 
m
on
ie
s 
w
ill 
be
 n
ee
de
d 
to
 p
ur
ch
as
e 
ad
di
tio
na
l h
ar
dw
ar
e.
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Po
w
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in
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Pr
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ta
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eCAT 
Electronic Cataract Auditing Tool
Nigel Morlet Ɣ Jonathon Q Ng Ɣ Antony Clark 
Purpose
 $GYDQFHGEURZVHUEDVHGVRIWZDUHV\VWHP
 5HFRUGLQJVWDQGDUGLVHLQIRUPDWLRQ
 3URGXFHVRSHUDWLRQUHSRUWGLVFKDUJH
VXPPDU\DQGSRVWRSHUDWLYHRUGHUV
 3HUVRQDODXGLWLQJ
What information is recorded? 
 &RPSUHKHQVLYHOLVWRIPDQGDWRU\DQG
RSWLRQDOLWHPV
 ([DPSOHV
± $QDHVWKHVLD
± ,2/LPSODQW
± %ODGHV
± 0HGLFDWLRQV
± 3RVWRSHUDWLYHRUGHUV
How to use the form
 $VHFXULW\HQDEOHGZHEEDVHGSRUWDO
 /RJRQWRWKHV\VWHPXVLQJSDVVZRUG
Searching for patient
 3DWLHQWVDUHOLQNHGLQWRWKHV\VWHPWKURXJK
KRVSLWDOWKHDWUHOLVWV
 3DWLHQWVFDQEHVHDUFKHGIRUE\
 3DWLHQWLGHQWLILHUV 7KHDWUHOLVWE\GDWH
Using Template
 8WLOLVHFXVWRPLVHGWHPSODWH
WRUHGXFHGDWDHQWU\
 8SWRRIIRUPV
LQIRUPDWLRQFDQEH
SUHHQWHUHGRQWHPSODWH
 0XOWLSOHWHPSODWHVFDQEH
PDGH
Entering procedure
(mandatory items are in bold)
8VLQJDWHPSODWH
,WHPVIURPWHPSODWHZLOOEH
DXWRPDWLFDOO\ILOOHGRQIRUP
Viewing procedure
 2QFHDSDWLHQWVRSHUDWLRQKDVEHHQHQWHUHG
± &DQYLHZKLVWRULFDOOLVWRISURFHGXUHVSHUIRUPHG
± 9LHZ3')RISURFHGXUHUHSRUWV
Procedure reports
 3')UHSRUWV
JHQHUDWHGXVLQJ
HQWHUHGGDWD
 5HSRUWOD\RXWDQG
LQIRUPDWLRQFDQEH
FXVWRPLVHG
 3URGXFHV
± 3DWLHQWUHSRUW
± &RQVXOWDQWUHSRUW
± 0HGLFDOUHFRUGVUHSRUW
Procedure reports
Use of data
 &UHDWHVWDQGDUGLVHGUHSRUWV
 ([WUDFWRIGDWDFDQEHGRZQORDGHG	XVHG
LQSHUVRQDODXGLWLQJSURJUDP
  A
pp
en
di
x 
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U
se
r 
Ev
al
ua
ti
on
 
Q
ue
st
io
nn
ai
re
 
 
               
El
ec
tr
on
ic
 C
at
ar
ac
t A
ud
it
in
g 
To
ol
 (e
C
A
T)
 U
se
r 
Su
rv
ey
 
Da
te
: _
__
/_
__
/_
__
 
 Th
an
k 
yo
u 
fo
r p
ar
tic
ip
at
in
g 
in
 th
e 
im
pl
em
en
ta
tio
n 
of
 th
e 
C
at
ar
ac
t R
eg
is
try
.  
Pl
ea
se
 te
ll 
us
 w
ha
t y
ou
 th
ou
gh
t o
f t
he
 re
gi
st
er
 a
s 
th
is
 w
ill 
he
lp
 u
s 
im
pr
ov
e 
w
ha
t w
e 
do
 in
 th
e 
fu
tu
re
. 
 1.
 I
n 
w
hi
ch
 h
os
pi
ta
l h
av
e 
yo
u 
us
ed
 th
e 
ca
ta
ra
ct
 re
gi
st
ry
? 
 
 
Si
r C
ha
rle
s 
G
ar
de
ne
r H
os
pi
ta
l  
 
St
 J
oh
n 
of
 G
od
 S
ub
ia
co
 
 
R
oy
al
 P
er
th
 H
os
pi
ta
l 
 
St
 J
oh
n 
of
 G
od
 B
un
bu
ry
 
 
Fr
em
an
tle
 H
os
pi
ta
l 
 
Be
nt
le
y 
H
os
pi
ta
l 
 
Li
on
s 
Ey
e 
In
st
itu
te
 
 
Sw
an
 D
is
tri
ct
s 
H
os
pi
ta
l 
 
Ey
e 
Su
rg
er
y 
Fo
un
da
tio
n 
 
O
sb
or
ne
 P
ar
k 
H
os
pi
ta
l 
 
 
 
2.
 H
ow
 lo
ng
, o
n 
av
er
ag
e,
 d
oe
s 
it 
ta
ke
 y
ou
 to
 c
om
pl
et
e 
a 
pa
tie
nt
s 
op
er
at
io
n 
de
ta
ils
 a
nd
 
pr
od
uc
e 
ap
pr
op
ria
te
 p
ap
er
w
or
k 
us
in
g 
th
e 
ca
ta
ra
ct 
re
gis
try
 w
eb
-b
as
ed
 fo
rm
? 
 
M
in
ut
es
 
 
A.
  I
s 
th
is
 u
si
ng
 a
 c
us
to
m
is
ed
 te
m
pl
at
e?
  Y
 / 
N
 
 
B.
  I
f Y
es
, h
ow
 lo
ng
 d
id
 it
 ta
ke
 y
ou
 to
 s
et
 u
p 
yo
ur
 te
m
pl
at
e?
  
 
M
in
ut
es
 
  3.
 H
ow
 lo
ng
, o
n 
av
er
ag
e,
 d
oe
s 
it 
ta
ke
 y
ou
 to
 c
om
pl
et
e 
a 
pa
tie
nt
s 
op
er
at
io
n 
de
ta
ils
 a
nd
 
pr
od
uc
e 
ap
pr
op
ria
te
 p
ap
er
w
or
k 
us
in
g 
pa
pe
r r
ec
or
ds
? 
 
M
in
ut
es
 
 4.
 U
si
ng
 th
e 
7-
po
in
t s
ca
le
, p
le
as
e 
in
di
ca
te
 h
ow
 s
uc
ce
ss
fu
l t
he
 im
pl
em
en
ta
tio
n 
of
 th
e 
ca
ta
ra
ct
 re
gi
st
ry
 h
as
 b
ee
n 
fo
r y
ou
 a
t t
hi
s 
in
st
itu
tio
n.
  
 
1 
= 
no
t s
uc
ce
ss
fu
l  
   
   
   
  7
 =
 e
xt
re
m
el
y s
uc
ce
ss
fu
l  
  
1 
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Electronic Cataract Auditing Tool (eCAT) Maintenance Log 
 
Error Number 
Date 
Identified Site of Error/Change Brief Description of Error Date finalised 
EN01 17/06/09 Procedure template Remove K1/K2 and wound enlargement/final wound size from the mandatory 
items. (from previous request via email 06/04/09 from Jonathon) 
17/09/2009 
EN02 17/06/09 Procedure template On all templates Phaco Power appears to be mandatory, but it does not have 
an asterix. 17/09/2009 
EN03 17/06/09 Printable PDF forms The PDF forms (discharge etc.) apply the logo for the site where the user is 
logged not where the operation was performed. 9/1/2009 
EN04 17/06/09 Printable PDF forms The RPH PDF form has the SCGH phone number, not the RPH one. 9/1/2009 
EN05 18/06/09 Printable PDF forms Printable Patient Discharge Note/Print Final Copies icons are inactive 9/1/2009 
EN06 6/4/2009 IOL listing Please add Alcon SN60T3, Alcon SN60T4 and Alcon SN60T5 to the IOL drop 
down list. 
Added via Admin 
Console 
27/08/2009 
EN07 6/4/2009 Page Timer Reset the timer to the maximum time with any mouse click/keyboard entry. 
Have the counter start at 35 mins (2100 secs). Currently 900 secs (15mins) 
when change pages only. 21/09/2009 
EN08 15/7/2009 Theatre list page Extra date appears, one day past date selected. Moves to bottom of page 27/08/09 
EN09 16/7/2009 Assistant drop down list Jonathon Ng appears twice, once is misspelt Jonathan 27/08/09 
EN10 15/10/2008 Phacoemulsification 
template 
IOL models not added - MC50BD, SN60AT, SA60AT, MA60MA, CZ70BD, 
MTA4UO, SN60WF, MA60AC 
27/08/09 Added via 
Admin Console 
EN11 15/10/2008 Phaco Template - Op details Should be capsulotomy not capsulostomy 9/1/2009 
EN12 7/11/2008 Phaco Template - Op details Addition text box for lens and phaco machine type only works if the None 
type is selected from the drop down list. Need to create an 'other' type. 
Where is the added type stored?   
EN13 27/08/09 Provider table Check with Jeff the difference in access between the General User and the 
Admin User. 
17/09/2009 
 
 
 
 
Electronic Cataract Auditing Tool (eCAT) Maintenance Log 
 
Error Number 
Date 
Identified Site of Error/Change Brief Description of Error Date finalised 
EN14 1/9/2009 All screens except the login 
in screen 
eCAT becomes eCat on banner after login page. 
   
EN15 4/9/2009 Collapsible menus When you close downt the collapsible menus after ticking boxes the input is 
wiped out.  21/09/2009 
EN16 4/9/2009 eCAT log in screen Name not electronic Cataract auditing tool    
EN17 4/9/2009 Templates option on the ring 
menu 
Can't add and save a template on the ring menu, though we can when going 
through the Add template option when a patient page is open. 17/09/2009 
EN18 4/9/2009 Maintenance section Need a section for maintaining reports. Two functions for this section - must 
be able to define what is printed out in each report, i.e. select the options to 
include, and also select which reports to print. 17/09/2009 
EN19 4/9/2009 Printed reports Take the dcotor's HE number off the report.   
EN20 14/9/2009 Templates/Medications 
section in Maintenance 
When you  tick any of the medications to be included in the template, then 
attempt to use the template to add a new procedure, the form stops at the 
section where the meds should come up. You don’t get the bottom section of 
the form or any options to save. If you don’t select any meds to be on your 
template then it is all hunky dory when you go to use the template to put in a 
procedure and you can save. The error that appears on the bottom of the 
report when you add meds to your template is; ADODB.Recordset error 
800aOcc1. Item cannot be found in the collection corresponding to the 
requested name on ordinal /cats/int_procedure.asp.line 5118 
 17/09/2009 
EN21 14/9/2009 Operation Report In the Profile section where  the operation report is that you can un-select 
items from it all works fine UNTIL you unselect the Intra-op medications (this 
is misspelt, you have inta instead of intra). Once you unselect the intra-op 
medications box, you get an error message next to the Immediate post-op 
meds line on the operational report and there is nothing after that. The error 
is; Microsoft VBScript runtime error ‘800a01a8’ Object required, /cats/int-
procedure.asp,line 8826. If you don’t unselect this option everything works 
fine. 
17/09/2009 
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Error Number 
Date 
Identified Site of Error/Change Brief Description of Error Date finalised 
EN22 14/9/2009 Operation Report The operational reports at QE2 have a common number (730.1) down the side 
and the words operational report down the side of them.  This allows them to 
be filed correctly apparently. Add this to the operational report for QE2.  
  
EN23 14/9/2009 Difficulties section of the 
Maintenance Module 
Can't add a new difficulty to an existing difficulty group. The error reported is; 
[Microsoft][ODBC SQL Server Driver] [SQL Server] Cannot insert the value 
NULL into column ‘difDifficultyID’, table ‘CATS.dbo.tlu_Difficulty’,column 
does not allow NULLS. INSERT fails. 
21/09/2009 
EN24 14/9/2009 Difficulties section of the 
Maintenance Module 
Similarly we couldn’t add a new difficulty group either. The message was 
[Microsoft][ODBC SQL Server Driver] [SQL Server] Cannot insert the value 
NULL into column ‘digDifficultyGroupID’, table 
‘CATS.dbo.tlu_DifficlutyGroup’,column does not allow NULLS. INSERT fails. 
21/09/2009 
EN25 17/9/2009 Address section on Service 
Profile 
Doesn't overrride the service address details even though the heading says 
"Only complete the following information if you want to display different 
details to that of the service on your reports." 
  
EN26 24/09/2009 Adding and editing a 
procedure 
The boxes where there are arrows to allow increasing and decreasing of 
values only allow manual entry of data sometimes. All these number fields 
need to provide the option of manually entering data as well as the up and 
down arrows. 
  
EN27 24/09/2009 Blade size on Procedure page When you select Blade Size to be to 2 decimal places on the template or the 
procedure forms, e.g. 2.75, it is rounded up to a whole number when you go 
back into the procedure again, e.g. the 2.75 becomes 3.00. Can this be fixed 
please? 
   
EN28 24/09/2009 Numerical entry boxes with 
up and down triangles 
 Some of the number boxes that have the small coloured triangles next to 
them for selecting numbers can also be typed directly into and some can’t. 
Can we make it so that all of these boxes that have the triangles next to them 
can also have numbers typed directly into them please? 
   
Electronic Cataract Auditing Tool (eCAT) Maintenance Log 
 
Error Number 
Date 
Identified Site of Error/Change Brief Description of Error Date finalised 
EN29 24/09/2009 Printed Operation Report 
On the Operation Report, when you get the first preview, next to Operation 
Difficulties if you have selected None on the procedure then None is on the 
screen, but when you actually print the report instead of None you get --. Can 
we get the word None printed please?   
EN30 24/09/2009 Operation Report 
 The Operation Report prints all on one page nicely if you tick the option to 
include Intra-op medications on your service profile to include it in the report. 
If you don’t tick the Intra-op meds option but then select options to be 
printed after that, then on the Operation Report you get the Operation 
Difficulties line printed then a page break then the other things that you 
selected on the next page. Not sure why this is but that’s what happens.   
***** Extracting data for personal auditing     
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arch&(E
VER)&G
roup,&P
erth,&W
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Perth,&W
estern&
Austra
lia&
Email:&
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@curti
n.edu.a
u&
Phone&
+61W43
881299
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%
2&
“Big&da
ta”&is&a
&relativ
ely&new
&concep
t&that&d
escribe
s&data&s
o&large
&and&co
mplex&
that&it&e
xceeds
&the&sto
rage&or
&compu
ting&ca
pacity&
of&mos
t&system
s&to&per
form&
timely&
and&acc
urate&a
nalyses
.159,230 &H
ealth&g
enerate
s&huge&
amoun
ts&of&da
ta&from
&
a&wide
&array&o
f&sourc
es&such
&as&elec
tronic&h
ealth&re
cords&(
EHR),&h
ealth&in
suranc
e&
claims,
&and&ev
en&sma
rt&phon
e&appli
cations
&that&m
onitor&
patient
&health
.&It&is&th
e&
subject
&of&inte
nse&int
erest&a
s&indus
try&and
&resear
chers&a
like&rea
lize&the
&huge&
potent
ial&in&e
xtractin
g&value
&from&e
xisting
&data&sy
stems.&
The&‘bi
g&data&
revolut
ion’&
is&bein
g&incre
asingly
&suppo
rted&by
&nation
al&gove
rnmen
ts,&who
&are&fun
ding&
initiati
ves&des
igned&t
o&devel
op&and
&capita
lize&on
&big&da
ta.57,159
&
Even&b
efore&th
e&big&d
ata&rev
olution
,&health
&resear
chers&h
ave&lon
g&recog
nized&t
he&
value&i
n&large
&admin
istrativ
e&datab
ases.252
&The&la
st&deca
de&has&
seen&a&
dramat
ic&
increas
e&in&the
&their&u
se&for&o
phthalm
ic&resea
rch.33,2
15 &Thes
e&datab
ases&co
ntain&a
&
wealth
&of&info
rmatio
n&that&c
an&now
&be&acc
essed&i
n&a&tim
ely&and
&costWef
ficient&
manne
r&due&to
&advan
ces&in&c
omput
ing&pow
er&and&
the&dev
elopme
nt&of&ne
w&
analyti
cal&met
hodolo
gies&re
quired
&to&ana
lyze&th
em.95 &T
hese&ad
vances
&have&a
lso&
facilita
ted&dat
a&integ
ration&
proces
ses&tha
t&offer&
greater
&utility&
over&us
ing&
individ
ual&dat
abases
&for&hea
lth&rese
arch&e.
g.&linki
ng&pha
rmaceu
tical&cla
ims&da
ta&
to&hosp
ital&dis
charge
&data&a
llows&s
tudy&of
&health
&outcom
es&asso
ciated&
with&
medica
tion&us
e.&It&pro
mises&t
he&pote
ntial&fo
r&more
,&almos
t&limitl
ess,&am
ounts&o
f&
data&av
ailable
&for&res
earch.&
&
In&this&
review
&we&exp
lore&ad
ministr
ative&d
atabase
s&used&
in&opht
halmic
&resear
ch,&
how&th
ey&com
pare&w
ith&clin
ical&reg
istries,
&their&b
enefits
&and&lim
itation
s&and&
outline
&some&o
f&the&ne
w&deve
lopmen
ts&for&t
he&futu
re.&
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M
IN
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%D
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A%
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D
%C
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N
IC
AL
%R
EG
IS
TR
IE
S&
Admin
istrativ
e&datab
ases&us
ed&in&h
ealth&re
search
&are&pr
eWexist
ing&dat
asets&
whose&
primar
y&purp
ose&is&t
he&stor
age&of&i
nforma
tion&ro
utinely
&collect
ed&from
&
the&poi
nt&of&se
rvice,&u
sually&f
or&billi
ng&pur
poses&e
.g.&hosp
ital&ins
urance
&claims
&
inform
ation&a
nd&pha
rmaceu
tical&bi
lling&da
ta.&The
&variab
les&typ
ically&r
ecorde
d&
range&w
idely&b
ut&gene
rally&in
clude:&
a&patie
nt&spec
ific&ide
ntificat
ion&num
ber,&
demog
raphic&
details
&(e.g.&na
me,&sex
,&date&o
f&birth,
&and&ad
dress)&
and&lim
ited&
clinical
&data&(e
.g.&diag
nostic/
proced
ural&co
des&in&h
ealth&in
suranc
e&claim
s&data&o
r&
drug&co
des&in&p
harmac
eutical
&claims
&data).&
These&d
atabase
s&are&n
ormall
y&very&
3&
large,&c
over&la
rge&def
ined&po
pulatio
ns&with
in&a&giv
en&hea
lth&juri
sdictio
n,&and&
span&ye
ars&if&n
ot&deca
des&of&s
ervice&
(Table&
1).&
Clinica
l&regist
ries&are
&differe
nt&to&ad
ministr
ative&d
atabase
s.&They
&are&de
signed
&to&
collate
&detaile
d&and&s
pecific&
clinical
&inform
ation,&u
sually&f
or&qual
ity&assu
rance&
and&cli
nical&au
dit.&On
ly&a&few
&truly&p
opulati
onWbas
ed&oph
thalmic
&registr
ies&
curren
tly&exis
t,&thoug
h&this&n
umber
&is&incr
easing&
e.g.&cat
aract&s
urgery
,9,124 &an
d&
cornea
l&transp
lant&reg
istries.
29,38,1
68 &Thes
e&regis
tries&ar
e&powe
rful&too
ls&for&
health&
researc
h&since
&they&co
ntain&a
&level&o
f&detail
ed&clin
ical&inf
ormati
on&that
&
curren
t&admin
istrativ
e&datab
ases&sim
ply&can
not&ma
tch.&
D
AT
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IN
TE
GR
AT
IO
N
&
Data&in
tegrati
on&(als
o&know
n&as&da
ta&linka
ge)&inc
reases&
the&util
ity&of&in
dividua
l&
dataset
s&by&br
inging&
togethe
r&two&o
r&more
&differe
nt&sour
ces&of&d
ata&tha
t&relate
&to&
the&sam
e&perso
n,&fami
ly&or&ev
ent.100 &
Linking
&data&fo
r&health
&resear
ch&was
&first&
describ
ed&by&D
r.&Halb
ert&Dun
n&in&19
46&whe
n&he&pr
oposed
&the&co
ncept&o
f&a&‘boo
k&
of&life’,
&its&pag
es&the&r
ecords
&from&s
ignifica
nt&even
ts&in&a&p
erson’s
&life&e.g
.&birth,&
educat
ion,&ma
rriage,&
health&
and&de
ath&(Fi
gure&1)
.46 &&
Linkag
e&requi
res&ide
ntifiers
&comm
on&to&a
ll&datas
ets.79,20
4 &These
&may&b
e&uniqu
e&
(e.g.&a&p
atient’s
&insura
nce&nu
mber),
&or&par
tial&(e.g
.&name
,&date&o
f&birth,
&gende
r,&
place&o
f&birth,
&postco
de&etc.)
&and&ar
e&tradit
ionally
&match
ed&usin
g&three
&genera
l&
techniq
ues&(Ta
ble&2).&
Most&sy
stems&t
oday&u
se&prob
abilisti
c&match
ing&tec
hnique
s&
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e&even&
unique
&identif
iers&(e.
g.&socia
l&secur
ity&num
ber)&ca
n&be&in
accura
te&
due&to&
errors&
in&reco
rding.7
9 &
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&not&be
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ed&to&h
ealthWr
elated&
dataset
s&and&in
deed&a
ny&data
set&
with&th
e&appro
priate&i
dentifi
ers&can
&be&inte
grated.
&The&op
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ity&for&
ophtha
lmic&re
search
&is&ther
efore&li
mited&o
nly&by&
the&dat
a&availa
ble&e.g.
&linking
&
health&
and&me
teorolo
gical&da
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se&tren
ds&acro
ss&wea
ther&pa
tterns&t
o&
be&stud
ied,144 &
or&link
ing&cat
aract&o
peratio
n&data&
with&ro
ad&traf
fic&data
&allows
&its&
impact
&on&driv
ing&per
forman
ce&to&be
&examin
ed.162 &
Recogn
ition&of
&the&im
mense
&value&o
f&data&i
ntegrat
ion&in&s
upport
ing&hea
lth&
researc
h&has&le
d&to&a&s
ignifica
nt&expa
nsion&i
n&data&
linkage
&capaci
ty&and&
infrast
ructure
&across
&the&glo
be&with
&succes
sful&sys
tems&w
ell&esta
blished
&in&
Canada
,&Austra
lia,&the
&UK&and
&the&US
.105,205 &
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There&h
as&been
&some&s
keptici
sm&reg
arding&
the&val
ue&of&re
search
&arising
&from&
admini
strativ
e&data&
since&it
&is&obse
rvation
al&by&n
ature&a
nd&thes
e&datab
ases&w
ere&
never&i
ntende
d&for&u
se&in&he
alth&res
earch.1
5,28 &Thi
s&is&com
pounde
d&by&th
e&heavy
&
empha
sis&on&r
andom
ized&co
ntrolle
d&trials
&(RCT)&
as&the&‘
gold&st
andard
’&for&
evalua
ting&tre
atment
,&which
&ignore
s&the&li
mitatio
ns&inhe
rent&in
&RCT&
method
ology.&R
CTs&do
&not&ref
lect&rea
lWlife&co
mmuni
ty&prac
tice,&lea
ving&cli
nicians
&
to&use&t
heir&jud
gment&
in&extra
polatin
g&findin
gs&from
&trials&t
hat&rela
te&to&a&
highly&
selecte
d&patie
nt&that
&may&b
e&seldo
m&enco
untere
d.&Obse
rvation
al&stud
ies&usin
g&
large&d
atabase
s&can&c
omplem
ent&RCT
s&by&go
ing&som
e&way&t
owards
&addres
sing&
their&li
mitatio
ns.15 &Th
eir&larg
e&size&p
rovides
&whole
Wpopul
ation&c
apture
;&thereb
y&
avoidin
g&nonWr
eprese
ntative
&sampl
es&and&
selectio
n&bias,&
which&
may&oc
cur&in&
random
ized&tri
als.&The
y&meas
ure&the
&true&ef
fective
ness&of
&an&inte
rventio
n&that&i
s&
based&o
n&actua
l&‘real&w
orld’&pr
actice&w
hich&is&
highly&
variabl
e&unlik
e&the&h
ighly&
contro
lled&en
vironm
ent&in&R
CTs.&W
hole&po
pulatio
n&or&big
&observ
ational
&studie
s&&
are&als
o&bette
r&powe
red&to&s
tudy&ra
re&even
ts&and&
small&e
ffect&si
zes&due
&to&very
&
large&s
ample&
sizes,&a
nd&the&
typical
ly&long
&time&s
pan&co
vered&b
y&many
&databa
ses&
enable
s&longW
term&ev
ents&to
&be&exa
mined.
&Recall
&bias&an
d&bias&r
elated&
to&nonW
partici
pation&
and&los
s&to&fol
lowWup
&is&min
imized
&since&a
ll&eligib
le&peop
le&are&
include
d.&Beca
use&the
se&data
bases&a
re&prim
arily&cr
eated&f
or&adm
inistrat
ive&
purpos
es&then
&individ
ual&pat
ient&co
nsent&i
s&usual
ly&not&r
equired
&or&
warran
ted.100,
226 &
The&ad
vantag
es&and&
social&b
enefits
&of&rese
arch&ar
ising&fr
om&larg
e&admi
nistrat
ive&
data&an
d&data&
linkage
&system
s&over&
traditio
nal&res
earch&m
ethods
&are&sig
nifican
t&
and&inc
lude:& i. dec
reased
&cost&of
&resear
ch:&usin
g&existi
ng&data
&is&a&rel
atively
&cheap&
and&
effectiv
e&altern
ative&to
&perfor
ming&d
e#
no
vo
&studie
s.204,226
&&
ii. incr
eased&e
fficienc
y&of&res
earch:&
access&
to&exist
ing&clin
ical&inf
ormati
on&
vastly&r
educes
&the&tim
e&need
ed&com
pared&t
o&studi
es&requ
iring&p
rimary
&
data&co
llection
.&This&is
&particu
larly&im
portan
t&when
&assess
ing&safe
ty&of&
new&tr
eatmen
ts&such
&as&pos
tWmark
eting&s
urveilla
nce&of&n
ew&dru
gs.&20 &
iii. con
servati
on&of&p
atient&p
rivacy:
&the&pri
vacy&of
&individ
ual&pat
ients&is
&
conser
ved&sin
ce&it&is&
usually
&not&ne
cessary
&for&per
sonal&id
entifier
s&to&
5&
be&prov
ided&to
&resear
chers.2
59 &Usin
g&large
&admin
istrativ
e&datab
ases&
also&co
nserve
s&priva
cy&of&al
l&patien
ts,&rega
rdless&
of&whe
ther&th
ey&
would&
have&gi
ven&con
sent&to
&the&us
e&of&the
ir&infor
mation
.&A&con
sentW
based&a
pproac
h&conse
rves&th
e&priva
cy&only
&of&thos
e&who&d
o&not&
partici
pate,&u
sually&a
t&a&cost
&of&mak
ing&the
&resear
ch&irre
concila
bly&
imprac
tical.99 &
iv. add
ing&val
ue&to&e
xisting
&inform
ation&a
ssets:&i
ntegrat
ing&dat
asets&is
&a&nonW
invasiv
e&and&c
ostWeffe
ctive&m
eans&to
&genera
te&a&gre
ater&re
turn&on
&the&
substan
tial&exi
sting&in
vestme
nt&in&ro
utine&a
dminis
trative
&data&se
ts.197 &
It&also&
adds&va
lue&to&e
xisting
&data&se
ts&thro
ugh&ass
isting&i
n&quali
ty&
improv
ement&
of&data
&throug
h&the&li
nkage&p
rocess.
&
Limitat
ions&of
&studie
s&that&u
se&adm
inistrat
ive&dat
a&surro
und&the
&use&of&
data&
whose&
primar
y&purp
ose&is&n
ot&for&r
esearch
.33,104,21
5 &The&r
esearch
er&shou
ld&be&
cogniza
nt&of&ho
w&the&d
ata&wa
s&collec
ted&and
&coded.
&The&fir
st&hurd
le&relie
s&on&th
e&
patient
&with&a
&particu
lar&con
dition&s
eeking
&care&–&
if&it&is&n
ot&serio
us&enou
gh&to&
warran
t&seekin
g&healt
h&care&
it&will&n
ot&be&re
corded
&and&ca
nnot&be
&studie
d.&Ther
e&
also&ne
eds&to&b
e&a&cod
e&attac
hed&to&
the&con
dition&o
r&proce
dure&of
&intere
st&
(usuall
y&Inter
nationa
l&Classi
fication
&of&Dise
ases&co
des&(IC
D)&e.g.;
&ICDW10
175 &so&a
ny&
additio
nal&non
Wcoded
&clinica
l&data&c
annot&b
e&studi
ed.&Cod
es&may
&not&be
&specifi
c&
enough
&to&allo
w&more
&detaile
d&study
&(e.g.&‘g
laucom
a’&rathe
r&than&
‘pigme
nt&
dispers
ion&gla
ucoma
’)&and&m
ay&not&
necess
arily&in
dicate&
the&sev
erity&of
&a&
conditi
on.&Est
ablishi
ng&late
rality&t
o&a&par
ticular&
eye&is&a
&major&
proble
m&since
&
many&d
atasets
&histori
cally&di
d&not&r
ecord&t
his&info
rmatio
n&and&m
ay&limi
t&
investi
gation&
of&adve
rse&eve
nts.&
Data&qu
ality&an
d&comp
letenes
s&will&t
end&to&
vary&ac
ross&da
tabases
&and&va
riables
&
being&s
tudied.
&Some&e
rrors&a
re&less&
likely&t
o&occur
&e.g.&co
ding&fo
r&prima
ry&
surgica
l&proce
dures;&
while&o
thers&h
ave&bee
n&show
n&to&be
&preval
ent&e.g
.&omitte
d&
coding
&for&sec
ondary
&diagno
ses.104,
206,21
5 &Datab
ases&m
ay&also
&change
&over&ti
me&
with&ch
anges&i
n&code
s&and&t
he&add
ition&or
&deletio
n&of&va
riables
.&The&w
ay&data
&is&
genera
ted&or&c
ollated
&may&al
so&vary
&betwe
en&data
sets&an
d&with&
time.10
4 &
It&is&ess
ential&t
hat&the
&resear
cher&in
timatel
y&unde
rstand&
how&th
eir&data
&was&
genera
ted&and
&how&it
&may&h
ave&evo
lved&ov
er&time
.&A&clos
e&work
ing&rela
tionshi
p&
betwee
n&resea
rcher&a
nd&data
&custod
ian&is&e
ssentia
l&if&erro
rs&in&an
alysis&a
nd&
6&
interpr
etation
&are&to&
be&avoi
ded.&Va
lidation
&studie
s&with&
chart&r
eview&m
ay&be&
require
d&to&he
lp&quan
tify&the
&size&of
&these&i
ssues&w
ithin&an
y&given
&data&
collecti
on.8,77,1
43,192
,254 &
Care&m
ust&also
&be&tak
en&whe
n&calcu
lating&i
nciden
ce/pre
valence
&or&gen
eralizin
g&
results
&to&the&
wider&p
opulati
on&sinc
e&many
&databa
ses&con
tain&a&l
imited&
subset&
of&
the&pop
ulation
&that&is
&unlike
ly&to&be
&repres
entativ
e&of&the
&whole
.&For&ex
ample,
&
the&US&
Medica
re&data
base&on
ly&inclu
des&tho
se&who
&are&old
er&than
&65&yea
rs,&
disable
d,&or&po
or;&whi
le&priva
te&heal
th&insu
rance&c
ompan
y&claim
s&data&i
s&limite
d&
to&thos
e&who&c
an&affo
rd&heal
th&insu
rance&a
nd&omi
ts&the&m
ore&vul
nerable
&lower&
socioec
onomic
&groups
&and&ra
cial&mi
noritie
s&witho
ut&insu
rance&w
ho&are&
more&
likely&t
o&need
&care.&T
he&limi
ted&cov
erage&o
f&insura
nce&dat
abases
&also&m
eans&lo
ss&
to&follo
wWup&c
an&be&a
n&issue
&when&
patient
s&move
&in&and
&out&of&
the&ins
urance
&
organiz
ation.&C
onvers
ely&dat
abases
&in&juris
diction
s&with&
univer
sal&hea
lth&care
,&
and&pa
rticular
ly&data
&linkag
e&syste
ms,&are
&truly&p
opulati
onWbas
ed&and
&so&are&
readily
&genera
lized&w
ith&ver
y&little&
loss&to&
followW
up&that
&can&off
er&true
&measu
res&
of&incid
ence&an
d&preva
lence.&F
or&exam
ple,&lin
king&ca
ncer&re
gistry&d
ata&wit
h&data&
from&a&
local&ca
ncer&re
ferral&c
enter&in
&Germa
ny&incr
eased&t
he&inci
dence&o
f&uveal
&
melano
ma&by&
nearly&
four&tim
es&com
pared&t
o&using
&cancer
&registr
y&data&
alone&
(from&2
.3&to&8.
6&cases
&per&mi
llion&PY
).234 &&
Finally
,&analys
is&of&th
ese&dat
abases
&should
&take&in
to&acco
unt&the
&risk&of
&
confou
nding&d
ue&to&c
omorb
idity,&s
ocioWde
mograp
hic&fact
ors&and
&effect&
modific
ation.33
,215 &Mu
ltivaria
te&mod
eling&a
nd&othe
r&techn
iques&c
an&be&u
sed&to&
adjust&
for&the
se&effec
ts&so&lo
ng&as&th
ey&are&
presen
t&in&the
&data.&I
f&these
&limitat
ions&
are&add
ressed
&in&the&
study&d
esign,&d
ata&ana
lysis&an
d&inter
pretati
on;&the
n&any&
study&f
indings
&using&a
dminis
trative
&data&ca
n&still&p
rovide&
valuab
le&addi
tional&
inform
ation&to
&the&av
ailable
&eviden
ce.&
AP
PL
IC
AT
IO
N
S%
IN
%O
PH
TH
AL
M
IC
%R
ES
EA
RC
H
&
Large&a
dminis
trative
&databa
ses&hav
e&been&
used&in
&a&broa
d&range
&of&oph
thalmic
&
researc
h&studi
es&into
&diseas
e&surve
illance
,&diseas
e&etiolo
gy,&hea
lth&serv
ice&
utilizat
ion&and
&health
&outcom
es&(inc
luding&
postWm
arketin
g&surve
illance
).&
D
IS
EA
SE
%S
U
R
VE
IL
LA
N
CE
&
Data&on
&preval
ent&or&i
nciden
t&event
s&is&req
uired&t
o&unde
rstand&
pattern
s&of&
7&
disease
&in&the&
commu
nity&an
d&may&
be&read
ily&avai
lable&in
&health
&admin
istrativ
e&
databa
ses&(wi
th&the&c
aveats&
already
&outline
d).&Lar
ge&data
sets&ar
e&partic
ularly&
useful&
in&the&s
tudy&of
&rare&d
iseases
&due&to
&the&sh
eer&size
&of&the&
popula
tion&th
ey&
cover;&
and&sin
ce&man
y&span&
decade
s,&they&
are&als
o&ideal
&for&stu
dying&t
he&
longitu
dinal&p
atterns
&of&dise
ase.&Fo
r&exam
ple,&the
&incide
nce&of&p
rimary
&angle&
closure
&glauco
ma&(PA
CG)&wa
s&first&d
escribe
d&by&Er
ie&et&al
&in&199
7&using
&hospit
al&
admini
strativ
e&data&
from&th
e&Roch
ester&E
pidemi
ology&P
roject&(
REP);&t
hey&
reporte
d&an&an
nual&in
cidence
&of&8.3&
per&100
,000&(9
5%&CI,&
5.6W11.
0)&in&th
e&over&
40&yea
r&olds&i
n&Olms
tead&Co
unty,&M
inneso
ta&for&1
980W19
92.&51 &A
&simila
r&study
&
using&h
ospital
&admis
sion&da
ta&in&Si
ngapor
e&by&W
ong&et&
al&in&20
00&foun
d&the&
annual
&incide
nce&of&P
ACG&in
&an&Asi
an&pop
ulation
&was&hi
gher&at
&11.1&p
er&100,
000&
(95%&C
I,&10.4W
11.8).2
70 &Hu&e
t&al&use
d&whol
eWpopu
lation&h
ealth&in
suranc
e&claim
s&
data&fr
om&503
,687&pe
ople&in
&Taiwa
n&to&de
scribe&
the&rela
tionshi
p&betw
een&
catarac
t&surge
ry&and&
admiss
ion&for
&acute&a
ngle&clo
sure&ov
er&the&e
ightWye
ar&
period
&1997W2
004.&Th
ey&foun
d&a&sign
ificant&
correla
tion&be
tween&
the&dec
line&in&
acute&a
ngle&clo
sure&an
d&the&ri
se&in&ca
taract&s
urgery
&(Spear
man&ra
nk&r&=&W
0.407,&
P&
<&0.001
).102 &Ot
her&stu
dies&ha
ve&exam
ined&th
e&incid
ence&an
d/or&pr
evalen
ce&of&
vision&
loss&an
d&blind
ness,40
&glauco
ma,25,14
0,229,2
41,255
&diabet
ic&retin
opathy
,139,229 &
ageWrel
ated&m
acular&
degene
ration&
(ARMD
),121,139
&coWmo
rbidity
&with&A
RMD,27
1,275 &
retinal
&detach
ment,5
2,167,2
69 &sixth
&nerve&
palsy,1
87 &strab
ismus,1
61 &dryWe
ye&
disease
,272 &reti
nopath
y&of&pre
maturi
ty,78 &oc
ular&tra
uma,26
,27,268
&retinal
&vein&
occlusi
on,96 &en
dophth
almitis
,26,103,12
9,171,2
31,266
&and&sp
inal&su
rgeryWr
elated&
posteri
or&isch
emic&op
tic&neu
ropath
y.189 &
D
IS
EA
SE
%E
TI
O
LO
GY
&
While&i
t&is&not
&possib
le&to&es
tablish
&causal
ity&in&r
etrospe
ctive&o
bserva
tional&
studies
,&admin
istrativ
e&datab
ase&stu
dies&ca
n&assis
t&in&ide
ntifyin
g&poten
tial&fac
tors&
in&the&e
tiology
&of&ocu
lar&dise
ase&to&d
irect&fu
rther&s
tudy&in
&a&time
&and&co
st&effic
ient&
manne
r.&This&
is&parti
cularly
&useful
&in&the&
study&o
f&rare&d
iseases
&when&
large&
numbe
rs&are&r
equired
&to&esta
blish&an
y&mean
ingful&a
ssociat
ions.&V
ajdic&et
&al&used
&
data&fr
om&the
&Austra
lian&na
tionwid
e&kidne
y&dialy
sis&and
&transp
lant&reg
istry,&
linked&
with&th
e&cance
r&regist
ry,&to&g
enerate
&a&coho
rt&large
&enoug
h&to&stu
dy&the&
associa
tion&be
tween&
immun
osuppr
ession&
and&the
&rare&d
isease&
ocular&
squam
ous&
8&
cell&car
cinoma
&(SCC).
&The&st
udy&inc
luded&1
0,180&r
enal&tra
nsplan
t&patien
ts&over
&
86,898
&person
Wyears&
followW
up&and
&found&
a&20Wfo
ld&incre
ase&in&t
he&inci
dence&r
ate&
of&ocul
ar&OSC
C&in&im
munos
uppres
sed&pat
ients&(s
tandar
dized&i
nciden
ce&ratio
&
19.5,&9
5%&CI&6
.3W45.5
).260 &Th
ey&wer
e&the&fi
rst&to&r
eport&o
n&the&a
ssociat
ion&out
side&
of&the&k
nown&l
ink&wit
h&huma
n&immu
nodefic
iency&v
irus&an
d&adde
d&furth
er&weig
ht&
to&the&h
ypothe
sis&that
&immun
odefici
ency&ha
s&a&role
&in&ocu
lar&SCC
.&In&ano
ther&
more&r
ecent&s
tudy,&B
onamy
&et&al&re
ported
&finding
s&from&
their&p
opulati
onWbas
ed&
study&u
sing&lin
ked&po
pulatio
n&regis
tries&ex
aminin
g&the&ri
sk&of&la
te&retin
al&
detach
ment&in
&preter
m&infan
ts&born
&in&Swe
den.18 &T
his&larg
e&study
&of&ove
r&3&
million
&births&
spanne
d&35&ye
ars&sin
ce&197
3&with&
a&medi
an&follo
wWup&o
f&17.4&
years.&R
etinal&d
etachm
ents&af
ter&pre
term&b
irth&are
&rare&w
ith&just
&0.029&
cases&p
er&
1000&p
ersonWy
ears.&Si
gnifica
nt&risk&
factors
&were&b
irth&be
fore&32
&weeks
&and&m
ale&
gender
.&The&ri
sk&(HR
)&of&ret
inal&de
tachme
nt&for&e
xtreme
ly&pret
erm&inf
ants&(<
28&
weeks)
&and&pr
eterm&i
nfants&
(28W31
&weeks
)&was&1
9.2&and
&4.32&re
spectiv
ely&for&
infants
&born&1
973W19
86;&wh
ich&dec
reased
&to&8.95
&and&2.
80&resp
ectivel
y&for&
infants
&born&1
987W20
08&afte
r&the&in
troduc
tion&of&
routine
&retino
pathy&o
f&
premat
urity&sc
reening
.&Males
&were&n
early&tw
ice&as&l
ikely&to
&have&a
&late&re
tinal&
detach
ment.&
Other&e
xample
s&includ
e&a&stud
y&on&th
e&assoc
iation&b
etween
&reduce
d&sunsh
ine&
exposu
re&and&
increas
ed&ang
le&closu
re&glau
coma;2
56 &gene
tics&and
&open&a
ngle&
glaucom
a;253 &di
abetes&
and&an
&increa
sed&ris
k&of&gla
ucoma
,48 &sixth
&nerve&
palsy18
7,188 &an
d&acute
&conjun
ctivitis
;137 &risk
&factors
&for&cen
tral&ret
inal&ve
in&
occlusi
on;245 &a
nd&the&
lack&of&
associa
tion&be
tween&
vitamin
&D&defic
iency&a
nd&
macula
r&degen
eration
.44 & HEA
LT
H
%S
ER
VI
CE
S%
U
TI
LI
ZA
TI
O
N
&
Unders
tanding
&patter
ns&and
&trends
&in&eye&
service
&use&is&
essenti
al&to&ad
equate
&
plannin
g&by&go
vernm
ents&an
d&agen
cies&to&
anticip
ate&ser
vice&ne
eds&and
&costs.&
This&is&
particu
larly&im
portan
t&for&ap
preciat
ing&var
iations
&in&the&
pattern
s&of&car
e&
betwee
n&clinic
al&subW
popula
tions&(e
.g.&soci
odemo
graphic
&and&ge
ograph
ic&grou
ps)&
for&iden
tifying&
areas&o
f&servic
e&defici
ency&or
&ineffic
iency.&&
Large&h
ealth&a
dminis
trative
&databa
ses&are
&ideal&f
or&stud
ies&on&h
ealth&se
rvice&
utilizat
ion&sin
ce&they
&are&de
rived&fr
om&the
&delive
ry&of&th
ese&ser
vices&m
eaning
&
9&
every&c
linical&
service
&encoun
ter&is&‘c
apture
d’&to&pr
ovide&a
n&entir
eWpopu
lation&
cohort
&on&wh
ich&to&c
onduct
&resear
ch&with
out&the
&need&t
o&extra
polate&
finding
s.&
The&ric
hness&o
f&inform
ation&o
n&servi
ce&prov
ision&co
ntained
&in&thes
e&datab
ases&is&
reflecte
d&in&the
&volum
e&of&op
hthalm
ic&resea
rch&pub
lished&
in&this&
area.&T
he&
majori
ty&of&st
udies&h
ave&exa
mined&
trends&
and&pa
tterns&o
f&ophth
almic&s
ervices
&
use&ove
r&time,&
and&acr
oss&soc
ioWdem
ograph
ic&and&g
eograp
hic&gro
ups.&Ma
ny&of&
these&f
ocused
&on&tren
ds&in&ey
e&surge
ry&and&
use&of&o
phthalm
ic&drug
s&(part
icularly
&
for&glau
coma).
&
Pa
tt
er
ns
%o
f%c
ar
e&
Establi
shing&t
rends&i
n&ophth
almic&s
ervice&
use&ove
r&time&
is&easil
y&achie
ved&usi
ng&
admini
strativ
e&datab
ases&sin
ce&mos
t&span&
decade
s.&The&f
irst&dat
a&linka
ge&stud
y&to&
examin
e&trend
s&in&op
hthalm
ic&servi
ces&wa
s&the&O
xford&R
ecord&L
inkage
&Study,
&in&
the&Oxf
ord&reg
ion&of&t
he&UK&i
n&1991
.59 &The
&study&
found&t
he&use&
of&opht
halmic
&
service
s&incre
ased&16
.3%&ov
er&an&1
1Wyear&
period
&(1975
W1985)
,&while&
the&len
gth&
of&stay
&per&ad
mission
&to&hos
pital&de
creased
&from&6
.5&to&4.
8&days.
&Subseq
uently&
Ellwein
&et&al&an
alyzed&
data&fr
om&the
&US&Me
dicare&
databa
se&of&ov
er&65&y
ear&old
s&
to&look
&at&tren
ds&in&ey
e&care&u
tilizatio
n&and&t
he&type
&of&prov
iders&p
rovidin
g&this&
service
.49,50 &Th
ey&foun
d&a&6.7
%&rise&
(41.4%
&to&48.1
%)&in&t
he&prop
ortion&
of&peop
le&
accessi
ng&eye&
service
s&betw
een&19
91&and
&1998;&
and&tha
t&ophth
almolo
gists&
provid
ed&the&
majori
ty&of&ey
e&care&b
illed&un
der&Me
dicare&
(71%).
&
Identif
ying&ar
eas&of&u
nder&an
d&over&
servici
ng&is&im
portan
t&in&the
&equita
ble&
distrib
ution&o
f&limite
d&healt
h&resou
rces&pa
rticular
ly&to&vu
lnerabl
e&popu
lations
.&
Such&p
atterns
&of&serv
ice&deli
very&ar
e&readi
ly&iden
tified&u
sing&he
alth&
admini
strativ
e&datab
ases&th
at&cove
r&large&
popula
tion&co
horts&a
cross&g
eograp
hic&
and&de
mograp
hic&bou
ndaries
.&This&a
llows&p
atterns
&of&serv
ice&deli
very&ac
ross&
socioec
onomic
,&race,&g
ender,&
and&ge
ograph
ic&grou
ps&to&b
e&exam
ined.&In
&Weste
rn&
Austra
lia&link
ed&who
leWpopu
lation&h
ospital
&admin
istrativ
e&data&
was&us
ed&to&
describ
e&the&g
rowing
&inequi
ty&in&th
e&catar
act&sur
gery&ra
te&for&r
ural/re
mote&
(metro
politan
&patien
ts&had&
24%&m
ore&sur
gery)&a
nd&low
er&soci
oecono
mic&gro
ups&
(the&di
sadvan
taged&h
ad&9%&
less&su
rgery),
&despit
e&an&ov
erall&im
provem
ent&in&
access&
to&cata
ract&su
rgery.1
76,178
,261 &Oth
er&stud
ies&hav
e&found
&simila
r&
socioec
onomic
&and&ge
ograph
ic&varia
tions&in
&catara
ct&surg
ery&uti
lization
&in&the&
UK&
using&t
he&Oxfo
rd&reco
rd&link
age&stu
dy&(OR
LS)130 &a
nd&in&th
e&US&us
ing&Me
dicare&
10&
data.55
,118,21
0 &&
Racial&
variatio
n&in&the
&treatm
ent&of&g
laucom
a&was&r
eporte
d&in&sev
eral&US
&studie
s&
using&M
edicare
/Medic
aid&dat
a.&Most
&found&
the&rat
es&of&ey
e&servi
ce&use&
in&
African
WAmeri
cans&w
ere&as&m
uch&as&
50%&lo
wer&tha
n&Cauc
asians&
despite
&an&
increas
ed&prev
alence&
of&glau
coma&in
&the&Afr
icanWAm
erican&
popula
tion.45,8
0,113,1
84,264
&&
In&Wes
tern&Au
stralia,
&linkag
e&of&bli
nd&regi
ster&da
ta&with
&whole
Wpopul
ation&
hospita
l&data&a
llowed
&health
&utiliza
tion&by
&the&sev
erely&v
ision&im
paired&
to&be&
studied
&for&the
&first&ti
me.&Sig
nifican
tly&mor
e&hospi
tal&atte
ndance
s&for&bl
ind&adu
lts&
(incide
nce&rat
e&ratio&
[IRR]&1
.5,&95%
CI&1.1W2
.0)&and
&childre
n&(IRR&
4.2,&95
%CI&1.9
W
9.3)&wa
s&found
&compa
red&to&t
hose&w
ho&had
&no&visi
on&loss
.41,42 &Ot
her&exa
mples&
of&
studies
&of&patt
erns&of
&eye&se
rvice&u
tilizatio
n&in&sp
ecific&p
opulati
ons&inc
lude&th
ose&
in&wom
en&,91 &c
hildren
,133 &and
&diabet
ics.201,2
20 &&
Tr
en
ds
%in
%s
ur
ge
ry
%
Surgica
l&trend
s&are&p
articula
rly&suit
ed&to&st
udy&us
ing&larg
e&admi
nistrat
ive&
databa
ses&sin
ce&such
&encoun
ters&ar
e&almo
st&univ
ersally
&record
ed.&Cat
aract&
surger
y&rates
&have&in
creased
&drama
tically&
in&stud
ies&from
&most&W
estern&
countr
ies&sinc
e&the&a
doption
&of&pha
coemu
lsificat
ion,&wi
th&mos
t&repor
ting&a&
doublin
g&in&rat
es&ever
y&10&ye
ars&(Fig
ure&2a)
7,53,67
,84,92,
210,21
9 &that&a
re&proj
ected&t
o&
increas
e&furth
er.94 &Co
nverse
ly&the&i
ntrodu
ction&o
f&prost
agland
in&anal
ogues&a
nd&
increas
ed&upta
ke&of&la
ser&tra
beculo
plasty1
11 &has&s
een&the
&rate&of
&glauco
ma&
filterin
g&surge
ry&decl
ine&sign
ificantl
y&by&be
tween&
29&and
&75%&o
ver&a&1
0Wyear&
period
&since&t
he&mid
W1990s
&(Figur
e&2b).21
,131,18
5,195,2
50 &Retin
al&proc
edures
&have&
also&ch
anged&
signific
antly&in
&the&US
&medic
are&pop
ulation
&betwe
en&199
7&and&
2007,&p
articula
rly&an&e
xplosio
n&in&int
ravitre
al&injec
tions&(<
5000&p
rocedu
res&in&
1997&to
&812,41
3&proce
dures&i
n&2007
);&a&72%
&increa
se&in&vi
trectom
y&and&a
&69%&
decrea
se&in&sc
leral&bu
ckle&on
ly&surg
ery;&an
d&an&86
%&incr
ease&in
&pan&re
tinal&
photoc
oagula
tion&pr
ocedur
es.196 & Pharm
ac
oe
pi
de
m
io
lo
gy
&
Patient
&compl
iance&w
ith&pre
scribed
&treatm
ent&in&c
hronic&
disease
s&such&
as&
glaucom
a&is&not
oriousl
y&poor.
217 &Pha
rmaceu
tical&cla
ims&an
d&healt
h&insur
ance&
databa
ses&hav
e&been&
used&ex
tensive
ly&in&th
e&US&to
&study&
genera
l&trend
s&and&
pattern
s&in&eye
&drop&u
tilizatio
n&and&t
he&fact
ors&affe
cting&th
eir&use
.39,75,123
,235,23
6 &
11&
Claims
&data&h
as&the&a
dvanta
ge&over
&other&r
esearch
&metho
ds&sinc
e&they&
avoid&
recall&b
ias,&wh
ich&can
&be&pro
blemat
ic&in&stu
dies&th
at&rely&
on&self
Wreport
ing.&
Patient
&adhere
nce&and
&persis
tence&w
ith&thei
r&glauc
oma&m
edicati
on&pro
vides&a
n&
insight
&into&co
mplian
ce&and&
also&th
e&effect
iveness
&and&to
lerabili
ty&asso
ciated&
with&a&
particu
lar&dru
g&or&cla
ss&of&dr
ug.&Rea
rdon&et
&al&used
&health
&and&
pharm
aceutic
al&claim
s&data&f
rom&th
e&Proto
care&Sc
iences&
manag
ed&care
&databa
se&
to&stud
y&over&
28,000
&patien
ts&aged
&over&2
0&years
&who&w
ere&dis
pensed
&topica
l&
ocular&
hypote
nsives.
190,19
8,199,2
16 &They
&found&
that&dis
continu
ation&r
ates&we
re&
high;&o
nly&33%
&of&thos
e&presc
ribed&la
tanopr
ost&wer
e&still&u
sing&it&
after&1
2&
month
s&and&c
ontinu
ed&use&
in&othe
r&drug&
classes
&were&e
ven&low
er&(19%
).&They
&
also&fou
nd&lata
nopros
t&had&le
ss&rate
s&of&dis
continu
ation&c
ompar
ed&to&a
ll&other
&
glaucom
a&medi
cations
,&includ
ing&the
&other&p
rostagl
andin&a
nalogu
es.&Sim
ilar&
finding
s&were
&report
ed&in&la
ter&stud
ies.&No
rdstom
&et&al&fo
und&ha
lf&of&pa
tients&h
ad&
discon
tinued&
treatm
ent&by&
6&mont
hs&and
&that&th
ose&tak
ing&pro
staglan
dins&w
ere&
60%&le
ss&likel
y&to&dis
continu
e&comp
ared&to
&betaWb
lockers
&and&ca
rbonic&
anhydr
ase&inh
ibitors
.180 &Oth
er&stud
ies&usin
g&claim
s&data&f
urther&
suppor
t&the&
finding
s&from&
these&s
tudies,
13,43,8
6,221,2
33,267
,273,27
4 &includ
ing&one
&from&A
ustralia
&
using&n
ational
&popula
tionWba
sed&ph
armace
utical&c
laims&f
or&357
,099&pa
tients&t
hat&
confirm
ed&sup
erior&p
ersiste
ncy&for
&prosta
glandin
s.194 &&
Pharm
acoepid
emiolo
gy&stud
ies&usin
g&admi
nistrat
ive&dat
a&have&
their&o
wn&uni
que&
limitat
ions.215
&Caveat
s&that&s
hould&b
e&consi
dered&w
hen&est
imating
&patien
t&
compli
ance&in
clude:&
inaccur
acies&w
hen&a&p
atient&i
s&given
&sampl
e&medi
cations
&or&
their&m
edicati
on&is&ob
tained&
from&o
utside&
their&in
suranc
e&plan;
&being&
unable
&to&
ascerta
in&whe
ther&ce
ssation
&of&a&pr
escript
ion&is&d
ue&to&a
&manag
ement&
decisio
n&
by&the&
patient
’s&phys
ician&o
r&a&non
Wcompl
iant&pa
tient;&a
nd&that
&simply
&dispen
sing&
a&presc
ription
&does&n
ot&mea
n&the&p
atient&i
s&actua
lly&usin
g&the&m
edicati
on&as&
prescri
bed.&W
e&also&k
now&fr
om&val
idation
&studie
s&using
&chart&r
eview&t
hat&for
&
glaucom
a,&claim
s&data&a
lone&te
nds&to&
overes
timate&
disease
&severi
ty&and&
is&not&
able&to
&correc
tly&iden
tify&wh
ich&pat
ients&a
re&truly
&new&to
&treatm
ent.77,1
92,215
&The&
Glauco
ma&Adh
erence
&and&Pe
rsisten
cy&Stud
y&attem
pted&to
&addres
s&some
&of&thes
e&
limitat
ions&by
&using&a
&combi
nation&
of&heal
th&insu
rance&c
laims&d
ata&and
&pharm
acy&
claims&
data,&v
alidate
d&with&
chart&r
eview&a
nd&stru
ctured&
intervi
ew&of&p
atients
&and&
physici
ans.77 &E
ven&tak
ing&the
se&facto
rs&into&
accoun
t,&adhe
rence&a
nd&per
sistenc
y&
12&
rates&w
ere&stil
l&poor.&
They&fo
und&tha
t&only&1
0%&of&p
atients
&were&c
ontinu
ously&
persist
ent&wit
h&presc
ribed&t
reatme
nt&over
&a&1&yea
r&perio
d&and&a
t&1&yea
r&only&
59%&w
ere&adh
erent&t
o&any&o
cular&h
ypoten
sive&tre
atment
.&
H
EA
LT
H
%O
U
TC
O
M
ES
&
In&cont
rast&to&
traditio
nal&clin
ical&tria
ls,&heal
th&outc
omes&r
esearch
&examin
es&
clinical
&practic
e&as&it&i
s&actua
lly&perf
ormed
&in&the&
commu
nity&to&
answer
&questi
ons&
about&‘
real&wo
rld’&effe
ctivene
ss.&Hea
lth&adm
inistrat
ion&dat
abases
,&being&
born&o
ut&
of&actu
al&prac
tice,&ar
e&there
fore&pa
rticular
ly&well
&placed
&for&out
comes&
researc
h.&
They&a
lso&do&n
ot&suffe
r&from&
some&o
f&the&lim
itation
s&inher
ent&in&o
ther&tra
ditiona
l&
cohort
,&caseWc
ontrol&
and&ran
domize
d&contr
olled&tr
ials.&Stu
dies&of
&health
&
outcom
es&in&op
hthalm
ic&resea
rch&hav
e&gener
ally&foc
used&on
&surgic
al&safet
y,&
monito
ring&ad
herenc
e&to&be
st&prac
tice,&an
d&postW
market
ing&sur
veillan
ce.&
Su
rg
ic
al
%s
af
et
y%
&
Outsid
e&of&the
&clinica
l&trials,
&monito
ring&su
rgical&s
afety&ty
pically
&relies&
on&
reporti
ng&adv
erse&ev
ents&th
rough&c
ase&ser
ies&from
&single&
or&mul
tiple&ce
nters&o
r&
clinics.
&Events
&identif
ied&in&t
his&way
&may&b
e&selec
tive&or&
incomp
lete.&Th
ey&also
&do&
not&nec
essaril
y&reflec
t&the&pr
actice&o
ccurrin
g&in&the
&wider&
commu
nity&wh
ere&
there&is
&likely&s
ignifica
nt&vari
ation&in
&surgic
al&case
&mix&an
d&comp
lexity,&s
urgeon
&
experie
nce,&an
d&quali
ty&of&av
ailable
&equipm
ent.&Wh
ile&clin
ical&reg
istries&
may&
addres
s&most&
of&thes
e&issue
s,&admi
nistrat
ive&dat
asets&a
re&mor
e&likely
&to&be&
comple
te&and&
less&ea
sily&‘ga
med’.&
The&ex
cellent
&safety&
profile
&of&cata
ract&su
rgery&r
equires
&very&la
rge&sam
ple&size
s&
over&pr
olonge
d&perio
ds&of&ti
me&to&i
dentify
&and&ad
equate
ly&stud
y&trend
s&and&r
isks&
of&adve
rse&eve
nts.&Us
ing&Me
dicare&
data,&S
tein&et&
al&foun
d&just&0
.5%&of&
220,00
0&
catarac
t&surge
ries&res
ulted&in
&a&serio
us&adve
rse&eve
nt&over
&a&13Wy
ear&per
iod&
(1994W
2006);
&and&be
cause&o
f&the&la
rge&sam
ple&size
&they&w
ere&abl
e&to&rep
ort&on&
a&
signific
ant&dec
lining&t
rend.24
0 &In&We
stern&A
ustralia
&a&simil
ar&stud
y&of&12
9,982&
catarac
t&proce
dures&u
sing&wh
oleWpop
ulation
&hospit
al&adm
inistrat
ive&dat
a&found
&
1.6%&h
ad&a&se
rious&a
dverse
&event&
and&the
re&was
&a&simil
ar&decl
ining&tr
end&ov
er&a&
22&yea
rs&(198
0W2001
).30 &Bel
l&et&al&f
ound&s
urgeon
&operat
ive&vol
ume&w
as&
import
ant&in&t
he&risk
&of&adv
erse&ou
tcomes
&by&poo
ling&da
ta&from
&provin
cial&hea
lth&
insuran
ce&claim
s&data&f
or&over
&230&su
rgeons
&and&28
4,797&c
ataract
&surger
ies&in&
13&
Ontario
;&surge
ons&per
formin
g&over&
1,000&c
ataract
&proced
ures&pe
r&year&h
ad&0.1%
&
advers
e&event
s&comp
ared&to
&0.8%&i
n&those
&perfor
ming&5
0W250&p
rocedu
res&(OR
&
0.14,&9
5%CI&0
.09W0.2
3).11 &&
A&large
&sampl
e&size&i
s&partic
ularly&r
elevan
t&to&the
&study&
of&rare
r&event
s&e.g.&
endoph
thalmit
is.&Stud
ies&usin
g&healt
h&insur
ance&cl
aims&an
d&hosp
ital&
admini
strativ
e&data&
showed
&the&inc
idence
&of&end
ophtha
lmitis&r
anged&
betwee
n&1&
and&2&p
er&1,00
0&catar
act&sur
geries.
58,93,1
15,117
,129,14
4,179,2
31 &Samp
le&sizes
&in&exce
ss&of&
100,00
0&in&the
se&stud
ies&allo
wed&id
entifica
tion&of&
potent
ial&risk
&factors
&includ
ing&
increas
ed&risk
&in&mal
es,&the&
elderly
,&compl
icated&
surger
y,&lowe
r&surge
on&volu
me, 
and&su
rgery&i
n&priva
te&facil
ities.58,
93,115
,117,12
9,144,1
79,231
&
Javitt&e
t&al&use
d&US&m
edicare
&claims
&data&to
&be&the
&first&to
&demon
strate&a
&
statisti
cally&si
gnifica
nt&incr
eased&r
isk&of&r
etinal&d
etachm
ent&afte
r&intrac
apsular
,&
extraca
psular&
and&ph
acoemu
lsificat
ion&cat
aract&s
urgery
.114,117 &T
hey&fou
nd&
greates
t&risk&o
f&retina
l&detac
hment&
with&in
tracaps
ular&su
rgery&(
1.55%)
&and&w
ere&
the&firs
t&to&des
cribe&a
n&incre
ased&ri
sk&with
&phacoe
mulsifi
cation&
compa
red&to&
extraca
psular&
surger
y&(1.17
%&vs&0
.9%).&T
hey&als
o&found
&a&stati
stically
&signifi
cant&
increas
ed&risk
&in&mal
es&(RR&
1.66),&y
ounger
&patien
ts&(RR&
3.70&65
W69&vs&
80W89&y
rs),&
whites
&(RR&3.
85)&and
&surger
y&wher
e&anter
ior&vitr
ectomy
&was&pe
rforme
d&(RR&
4.5).&It&
was&on
ly&thro
ugh&a&l
arge&sa
mple&s
ize&tha
t&they&w
ere&abl
e&to&con
firm&th
ese&
finding
s&(whic
h&had&p
revious
ly&been
&suspec
ted&but
&not&co
nfirme
d&due&t
o&limite
d&
sample
&sizes&o
f&previo
us&stud
ies).&Ot
her&lar
ge&data
base&st
udies&h
ave&sin
ce&
confirm
ed&thes
e&findin
gs.14,16,
17,31,5
2,207,2
23 &&
The&co
mbinat
ion&of&r
elative
ly&unco
mmon&
proced
ures&an
d&rare&
compli
cations
&
further
&highlig
hts&the
&need&f
or&who
leWpopu
lation&m
ethodo
logy&an
d&large
&sampl
e&
sizes.&H
aargaa
rd&et&al
&demon
strated
&this&in
&their&r
eport&o
f&the&lo
ngWterm
&risk&of
&
retinal
&detach
ment&a
fter&pe
diatric
&catara
ct&surg
ery&in&D
enmark
&1977&–
&2005.8
7 &
Despite
&28&yea
rs&of&da
ta&and&
1,043&e
yes&(65
6&child
ren)&ha
ving&pe
diatric
&catara
ct&
surger
y,&only
&25&eye
s&(23&c
hildren
)&devel
oped&a
&retinal
&detach
ment.&T
hey&
demon
strated
&that&3%
&of&chil
dren&w
ith&isol
ated&pe
diatric&
catarac
t&will&d
evelop
&a&
retinal
&detach
ment&w
ithin&20
yrs&of&s
urgery
.&Signif
icant&ri
sk&facto
rs&were
&menta
l&
retarda
tion&(2
3%)&an
d&catar
act&plu
s&other
&ocular
&or&syst
emic&p
atholog
y&(16%
).&
Import
antly&p
rimary
&poster
ior&cap
sulotom
y&and&a
nterior
&vitrect
omy&di
d&not&
increas
e&the&ri
sk&of&re
tinal&de
tachme
nt.&
14&
One&ca
veat&of
&purely
&databa
se&stud
ies&is&th
eir&limi
ted&abi
lity&to&s
tudy&a&
broad&
range&o
f&risk&fa
ctors&a
s&they&m
ay&not&
be&code
d,&or&th
e&accur
acy&of&c
oding&f
or&that
&
risk&is&
incons
istent&e
.g.&smo
king.&C
aseWcon
trol&me
thodolo
gies&us
ing&cha
rt&revie
w&
for&the
&cases&a
nd&a&ra
ndom&s
ample&
of&the&u
nWaffec
ted&pop
ulation
&may&o
vercom
e&
this&pro
blem.&F
or&exam
ple&the
&Endop
hthalm
itis&Pop
ulation
&Study&
of&Wes
tern&
Austra
lia&used
&popula
tionWw
ide&hos
pital&ad
ministr
ative&d
ata&for&
an&enti
re&
catarac
t&surge
ry&coho
rt&of&11
7,083&o
ver&a&2
0Wyear&
period
&and&20
5&cases
&of&
endoph
thalmit
is.&Ever
y&case&
of&endo
phthalm
itis&wa
s&valida
ted&wit
h&chart
&review
&
and&a&n
ested&c
aseWcon
trol&stu
dy&was
&used&t
o&ident
ify&imp
ortant&
surgica
l&and&n
onW
surgica
l&risk&fa
ctors,&i
ncludin
g&previ
ously&u
nrepor
ted&ass
ociatio
ns&with
&winter
&
proced
ures&(O
R&1. 48
&95%&C
I&1.00–
2.18)&a
nd&con
curren
t&eyelid
&surger
y&(OR&
23.50,&
95%&CI
&8.50–6
4.98).1
44,179
&&
A&simil
ar&nest
ed&case
Wcontro
l&study
&examin
ed&risk
&factors
&for&ret
inal&de
tachme
nt&
after&ca
taract&s
urgery
&in&the&
Medica
re&popu
lation.1
16,257
&They&f
ound&a
n&incre
ase&
risk&wi
th&Nd:Y
AG&cap
sulotom
y&(OR&3
.8,&95%
&CI&2.4W
5.9)&alo
ng&with
&other&r
isk&
factors
&for&ret
inal&de
tachme
nt&that
&includ
ed:&axia
l&length
,&a&histo
ry&of&la
ttice&
degene
ration&
or&retin
al&deta
chmen
t&or&ocu
lar&trau
ma,&an
d&refra
ctive&er
ror.257 &
Other&c
ataract
&surger
y&outco
mes&stu
died&us
ing&link
ed&data
&includ
e&the&im
pact&of
&
catarac
t&surge
ry&on&th
e&incre
ased&ri
sk&of&co
rneal&o
edema
;24 &redu
ced&veh
icle&
crash&r
isk&(thr
ough&li
nkage&w
ith&roa
d&accid
ent&dat
abases
);162,164
&an&incr
eased&
risk&of&
falls&(th
rough&l
inkage
&with&e
mergen
cy&room
&databa
ses);163
,165 &red
uced&
admiss
ion&for
&depres
sion&(th
rough&l
inkage
&to&men
tal&hea
lth&serv
ices);16
6 &and&
reduce
d&risk&o
f&death
&(by&lin
king&to
&death&
registe
rs).71,24
8 &
Studies
&report
ing&out
comes&
for&oth
er&surg
ical&pro
cedure
s&are&fe
wer&in&
numbe
r&
and&inc
lude&ad
verse&e
vents&a
fter&gla
ucoma
Wrelate
d&proce
dures3
4,237,2
58 ,&pars
&
plana&v
itrecto
my,238 &
and&pe
netrati
ng&kera
toplast
y.1 &
M
on
it
or
in
g%
ad
he
re
nc
e%
to
%b
es
t%p
ra
ct
ic
e&
Admin
istrativ
e&datas
ets&are
&being&
increas
ingly&u
sed&to&a
udit&ad
herenc
e&by&
patient
s&and&p
hysicia
ns&to&‘b
est&pra
ctice’.&T
hey&are
&felt&to&
offer&a&
more&a
ccurate
&
picture
&of&real
&world&
practic
e&since
&they&a
re&not&a
ffected
&by&rec
all&bias
&presen
t&in&
traditio
nal&sur
veys&or
&clinica
l&regist
ries.&Sc
reening
&for&dia
betic&re
tinopat
hy&is&
particu
larly&su
ited&to&
such&an
&approa
ch&due
&to&wel
lWestab
lished&
clinical
&
guideli
nes&and
&the&ab
ility&to&
readily
&identif
y&servi
ce&enco
unters&
within&
most&
15&
admini
strativ
e&datas
ets.&Rep
orts&fro
m&heal
th&claim
s&datab
ases&su
ggest&e
ye&
examin
ation&r
ates&fo
r&diabe
tics&are
&univer
sally&po
or.&Wan
g&et&al&f
ound&o
nly&53%
&
of&175,
015&dia
betic&M
edicare
&benefi
ciaries
&had&at
&least&o
ne&eye&
care&vi
sit&in&a
&1&
year&pe
riod,&an
d&only&
67%&w
ithin&2&
years.2
63 &Simi
lar&pro
portion
s&were
&report
ed&
using&c
laims&d
ata&else
where&
in&the&U
S.5,128,1
40,186
,220,22
8 &While
&in&Nov
a&Scoti
a,&
Canada
&longitu
dinal&c
laims&d
ata&ove
r&10&ye
ars&ind
icated&
only&14
.4%&of&
diabeti
cs&
had&at&
least&on
e&eye&e
xamina
tion&co
nsisten
tly&each
&year.13
6 &Facto
rs&cons
istently
&
associa
ted&wit
h&less&a
ttendan
ce&are&y
ounger
&age,&m
ale&gen
der,&eth
nic&min
orities,
&
lower&e
ducatio
n&level
,&and&lo
wer&so
cioecon
omic&st
atus.173
,2
28
,2
63
&Direct
&mail&
remind
ers&to&i
mprov
e&low&a
ttendan
ce&was
&studie
d&but&th
ey&wer
e&found
&to&hav
e&
only&a&
short&li
ved&an
d&mode
st&effec
t&at&bes
t..89,191 &
&
The&pr
actice&p
atterns
&of&phy
sicians
&treatin
g&glauc
oma&ha
s&receiv
ed&som
e&
attenti
on.&Frie
dman&e
t&al&fou
nd&usin
g&healt
h&insur
ance&da
ta&that&
17%&of
&
glaucom
a&suspe
cts&and
&16%&d
iagnose
d&with&
glaucom
a&did&n
ot&have
&a&
docum
ented&f
ollowWu
p.&They
&also&fo
und&on
ly&half&
of&thes
e&patie
nts&had
&at&leas
t&
one&VF
&test&w
ithin&th
e&follow
Wup&per
iod&and
&just&13
%&had&
optic&d
isc&ima
ging&
(media
n&follow
Wup&440
&days).7
6  Colem
an&et&a
l&found
&less&th
an&half
&of&US&m
edicare
&
patient
s&patie
nts&und
ergoing
&glauco
ma&sur
gery&ha
d&gonio
scopy&p
erform
ed&in&th
e&
preced
ing&4W5
&years, 
36
 a
nd
 ju
st
&70%&h
ad&a&fie
ld&test&
in&the&p
recedin
g&1&yea
r.35 &
M
or
e 
re
ce
nt
ly
 S
te
in
 e
t a
l d
em
on
st
ra
te
d 
a 
ch
an
ge
 in
 p
ra
ct
ic
e 
fo
r g
la
uc
om
a 
m
on
ito
rin
g 
w
ith
 u
se
 o
f v
is
ua
l f
ie
ld
 te
st
in
g 
fa
lli
ng
 b
y 
44
%
 w
hi
le
 th
e 
us
e 
of
 o
th
er
 o
cu
la
r i
m
ag
in
g 
m
od
al
iti
es
 in
cr
ea
se
d 
by
 1
47
%
 fr
om
 2
00
1 
to
 2
00
9.
24
3 &&
Po
st
Nm
ar
ke
ti
ng
%s
ur
ve
ill
an
ce
&
Monito
ring&th
e&safety
&of&new
&drugs&
or&med
ical&dev
ices&fol
lowing
&their&
widesp
read&re
lease&in
to&the&c
ommun
ity&is&an
&impor
tant&pa
rt&of&he
alth&ou
tcomes
&
researc
h.&Appr
ovals&fo
r&their&
use&are
&based&
on&strin
gent&te
sting&in
&the&set
ting&of&
highly&
contro
lled&cli
nical&tr
ials;&bu
t&these
&trials&a
re&gene
rally&lim
ited&by
&small&
sample
s&sizes&
of&selec
t&popul
ations&
that&pe
rhaps&b
ear&litt
le&rese
mblanc
e&to&the
&
wider&c
linical&
setting
&where
&the&pro
ducts&a
re&used
.&So&pos
tWmark
eting&
surveil
lance&b
ecomes
&essent
ial&to&a
ssess&th
e&safety
&of&new
&medic
al&prod
ucts&on
ce&
release
d.&
Inform
ation&r
egardin
g&medi
cation&
safety&i
s&typica
lly&man
aged&th
rough&n
ational
&
drug&su
rveillan
ce&bodi
es&e.g.&t
he&US&F
ood&an
d&Drug
&Admin
istratio
n&(FDA
)&agenc
y.&
16&
Report
ing&adv
erse&ev
ents&to
&these&b
odies&c
ommon
ly&relie
s&on&vo
luntary
&
submis
sion,&w
hich&m
ay&be&fr
om&mu
ltiple&s
ources
&i.e.&dir
ectly&fr
om&the
&
manufa
cturing
&compa
ny,&the
&public
,&or&ind
epende
nt&orga
nizatio
ns.&The
&proble
m&
with&th
is&appr
oach&is
&it&cann
ot&prov
ide&use
ful&pop
ulation
&incide
nce&rat
es&sinc
e&
the&pop
ulation
&at&risk
&is&not&
quantif
ied.&Th
ere&is&a
lso&sign
ificant&
underW
reporti
ng&
and&va
riabilit
y&in&the
&quality
&of&repo
rting.20
3 &
Admin
istrativ
e&datab
ases&ar
e&ideal&
to&assis
t&in&pos
tWmark
eting&s
urveilla
nce&du
e&
to&their
&large&p
opulati
on&coh
orts&all
owing&
rare&ad
verse&e
vents&t
o&be&stu
died,&
ready&a
ccess&to
&curren
t&data,&
and&rel
ative&co
st&effec
tivenes
s&comp
ared&to
&
traditio
nal&tria
ls.&The&
US&FDA
&has&re
cognize
d&their
&value&i
n&sever
al&repo
rts,&and
&
they&re
comme
nded&a
&greate
r&use&o
f&popul
ationWb
ased&da
tasets&t
o&enha
nce&po
stW
market
ing&sur
veillan
ce&syst
ems.23 &
&
There&a
re&a&lim
ited&nu
mber&o
f&studie
s&makin
g&use&o
f&admin
istrativ
e&and&l
inked&
dataset
s&in&po
stWmar
keting&
surveil
lance&o
f&ophth
almic&d
rugs&an
d&devic
es&desp
ite&
them&b
eing&id
eal&for&
this.&Fr
ench&et
&al&have
&publis
hed&sev
eral&stu
dies&us
ing&
clinical
&and&ph
armacy
&data&fr
om&the
&US&Vet
erans&H
ealth&A
dminis
tration
&databa
se&
that&ex
plored
&the&ass
ociatio
n&betw
een&dru
gs&and&
eye&dis
ease.&T
hey&fou
nd&a&
tempor
al&relat
ionship
&betwe
en&com
mence
ment&o
f&aman
tadine&
and&the
&onset&o
f&
cornea
l&edem
a&in&a&s
mall&pr
oportio
n&of&pa
tients&(
0.12%)
,&which
&suppo
rted&
earlier
&case&re
ports&o
f&the&as
sociatio
n.61 &Th
ey&repo
rted&th
at&479,
489&me
n&using
&
phosph
odieste
rase&in
hibitor
s&had&a
&small,&
but&not
&signifi
cant,&in
creased
&risk&of
&
anterio
r&ische
mic&op
tic&neu
ropath
y;63,160 &
and&no
&associ
ation&w
ith&cen
tral&ser
ous&
retinop
athy.64
&They&a
lso&fou
nd&no&a
ssociat
ion&bet
ween&t
he&bisp
hospho
nates&a
nd&
uveitis
/scleri
tis&(OR
&1.23,&9
5%&CI&0
.85W1.7
9).62 &In
&anothe
r&study
&they&
demon
strated
&an&inte
resting
&reduce
d&risk&o
f&death
&with&a
ny&glau
coma&
medica
tion&(O
R&0.93;
&95%&C
I&0.90W0
.95),66 &
which&
confirm
ed&find
ings&fro
m&earli
er&
large&d
atabase
&studie
s.81,239 &
The&saf
ety&of&t
he&anti
WVEGF&
treatm
ents&fo
r&neova
scular&
ARMD&
was&re
cently&
studied
.&Frenc
h&et&al&
found&n
o&differ
ence&in
&the&ris
k&of&mo
rtality&
for&bev
acizum
ab&
or&rani
bizuma
b&(OR&0
.89,&95
%CI&0.7
4W1.06)
&in&a&co
hort&of
&3,210&
patient
s&given
&
intravi
treal&an
tiWVEGF
&and&11
7,364&u
nexpos
ed&ARM
D&patie
nts.68 &T
his&was
&
suppor
ted&by&
a&Cana
dian&st
udy&tha
t&used&
insuran
ce&claim
s&data&f
or&91,3
78&
patient
s&in&On
tario.22
&While&
an&Aus
tralian
&study&
found&a
&small&b
ut&sign
ificantl
y&
17&
increas
ed&risk
&of&myo
cardial
&infarct
ion&(OR
&2.3,&95
%&CI&1.
2W4.5).1
32 &
Other&e
xample
s&includ
e&findin
g&no&ris
k&of&con
gestive
&heart&f
ailure&w
ith&top
ical&
glaucom
a&medi
cations
;169 &inc
onsiste
nt&resu
lts&abo
ut&the&r
eductio
n&in&Nd
:YAG&
laser&ca
psuloto
my&rat
es&with
&the&int
roduct
ion&of&s
quare&e
dge&int
raWocul
ar&
lenses,
32 &an&in
creased
&risk&of
&retinal
&detach
ment&w
ith&ora
l&fluoro
quinoln
es,56 &an
d&
the&app
arent&p
rotecti
ve&effe
ct&of&st
atins&in
&open&a
ngle&gl
aucom
a.242 &&
H
EA
LT
H
%E
CO
N
O
M
IC
S&
Determ
ining&th
e&cost&a
nd&dem
and&for
&ophtha
lmic&se
rvices&i
s&an&im
portan
t&for&
health&
care&pl
anning
,&partic
ularly&i
n&the&c
limate&
of&dwin
dling&h
ealth&b
udgets
&and&
rapidly
&increa
sing&he
alth&ca
re&cost
s.&Adm
inistrat
ive&dat
a&are&p
articula
rly&use
ful&
for&esti
mating
&these&c
osts&sin
ce&they
&are&rec
orded&a
t&the&po
int&of&s
ervice&
and&
usually
&contai
n&billin
g&infor
mation
&to&calc
ulate&a
ctual&co
sts.&&
Examp
les&are
&numer
ous,&pa
rticular
ly&stud
ies&usin
g&Medi
care&cla
ims&da
ta.&
Finding
s&have&
include
d:&cata
ract&su
rgery&c
ost&USD
$2500&
in&1991
;244 &the
re&was
&a&
10W25%
&decrea
se&in&th
e&cost&o
f&eye&ca
re&to&M
edicare
&during
&the&19
90s&de
spite&a
n&
increas
e&in&the
&propo
rtion&o
f&benef
iciaries
&receiv
ing&eye
&care&(d
ue&to&a
&reduct
ion&
of&cata
ract&su
rgery&p
aymen
ts);50,20
8 &physi
cian&re
imburs
ement&
as&fee&f
or&serv
ice&is&
associa
ted&wit
h&appro
ximate
ly&twic
e&the&ra
te&and&
cost&of
&catara
ct&surg
ery&
compa
red&to&a
&cost&ca
pitatio
n&mode
l;225 &fee
&cuts&fo
r&ophth
almic&s
urgery
&
increas
ed&volu
me&but
&had&no
&effect&
on&ove
rall&cos
t;120 &inc
reasing
&surgeo
n&supp
ly&
increas
ed&acce
ss&to&su
rgeons
&but&did
&not&inc
rease&t
he&dem
and&for
&service
s&by&
individ
ual&pat
ients;&5
4 &vision
&loss&is
&associ
ated&w
ith&and
&extra&U
SD$2,1
93&to&
$4,443
&in&hea
lth&care
&costs&o
r&USD$
2.14&bi
llion&fo
r&the&en
tire&Me
dicare&
popula
tion&in&
2003;1
22 &intro
ducing
&prosta
glandin
s&for&gl
aucom
a&incre
ased&
adhere
nce&wit
hout&si
gnifica
ntly&inc
reasing
&costs;1
3 &the&co
st&of&po
stWoper
ative&
compli
cations
&like&en
dophth
almitis
&(US$1
6,142&h
igher&c
laims&p
er&case
)211 &and
&
cystoid
&macul
ar&edem
a&(40W5
0%&hig
her&cla
ims&an
d&paym
ents).21
2 &Studi
es&have
&
also&ca
lculate
d&the&c
ost&of&p
rovidin
g&speci
fic&oph
thalmic
&medic
ations&
(e.g.&ey
e&
drops)
,60,106 &w
hile&oth
ers&hav
e&quan
tified&t
he&sign
ificantl
y&highe
r&health
&
expend
iture&as
sociate
d&with&
diabeti
c&retino
pathy1
38,213
&and&di
abetic&
macula
r&
oedem
a;222 &AR
MD;37,9
0 &and&p
rimary
&open&a
ngle&gl
aucom
a&(USD
&$242&t
o&
$1,570
).142,193
,195 &
18&
FU
TU
RE
%A
D
VA
N
CE
S%
A&majo
r&limita
tion&in&
using&a
dminis
trative
&data&fo
r&health
&resear
ch&is&th
e&lack&o
f&
robust
&clinica
l&detail
&that&pr
eclude
s&more
&detaile
d&analy
sis&bey
ond&tha
t&of&bas
ic&
diagno
stic&and
&proced
ure&cod
es.&Wh
ile&nest
ed&case
Wcontro
l&studie
s&may&o
ffer&
some&s
olution
&by&allo
wing&a
&manag
eable&n
umber
&of&case
s&for&ch
art&rev
iew,&it&
is&at&
the&cos
t&of&tim
ely&and
&efficie
nt&rese
arch.&
Clinica
l&regist
ries&off
er&anot
her&sol
ution.&A
n&excel
lent&ex
ample&
of&a&suc
cessful
&
popula
tionWba
sed&oph
thalmic
&clinica
l&regist
ry&is&th
e&Swed
ish&nat
ional&ca
taract&
registe
r&(NCR
).&The&N
CR&beg
an&in&1
992&an
d&now&
contain
s&over&
1&millio
n&catar
act&
proced
ures&re
presen
ting&95
.6%&of&
catarac
t&surge
ries&pe
rforme
d&in&Sw
eden.9 &
Detaile
d&preW,&
intraW,&
and&po
stWoper
ative&cl
inical&i
nforma
tion&ha
s&allow
ed&inW
depth&a
nalysis
&of&cata
ract&su
rgery&t
rends&a
nd&outc
omes&in
&
particu
lar.3,6,9,
10,85,9
3,110,1
25,135
,145W15
8,170,2
46,247
,251,26
5 &&
Like&m
any&clin
ical&reg
isters,&
the&dat
a&conta
ined&in
&the&NC
R&are&s
ubmitt
ed&by&
partici
pating&
center&
via&a&fo
rm&for&
each&ca
taract&p
rocedu
re.&This
&metho
d&is&
potent
ially&su
bject&to
&error&f
rom&da
ta&entr
y&and&t
ranspo
sition&w
hen&cop
ying&da
ta&
from&th
e&medi
cal&reco
rd&and&
from&th
e&form&
onto&th
e&datab
ase.88 &I
t&is&also
&
duplica
tion&of&
data&en
try.&
If&phys
icians&a
re&to&be
&encou
raged&t
o&contr
ibute&to
&clinica
l&regist
ries&the
n&the&
proces
s&shoul
d&be&a&s
eamles
s&integ
ration&
that&do
esn’t&d
isrupt&p
hysicia
n&
workfl
ow.&Ide
ally&da
ta&wou
ld&be&tr
ansferr
ed&dire
ctly&fro
m&the&c
linical&
record
&into&
the&clin
ical&reg
istry&da
tabase&
withou
t&the&ne
ed&for&d
uplicat
ion&of&d
ata&ent
ry.&
Improv
ements
&will&co
me&wit
h&autom
ated&da
ta&colle
ction&m
ethods
&and&ne
w&
analyti
c&techn
iques.&
%
Au
to
m
at
ed
%d
at
a%
ex
tr
ac
ti
on
%a
nd
%c
ol
le
ct
io
n%
Purpos
e&built&
clinical
&registr
ies&agg
regated
&by&scra
ping&da
ta&from
&electro
nic&
health&
record
s&(EHR
)&offers
&a&prac
tical&an
d&effici
ent&sol
ution.&T
his&was
&
demon
strated
&in&the&
UK&in&t
he&nati
onal&ca
taract&d
atabase
&which
&collate
d&data&
from&E
HR&acr
oss&12&
NHS&tr
usts&fo
r&55,56
7&catar
act&ope
rations
&betwe
en&200
1&and&
2006.12
,47,124
,126,13
4,174,2
32 &This
&projec
ted&laid
&the&gro
undwo
rk&that
&has&
subseq
uently&
been&ex
tended
&to&a&na
tional&o
phthalm
ology&d
atabase
.107W109 &
Althou
gh&only
&40%&o
f&ophth
almic&p
ractice
s&in&the
&USA&us
e&an&EH
R&the&A
merica
n&
19&
Academ
y&of&Op
hthalm
ology’s
&newly
&comm
issione
d&IRIS&R
egistry
&(Intell
igent&
Resear
ch&in&Si
ght)&of
fers&the
&promi
se&of&a&
nationa
l&comp
rehens
ive&eye
&diseas
e&
registe
r.&It&is&d
esigned
&to&assi
st&in&de
livering
&quality
&patien
t&care&t
hrough
&
measu
ring&an
d&repor
ting&ou
tcomes
&and&be
nchWma
rking.4
&A&brea
kthrou
gh&in&th
e&
design
&of&the&
registr
y&was&i
ts&integ
ration&
with&ph
ysician
&EHR&th
at&avoi
ds&
disrupt
ion&of&p
hysicia
n&work
flow&an
d&dupli
cate&da
ta&entr
y&that&a
re&majo
r&
barrier
s&to&the
&implem
entatio
n&and&o
ngoing
&succes
s&of&clin
ical&reg
istries.
4 &
Despite
&the&cu
rrent&p
olitical
&impera
tive,&im
provin
g&the&d
esign&a
nd&ergo
nomics
&of&
EHR’s&w
ill&be&re
quired
&to&exp
and&the
ir&use&t
hrough
out&the
&wider&
ophtha
lmic&
commu
nity.&&H
owever
&as&a&st
andWalo
ne&data
base,&IR
IS&will&
provid
e&signif
icant&
insight
s&into&o
phthalm
ic&disea
se&and&
clinical
&practic
e&on&an
&individ
ual&and
&
popula
tion&lev
el.&&
Method
s&are&re
quired
&to&utili
ze&the&e
xisting
&inform
ation&h
eld&elec
tronica
lly&as&
text&file
s,&as&th
ere&is&a
&huge&a
mount
&of&lega
cy&data
&stored
&since&t
he&adv
ent&of&
wordWp
rocesso
rs.&&Tha
t&inform
ation&w
ould&pr
ovide&f
urther&
import
ant&his
torical&
data&to
&assess
&trends
&in&diag
nosis&a
nd&man
agemen
t.&Such
&techni
ques&m
ay&also
&
enable
&integra
tion&of&
written
&report
s&from&
other&a
reas&su
ch&as&p
atholog
y&and&
radiolo
gy.&
There&i
s&also&t
he&pote
ntial&to
&suppo
rt&a&vas
t&progr
am&of&o
phthalm
ic&resea
rch&
throug
h&data&
integra
tion&pr
ocesse
s&into&a
reas&th
at&dete
rmine&s
ocial&an
d&
econom
ic&dete
rminan
ts&of&he
alth&su
ch&as&e
ducatio
nal&and
&welfar
e&recor
ds.&The
&
impact
&of&oph
thalmic
&diseas
e&on&ot
her&hea
lth&out
comes&
e.g.&inju
ry&and&
mental
&
health&
may&be
&useful
ly&asse
ssed&w
ith&data
&integr
ation.&&
As&mor
e&data&
source
s&are&cr
eated&a
nd&data
&integra
tion&pr
ocess&a
llows&t
he&link
age&
of&mult
iple&da
ta&sour
ces,&the
n&the&v
olume&
of&data
&availab
le&for&r
esearch
&will&
continu
e&to&gro
w.&This
&begs&th
e&quest
ion&W&ho
w&do&y
ou&then
&deal&w
ith&suc
h&
massiv
e&amou
nts&of&d
ata?&Bi
g&data&
method
ologies
&being&
develo
ped&all
ow&the
&
efficien
t&study
&of&larg
e&datab
ases&us
ing&ma
chine&l
earning
&algorit
hms&th
at&offer
&
the&pro
mise&of
&better
&predic
tive&mo
dels,&th
e&abilit
y&to&de
al&with
&nonWva
lidated
&
‘dirty’&d
ata&wit
hout&th
e&need
&for&com
prehen
sive&da
ta&clean
ing,&an
d&faste
r&
compu
ting&wi
th&mor
e&data.1
27 &&
SU
M
M
AR
Y&
20&
Large&a
dminis
trative
&and&lin
ked&da
tabases
&are&rea
dily&av
ailable
&and&ric
h&sourc
es&
of&infor
mation
&for&oph
thalmic
&resear
ch.&Muc
h&use&h
as&alre
ady&be
en&mad
e&of&
them&w
ith&a&tr
end&tow
ards&in
creasin
g&outpu
t&as&res
earche
rs&reali
ze&thei
r&value
&in&
addres
sing&a&w
ide&ran
ge&of&re
search
&questi
ons,&pa
rticular
ly&relat
ing&to&
ophtha
lmic&se
rvice&u
tilizatio
n&and&o
utcome
s.&Their
&value&i
n&postW
market
ing&
surveil
lance&o
f&new&d
rugs&an
d&devic
es&is&pa
rticular
ly&wort
h&notin
g.&
Admin
istrativ
e&datas
ets&are
&not&wi
thout&t
heir&lim
itation
s&but&m
any&of&
them&c
an&
be&over
come&w
ith&app
ropriat
e&study
&design
,&analys
is&and&c
areful&i
nterpre
tation.&
The&de
velopm
ent&of&c
linical&
registr
ies&and
&big&da
ta&anal
ysis&tec
hnique
s&is&a&
promis
ing&tren
d&that&h
as&the&p
otentia
l&to&allo
w&more
&rapid&a
nalysis
&withou
t&the&
need&fo
r&exten
sive&da
ta&valid
ation.&T
heir&be
nefits&i
n&provi
ding&a&
‘real&w
orld’&vi
ew&
of&opht
halmic
&diseas
e,&servi
ces&and
&outcom
es&in&a&
timely&
fashion
&that&co
nserve
s&
the&hea
lth&doll
ar&shou
ld&not&u
nderWe
stimate
d.&&
M
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H
O
D
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H
&
A&PubM
ed&and
&Web&o
f&Scienc
e&searc
h&was&p
erform
ed&for&t
he&term
s&
“admin
istrativ
e&data”
,&“medi
care”,&“
claims&
data”,&“
data&lin
kage”,&
“record
&linkag
e”,&
“insura
nce&dat
a”,&“pha
rmaceu
tical&da
ta”,&“po
stWmar
keting&
surveil
lance”,
&
”regist
ry”,&and
&”regist
er”&in&v
arious&
combin
ations&
with&op
hthalm
ic&relat
ed&term
s&
“ophth
almolo
gy”,&“ey
e”,&“vis
ion”,&“g
laucom
a”,&“ma
cular&d
egener
ation”,&
“catara
ct”,&
“blind”
,&“diabe
tic&reti
nopath
y”,&and
&“optic”
#across
&all&yea
rs.&A&re
view&o
f&the&
abstrac
ts&iden
tified&r
elevan
t&article
s,&whic
h&were
&confirm
ed&afte
r&readi
ng.&The
&
citation
s&from&
these&a
rticles&
were&a
lso&use
d&to&ide
ntify&ar
ticles&n
ot&foun
d&with&
the&
above&s
earch&t
erms.&A
ny&non
WEnglis
h&refer
ences&w
ere&exc
luded.&
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almic&r
esearch
%
D
at
as
et
&
Co
un
tr
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00,&
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&248W2
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,&266,&2
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Medica
l&cover
&for&peo
ple&age
d&65+&y
ears;&o
r&unde
r&65&ye
ars&wit
h&certa
in&
disabil
ities;&a
nd&peo
ple&of&a
ny&age&
with&en
dWstage
&renal&d
isease.
&Cover&
include
s&
hospita
lization
,&medic
al&insu
rance,&
and&pr
escript
ion&dru
gs.&Mos
t&studie
s&use&a
&5%&
random
&sampl
e&syste
matica
lly&sele
cted&us
ing&the
&same&a
lgorith
m&each
&year&
provid
ed&by&t
he&Cen
tre&for&
Medica
re&and&
Medica
id&Serv
ices&(C
MS).&
M
ed
ic
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re
se
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%fi
le
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133,&16
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USA&
Joint&fe
deral&a
nd&stat
e&funde
d&progr
am&to&p
rovide&
low&cos
t&medic
al&care
&for&low
W
income
&people
,&famili
es&and&
childre
n,&preg
nant&w
omen,&
the&eld
erly,&an
d&peop
le&
with&di
sabiliti
es.&The
re&are&s
trict&el
igibility
&requir
ements
&that&va
ry&by&s
tate.&&
Ve
te
ra
ns
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ea
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at
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se
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&
USA&
Health
&data&fr
om&8.9
&million
&Ameri
can&mi
litary&v
eterans
&over&a
&netwo
rk&of&
approx
imately
&172&ho
spitals
,&379&cl
inics,&1
32&nur
sing&ho
mes&pl
us&othe
r&
contrac
tual&pr
oviders
&across
&all&US&
states&a
nd&som
e&territ
ories.&E
ligibilit
y&for&
covera
ge&dep
ends&o
n&the&r
ecipien
t&havin
g&a&serv
iceWrela
ted&dis
ability&
or&bein
g&
poor.&T
he&vast
&majori
ty&cove
red&are
&male&(
95%).&
IM
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141,&26
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USA&
Integra
ted&cla
ims&da
tabase
&of&ove
r&100&c
ommer
cial&ins
urers.&M
edical&a
nd&
pharm
acy&dat
a&linke
d&at&the
&individ
ual&lev
el&for&7
0&millio
n&cover
ed&peo
ple&
belong
ing&to&6
4&natio
nal&and
&region
al&man
aged&ca
re&orga
nisatio
ns&sinc
e&1998
.&
&
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da
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se
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USA&
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&Data&C
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trends
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care&Sc
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Manag
ed&
Care&da
tabase
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Medco
&Health
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ns&and
&Health
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di
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ea
lt
h%
ad
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in
is
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at
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e%
da
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se
s21,&7
8,&101,
&
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Canada
&H
ealth&a
dminis
trative
&data&co
llected
&by&the
&provin
ces&in&t
he&deli
very&of
&univer
sal&
health&
care&fo
r&Canad
ian&citi
zens&an
d&resid
ents.&T
he&deli
very&of
&health
&care&an
d&
data&co
llection
&varies
&across
&the&pr
ovince
s&but&ty
pically
&includ
es&phys
ician&
billings
,&hospit
al&sepa
rations
,&prescr
iption&d
rug&cla
ims,&em
ergenc
y&and&
ambula
tory&ca
re,&hom
e&care&a
nd&reh
abilitat
ion&dat
a.&&
&
&
&
&
Bu
re
au
%o
f%N
at
io
na
l%H
ea
lt
h%
In
su
ra
nc
e%
Re
se
ar
ch
%D
at
ab
as
e58,&
96,&98,
&102,&1
03,&223
,&224 &97 &
Taiwan
&T
he&Bur
eau&of&
Nation
al&Heal
th&Insu
rance,&
Taiwan
&(BNHI
)&provi
des&hea
lth&
covera
ge&to&>
98%&of
&the&23
&million
&Taiwa
nese&po
pulatio
n&(inclu
ding&fo
reigner
s).&
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hospita
l&inpati
ent&cla
ims,&am
bulator
y&care,&
and&pr
escript
ion&
drugs&c
laims.&D
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sets&av
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&for&res
earch&i
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&the&lon
gitudin
al&heal
th&
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ce&data
set&–&a&
random
ly&selec
ted&coh
ort&of&1
,073,89
1&subje
cts&and
&all&the
ir&
claim&d
ata&(da
taWfiles
&are&av
ailable
&for&coh
ort&sele
cted&in
&years&2
000,&20
05&and
&
2010).
&Other&
data&su
bsets&in
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edicine
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r,&
diabete
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isease,
&traffic
&accide
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&rehabi
litation
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Denma
rk&
Establi
shed&in
&1977,&
the&Nat
ional&H
ospital
&Patien
t&Regis
ter&(NP
R)&cont
ains&
inform
ation&fr
om&inp
atient&h
ospital
&stays&i
n&Denm
ark.&It&c
an&be&c
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red&
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sal&from
&2000&w
hen&the
&NPR&b
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the&me
thod&of
&fundin
g&hosp
itals.&
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lia&
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DLS&co
nsists&o
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wide&co
re&deWi
dentifi
ed&link
ed&data
sets&co
mprisi
ng&
hospita
l&morb
idity&co
llection
,&emerg
ency&at
tendan
ces,&bir
ths,&de
aths&an
d&
marria
ges&reg
ister,&m
idwive
s&notifi
cations
,&cance
r&notifi
cations
,&and&m
ental&h
ealth&
registr
ations.
&Plus&li
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&to&othe
r&gover
nment&
datase
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Main&R
oads&
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ment.&I
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s&a&hist
orical&p
opulati
on&of&3
.7&milli
on&peo
ple&ove
r&30&ye
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The&RE
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&of&all&r
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&all&pat
ients&o
f&the&M
ayo&Cli
nic,&the
&Olmste
d&Medi
cal&Cen
ter,&
and&oth
er&sma
ller&me
dical&p
ractice
s.202 &By
&2010&t
he&proj
ect&enc
ompas
sed&
6,239,3
53&per
sonWye
ars&of&f
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p&for&5
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uals.202
&!
O
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ge
%S
tu
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59,&130
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UK&
The&OR
LS&com
prises&
over&10
&million
&record
s&from&
a&histo
rical&po
pulatio
n&of&ov
er&
five&mi
llion&pe
ople&in
&the&Ox
ford&re
gion&an
d&consi
sts&of&c
omput
erized,
&irreve
rsibly&
anonym
ized7&a
bstract
s&of&rec
ords&of
&morbi
dity&(h
ospital
&separa
tions),&
births&
and&
deaths
&from&1
963&to&
presen
t&date.&
In
st
it
ut
e%
of
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%
Ev
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ua
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%S
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(I
CE
S)
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O
nt
ar
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11,&22,
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Canada
&T
he&ICES
&Data&R
eposito
ry&cons
ists&of&d
eWident
ified&lin
ked&he
alth&da
tasets&a
cross&
most&o
f&the&pu
blically
&funded
&health
&servic
es&sinc
e&1986
&in&Ont
ario&for
&
approx
imately
&13&mil
lion&pe
ople.&&
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i. Un
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ue
%m
at
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g%
(d
et
er
m
in
is
ti
c%
m
at
ch
in
g)
&W&data&
are&link
ed&acco
rding&t
o&
unique
&identif
iers&e.g
.,&health
&insura
nce&nu
mber.&T
his&wou
ld&be&th
e&most
&
expedi
tious&w
ay&to&li
nk&data
&yet&is&l
imited&
since&fe
w&data
sets&sh
are&a&
commo
n&ident
ifier.&In
&additio
n,&due&
to&reco
rding&e
rrors&th
is&meth
od&may
&
only&id
entify&8
0W85%
&of&true
&match
es.79 &
ii. F
uz
zy
%m
at
ch
in
g&W&data
&are&lin
ked&acc
ording
&to&part
ial&iden
tifiers&(
usually
&
multip
le)&e.g.;
&name,
&date&o
f&birth,
&addres
s&etc.&T
his&tech
nique&a
llows&f
or&a&
margin
&for&err
or&by&li
nking&r
ecords
&that&ar
e&almo
st&the&s
ame.&T
he&com
puter&
will&eit
her&pre
sent&a&c
hoice&o
f&match
es&to&th
e&user&
or&will&
rely&on
&a&scori
ng&
system
&to&con
firm&a&m
atch.&T
his&usu
ally&ide
ntifies&
85W90%
&of&true
&match
es.79 &
iii. P
ro
ba
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ti
c%
m
at
ch
in
g&W&the&
decisio
n&regar
ding&a&
match&
is&mad
e&using
&
decisio
n&rules
&that&ar
e&built&
into&a&s
oftwar
e&packa
ge.&The
se&are&b
ased&on
&the&
probab
ility&tha
t&two&r
ecords
&are&fro
m&diffe
rent&pe
ople&gi
ven&the
y&have&
the&
same&id
entifier
s.&The&p
robabi
lities&a
re&then
&aggreg
ated&to
&form&a
&score&a
nd&a&
link&is&c
onfirm
ed&if&a&p
redefin
ed&thre
shold&i
s&reach
ed.&Thi
s&typica
lly&
identif
ies&95W
99%&of
&true&m
atches&
with&a&
1W2%&f
alse&po
sitive&r
ate.79,11
2,204 &
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Figure&
2a.!Tre
nds&in&
catarac
t&proce
dure&ty
pes&(19
80&to&1
998).&(
!),&Intr
acapsu
lar;&
(▾),&ex
tracaps
ular;&("
),&phac
oemuls
ificatio
n;&(#),&
other.&
&
&
& Figure&
2b.&Hos
pital&ad
mission
&rates&p
er&100,
000&po
pulatio
n&for&tr
abecule
ctomy:
&
English
&nation
al&data
&from&1
989/90
&to&200
8/9&me
asured
&as&epis
odes&an
d&peop
le&
per&yea
r.&
&
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Additionally, Antony is an extremely personable and mature character who was an absolute delight to have as 
part of the Ophthalmology team. He has an energetic and up-beat personality and always came to work with a 
smile that brought a tangible vibrancy to the clinic. I have not met a member of staff who has not enjoyed 
working with him.   
 
 
I very much look forward to welcoming Antony back to our department as an attending consultant when he 
returns from his fellowships.  Any fellowship program that chooses to take Antony will gain the whole package: 
clinical proficiency balanced by an enthusiasm to learn; intelligence edged with humour; and a solid work ethic 
enhanced by strong interpersonal skills.  
 
 
In short, Antony is one of the best trainees I have had the pleasure to teach and work with.  I would strongly 
recommend Antony in his application for a clinical fellowship in your centre. 
 
 
Please do not hesitate to contact me should you need any further information. 
 
 
 
Yours sincerely 
  
Geoffrey LAM 
 
Clinical Associate Professor 
University of Western Australia  
Centre for Ophthalmology and Visual Science 
and 
School of Paediatrics and Child Health 
 
Consultant Ophthalmologist 
 
Head of Ophthalmology 
Princess Margaret Hospital for Children 
175!
13.Appendix!7:!Copyright!statements!!!The!following!journals!in!which!articles!from!this!thesis!are!published!provide!authors!with!rights! to! include! their! journal!articles! in! the! their! thesis!without!the!need!for!written!approval:!
• Acta!Ophthalmologica!
• Australian!Health!Review!
• British!Journal!of!Ophthalmology!
• Clinical!and!Experimental!Ophthalmology!!
• Ophthalmology!
• Retina!Written!approval!was!obtained!from!the!following!journals!to!include!copies!of!journal!articles!that!form!part!of!this!thesis:!
• Australian! Family! Physician! (note! the! exclusion! from! including! the!published!journal!article!within!the!digital!thesis!repository)!
• Archives!of!Ophthalmology!(JAMA!Ophthalmology)!! !
176#
## #
 
 
 
 
27 August 2014 
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Thank you for your request to use your published article from Australian Family Physician (AFP) as part of your thesis. 
 
The RACGP is happy to grant you permission to include the following AFP article: 
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3. In granting permission to reproduce the above work, the College makes no representation or warranty that: 
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matter; or 
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4. The RACGP does not grant permission for institutional deposit of articles published in AFP or any other RACGP 
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works. Permission must be requested on a case-by-case basis.  
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Bevan Wang  
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